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ABSTRACT 
Strategies for expediting preclinical development of drugs include using 
alternative (different to clinical) formulations or exposure routes to 
reduce compound usage. This may alter pharmacokinetics and hence 
efficacy and/or toxicopathology compared with the final formulation. 
Three p38 mitogen-activated kinase inhibitors (similar in vitro potency) 
with different physicochemical properties were administered to rats as 
dry powder or nebulised aerosols to investigate the influence of 
changes in particulate form on in vivo endpoints. 
When rats settled in restraint tubes before aerosol administration, 
inhaled doses calculated from lung function measurements were 
consistent with values derived from body weights using a published 
algorithm. Drug-lung deposition was 12% of the inhaled dose, 
correlating with the rat deposition fraction (10%) used by US-FDA 
officials when reviewing regulatory submissions. 
Drug persistence (GSK-899) in rat lung was associated with increased 
efficacy (inhibition of lipopolysaccharide-induced inflammation) four 
hours post challenge, compared with two readily absorbed drugs. 
However, administration of GSK-899 at a higher dose for 28 days 
resulted in accumulation of drug and alveolar macrophage aggregates 
in lungs with infiltration of neutrophils, a consequence of accumulating 
‘nuisance particles’ and mild irritancy by GSK-899. GSK-361 (lipophilic; 
membrane permeable) resulted in lower lung exposure and efficacy, 
and no lung toxicopathology. Repeating experiments with compounds 
of different pharmacologies would confirm if these physicochemical 
properties support general trends for inhaled drugs or represent 
standalone results for these molecules. Changing aerosol form did not 
fundamentally change the nature of toxicopathology but presented 
technical limitations for evaluating the dose response. 
This thesis demonstrated changes in aerosol form could modulate 
dose response without changing the nature of toxicopathology. 
Membrane permeability had a more profound effect on lung clearance 
and toxicopathology than aqueous solubility. Given technical limitations 
for drugs of low aqueous solubility, the aerosol form intended for 
clinical formulations should be used in early preclinical studies.  
 
vi 
 
TABLE OF CONTENTS 
Declaration .................................................................................................... ii 
Acknowledgements ....................................................................................... iii 
Abstract......................................................................................................... v 
Table of Contents ......................................................................................... vi 
List of Tables ............................................................................................... xi 
List of Figures ............................................................................................. xv 
List of Abbreviations ................................................................................... xxii 
Glossary of Terms ..................................................................................... xxvi 
 
1. General introduction 
1.1. Introduction ..................................................................................... 2 
1.2. The respiratory tract ........................................................................ 2 
1.2.1. Proximal conductive airways ........................................................... 3 
1.2.2. Distal respiratory region (lungs) ..................................................... 10 
1.2.3. Macrophages ................................................................................ 11 
1.3. Drug delivery devices .................................................................... 12 
1.4. Challenges in non clinical lung delivery and respiratory drug 
development ............................................................................. 16 
1.4.1. Regulatory testing of drugs ............................................................ 18 
1.4.2. Animal models for investigating efficacy ........................................ 21 
1.4.3. Animals and ethics in scientific research ....................................... 22 
1.4.4. Exposure of animals to inhaled materials and common practices  
in drug development ................................................................. 27 
1.4.5. Animal exposure and understanding dosimetry ............................. 38 
1.4.6. Fate of molecules post inhalation exposure ................................... 40 
1.5. Chronic Obstructive Pulmonary Disease ....................................... 45 
1.5.1. p38 mitogen activated protein kinase inhibitors ............................. 46 
1.6. Thesis aims and objectives ........................................................... 48 
 
2. Multivariate based selection of p38 mitogen-activated protein 
kinase inhibitors and investigation of pharmacokinetics in rats 
following a single inhalation exposure 
2.1. Introduction ................................................................................... 52 
2.1.1. Principal component analysis of physicochemical properties of 
compounds ............................................................................... 53 
2.1.2. Aims and objectives ...................................................................... 55 
2.2. Materials and methods .................................................................. 57 
2.2.1. Principal component analysis of the physicochemical properties  
of six p38 MAPK inhibitors ........................................................ 57 
2.2.2. Test articles ................................................................................... 61 
2.2.3. Dissolution rates of p38 MAPK inhibitors in simulated lung fluid .... 62 
2.2.3.1. Sample preparation for dissolution testing ..................................... 62 
2.2.3.2. Preparation of simulated lung fluid ................................................ 63 
2.2.3.3. Evaluation of dissolution ................................................................ 63 
2.2.4. Investigating the pharmacokinetics of p38 MAPK inhibitors in  
rats after a single inhaled dose ................................................. 65 
vii 
 
2.2.4.1. Test system and animal husbandry ............................................... 65 
2.2.5. Aerosol Generation and formulation details ................................... 66 
2.2.5.1. Dry powder formulations of p38 MAPK inhibitors ........................... 67 
2.2.5.2. Generation of dry powder aerosols of p38 MAPK inhibitors ........... 68 
2.2.5.3. Liquid formulations of p38 MAPK inhibitors ................................... 69 
2.2.5.4. Nebulisation of droplet aerosols .................................................... 72 
2.2.5.5. Rodent inhalation exposure system ............................................... 73 
2.2.5.6. Aerosol characterisation ................................................................ 76 
2.2.5.7. Calculation of the estimated inhaled dose ..................................... 82 
2.2.5.8. Pharmacokinetic profiling of p38 MAPK inhibitors in blood/plasma 
and lung .................................................................................... 82 
2.2.5.9. Analysis of drug lung distribution by matrix assisted laser 
desorption/ionization (MALDI) ................................................... 85 
2.3. Results and discussion .................................................................. 87 
2.3.1. Principal component analysis of the physico chemical parameters  
of six p38 MAPK inhibitors ........................................................ 87 
2.3.2. X-ray powder diffraction of amorphous GSK-899 .......................... 95 
2.3.3. In vitro dissolution of p38 MAPK inhibitors ..................................... 96 
2.3.4. Selection of p38 MAPK inhibitors for in vivo investigation of 
pharmacokinetics ...................................................................... 97 
2.3.5. Scanning electron microscopy of particles ..................................... 99 
2.3.6. Pharmacokinetics of p38 MAPK inhibitors in rats following a  
single inhaled dose ................................................................. 103 
2.3.6.1. Inhalation exposure of rats to p38 MAPK inhibitors and estimation  
of the inhaled dose ................................................................. 103 
2.3.6.2. Systemic and pulmonary pharmacokinetics and lung distribution  
of p38 MAPK inhibitors in rats ................................................. 107 
2.4. Conclusion .................................................................................. 125 
 
3. Estimation of inhaled doses in rats from lung function data and 
refinement of tube restraint in scientific procedures 
3.1. Introduction ................................................................................. 130 
3.1.1. Aims and objectives .................................................................... 132 
3.2. Materials and methods ................................................................ 133 
3.2.1. Head-out plethysmography and data capture of lung function 
measurements ........................................................................ 133 
3.2.2. Investigating lung function and dosimetry in rats ......................... 134 
3.2.2.1. Preliminary analysis of lung function data .................................... 135 
3.2.3. Test system and animal husbandry ............................................. 135 
3.2.4. Method acquisition (Design 1) ..................................................... 136 
3.2.4.1. Investigating lighting colour during tube restraint ......................... 138 
3.2.4.2. Statistical analysis of lung function data ...................................... 139 
3.2.4.3. Methodological outcomes of Design 1 ......................................... 139 
3.2.5. Colour of lighting and duration of acclimatisation protocols for  
tube restraint (Design 2) ......................................................... 139 
3.2.5.1. Data analysis of measured and body weight derived estimates  
of minute volume .................................................................... 142 
3.2.5.2. Data analysis of estimated lung deposited dose and measured  
drug-lung concentrations ........................................................ 142 
viii 
 
3.2.5.3. Statistical analysis of lung function data and drug-lung  
concentration in lung tissue ..................................................... 142 
3.2.5.4 Methodological outcomes of Design 2 ......................................... 143 
3.2.6. Settling rats before aerosol administration (Design 3) ................. 143 
3.2.6.1. Statistical analysis of lung function data and drug-lung  
concentration in lung tissue ..................................................... 145 
3.2.6.2. Methodological outcomes of Design 3 ......................................... 146 
3.2.7. Incorporation of lung function measurements into repeat-dose 
inhalation studies (Design 4) ................................................... 146 
3.2.7.1 Statistical analysis of lung function data ...................................... 147 
3.2.8. Aerosol generation of p38 MAPK inhibitors and inhalation  
exposure of rats ...................................................................... 148 
3.2.8.1. Test articles ................................................................................. 149 
3.2.8.2. Aerosol Generation and formulation details ................................. 149 
3.2.8.3. Aerosol characterisation .............................................................. 150 
3.3. Results and discussion ................................................................ 152 
3.3.1. Breath frequency and minute volume of rats restrained in tubes . 152 
3.3.1.1. Influence of lighting colour and duration of tube acclimatisation  
on breath frequency and minute volume of rats ...................... 157 
3.3.1.2. Breath frequency and minute volume of rats allowed to settle  
before aerosol administration .................................................. 160 
3.3.2.3. Effect of neck restraint on breath frequency and minute volume  
of rats during repeat dose studies ........................................... 163 
3.3.2. Relationship between measured minute volume and pre  
exposure body weight ............................................................. 169 
3.3.3. Comparison of measured lung concentrations and estimated 
pulmonary doses .................................................................... 172 
3.4. Conclusion .................................................................................. 179 
 
4. Suppression of lipopolysaccharide induced acute lung 
inflammation in rats by single prophylactic doses of p38 
mitogen activated protein kinase inhibitors 
4.1. Introduction ................................................................................. 184 
4.1.1 Aims and objectives .................................................................... 188 
4.2. Materials and methods ................................................................ 190 
4.2.1. Test articles ................................................................................. 190 
4.2.2. Investigating efficacy and exposure of inhaled p38 MAPK  
inhibitors in rats ....................................................................... 191 
4.2.2.1. Efficacy of GSK-899 determined using neutrophil counts in  
BALF (Design A) ..................................................................... 193 
4.2.2.2. Evaluation of endpoints used to determine inhibition of lung 
inflammation by GSK-677 (Design B) ..................................... 194 
4.2.2.3. Efficacy of GSK-899 measured using lung image analysis  
(Design C) .............................................................................. 196 
4.2.2.4. Efficacy of GSK-361 using neutrophil counts in BALF and lung  
image analysis (Design D) ...................................................... 196 
4.2.3. Test system and animal husbandry ............................................. 197 
4.2.4. Aerosol generation of p38 MAPK inhibitors and inhalation  
exposure of rats ...................................................................... 197 
ix 
 
4.2.4.1. Dry powder formulations of p38 MAPK inhibitors ......................... 198 
4.2.4.2. Liquid formulations of p38 MAPK inhibitors ................................. 199 
4.2.4.3. Aerosol Generation and formulation details ................................. 201 
4.2.4.4. Inhalation exposure of rats .......................................................... 201 
4.2.4.5. Aerosol characterisation .............................................................. 201 
4.2.4.6. Calculation of the estimated inhaled dose ................................... 203 
4.2.5. Antigen challenge of rats ............................................................. 203 
4.2.6. Assessment of biomarkers for lung inflammation ........................ 204 
4.2.6.1. Bronchoalveolar lavage of lungs for analysis of TNFα and/or  
cell counts (Designs A, B and D) ............................................ 204 
4.2.6.2. Lung sampling and processing for image analysis ...................... 205 
4.2.6.3. Determination of the 50% effective dose (ED50) for inhibition  
of LPS-induced lung inflammation .......................................... 210 
4.2.7. Bioanalysis of p38 MAPK inhibitors in rat plasma and lung ......... 210 
4.2.7.1. Plasma sampling for analysis of p38 MAPK inhibitors ................. 210 
4.2.7.2. Lung sampling for homogenisation and analysis of p38 MAPK 
inhibitors ................................................................................. 211 
4.3. Results and discussion ................................................................ 212 
4.3.1. Inhalation exposure of rats to p38 MAPK inhibitors ..................... 212 
4.3.2. Temporal variability of rat neutrophils in BALF four hours after  
an LPS challenge .................................................................... 216 
4.3.3. Pulmonary and systemic exposure of rats to GSK-677 and  
endpoints for investigating inhibition of acute lung  
inflammation (Design B) .......................................................... 220 
4.3.4. Pulmonary and systemic exposure of rats to GSK-899 and  
inhibition of inflammation ........................................................ 226 
4.3.5. Pulmonary and systemic exposure of rats to GSK-361 and  
inhibition of inflammation (Design D) ....................................... 232 
4.4. Conclusion .................................................................................. 236 
 
5. Toxicopathology of p38 mitogen-activated protein kinase 
inhibitors in rats after inhalation of fixed doses for 28 days 
5.1. Introduction ................................................................................. 242 
5.1.1 Aims and objectives .................................................................... 244 
5.2. Materials and methods ................................................................ 246 
5.2.1. Test articles ................................................................................. 246 
5.2.2. In vitro cytotoxicity and morphology of NR8383 rat macrophage  
cells incubated with particles................................................... 246 
5.2.2.1. Treatment of cells to investigate cytotoxicity and release of 
inflammatory cell mediators .................................................... 247 
5.2.2.2. Analysis of cytotoxicity by measurement of lactate  
dehydrogenase leakage from treated cells .............................. 248 
5.2.2.3. Analysis of inflammatory cell mediators ....................................... 249 
5.2.2.4. Treatment of cells to investigate cell morphology ........................ 249 
5.2.2.5. Processing cells for examination of morphology by transmission 
electron microscopy ................................................................ 250 
5.2.3. Investigating the toxicopathology and exposure of inhaled p38  
MAPK inhibitors in rats ............................................................ 252 
x 
 
5.2.3.1. Dose selections for investigating pulmonary toxicopathology in  
rats ......................................................................................... 253 
5.2.3.2. Investigating mechanisms of toxicopathology seen in rats  
inhaling p38 MAPK inhibitors .................................................. 256 
5.2.4. Test system and animal husbandry ............................................. 260 
5.2.5. Subcutaneous dosing of rats ....................................................... 261 
5.2.6. Aerosol generation of p38 MAPK inhibitors and inhalation  
exposure of rats ...................................................................... 261 
5.2.6.1. Dry powder formulations of p38 MAPK inhibitors ......................... 261 
5.2.6.2. Liquid formulations of p38 MAPK inhibitors ................................. 262 
5.2.6.2. Aerosol Generation and formulation details ................................. 263 
5.2.6.3. Inhalation exposure of rats .......................................................... 264 
5.2.6.4. Aerosol characterisation .............................................................. 264 
5.2.6.5. Calculation of the estimated inhaled dose ................................... 266 
5.2.6.6. Bioanalysis of p38 MAPK inhibitors in rat plasma and lung ......... 266 
5.2.7. Terminal investigations ................................................................ 267 
5.2.7.1. Bronchoalveolar lavage of lungs for transmission electron 
microscopy of macrophages ................................................... 267 
5.2.7.2. Histopathological examination of tissues ..................................... 268 
5.3. Results and discussion ................................................................ 273 
5.3.1. In vitro analysis of cytotoxicity, cytokine release and  
morphology of cells incubated with particles ........................... 273 
5.3.2. Toxicopathology of p38 MAPK inhibitors in rats following 28  
days of inhalation exposure .................................................... 276 
5.3.2.1. Inhalation exposure of rats to p38 MAPK inhibitors and  
estimation of the inhaled dose ................................................ 277 
5.3.2.2. Pulmonary and systemic exposure of rats to GSK-899 and 
toxicopathology after 28 days ................................................. 279 
5.3.2.3. Pulmonary and systemic exposure of rats to GSK-677 and 
toxicopathology after 28 days ................................................. 309 
5.3.2.4. Pulmonary and systemic exposure of rats to GSK-361 and 
toxicopathology after 28 days ................................................. 322 
5.4. Conclusion .................................................................................. 331 
 
6. General Discussion 
6.1. General Discussion ..................................................................... 340 
6.2. Limitations and further work ........................................................ 353 
6.3. Summary ..................................................................................... 356 
 
REFERENCES ......................................................................................... 361 
 
APPENDICES........................................................................................... 379 
 
ADDENDA ................................................................................................ 449 
xi 
 
LIST OF TABLES 
CHAPTER 1 
1.1. Proportion of particles deposited in the lungs and respiratory  
tract of mice, rats, guinea pigs, dogs, monkeys and humans .... 40 
CHAPTER 2 
2.1. Salt form and purity of p38 MAPK inhibitors used for dissolution 
testing (in vitro) and inhalation exposure of rats (in vivo) ........... 62 
2.2. Aqueous solutions of p38 MAPK inhibitors nebulised for single 
inhalation exposure of rats ........................................................ 70 
2.3. Theoretical effective cut off diameter cut points (ECDs) for a  
Marple 296 cascade impactor ................................................... 81 
2.4. ‘In silico’ physicochemical parameters for principal component 
analysis of six p38 MAPK inhibitors .......................................... 87 
2.5. Scoring system used for pKa acid and base class definitions for  
in silico parameters listed in Table 2.4 ...................................... 89 
2.6. Measured physicochemical parameters for principal component 
analysis of six p38 MAPK inhibitors .......................................... 90 
2.7. Statistical summary data for principal component analysis of 
measured physicochemical parameters of six p38 MAPK 
inhibitors ................................................................................... 95 
2.8. In vitro dissolution rates of five crystalline p38 MAPK inhibitors  
and amorphous GSK-899 in simulated lung fluid ...................... 97 
2.9 Key in vitro physicochemical parameters of p38 MAPK inhibitors 
selected for in vivo evaluation of lung exposure in rats ............. 98 
2.10. Index of figures showing scanning electron microscopy (SEM) of 
input materials and aerosol samples ......................................... 99 
2.11. Estimated inhaled doses in rats and aerosol characterisation  
data for p38 MAPK inhibitors .................................................. 104 
2.12. Estimation of fine particle fraction of aerosols of p38 MAPK  
inhibitors by interpolation of particulate size data .................... 106 
2.13. Index of figures presenting concentrations of p38 MAPK  
inhibitors in lung and plasma, and relative lung distribution ..... 107 
2.14. Lung weights and estimated circulating blood volume of rats ...... 108 
2.15. Distribution of drug between lung tissue and blood residing in 
vasculature, and indexing of appendices for individual data .... 109 
2.16. Pharmacokinetics of mean p38 MAPK inhibitor concentrations in 
lung homogenate after single exposure of rats to test articles . 122 
2.17. Pharmacokinetics of mean p38 MAPK inhibitor concentrations in 
plasma after single exposure to test articles ........................... 123 
2.18. Ranking of p38 MAPK inhibitors and aerosol forms for systemic  
and lung exposure .................................................................. 124 
xii 
 
CHAPTER 3 
3.1. Tube restraint protocol for acclimatisation of rats to plethysmographs 
and a 31-day observation period (Design 1) ........................... 137 
3.2. Tube restraint protocol for acclimatisation of rats to plethysmographs 
and aerosol administration (Design 2) ..................................... 141 
3.3. Tube restraint protocol for acclimatisation of rats to plethysmographs 
and aerosol administration (Design 3) ..................................... 145 
3.4. Tube restraint protocol for acclimatisation of rats to head-out 
plethysmography and aerosol administration (Design 4) ......... 147 
3.5. Aqueous solutions of p38 MAPK inhibitors nebulised for single 
inhalation exposure of rats ...................................................... 149 
3.6. Duration of exposure, target doses and aerosol concentrations  
of p38 MAPK inhibitors for exposure of rats ............................ 150 
3.7. Aerosol sampling volumes for aerosol concentration and  
particle size analysis ............................................................... 151 
3.8. Index of figures and tables summarising lung function data,  
inhaled doses and lung concentrations of p38 MAPK  
inhibitors in rats ....................................................................... 152 
3.9. Breath frequency (breaths per minute) of rats during a 60-minute 
inhalation exposure period ...................................................... 159 
3.10. Minute volume of rats during a 60-minute inhalation exposure  
period ..................................................................................... 160 
3.11. Breath frequency of rats during a 30-minute inhalation exposure 
period ..................................................................................... 162 
3.12. Minute volume of rats during a 30-minute inhalation exposure  
period ..................................................................................... 163 
3.13. Measured and body weight-derived estimates of minute volume  
of rats during a single 60-minute exposure period ................... 170 
3.14. Measured and body weight-derived estimates of minute volume  
of rats during a single 30-minute exposure period ................... 172 
3.15. Estimated inhaled doses in rats and aerosol characterisation  
data for crystalline GSK-899 ................................................... 173 
3.16. GSK-899 concentration in rat lung homogenate after a single 
inhalation exposure (breakdown of groups) ............................ 174 
3.17. Estimated inhaled doses in rats and aerosol characterisation  
data for GSK-677 and GSK-361 ............................................. 175 
CHAPTER 4 
4.1. Purity of crystalline p38 MAPK inhibitors used for inhalation  
exposure of rats ...................................................................... 190 
4.2. Summary of aerosol particle sizes for amorphous GSK-899 ........ 190 
4.3. In vitro binding and potency of p38 MAPK inhibitors .................... 197 
4.4. Dry powder formulations of p38 MAPK inhibitors, canister  
volumes, target doses and aerosol concentrations for  
exposure of rats ...................................................................... 198 
4.5. Vehicles used for nebulisation of p38 MAPK inhibitors and  
repeated inhalation exposure of rats ....................................... 199 
xiii 
 
4.6. Formulation concentrations, target doses and aerosol  
concentrations for exposure of rats to p38 MAPK inhibitors .... 200 
4.7. Target aerosol concentrations and aerosol sampling volumes .... 202 
4.8. Aerosol characterisation data and inhaled doses of GSK-899  
in rats (single 30-minute exposure) ......................................... 212 
4.9. Aerosol characterisation data and inhaled doses of GSK-899  
in rats (single 30-minute exposure) ......................................... 213 
4.10. Aerosol characterisation data and inhaled doses of GSK-677  
in rats (single 30-minute exposure) ......................................... 214 
4.11. Aerosol characterisation data and inhaled doses of GSK-361  
in rats (single 30 or 60-minute exposure) ................................ 215 
4.12. Estimated inhaled doses of GSK-677 to achieve 50% reduction 
(ED50) in inflammation endpoints evaluated using an acute  
lung inflammation model in rats .............................................. 225 
4.13. Estimated inhaled dose of GSK-899 to achieve 50% reduction 
(ED50) in inflammation endpoints evaluated using an acute  
lung inflammation model in rats .............................................. 232 
4.14. Estimated inhaled dose of GSK-361 to achieve 50% reduction 
(ED50) in inflammation endpoints evaluated using an acute  
lung inflammation model in rats .............................................. 235 
4.15. Ranking of the exposure of rats to p38 MAPK inhibitors  
following a single inhaled administration ................................. 237 
4.16. Estimated inhaled doses of p38 MAPK inhibitors to achieve  
50% reduction (ED50) in inflammation endpoints evaluated  
using an acute lung inflammation model in rats ...................... 238 
CHAPTER 5 
5.1. Purity of p38 MAPK inhibitors used for repeated administration  
to rats ..................................................................................... 246 
5.2. Volume of dust feed canisters, target doses and aerosol 
concentrations for exposure of rats to p38 MAPK inhibitors .... 262 
5.3. Vehicles used for nebulisation of p38 MAPK inhibitors and  
repeated inhalation exposure of rats ....................................... 262 
5.4. Formulation concentrations, target doses and aerosol  
concentrations for exposure of rats to p38 MAPK inhibitors .... 263 
5.5. Target aerosol concentrations and aerosol sampling volumes .... 265 
5.6. Summary of inhaled doses, duration of treatment and sampling  
of lungs by bronchoalveolar lavage ......................................... 268 
5.7. Summary of tissues examined by light microscopy after  
treatment of rats for 28 days ................................................... 272 
5.8. In vitro cytotoxicity (EC50) data for p38 MAPK inhibitors ............. 273 
5.9. Index of figures and tables for dosimetry, drug-lung and  
plasma concentrations and representative microscopy  
images in rats ......................................................................... 276 
5.10. Estimated inhaled doses and characterisation of dry powder  
aerosols administered to rats over 28 days ............................. 278 
xiv 
 
5.11. Estimated inhaled doses and characterisation of nebulised  
aerosols administered to rats over 28 days ............................. 279 
5.12. Pharmacokinetics of GSK-899 in plasma after inhaled  
administration of micronised crystals ...................................... 282 
5.13. Histopathology of the respiratory tract of rats exposed to  
micronised crystalline GSK-899 for 28 days ............................ 285 
5.14. Pharmacokinetics of GSK-899 in plasma after inhaled  
administration of amorphous powder ...................................... 291 
5.15. Histopathology of the respiratory tract of rats exposed to  
amorphous GSK-899 for 28 days ............................................ 293 
5.16. Pharmacokinetics of GSK-899 in plasma after inhaled  
administration of nebulised solutions ...................................... 298 
5.17. Histopathology of the respiratory tract of rats exposed to  
nebulised GSK-899 for 28 days .............................................. 300 
5.18. Pharmacokinetics of GSK-899 in plasma after subcutaneous  
administration of a solution ..................................................... 304 
5.19. Histopathology of lungs and injection sites of rats dosed 
subcutaneously with GSK-899 for 28 days .............................. 305 
5.20. Pharmacokinetics of GSK-677 in plasma after inhaled  
administration of micronised crystals ...................................... 311 
5.21. Histopathology of the respiratory tract of rats exposed to  
micronised crystalline GSK-677 for 28 days ............................ 313 
5.22. Pharmacokinetics of GSK-677 in plasma after inhaled  
administration of a nebulised solution ..................................... 316 
5.23. Histopathology of the respiratory tract of rats exposed to  
nebulised GSK-677 for 28 days .............................................. 318 
5.24. Pharmacokinetics of GSK-361 in plasma after inhaled  
administration of micronised crystals ...................................... 325 
5.25. Pharmacokinetics of GSK-361 in plasma after inhaled  
administration of nebulised solution ........................................ 330 
5.26. Key findings for in vitro and in vivo assessment of  
toxicopathology and exposure of p38 MAPK inhibitors ............ 331 
CHAPTER 6 
6.1. Ranking of key findings for in vitro and in vivo assessment of  
p38 MAPK inhibitors ............................................................... 345 
6.2. Median effective dose (ED50; single exposure) and non-effect  
levels (28 days) for inhaled p38 MAPK inhibitors administered  
to rats ..................................................................................... 350 
xv 
 
LIST OF FIGURES 
CHAPTER 1 
1.1. Fractional deposition of inhaled particles in humans ................ 4 
1.2. Diagrammatic representation of the human and rodent respiratory 
tracts ........................................................................................... 5 
1.3. Comparison of the human respiratory epithelium at different lung 
locations ..................................................................................... 8 
1.4. Clinical inhalers and a nebuliser for dosing patients ...................... 15 
1.5. Total procedures performed in Great Britain during 2016 .............. 24 
1.6. Refinement of drug development programmes to reduce animal use 
associated with drug attrition due to adverse lung pathology .... 25 
1.7 Dynamic single pass exposure systems for the non-clinical 
administration of aerosols ......................................................... 35 
1.8. Restraint of animals for snout only inhalation exposure ................. 36 
1.9. Mechanisms of transmembrane absorption of molecules .............. 42 
CHAPTER 2 
2.1. Illustration of principal component analysis ................................... 54 
2.2. Chemical structures of six p38 MAPK inhibitors shortlisted for 
potential investigation of in vivo endpoints ................................ 58 
2.3. Schematic of apparatus used to evaluate dissolution of p38  
MAPK inhibitors in simulated lung fluid ..................................... 64 
2.4. Design to investigate plasma and lung concentrations and lung 
distribution of p38 MAPK inhibitors in rats after a single  
inhaled dose ............................................................................. 65 
2.5. Aerosol generator for dispersal of dry powder formulations ........... 69 
2.6. Air jet nebuliser used to disperse solutions or suspensions ........... 73 
2.7. Snout only inhalation exposure system incorporating a  
flow-through chamber for administration of aerosols to rats ...... 75 
2.8. Apparatus for sampling the chamber atmosphere for measurement 
of aerosol concentration of drug analyte ................................... 78 
2.9. Sampling chamber air using a cascade impactor to determine the 
particle size distribution of drug analyte .................................... 79 
2.10. Score plot for principal component analysis of estimated ADME  
and physicochemical properties for six p38 MAPK inhibitors..... 93 
2.11. Loading plot for principal component analysis of calculated ADME  
and physicochemical properties for six p38 MAPK inhibitors..... 93 
2.12. Score plot for principal component analysis of the measured 
physicochemical properties for six p38 MAPK inhibitors ........... 94 
2.13. Loading plot for principal component analysis of measured 
physicochemical parameters of six p38 MAPK inhibitors .......... 94 
2.14. X-ray powder diffraction of amorphous and crystalline GSK-899 ... 95 
2.15. In vitro dissolution of five crystalline p38 MAPK inhibitors and 
amorphous GSK-899 in simulated lung fluid ............................. 96 
xvi 
 
2.16. Scanning electron microscopy of ‘inhalation grade lactose’ used as 
excipient in dry powder formulations of p38 MAPK inhibitors .. 100 
2.17. Scanning electron microscopy of crystalline GSK-899 ................. 100 
2.18. Scanning electron microscopy of amorphous GSK-899 ............... 101 
2.19. Scanning electron microscopy of crystalline GSK-677 ................. 102 
2.20. Scanning electron microscopy of crystalline GSK-361 ................. 102 
2.21. Estimation of fine particle fraction (% mass <5µm aerodynamic 
diameter) by interpolation of particulate size data ................... 106 
2.22. GSK-899 concentrations in lung homogenate sampled from  
rats after a single inhaled dose ............................................... 110 
2.23. GSK-899 concentrations in plasma sampled from rats after a  
single inhaled or intravenous dose .......................................... 111 
2.24. GSK-899 in lungs of rats inhaling crystalline drug imaged by  
matrix assisted laser desorption/ionization with mass 
spectrometry imaging .............................................................. 112 
2.25. GSK-899 in lungs of rats inhaling amorphous drug imaged by  
matrix assisted laser desorption/ionization with mass 
spectrometry imaging .............................................................. 112 
2.26. GSK-899 in lungs of rats inhaling nebulised drug imaged by  
matrix assisted laser desorption/ionization with mass 
spectrometry imaging .............................................................. 113 
2.27. GSK-677 concentrations in lung homogenate sampled from  
rats after a single inhaled dose ............................................... 114 
2.28. GSK-677 concentrations in plasma of rats after a single inhaled or 
intravenous dose .................................................................... 115 
2.29. GSK-677 in lungs of rats inhaling crystalline drug imaged by  
matrix assisted laser desorption/ionization with mass 
spectrometry imaging .............................................................. 116 
2.30. GSK-677 in lungs of rats inhaling nebulised drug imaged by  
matrix assisted laser desorption/ionization with mass 
spectrometry imaging .............................................................. 116 
2.31. GSK-361 concentrations in lung homogenate sampled from  
rats after a single inhaled dose ............................................... 117 
2.32. GSK-361 concentrations in plasma of rats after a single  
inhaled or intravenous dose .................................................... 118 
2.33. GSK-361 in lungs of rats inhaling crystalline drug imaged by  
matrix assisted laser desorption/ionization with mass 
spectrometry imaging .............................................................. 118 
2.34. GSK-361 in lungs of rats inhaling nebulised drug imaged by  
matrix assisted laser desorption/ionization with mass 
spectrometry imaging .............................................................. 119 
2.35. SB-445 concentrations in lung homogenate sampled from rats  
after a single inhaled dose ...................................................... 120 
2.36. SB-445 concentrations in plasma sampled from rats after a  
single inhaled or intravenous dose .......................................... 120 
xvii 
 
CHAPTER 3 
3.1. Head-out plethysmography in rats ............................................... 134 
3.2. Evolution of study designs for investigation of light, duration of  
tube acclimatisation and conditioning of rats on lung function . 135 
3.3. Design of a preliminary study to measure lung function over four 
weeks and consider the impact of lighting conditions .............. 138 
3.4. Latin square design of study to investigate effects of lighting and 
duration of tube acclimatisation on lung function and dose ..... 140 
3.5. Simple study design to investigate lung function measurements  
and drug-lung concentrations after a single inhaled dose of  
GSK-361 or GSK-677 ............................................................. 144 
3.6. Experimental design to investigate lung function of rats during  
a 28-day inhalation study ........................................................ 148 
3.7. Breath frequency of rats restrained in tubes once daily for  
28 days ................................................................................... 153 
3.8. Minute volume of rats restrained in tubes once daily for  
28 days ................................................................................... 154 
3.9. Breath frequency of rats restrained in tubes under red or  
white lighting ........................................................................... 155 
3.10. Minute volume of rats restrained in tubes under red or white  
lighting .................................................................................... 156 
3.11. Breath frequency of rats exposed to GSK-899 for 60 minutes  
after a tube acclimatisation protocol of two or six days and  
under red or white lighting ....................................................... 158 
3.12. Minute volume of rats exposed to GSK-899 for 60 minutes  
after a tube acclimatisation protocol of two or six days and  
under red or white lighting ....................................................... 159 
3.13. Breath frequency of rats exposed to crystalline or  
nebulised aerosols for 30 minutes........................................... 161 
3.14. Minute volume of rats exposed to crystalline or nebulised  
aerosols for 30 minutes ........................................................... 162 
3.15. Breath frequency of rats administered GSK-361 for 28 days ....... 164 
3.16. Breath frequency of rats administered GSK-361 for 28 days ....... 165 
3.17. Minute volume of rats administered GSK-361 for 28 days ........... 166 
3.18. Minute volume of rats administered GSK-361 for 28 days ........... 167 
3.19. Breath frequency in rats over a 28-day treatment period ............. 168 
3.20. Measured minute volume and the body weight derived estimate  
in rats over a 28-day treatment period .................................... 169 
3.21. Measured minute volume and the body weight derived estimate 
against body weight of rats during a single exposure .............. 170 
3.22. Measured minute volume and the body weight derived estimate 
against body weight of rats during a single exposure .............. 171 
3.23. Measured minute volume and the body weight derived  
estimate against body weight of rats over 28 days .................. 172 
xviii 
 
3.24. Measured and predicted lung concentrations in rats after a  
single inhaled dose of GSK-899 and tube acclimatisation  
for two or six days under red or white light .............................. 174 
3.25. Measured and predicted lung concentrations in rats after a single 
inhaled dose of GSK-677 or GSK-361 .................................... 176 
3.26. Measured lung concentrations of GSK-899 as a proportion of the 
estimated inhaled dose in rats after a single exposure ............ 177 
CHAPTER 4 
4.1. Normal alveolus and injured alveolus in the acute phase of  
acute lung injury and acute respiratory distress syndrome ...... 185 
4.2. Study design used for investigating inhibition of lipopolysaccharide 
induced lung inflammation after a single dose of an inhaled  
p38 MAPK inhibitor ................................................................. 192 
4.3. Inhibition of lipopolysaccharide induced lung inflammation in  
rats after prophylactic administration of GSK-899 ................... 193 
4.4. Inhibition of lipopolysaccharide induced inflammation in rat  
lungs after prophylactic administration of GSK-677 ................. 195 
4.5. Intratracheal instillation of a solution ............................................ 204 
4.6. Example of image analysis of rat lungs for biomarkers of 
inflammation ........................................................................... 209 
4.7. Neutrophil counts in bronchoalveolar lavage fluid sampled from 
control animals four hours after intratracheal instillation of 
lipopolysaccharide .................................................................. 217 
4.8. Neutrophils as a proportion of leukocytes in bronchoalveolar  
lavage fluid sampled from control rats four hours after 
intratracheal instillation of lipopolysaccharide.......................... 218 
4.9. Recovery of bronchoalveolar lavage fluid sampled from control 
animals ................................................................................... 219 
4.10. GSK-677-concentrations in lung homogenate sampled from  
rats after a single inhaled dose (Study R31400N) ................... 220 
4.11. GSK-677 concentrations in plasma sampled from rats after  
a single inhaled dose (Study R31400N) .................................. 221 
4.12. Tumour necrosis factor-alpha in serum, relative to controls,  
sampled from an acute lung inflammation model in rats 
administered GSK-677 (Study R31400N) ............................... 222 
4.13. Tumour necrosis factor-alpha in broncho-alveolar lavage fluid,  
relative to controls, sampled from an acute lung inflammation 
model in rats administered GSK-677 (Study R31400N) .......... 223 
4.14. Neutrophils in bronchoalveolar lavage fluid, relative to controls, 
harvested from an acute lung inflammation model in rats 
administered GSK-677 (Study R31400N) ............................... 223 
4.15. Proportion of lung tissue stained for myeloperoxidase or 
chloroacetate esterase, relative to controls, in an acute lung 
inflammation model in rats administered GSK-677 (Study 
R31400N) ............................................................................... 224 
4.16. GSK-899 concentrations in lung homogenate sampled from  
rats after a single inhaled dose (Study R30820N) ................... 227 
xix 
 
4.17. GSK-899 concentrations in plasma sampled from rats after a  
single inhaled dose (Study R30820N) ..................................... 228 
4.18. Neutrophils in bronchoalveolar lavage fluid, relative to controls, 
harvested from an acute lung inflammation model in rats 
administered GSK-899 (Study R30820N) ............................... 229 
4.19. GSK-899 concentrations in lung homogenate sampled from  
rats after a single inhaled dose (Study R31763N) ................... 230 
4.20. GSK-899 concentrations in plasma sampled from rats after a  
single inhaled dose (Study R31763N) ..................................... 231 
4.21. GSK-361 concentrations in lung homogenate sampled from  
rats after a single inhaled dose (Study R31765N) ................... 233 
4.22. GSK-361 concentrations in plasma sampled from rats after a  
single inhaled dose (Study R31765N) ..................................... 233 
4.23. Neutrophils in bronchoalveolar lavage fluid, relative to controls, 
harvested from an acute lung inflammation model in rats 
administered GSK-361 (Study R31765N) ............................... 234 
CHAPTER 5 
5.1. Generic outline of experimental design to investigate pulmonary 
toxicology following inhaled administration of p38 MAPK  
inhibitors for 28 days ............................................................... 252 
5.2. Chemical structures of two structurally similar isomers with  
different pharmacological potencies ........................................ 257 
5.3. Outline of experimental design to investigate pulmonary  
toxicology after subcutaneous administration of GSK-899  
for 28 days .............................................................................. 259 
5.4. Trimming patterns for standardization of tissue sections for 
histopathological examination ................................................. 270 
5.5. Cytotoxicity assessed by leakage of lactate dehydrogenase  
from NR8383 rat alveolar macrophage cells incubated with  
a p38 MAPK inhibitor .............................................................. 274 
5.6. Transmission electron microscopy of NR8383 rat alveolar 
macrophage cells incubated with a p38 MAPK inhibitor .......... 275 
5.7. Drug-lung concentrations in rats following inhaled administration  
of crystalline GSK-899 for one or 28 days ............................... 280 
5.8. GSK-899 concentrations in rat plasma up to 24 hours after  
inhaled doses of crystalline GSK-899 on Days 1 and 28 ......... 281 
5.9. Normal macrophage sampled from a rat (control) after inhaled 
administration of lactose vehicle for 3 days ............................. 283 
5.10. Macrophages containing crystalline particles after inhalation of 
GSK-899 for 3 days ................................................................ 284 
5.11. Representative histology of control rat lung and treatment related 
changes after inhalation of crystalline GSK-899 for 28 days ... 286 
5.12. Representative histology of control rat bronchus associated  
lymphoid tissue (BALT) and increased cellularity after  
inhalation of crystalline GSK-899 for 28 days .......................... 287 
xx 
 
5.13. Representative histology of control rat larynx and changes after 
inhalation of crystalline GSK-899 for 28 days .......................... 287 
5.14. Drug-lung concentrations in rats following inhaled administration  
of amorphous GSK-899 for one or 28 days ............................. 288 
5.15. GSK-899 concentrations in rat plasma up to 24 hours after  
inhaled doses of amorphous GSK-899 on Days 1 and 28 ....... 290 
5.16. Macrophages containing amorphous particles after inhalation  
of GSK-899 for 3 days ............................................................ 292 
5.17. Representative histology of control rat lung and treatment related 
changes after inhalation of amorphous GSK-899 for 28 days . 294 
5.18. Representative histology of control rat larynx and treatment  
related changes after inhalation of amorphous GSK-899 for  
28 days ................................................................................... 295 
5.19. Drug-lung concentrations in rats following inhaled administration  
of nebulised GSK-899 for one or 28 days ............................... 296 
5.20. GSK-899 concentrations in rat plasma up to 24 hours after  
inhalation of nebulised doses on Days 1 and 28 ..................... 297 
5.21. Macrophages after inhalation of nebulised vehicle or GSK-899  
for 3 days ................................................................................ 299 
5.22. Representative histology of control rat lung and treatment  
related changes after inhalation of nebulised GSK-899 for  
28 days ................................................................................... 301 
5.23. Representative histology of rat lung and treatment related  
changes after inhalation of nebulised GSK-899 and/or  
vehicle for 28 days .................................................................. 301 
5.24. Drug-lung concentrations in rats after subcutaneous  
administration of GSK-899 for one or 28 days ......................... 302 
5.25. GSK-899 concentrations in rat plasma up to 24 hours after 
subcutaneous administration on Days 1 and 28 ...................... 303 
5.26. Representative histology of control rat lung and after  
subcutaneous administration of GSK-899 for 28 days ............. 304 
5.27. Representative histology of bronchus associated lymphoid  
tissue after subcutaneous administration of GSK-899 and/or 
vehicle for 28 days .................................................................. 306 
5.28. Representative histology of thymus after subcutaneous 
administration of GSK-899 and/or vehicle for 28 days ............. 307 
5.29. Representative histology of subcutaneous injection site after 
administration of GSK-899 and/or vehicle for 28 days ............. 308 
5.30. Drug-lung concentrations in rats following inhaled administration  
of crystalline GSK-677 for one or 28 ....................................... 309 
5.31. GSK-677 concentrations in rat plasma up to 24 hours after  
inhaled doses of crystalline GSK-677 on Days 1 and 28 ......... 310 
5.32. Macrophages after inhalation of crystalline GSK-677 for 3 days .. 312 
5.33. Drug-lung concentrations in rats following inhaled administration  
of nebulised GSK-677 for one or 28 days ............................... 314 
5.34. GSK-677 concentrations in rat plasma up to 24 hours after  
nebulised doses on Days 1 and 28 ......................................... 315 
xxi 
 
5.35. Macrophages after inhalation of nebulised vehicle or GSK-677  
for 3 days ................................................................................ 317 
5.36. Representative histology of control rat lung and treatment  
related changes after inhalation of nebulised GSK-677 for  
28 days ................................................................................... 319 
5.37. Representative histology of control rat nasal cavity and mild  
irritancy after inhalation of nebulised GSK-677 for 28 days ..... 320 
5.38. Representative histology of control rat larynx and mild irritancy  
after inhalation of nebulised GSK-677 for 28 days .................. 321 
5.39. Representative histology of control ventral pouch of rat larynx  
and mild irritancy after inhalation of nebulised GSK-677 for  
28 days ................................................................................... 322 
5.40. Drug-lung concentrations in rats following inhaled administration  
of crystalline GSK-361 for one or 28 days ............................... 323 
5.41. GSK-361 concentrations in rat plasma up to 24 hours after  
inhaled doses of crystalline GSK-361 on Days 1 and 28 ......... 324 
5.42. Macrophages after inhalation of lactose vehicle or crystalline 
GSK-361 for 28 days .............................................................. 326 
5.43. Representative histology of control rat lung and after inhalation  
of crystalline GSK-361 for 28 days .......................................... 327 
5.44. Drug-lung concentrations in rats following inhaled administration  
of nebulised GSK-361 for one or 28 days ............................... 328 
5.45. GSK-361 concentrations in rat plasma up to 24 hours after  
nebulised doses on Days 1 and 28 ......................................... 329 
5.46. Representative histology of control rat lung and after inhalation  
of nebulised GSK-361 for 28 days .......................................... 330 
CHAPTER 6 
6.1. Chemical structures of three p38 MAPK inhibitors selected for 
investigation of in vivo endpoints ............................................ 343 
xxii 
 
LIST OF ABBREVIATIONS 
AAPS Association of Pharmaceutical Scientists 
ABC ATP-binding cassette transporter 
ADA anti-drug antibody 
ANOVA analysis of variance 
AUC area under the (drug) concentration time curve 
A(SP)A Animal (Scientific Procedures) Act, 1986 (UK) 
ATP adenosine triphosphate 
BAL bronchoalveolar lavage 
BALF bronchoalveolar lavage fluid 
BALT bronchus-associated lymphoid tissue 
BC before Christ 
BF breath frequency (by head-out plethysmography) 
CAE chloroacetate esterase 
CCSP club cell secretory protein 
CD cluster of differentiation 
(CD68, CD3 and CD79 glycoproteins expressed by 
macrophages, T- and B-lymphocytes respectively) 
CFC chlorofluorocarbon 
CHI chromatographic hydrophobicity index 
CHCA α-cyano-4-hydroxycinnamic acid 
Cmax maximum (drug) concentration in stated medium 
COPD chronic obstructive pulmonary disease 
Ct target (aerosol) concentration 
CV coefficient of variation 
DNA deoxyribonucleic acid 
DPI dry powder inhaler 
ECD effective cut-point diameter 
ED50 median effective dose 
EDTA ethylenediaminetetraacetic acid (anticoagulant) 
EEC European Economic Community 
EMA, EMEA European Medicines Agency 
EPA Environmental Protection Agency (USA) 
xxiii 
 
EU European Union 
eRMV estimated respired minute volume  
(calculated from body weight using an algorithm) 
FDA Food and Drug Administration (USA) 
FTIH first time in humans (first clinical trial)  
GI-GOLD Global Initiative for Chronic Obstructive Lung Disease 
GRO growth-regulated oncogene 
GSD (σg) geometric standard deviation 
GSK GlaxoSmithKline 
GSK-340 GSK719340A (parent compound) 
GSK-361 GSK678361A (parent compound) 
GSK-677 GSK610677B (hydrochloride salt) 
GSK-899 GSK258899B (mesylate salt) 
HFA hydrofluoroalkane 
HOP head-out plethysmography 
HLOQ higher limit of quantification 
HPLC high performance liquid chromatography 
HLPC-
MS/MS 
HPLC with tandem mass spectrometry 
HPLC-UV HPLC with ultraviolet detection for quantification  
HPβCD 2-hydroxypropyl-beta-cyclodextrin 
HRP horseradish peroxidase 
IAM immobilised artificial membrane column 
iCBS inhalation Biopharmaceutics Classification System 
ICH International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use 
ICS/LABA inhaled corticosteroid and long-acting beta-2-agonist 
IMS industrial methylated spirits 
LLOQ lower limit of quantification 
IDe estimated inhaled dose 
IDt target inhaled dose 
IL interleukin 
IMS industrial methylated spirits 
KC keratinocyte chemoattractant 
LDH lactate dehydrogenase 
xxiv 
 
LPS lipopolysaccharide   
MALDI-MSI matrix assisted laser desorption/ionization with mass 
spectrometry imaging 
MANOVA multivariate analysis of variance  
(cited when three or more variables were analysed) 
MAPK mitogen-activated protein kinase 
MCP-1 monocyte chemotactic protein 1 
M-cell microfold cells (antigen transport/presenting cells in 
mucosal membranes) 
MHRA Medicines and Healthcare Products Regulatory 
Agency (UK) 
MMAD mass median aerodynamic diameter 
MV minute volume (measured by plethysmography) 
MVA multivariate analysis 
NGI Next Generation Impactor 
NHS National Health Service (UK) 
NICE National Institute for Health and Care Excellence (UK) 
MPO myeloperoxidase 
NIPALS Nonlinear Iterative PArtial Least Squares (reiterative 
algorithm for approximating data for MVA or PCA)  
NOAEL no observed adverse effect level, defined as the 
highest evaluated dose that does not harm the test 
animals (Kerlin et al., 2016) 
NRC National Research Council (USA) 
OECD Organisation for Economic Co-operation and 
Development 
PCA principal component analysis 
Pgp P-glycoprotein 1 
pMDI pressurised metered dose inhaler 
PSD particle size distribution 
PVDF polyvinyldifluoride 
QC quality control 
RMV respired minute volume 
RNA ribonucleic acid 
RPM revolutions per minute 
SB-323 SB-681323T (tosylate salt) 
xxv 
 
SB-445 SB-731445T (tosylate salt) 
SIMS secondary ion mass spectrometry 
TEM transmission electron microscope 
TFA trifluoroacetic acid 
TNF tumour necrosis factor 
TOF time of flight 
Tmax time to maximum (drug) concentration (Cmax) 
UAR Understanding Animal Research 
UK United Kingdom of Great Britain and Northern Ireland 
USA United States of America 
USP United States Pharmacopeia 
VDSS volume of distribution at steady state 
VDUSS unbound volume of distribution at steady state 
v/v volume for volume 
WHO World Health Organisation 
w/v weight for volume 
w/w weight for weight 
XRPD X-ray powder diffraction 
ABBREVIATIONS FOR GSK INFRASTRUCTURE 
ASD Analytical Services and Development 
BIB Bioanalysis, Immunogenicity and Biomarkers 
CPD Clinical Pathology and Diagnostics 
DDS Drug Design and Selection   
DPDD Drug Product Design and Development 
IVSD In Vivo Science and Delivery 
NCE-MD New Chemical Entity - Molecular Discovery 
MSD-ISDM Mechanistic Safety and Disposition - Investigative 
Safety and Drug Metabolism 
PDS Product Development and Supply 
PPE Product and Process Engineering 
PSE Particle Sciences and Engineering 
TBM Toxicology and Biometabolism 
TMCP Translational Medicine and Comparative Pathobiology 
xxvi 
 
GLOSSARY OF TERMS 
3Rs Replacement, reduction, refinement: fundamental 
principles for the ethical use of animals in research. 
in silico Computational models (‘in silicon [chips]’) e.g. for 
chemistry or biological properties. 
in situ Latin: “in the situation”; situated in the natural or 
original place or position 
in utero Latin: “in the uterus”; unborn. 
in vitro Latin: “within the glass”: procedures performed 
outside a living organism. 
in vivo Latin: “within the living”: procedures performed 
using a living organism. 
linear-up, log 
down 
Calculation of AUC using linear trapezoidal rule up 
to Cmax (untransformed data for drug absorption) 
and log-trapezoidal rule after Cmax (log-transformed 
data for drug elimination phase). 
Log D Distribution coefficient of ionised plus non-ionised 
forms of a compound between aqueous and organic 
phases. 
Log P Partition coefficient of a non-ionised compound 
between aqueous and organic phases. 
M1 macrophage A “classically activated” macrophage with cytotoxic, 
inflammatory and antiproliferative properties. 
M2 macrophage Macrophage with anti-inflammatory properties; 
associated with remodelling and regeneration of 
damaged tissue. 
NR8383 In vitro alveolar macrophage cell line. 
pKa, pKb Log10 of acid and base dissociation constants. 
pneumotach Cell containing thin film across which changes in air 
pressure can be measured by a transducer 
(plethysmography). 
transducer Device that converts changes in air pressure into an 
analogue signal for data capture (plethysmography). 
 
 
  
CHAPTER ONE 
General introduction
Chapter One 
2 
 
1.1. Introduction 
Ischaemic heart disease, stroke, lower respiratory infections and 
chronic obstructive lung disease (COPD) were the four major causes of 
death worldwide in 2015 (WHO, 2017), with an estimated three million 
people in the United Kingdom having COPD of whom 900,000 people 
have been diagnosed (NICE, 2010). GSK was the market leader in 
terms of revenue ($9.4 billion) from respiratory disease products in 
2015, accounting for 33.6% of this drug market (Research-Markets, 
2016). Despite the successes of pharmaceutical corporations in 
developing inhaled medicines, there is still an unmet need for 
developing new respiratory medicines, particularly in the developing 
world where general access to healthcare is poor and resources are 
limited (Aït-Khaled et al., 2001). 
1.2. The respiratory tract 
The primary functions of the respiratory tract are olfaction and gaseous 
exchange at an air-blood interface, to facilitate replenishment of 
oxygen supply for aerobic respiration and facilitate removal of volatile 
or gaseous waste products, most notably carbon dioxide (CO2). To 
facilitate gaseous exchange on the scale required to sustain large 
organisms such as mammals, reptiles and birds, a large permeable 
surface is required across which gases can readily traverse into a 
circulatory system. This represents a risk to the animal in terms of its 
internal exposure to inhaled environmental toxins, nuisance materials 
or airborne pathogens, and complex protective mechanisms have 
evolved to mitigate this. However, the functional nature of the lung also 
provides an opportunity for the deliberate and rapid exposure of a 
subject for better (anaesthetics and pharmaceuticals) or worse 
(pesticides and chemical or biological weapons). Utilising the inhaled 
route to administer drugs for the treatment of respiratory disease 
permits direct exposure of the target organ using small doses, 
particularly if drugs are designed to: 
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• have high potency, receptor affinity and protein binding 
• slowly dissociate from its target receptor 
• limit systemic exposure and hence the potential for ‘off target’ 
effects of a drug (Owen, 2013). 
Air is a relatively harsh climate and detrimental to exposed cells. A 
secondary function of the respiratory tract is therefore to condition the 
inhaled air, filtering and/or humidifying it and modulating temperature 
before it reaches the epithelial cells in the lower respiratory tract. 
The respiratory tract thus consists of two functional regions, the 
proximal conductive airways to condition inhaled air and the distal 
respiratory region for gaseous exchange (Harkema et al., 2013). The 
degree of particulate deposition in regions of the respiratory tract 
changes with particle size (Figure 1.1). There are anatomical 
differences between the respiratory tracts of mammals (Figure 1.2) with 
implications for an animal’s breathing and aerosol deposition. Key 
differences are summarised for each respiratory tract tissue. 
1.2.1. Proximal conductive airways 
The proximal conductive airways consist of the nasal cavity, pharynx, 
larynx, trachea and bronchi. The mucosa lining the conductive airways 
is very specialised, with the composition of cells in the epithelium 
changing throughout the respiratory tract to facilitate various functions. 
Nasal cavity 
The nose or snout of land-based mammals accommodate the external 
nares (nostrils), which accommodate coarse hairs (vibrissæ) to trap 
large particulates. The nares open into the nasal cavity, which contains 
ridges of bone called turbinates that project into the nasal cavity.  
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Figure 1.1: Fractional deposition of inhaled particles in humans. 
Particulate of <0.5µm or 1 to 10µm have the highest probability for deposition 
in the respiratory tract. Orally inhaled particles of ≤5 µm diameter and nasally 
inhaled particles of ≤3 µm diameter are thought to deposit in the lower 
airways of humans (NRC, 2006). Snipes (1994) reproduced with permission 
of Medical Physics Publishing, Wisconsin, USA. 
The turbinates direct inhaled air over chemoreceptors in the olfactory 
neuroepithelium, which initiate a cascade of neuronal events when 
stimulated resulting in the transmission of signals to the olfactory bulb 
in the forebrain and the perception of odours (Ressler et al., 1993). The 
nasal turbinates, which increase the surface area in the nasal cavity, 
are also an air conditioner (humidifying air and regulating temperature) 
and protect the delicate lung parenchyma by trapping inhaled 
particulates, absorbing water-soluble or reactive gases/vapours and 
metabolising xenobiotics (Harkema et al., 2013). The complexity of the 
turbinates vary considerably between macrosmatic species (animals 
with highly developed olfaction) such as dogs, rodents and rabbits, and 
microsmatic species (animals with poor olfaction) such as primates 
(Lewis and McKevitt, 2013). 
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1.2A: human 
 
 
1.2B: rodent 
 
Figure 1.2: Diagrammatic representation of the human and rodent 
respiratory tracts. Dots along the laryngeal and tracheobronchial airways 
indicate intramural cartilage. 1.2A: human respiratory tract; breathing is 
nasally or orally, particularly with increased activity. 1.2B: rodent respiratory 
tract. Rodents are obligate nasal breathers and their nasal turbinates are 
more convoluted than those of humans. Harkema et al. (2013) reproduced 
with permission of Elsevier. 
Primates, cats and dogs readily breathe orally or nasally. However, 
prey species including rodents, rabbits, deer and equine species have 
evolved to breath nasally (Lewis and McKevitt, 2013, Negus, 1927) 
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concurrently with grazing, in order to detect predators in their blind spot 
and to smell poisonous plants not visible to their laterally placed eyes 
during grazing (Negus, 1927). Obligate nasal breathing has 
implications for the deposition of aerosols in the respiratory tract of 
such prey species, including pigs (Larson and Herring, 1996, Moon and 
Smith, 1996, Jones et al., 2001), with a higher proportion of particulate 
retained in the nasal cavities. 
Pharynx 
The pharynx is cartilaginous and connects the nasal and oral cavities 
to the larynx; regions of the pharynx adjacent to these cavities are 
referred to as the oropharynx and nasopharynx respectively. The 
nasopharynx makes a downward bend as it progresses from the nasal 
cavity to the larynx, which varies for the natural posture of the animal. 
This bend is gradual in animals of a pronograde (horizontal) posture, 
such as rats (15º) and dogs (30º), and sharper in species of an 
orthograde (upright) posture such as the rhesus monkey (80º) 
(Schreider and Raabe, 1981). 
Larynx 
The larynx is cartilaginous and connects the pharynx to the trachea. 
The glottis, the mid-section of the larynx, accommodates the vocal 
chords necessary for phonation. A key anatomical difference between 
species is the topography of the laryngeal diverticula (pouches), which 
are bilateral in dogs and primates and ventral in rodents; the function is 
unclear but the pouches may amplify vocalisations in some species 
(Lewis and McKevitt, 2013). 
The epiglottis is a cartilaginous structure at the anterior end of the 
larynx, and is generally more developed in macrosmatic species 
(species with highly developed olfaction) and deficient in microsmatic 
species (animals with poor olfaction). In obligate nasal breathers, the 
epiglottis seals the oral cavity ensuring inspired air enters via the nares 
and passes over the olfactory (Negus, 1927). 
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Trachea and bronchi 
The trachea is a conducting airway from the larynx to the carina, a 
ridge of cartilage where the airway bifurcates into two mainstem 
bronchi (Figure 1.2A), which in turn divide into smaller bronchi. This 
branching of airways is dichotomous in humans but monopodial in 
most mammalian species in which daughter branches are of unequal 
diameter (Harkema et al., 2013). 
U-shaped cartilaginous rings incorporated into the lateral and ventral 
walls of the trachea maintain an open airway; the dorsal wall consists 
of flexible fibroelastic and smooth muscle. The walls of the tracheal, 
bronchi and bronchioles consist of three layers, the mucosa (mucus 
membrane), submucosa (connective tissue) and the adventitia (loose 
connective tissue securing the airway to adjacent lung tissue). Smooth 
muscle between the mucosa and submucosa contracts and relaxes to 
constrict and dilate the respiratory airways respectively. 
The cellular composition and thickness of the mucosa (pseudostratified 
respiratory epithelium) lining the lumen of the airways changes greatly 
from the proximal to the distal regions (Figure 1.3). The trachea 
consists of tall columnar ciliated cells, which progresses to cuboidal 
cells in the bronchioles and a thin squamous epithelium in the alveoli. 
Although the proportion of ciliated cells in the respiratory epithelium is 
consistent across species, differences are seen in the relative 
dimensions of the airways and the composition of other cell 
phenotypes. For example, the thickness of the epithelium at the 
trachea in humans is three times that of monkeys and ten times that of 
rodents (Harkema et al., 2013). 
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Figure 1.3: Comparison of the human respiratory epithelium at different 
lung locations. Epithelial cells from three regions of human lung are drawn 
to scale. As airborne particles penetrate deeper into the lung, the epithelium 
becomes thinner. A 2 μm diameter particle typically contains hundreds of 
millions/billions of small molecules depending on whether it is a liquid droplet 
or solid particle. Solid particles are too large to be absorbed directly and must 
first dissolve to release their drug(s) for absorption. The dark orange colour in 
the figure represents the liquid layer, which gets progressively thinner as the 
airways become narrower until the thickness is <0.1 μm at the alveoli. The 
bronchial epithelium is constituted of basal cells (stem or progenitor cells for 
the epithelium that differentiate to form other cells in the event of injury or 
apoptosis), ciliated cells (facilitate migration of the mucus blanket), goblet 
cells (secrete mucous) and brush cells (involved in drug metabolism). These 
cell types persist in smaller airways but are shorter. The basal lamina is an 
extracellular matrix of various biopolymers to which the epithelial cells are 
attached. Adapted from Patton and Byron (2007) and reproduced with 
permission of the Nature Publishing Group. 
Ciliated cells are the most common cell phenotype in the respiratory 
epithelium of mammals and, together with secretory cells, facilitate 
mucociliary clearance of foreign materials including particles and 
bacteria. The synchronised cilia (12 to 15 beats/second; 200 to 300 
cilia/cell) move the mucous blanket towards the oesophageal opening 
at the larynx, where the material is constantly swallowed (Harkema et 
al., 2013). The mucous blanket lines the airways and contains mucins 
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(glycoproteins), to form a gel-like fluid, and surfactants (mainly 
phospholipids) to reduce the surface tension and prevent airway 
collapse during exhalation. Both components also interact with viruses 
and pathogens respectively as part of the innate immune system to 
enhance macrophage and neutrophil responses (Lewis and McKevitt, 
2013). This layer is therefore an important physical barrier for trapping 
and facilitating removal of airborne particulates and pathogens. 
Brush cells are uncommon in the respiratory epithelium but are found 
in the nasal and tracheobronchial epithelia. With chemoreceptors and 
basolateral contact with neurones, they appear to have a sensory role. 
There are three key types of secretory cell in the respiratory epithelium: 
• Mucous cells are the most common phenotype in the 
tracheobronchial airways of primates and dogs, but are 
restricted to the trachea and extrapulmonary bronchi of healthy 
pathogen-free rodents. These cells secrete the epithelial lining 
fluid containing glycoproteins (mucins), lipids, proteins and salts, 
a protective layer that moisturises and lubricates the airway. 
Exposure to irritants increases mucous production and, with 
repeated insult, may result in hyperplasia, an abnormal increase 
in the number of these cells (Harkema et al., 2013). 
• Club cells are found mainly in the terminal bronchioles of 
primates but are the primary secretory cell throughout the 
tracheobronchial airways of mice. The cells secrete proteins 
including the club cell secretory protein (CCSP; 10 kDa in size) 
and surfactants into the epithelial lung fluid. The cells also 
metabolise xenobiotics through cytochrome P450-dependent 
mixed-function oxidases and are progenitor cells for ciliated and 
other secretory cells (Harkema et al., 2013). 
• Serous cells are the predominant secretory cells in the trachea, 
extending to proximal intrapulmonary bronchioles of rats. They 
also occur in rodent nasal airways and human bronchi. Serous 
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cells produce mucous, antibacterial agents and lactoferrin, an 
iron-binding glycoprotein that degrades viral RNA as part of the 
innate immune system (McCormick et al., 1974). 
1.2.2. Distal respiratory region (lungs) 
The anatomical organisation of lungs into lobes varies significantly 
between species, with the lungs of non-human primates divided into six 
lobes (two off the left bronchus and four off the right bronchus). In rats, 
the left lung is a single lobe and the right lung consists of four lobes 
(Lewis and McKevitt, 2013). The upper airways in the lungs also 
contain several generations of non-respiratory bronchioles (conducting 
airways lacking alveolar ducts). The distal respiratory region, located in 
the lungs, consists of respiratory bronchioles, alveolar ducts and 
alveolar sacs, with the alveolar parenchyma (functional tissue) 
presenting a large surface area for gaseous exchange with the 
perfusing blood. 
Respiratory bronchioles are poorly ‘alveolised’ and form the transitional 
airways between the non-respiratory bronchioles and the lung 
parenchyma. Several generations of respiratory bronchioles are seen 
in dogs and primates and are absent or present as a single generation 
in rodents and rabbits (Harkema et al., 2013). 
The lung parenchyma is approximately 90% of the total lung volume in 
mammals. An intricate clustering of alveoli (sacs), supported by the 
interstitium (mainly fibroblasts), optimises the surface area generated 
within the lung volume. The human lung contains approximately 500 
million alveoli, equating to a surface area of 100 square meters. The 
ratio of surface areas for the alveolar and capillary lumens is near 
parity, with a mean separation between the two surfaces of just 0.4 µm 
in rats and 0.6 µm in humans facilitating efficient gaseous exchange. 
Alveoli are composed of two cell types: 
• Type I pneumocytes, a water-tight but gas-permeable 
membrane of thin cells lining 95% of the alveolar air space; 
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• Type II pneumocytes cells produce, store and secrete alveolar 
secretions and regulate the composition and volume of the fluid 
in the lumen. In addition, these cells replenish damaged Type I 
pneumocytes (Harkema et al., 2013).  
The air in the alveolar sacs is ventilated tidally, with expansion and 
contraction of the lungs facilitated by movement of the diaphragm and 
ribcage. Gases diffuse across the thin epithelium from a higher 
concentration to a lower one, such that the haemoglobin in 
erythrocytes becomes re-oxygenated and CO2 diffuses into the 
alveolar airspace. The waste air is then vented (exhaled) and 
replenished with inhalation of fresh air. 
1.2.3. Macrophages 
Macrophages play a protective role as part of the innate immune 
system in the lung. They also play a key role in clearance of particles 
from the alveolar spaces of lungs, and migrate towards deposition sites 
and phagocytosed particles (Warheit and Hartsky, 1993). 
Macrophages in the interstitium are derived from haematopoietic stem 
cells in the bone marrow and migrate to the lungs via the circulatory 
system (Geiser, 2010). Once in the interstitium, they phagocytose 
particulates that crossed the epithelium, or move into the alveolar 
space and differentiate to form alveolar macrophages. Although 
alveolar macrophages typically differentiate from circulating monocytes 
after migration into the alveoli, they undergo extensive proliferation in 
situ as part of an inflammatory response mediated by T-helper Type 2 
cells (Murray and Wynn, 2011).  
Activated macrophages can be classed as “classically activated” (M1), 
with inflammatory, cytotoxic and antiproliferative properties, and 
“alternatively activated” (M2), which are anti-inflammatory and involved 
in remodelling and regeneration of damaged tissue. A macrophage can 
change between the M1 and M2 states depending upon the stage of 
the inflammatory or disease process (Lewis and McKevitt, 2013, 
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Murray and Wynn, 2011). Although much has been published about 
the activation state of macrophages in relation to immune function 
(Martinez and Gordon, 2014, Mosser and Edwards, 2008), the 
relationship between activation state and the endocytosis of drug 
particles is unclear. The time taken for macrophages to endocytose 
particles is fast but differs between species. Approximately 50% to 75% 
of particles are typically endocytosed within 2 to 3 hours of particle 
deposition, ≥90% by 10 hours and nearly 100% at 24 hours (Geiser, 
2010). This has potential implications for inhaled medicines and their 
duration of action, since particles endocytosed by alveolar 
macrophages are compartmentalised, potentially impeding modulation 
of the target pharmacology. 
Alveolar macrophages may leave the lung via mucociliary clearance, a 
key mechanism for clearance of inhaled particles, or transepithelial 
migration and subsequent movement into the lymphatic system. The 
latter route facilitates presentation of particles to dendritic 
(macrophage-like) cells specialised for antigen presentation (Lewis and 
McKevitt, 2013). The clearance time for macrophage-associated 
particles is relatively short in conducting airways (24 to 48 hours; 
primarily via muciliary clearance) and longer from the alveolar region 
(weeks to months). However, the time taken for macrophage clearance 
is species dependent; quickest in rodents and sheep but slower for 
primates, dogs and guinea pigs (Geiser, 2010). 
1.3. Drug delivery devices 
The origins of inhaled therapies are most likely ubiquitous and date 
back at least 4000 years. The smoking of herbal preparations to treat 
respiratory diseases represents early attempts to target the drug at the 
diseased tissue. Ayurvedic therapies (India circa 2000 BC) included 
smoking Datura species containing potent alkaloids with anticholinergic 
bronchodilatory effects. Pipes (circa 1500 BC) for smoking tobacco and 
other herbal products were also found in Central and South America 
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(Anderson, 2005). Egyptian papyrus scrolls (circa 1554 BC) 
documented a method for smoking the fumes of black henbane 
(Hyoscyamus niger, which contains the muscarinic antagonist atropine) 
over a hot brick (Stein and Thiel, 2017) and described inhaled 
administration of nasal snuffs and vapours (Shehata, 2008). 
Circa 400 BC, Hippocrates was credited with the design of an early 
inhaler consisting of a pot with a reed in the lid through which a patient 
could inhale the vapour (Anderson, 2005). However, little changed in 
respiratory medicine until the industrial revolution (1760), when new 
manufacturing processes and technical discoveries radically changed 
drug delivery. Previously, the inhaled drug was prepared by the 
physician or patient. With industrial practices, inhalers and medicines 
were mass produced remote from patients. Techniques developed to 
isolate active ingredients also enhanced the potency and safety of 
inhaled drugs. An English physician first described the “inhaler” for 
administration of opium to treat cough (Mudge, 1779); the device was a 
pewter tankard with an adapted lid incorporating a tube and valve 
through which the patient could inhale and exhale a steamed vapour 
(Anderson, 2005, Stein and Thiel, 2017).  
Further innovations followed in the latter 1800s, with invention of the 
atomiser to disperse liquids as a fine spray, and then its modification to 
produce the nebuliser, an atomiser incorporating baffles to remove 
large non-respirable droplets (Nikander and Sanders, 2010). During 
this time, the first dry powder inhalers (DPIs) were developed and 
“asthma cigarettes” containing stramonium (from Datura stramonium), 
tea leaves, belladonna (contains atropine), kola nuts (contain caffeine) 
and lobelia (contains a toxicant similar to nicotine) were 
commercialised (Stein and Thiel, 2017). The revolution in modern 
inhaler design came in 1955, when Riker Labs (now 3M Drug Delivery 
Systems) developed the pressurised metered dose inhaler (pMDI) and 
launched the first pMDI-drug formulation in 1957 (Anderson, 2005). 
However, despite the development of hydrofluoroalkane (HFA) 
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propellants to replace the chlorofluorocarbon (CFC) propellants phased 
out by implementation of the Montreal protocol in 1989 (to safeguard 
against depletion of the ozone layer), initial uncertainty regarding the 
future of pMDIs prompted the modern development of DPIs (de Boer et 
al., 2017). Nevertheless, the pMDI remains the predominant inhaler 
representing 80% of the global market for inhaled medicines (Telko 
and Hickey, 2005). 
Today, nebulisers, pMDIs and DPIs are the devices commonly used for 
administering inhaled drugs. There are advantages and disadvantages 
for each of these devices and selection of the drug and inhaler device 
depends upon the clinical application, the cognitive and physical ability 
of the patient (Geller, 2005) and the available drug-inhaler products of 
pharmaceutical companies. 
Many inhaled medicines are packaged into an inhaler, such as the 
pressurised metered dose inhaler (pMDI; Figure 1.4A) or a dry powder 
inhaler (DPI; Figure 1.4B). These portable devices are designed to 
dispense a fixed mass of drug that is inhaled by the patient within a few 
seconds. A pMDI contains a propellant that expels the aerosol when 
actuated by the patient. This requires considerable training by the 
patient to coordinate the actuation of the pMDI with their inspiratory 
flow. Whilst 40% to 60% of COPD patients adhere to the prescribed 
dosing regimen, just 10% of patients using pMDIs were able to perform 
all essential steps correctly; the most common error was failure to 
continue inhaling slowly after actuation of the pMDI (Restrepo et al., 
2008). Whist a poor technique can be mitigated by using a spacer, a 
small chamber from which the expelled dose can be inhaled 
(recommended for children), these spacers are more bulky and 
unpopular with many adults.  
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Figure 1.4: Clinical inhalers and a nebuliser for dosing patients. 
1.4A: pressurized metered dose inhaler (pMDI). 1.4B: dry powder inhaler 
(DPI). 1.4C: nebuliser. Image c/o Understanding Animal Research, UK. 
DPIs are generally easier to use than pMDIs because they are breath 
activated (Geller, 2005) and few patients develop a poor technique with 
chronic use. However, the peak inspiratory flow necessary to achieve a 
therapeutic effect is critical and DPIs cannot be used with spacers 
(Crompton, 1991). This is a disadvantage of some DPIs (inspiratory 
flow of 50 to 60 L/min) and patients achieving a low inspiratory flow 
rate, such as young children or COPD patients (Ashurst et al., 2000); 
17% of COPD patients in a study achieved an airflow of ≥40 L/min 
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(Dewar et al., 1999). DPIs utilising powder doses from foil blister packs 
are resistant to high humidity and offer advantages over capsule-based 
DPIs for stability and dose delivery of the drug formulation in tropical 
climates. 
Nebulisers are less portable, often requiring a pump or sonic device to 
generate a compressed air supply (Figure 1.4C) but can deliver higher 
doses than pMDIs or DPIs (Geller, 2005). The continuous delivery of a 
nebulised aerosol is better suited to rescue therapies, and nebulisers 
are typically used by paramedics on location, or at home or in 
healthcare centres to administer drugs over a longer dosing period.  
1.4. Challenges in non-clinical lung delivery and 
respiratory drug development 
Drug discovery and development are very time consuming and 
resource intensive processes. Estimates of the cost and time required 
to release a new drug onto the market vary, with seven to 12 years at a 
cost of $1.2 billion cited by Shankar et al. (2006) and an estimate of 
$0.87 to $2.0 billion by Adams and Brantner (2006). Just five in 40,000 
compounds tested in animals reach clinical (human) trials, of which just 
one eventually reaches the market (Kapetanovic, 2008). The 
pharmaceutical industry is under increasing pressure to reduce the 
cost of developing new drugs. Reducing the attrition of drug 
development programmes (increasing the success rate) and 
terminating non-viable assets sooner are two strategies for achieving 
this goal. Reducing the cost and resources to support non-clinical work 
is attractive if cost effective, and the use of surrogate formulations or 
administration routes to reduce compound usage in early drug 
development and thereby expedite preliminary evaluation of inhaled 
drugs in humans is sometimes proposed. However, such strategies 
defer de-risking potentially altered tolerability or toxicopathology of the 
final formulation and/or dose route until after the commitment of 
significant resources in support of the clinical development programme. 
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To improve patient compliance in treating chronic pulmonary diseases 
such as asthma and COPD, attempts have been made to simplify 
medication initially by combining drug products, and then by reducing 
the frequency of administration to the minimum. To this end, once daily 
dosing using inhalers have been evaluated (Buhl et al., 2003, Cazzola 
and Matera, 2008). A clinical trial with 10,355 patients administered 
Trelegy Ellipta, the only FDA-approved once-daily triple therapy 
(containing an inhaled corticosteroid, a long-acting muscarinic 
antagonist and a long-acting beta2-adrenergic agonist) indicated a 
reduction in COPD exacerbations (RNS-LSE#1, 2017, RNS-LSE#2, 
2017), i.e. the worsening of disease often associated with infection. 
Reducing the frequency of administration can be achieved through a 
variety of mechanisms to prolong the duration of action including:  
• very low solubility (e.g. inhaled corticosteroids like fluticasone 
propionate for treatment of asthma); 
• tissue retention due to hydrophobicity (e.g. salmeterol, a 
long-acting β2-adrenergic receptor agonist) or positively charged 
moderately lipophilic molecules (e.g. verapamil for treatment of 
hypertension); 
• particle engineering with excipients to slow the dissolution rate. 
Hydrophobic molecules can be absorbed rapidly into the systemic 
circulation and away from the lungs, consequently eliciting short-lived 
efficacy at target receptors within the respiratory tract. Strategies to 
slow absorption or prolong lung retention are thus attractive for treating 
chronic respiratory disease (Patton and Byron, 2007). 
Many inhaled drugs have been developed as dry powder formulations, 
notably as micronised crystals, to prolong physical stability and 
improve the control of clinical drug delivery (Crompton, 1991). In 
addition, inhaled drugs of relatively low aqueous solubility have been 
developed to limit systemic exposure after inhaled administration and 
to extend the duration of action for a single dose by slowing dissolution 
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of a drug in the lungs. A consequence of such drug design is the 
accumulation of undissolved drug in the lower respiratory tract with 
repeated administration, especially at higher doses typically employed 
in non-clinical toxicology studies conducted for safety assessment of 
inhaled molecules (Jones and Neef, 2012), with implications for the 
potential impairment of lung function (Fröhlich, 2017). 
In the twentieth century, many published studies investigating 
respiratory tract clearance were conducted using inhaled particles 
containing radionuclides, in which the reported data pertained to both 
clearance of the administered particles and also any radionuclides that 
became dissociated following lung deposition (Cuddihy and Yeh, 
1988). Adaptive lung changes and adverse lesions associated with 
lung burden have also been described in detail for nuisance 
particulates, e.g. minerals (Pauluhn, 2008), environmental pollutants 
(Miller, 2000) and pigments (Lee et al., 1986), the mechanisms of 
which are independent of pharmacology-mediated toxicology. 
However, little has been published about the toxicopathology of inhaled 
pharmaceuticals. 
1.4.1. Regulatory testing of drugs 
The development of drugs as dry powder formulations for treatment of 
respiratory diseases has presented significant challenges. This is in 
part due to a relatively narrow therapeutic index, i.e. the multiple of the 
clinical dose in humans to the no observed adverse effect level 
(NOAEL), established from in vivo toxicity studies in animals; the 
NOAEL is the highest evaluated dose that does no harm to the test 
animals (Kerlin et al., 2016). Regulatory authorities apply factors for 
safety margins between the animal NOAELs and human doses. The 
United States (US) Food and Drug Administration (FDA) arguably 
applies the most conservative margins for inter-species differences in 
lung deposited dose, by assuming 10% and 25% of an aerosol are 
deposited in the lungs of rats and dogs respectively, and assuming 
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100% of a clinical dose is retained in the lungs of humans. The 
publication of Snipes (1989), upon which these margins are believed to 
be based, is generally in line with the lung deposition fractions for 
animals but not humans (25% and 40% for nasally and orally inhaled 
aerosols of 2µm aerodynamic diameter respectively). An additional 
margin of 10-fold for rats and 6-fold for non-rodents is applied for 
unmonitorable findings (Lewis and McKevitt, 2013, Owen, 2013, 
Forbes et al., 2011, Jones and Baldrick, 2013) such as 
histopathological lung changes in animals that lack a clinical marker for 
humans. Taken together, the applied safety margins applied to 
therapeutic indices are 100-fold in rodents and 24-fold in non-rodents. 
Regulation of non-clinical drug development has often been prompted 
by tragedies resulting in the death or suffering of humans (Kille, 2013), 
which identified gaps in the scientific knowledge and/or practices of the 
day. Regulatory agencies were initially founded by sovereign states to 
safeguard their citizens against consumer products. The FDA was 
founded in the USA in 1930 but can trace its origins back to the US 
Patent Office circa 1848 and its chemical analysis of agricultural 
products. In 1906, the “Pure Food and Drugs Act” prohibited the 
interstate trade in adulterated or misbranded food and drugs (FDA, 
2017). The requirement for pre-market testing of pharmaceuticals as 
evidence of safety for new drugs was first enacted in the “Federal 
Food, Drug and Cosmetic Act” of 1938 (Kille, 2013). 
Regulation of pharmaceuticals in the United Kingdom (UK) has similar 
origins to that in the USA; the “Adulteration of Food and Drugs Act, 
1860” and the “Sale of Food and Drugs Act, 1875” were passed during 
the industrial revolution in response to industrialists infuriated by high 
absenteeism due to the consumption of adulterated foods. The Society 
of Public Analysts was founded after revision of the “Adulteration of 
Food and Drugs Act, 1872” made provision for the appointment of 
public analysts. Whilst the “Food and Drugs Act, 1938” introduced 
penalties for false or misleading labelling and advertising, it was not 
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until the “Medicines Act, 1968” that control of drugs for clinical and 
veterinary use were legislated separately to food (Dawson, 2014). This 
legislation followed outcry over birth defects after prescription of 
thalidomide to pregnant mothers in the late 1950s and early 1960s to 
alleviate morning sickness. To prevent reoccurrence of such a tragedy, 
the Committee on Safety of Drugs was established in 1963 and was 
superseded by the Committee on Safety of Medicines in 1968 and the 
Commission on Human Medicines in 2005 (MHRA, 2012). 
There are two key elements to drug regulation. Firstly, there are 
guidelines outlining the data requirements necessary to support an 
application for the licenced marketing of a drug. Historically, these 
guidelines were implemented by each agency responsible for the 
control of drugs in the respective country. The harmonisation of 
guidelines was pioneered in Europe during the late 1980s with 
progression of the common market. During this period, the 
pharmaceutical industry and regulators for the three major 
pharmaceutical markets (USA, Europe and Japan) also discussed 
harmonisation of requirements for testing pharmaceuticals, with a view 
to eliminating unnecessary duplication of work, and ultimately reducing 
the resources, time, cost and number of animals required to bring 
drugs to various pharmaceutical markets (Jones and Baldrick, 2013). 
Since its inception in 1990, the International Council for Harmonisation 
of Technical Requirements for Pharmaceuticals for Human Use (ICH) 
has developed and maintained guidelines to generate comprehensive 
datasets to satisfy regulatory requirements for global licencing of drugs 
(ICH, 2017). Experimental protocols based on this guidance continue 
to evolve within pharmaceutical companies and contract research 
organisations to fulfil the regulatory obligations and accommodate the 
bespoke requirements of drug development programmes. 
Secondly, there is a formal review of the data submission undertaken 
by a regulatory agency responsible for the market in question. This 
review includes characterisation of the drug product, hazard evaluation 
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(toxicology) and a complex risk assessment including consideration of 
toxicity observed in animals, the likelihood of an adverse outcome 
occurring in patients at anticipated doses, and a risk-benefit analysis of 
the potential side effects verses therapeutic prognosis of the disease. 
Each nation is responsible for the regulatory approval and licensing of 
drugs administered to its resident population. In 1965, the European 
Economic Community mandated that “No proprietary medicinal product 
may be placed on the market in a Member State unless an 
authorisation has been issued by the competent authority of that 
Member State” (EEC, 1965), and this passed into British law with the 
“Medicines Act, 1968”. With funding from the European Union (EU), 
member states and the pharmaceutical industry, the European 
Medicines Agency (EMA) was founded in 1995 to harmonise the 
national medicine regulatory agencies of EU member states (EMA-1, 
2017). Drawing on the resources of the regulatory agencies of member 
states, approval of new medicines for licensing in the European 
Economic Area (EEA) was facilitated under a reciprocal agreement 
without the need to obtain regulatory approval from each agency, 
reducing the cost of approving a new drug across the EEA and the time 
taken to prescribe new drugs to European patients. Following the UK 
announcement to leave the EU on 30-Mar-2017, implications for the 
reciprocal agreements between the Medicines and Healthcare 
Products Regulatory Agency (MHRA, UK) and the EMA or a need for 
duplicate reviews are unknown (Gulland, 2016, EMA-2, 2017). 
Nevertheless, the legal requirement for licensing new drugs will persist. 
1.4.2. Animal models for investigating efficacy 
Unlike non-clinical safety studies, there are no regulatory guidelines for 
animal models used to predict potential clinical efficacy per se. Animal 
models must be relevant to mechanism(s) of interest in patients. 
However, interspecies differences may present limitations for disease 
models such as asthma, which does not spontaneously develop in 
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laboratory species. Consequently, most animal ‘asthma models’ 
targeting the T-helper cell Type 2 response first require sensitisation of 
the species to an allergen that is subsequently used to challenge the 
airways and provoke an allergic response (Zosky and Sly, 2007). 
Development of suitable animal models may be hampered if the 
aetiology of the human disease is poorly understood; various animal 
models developed for pulmonary fibrosis mimic some but never all of 
the features of human idiopathic pulmonary fibrosis (Moeller et al., 
2008). Additional models may be technically challenging and costly, 
such as induction of a COPD-like disease in rodents after repeated 
inhaled administration of cigarette smoke. Underexposure of rodents to 
cigarette smoke may result in development of minimal disease or 
overexposure may result in effects associated with non-specific particle 
overload (Wright et al., 2008). Researchers may therefore use a model 
to demonstrate engagement of a relevant mechanism in healthy 
animals, such as inhibition of inflammation, instead of using a disease 
model per se. Pre-clinical models are initially based upon available 
scientific literature or unpublished data, validated for novel 
pharmacological targets and may also be adapted for project 
requirements. 
1.4.3. Animals and ethics in scientific research 
The use of animals in scientific research was essential to our 
understanding of diseases and underpinned major advances in modern 
medicine including development of vaccines, medicines, blood 
transfusion and dialysis, organ transplants and surgical procedures. 
Nevertheless, since domestication of dogs 15,000 years ago (Driscoll 
et al., 2009), humans have shared an emotional attachment to 
companion animals (Dotson and Hyatt, 2008) and the use of animals in 
scientific research is consequently an emotive and contentious topic. 
Scientists have a moral obligation to use alternative investigations to 
animal experiments where possible (replacement), to design 
experiments that minimise the number of animals and/or licensed 
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procedures required to achieve the scientific objectives (reduction) and 
to use appropriate humane endpoints (Morton, 1999) to minimise the 
potential for suffering or distress (refinement). These concepts, known 
as the “3Rs”, were first described by Russel and Burch (1959) and are 
now fundamental to the ethical review process and regulation of in vivo 
experiments (Festing and Wilkinson, 2007). Whilst the EU ban on the 
animal testing of cosmetic products and marketing cosmetics tested on 
animals (Pauwels and Rogiers, 2007) represented a significant 
milestone in the application of the 3Rs, the complexity of respiratory 
drug delivery and the biological responses of intact animals to 
pharmaceuticals are such that the most complete assessment of 
pulmonary drug delivery, efficacy and toxicity is currently achieved in 
vivo (Fernandes and Vanbever, 2009, Holländer, 1988). 
The “Cruelty to Animals Act, 1876” passed by the UK parliament was 
the world’s first legislation to set limits and instigate licensing for use of 
animals in scientific research. It was superseded by the “Animal 
(Scientific Procedures) Act, 1986” (A(SP)A), which probably represents 
the most stringent control of animal experimentation in the world 
(Wells, 2011). The act governs all scientific research in the UK using 
species of vertebrate (excluding humans) or cephalopod (Home Office, 
2013), and outlines legal implications for scientists performing 
procedures in breach of licences for the named establishment, project 
and individual operator. 
Statistics published annually by the UK Home Office are the most 
comprehensive dataset for animal research in the world and facilitate 
monitoring of trends in the numbers of animals used in the UK. Recent 
increases in animal procedures are mainly attributable to the creation 
and breeding of genetically altered animals, which accounted for 49% 
of procedures in 2016 (Figure 1.5A). Conversely, the number of 
experimental procedures in normal animals has declined steadily since 
1987 (UAR, 2017), most of which were performed in rodents 
(Figure 1.5B). 
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1.5A: Total procedures by purpose 
T o ta l p ro c e d u re s  =  3 .9 3 2  m ill io n
C re a t io n /b re e d in g  o f
G A  a n im a ls  (4 8 .5 8 % )
P u re  re s e a rc h  (2 8 .4 8 % )
R e g u la to ry  (1 3 .5 3 % )
T ra n s la tio n a l/a p p lie d
s tu d ie s  (8 .6 7 % )
O th e r  (0 .7 4 % )
 
1.5B: Experimental procedures by species 
T o ta l p ro c e d u re s  =  2 .0 2 8  m illio n
M ic e  (6 0 .1 7 % )
F is h  (1 4 .1 5 % )
R a ts  (1 1 .7 9 % )
B ird s  (7 .4 0 % )
O th e r (5 .6 2 % )
H o rs e s  (0 .4 4 % )
D o g s  (0 .2 4 % )
N H P s  (0 .1 8 % )
C a ts  (0 .0 1 % )
S p e c ia lly  p ro te c te d :
 
Figure 1.5: Total procedures performed in Great Britain during 2016 
(Home Office, 2017). 1.5A: total procedures shown by purpose. 1.5B: total 
experimental procedures shown by species (excludes creation or breeding of 
genetically altered animals); NHP = non-human primates. 
The UK Home Office does not capture data in sufficient detail to 
indicate the use of animals by therapeutic areas in drug development 
or the exposure routes used for dose administration. The number of 
animals used to support development of a drug depends upon the 
therapeutic indication (e.g. short-term “rescue therapy” or long-term 
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treatment of chronic disease), differences between laboratory protocols 
or project plans, and the conventional or bespoke experiments required 
to address liabilities or further characterise results. Nevertheless, 
unpublished corporate guidance for drug development suggests at 
least 3000 animals are required to assess the non-clinical safety of a 
drug developed for chronic administration to humans. With just one in 
8,000 drugs tested in animals progressing to clinical trials 
(Kapetanovic, 2008), pharmaceutical companies are adapting 
experimental designs to minimise animal use in research (Figure 1.6). 
 
 
Figure 1.6: Refinement of drug development programmes to reduce 
animal use associated with drug attrition due to adverse lung pathology. 
Review of attrition for inhaled drugs in the GSK portfolio indicated detection of 
adverse lung pathology increased significantly when administered to animals 
for 28 days or longer. Adaption of non-clinical safety programmes to include a 
‘translational’ rat study designed to discharge this liability reduced animal 
usage by 211 rats and 36 non-rodents if adverse pathology developed over 
28 days of treatment. Key: GLP = Good Laboratory Practice (audited studies 
for regulatory submission); FTIH = first time in humans; NR = non-rodents; 
m/f = male/female 
point at which detection of adverse lung pathology is likely; subsequent 
studies assessing chronic, reproductive or immuno-toxicology, carcinogenicity 
or other endpoints are unlikely to be impacted by unforeseen lung toxicity. 
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Use of alternative dose forms and delivery platforms, e.g. nebulised 
solutions, are sometimes proposed to circumvent problems in early 
drug development, such as potentially time-consuming salt selection 
programmes or scaling-up chemical synthesis of sufficient drug for 
inhaled administration of dry powder formulations to animals. Although 
such an approach expedites preliminary evaluation of a drug in 
humans, this must be weighed against potential failure to discharge the 
risk of tolerability or toxicopathology of the final formulation resulting in 
use of additional animals. For example, if a drug was to be marketed 
as a dry powder inhaler product but early development of the drug was 
expedited using a nebulised solution to support “first time in humans”, 
nebulised delivery would also be applied during the non-clinical studies 
using approximately 265 animals (Figure 1.6). A preliminary bridging 
study using the final dry powder formulation would subsequently be 
undertaken using rodents by default, or the non-rodent species if more 
sensitive to the observed toxicopathology. If this bridging study (circa 
56 rats or 6 non-rodents) identified adverse lung toxicopathology 
precluding development of a viable medicine, the ‘expedited strategy’ 
would arguably represent unnecessary use of 194 to 310 additional 
animals and exposure of healthy human volunteers when compared to 
evaluation of the dry powder formulation using GSK’s ‘translational’ 
approach. Increased understanding of the implications of changing 
aerosol form will thus inform decisions in early drug development 
programmes and ensure best practice in line with the 3Rs for 
non-clinical safety assessment of inhaled drugs. 
All animal studies performed in support of this thesis were ethically 
reviewed and performed in accordance with the UK Animals (Scientific 
Procedures) Act 1986 and the GSK Policy on the Care, Welfare and 
Treatment of Animals. 
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1.4.4. Exposure of animals to inhaled materials and 
common practices in drug development 
Non-clinical studies performed to characterise the general toxicology 
(and ideally efficacy) of a candidate drug typically administer 
compounds via the most clinically relevant route, i.e. the exposure 
route anticipated for dosing humans. Whilst the precise administration 
of a drug to animals by injection or orally (by intubation of the stomach) 
is relatively simple, inhaled administration presents considerably more 
technical and logistical challenges. 
Selection of species in regulatory studies is often based upon guideline 
requirements for non-clinical safety, availability of historical baseline 
data, and the biological relevance of a species to humans. Animals 
must also be small enough to permit handling and inhalation exposure 
in sufficient numbers for the experiment, and large enough for 
measurement of the endpoints required to achieve the objectives. 
Development of new animal models for inhaled delivery is slower than 
for other exposure routes, not least because of the relatively small 
number of inhalation studies published and difficulties in engineering 
solutions for handling and exposing alternative species (Pauluhn and 
Mohr, 2000). The rat is the most commonly used rodent for non-clinical 
inhalation toxicology studies, with mice normally considered as a 
second rodent species for evaluation of carcinogenicity, or as a 
preferred alternate rodent species if the aetiology of toxicity observed 
in rats indicates the mouse is a more relevant species in comparison to 
humans, for example if metabolic or anatomical differences lead to 
toxicity. Historically, dogs and non-human primates were used as 
non-rodent species for inhalation toxicology studies. Since these 
species are specially protected under the EU and A(SP)A legislation, 
there is increasing pressure to consider the minipig as a non-rodent 
species for inhalation toxicology studies. Whilst the capability has been 
developed by at least one research organisation, no respiratory drug 
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development programmes to date have used the minipig as the 
non-rodent species. 
Investigation of the effects of airborne materials (aerosols, vapours and 
gases) on animals dates back at least 150 years (MacFarland, 1983), 
with development of head-only exposure of animals first described 
almost 70 years ago (Princi et al., 1949). Whilst inhalation exposure 
systems have improved with availability of new materials or 
development of ancillary apparatus, the basic methodological principles 
have hardly changed (MacFarland, 1983). Inhalation exposure systems 
used in non-clinical experiments consist of two key elements: the 
apparatus to generate a test atmosphere containing a compound or 
formulation in air, and apparatus designed to present the resultant test 
atmosphere to the animals. 
Two fundamental elements are also found within the engineered 
infrastructure of the laboratory itself. The quality of air used for 
presentation of the test article to animals is immensely important. The 
air supply should be clean and is normally dried and filtered 
accordingly. Noteworthy considerations for air quality include relative 
humidity, temperature and contaminant foreign particles, which could 
have a direct effect on the animal or act as nuclei for the absorption of 
gaseous or liquid materials, concentrating a test material onto a 
particle. A system of valves and airflow meters are also required to 
control and monitor the compressed air supply and exhaust vacuum for 
an exposure system during generation of the test atmosphere. 
Exposure systems must also contain the test article to prevent passive 
exposure of the operators. Each exposure system should therefore be 
contained within a ventilated cabinet so that any test aerosol emitted 
from the exposure system is removed from the surrounding 
environment. Operators entering the cabinet should wear personal 
protective equipment including suitable face masks or respirators. 
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Test atmosphere generation 
Animals must be exposed to a test atmosphere containing the 
candidate drug for a longer period of time than human patients to 
achieve higher target doses, which are multiples of the anticipated 
human dose scaled for conservative factors applied for species-related 
differences in lung deposition (Degeorge et al., 1997, Jones and 
Baldrick, 2013). Furthermore, the design of the clinical inhaler and/or 
composition of the clinical formulation are normally unknown in early 
drug development. Non-clinical laboratories therefore use custom or 
commercially available apparatus or adapt existing clinical devices to 
generate reproducible test atmospheres for sustained periods. 
Furthermore, given the conservative safety margins applied in dose 
selections, more ‘industrial’ devices such as atomisers may be used to 
achieve a higher feed rate than that achieved using clinical devices. 
Test atmospheres can be broadly classified according to the physical 
properties of the constituent materials: 
● solids, such as dusts, fibres (e.g. asbestos) and nanoparticles 
● fluid droplets (non-volatile liquids) 
● gases or vapour (generated from volatile liquids) 
● pyrolysis products such as fumigants, tobacco or fire smoke. 
A test atmosphere may be generated as a combination of these 
phases, such as droplets and vapour (from ‘semi-volatile’ liquids or a 
mixture of volatile and non-volatile liquids), a mixture of solids, liquids 
and vapour (nebulised suspensions), or particulate and vapour 
(sublimable solids). The apparatus used to generate a test atmosphere 
will therefore depend upon the physical state of the test article or 
formulation. Whilst inhaled anaesthetics are administered as gas or 
vapour mixtures with air or oxygen, most pharmaceuticals are solid at 
room temperature and were traditionally formulated as simple mixtures 
of drug(s) with excipients. Candidate drugs are thus typically presented 
to animals as powder aerosols or a nebulised solution or suspension.  
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Micronised crystalline drugs are robust and can generally be 
compressed and dispersed in air without compromising or impairing 
dissociation of primary particles in the formulation. However, with an 
increasing trend to develop biopharmaceuticals (biologically sourced 
drugs such as antibodies, peptides or oligonucleotides) for inhaled 
administration and increased use of engineered particles to stabilise, 
target and/or modulate release of drugs (Vehring, 2008), care must be 
taken to ensure such formulations and the drug activity are not 
compromised during aerosol generation. 
When a test material is administered to animals via non-inhaled routes, 
the material is normally dissolved or dispersed in a vehicle and 
administered directly to the animals. Consequently, the concentration 
of the ‘active drug’ in the dosed formulation is normally the same as the 
nominal concentration prepared by the dispensary. This is not the case 
when formulations are dispersed in air for inhalation; a propellant 
(pMDI) will vaporise and particles of different densities, size or shape 
will have different aerodynamic properties and may sediment to 
differing degrees within the apparatus. Aerosols are therefore 
characterised for the concentration of the drug in the aerosol presented 
to animals; simple reverse phase high performance liquid 
chromatography may be sufficient for some biopharmaceuticals but 
indirect measurements such as absorbance may be necessary. In 
addition, biopharmaceutical particulates should also be evaluated to 
confirm that the large molecules remain active following aerosol 
generation and are not denatured by complications of the inhalation 
exposure procedure including shearing-stress, aggregation of proteins 
at air-liquid interfaces or ‘extremes’ of temperature (Hertel et al., 2015). 
A variety of dust generators are available for the dispersal of solid 
materials into an air stream. Some devices such as the Wright dust 
feed (Wright, 1950) introduce the powder into an air stream by scraping 
the powder from a canister containing compressed test material. Other 
devices avoid the need for compression, for example by drawing a 
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free-flowing powder into a stream of air using a venturi (Cheng et al., 
1989) or by expelling the powder from prefilled capsules using 
compressed air (Paul et al., 2012). The selection of apparatus may be 
influenced by the properties of the powder formulation, which may 
preclude use of some devices suitable for aerosol generation. For 
example, particles of uniform size or mutually repelled by electrostatic 
charge may be unsuitable for compression into a canister, or adhesion 
of particles may impede the free-flowing movement of a powder. 
Pharmaceuticals intended for respiratory indications are sometimes 
preformulated as a suspension in a pMDI, which contains a relatively 
insoluble drug maintained as a slurry in liquefied propellant, solvent 
and surfactant. Exposure of animals using pMDIs is relatively straight 
forward but apparatus used for discharging the test article must agitate 
the canisters between actuations to ensure adequate mixing of the 
propellant, drug and excipients. Care must also be taken to avoid 
frequent discharge resulting in excessive cooling or freezing of the 
valve due to evaporation of propellant/solvent; carousels are 
sometimes used to accommodate pMDIs for simultaneous discharge, 
increasing the total dose discharged each actuation. 
For dispersal of liquid formulations, many devices are available 
commercially. Air jet nebulisers or atomisers are probably the most 
versatile because they disperse solutions or suspensions by directing 
compressed air through the liquid formulation, ‘breaking the liquid mass 
up’ into droplets. Clinical devices hold a reservoir of the liquid and are 
easily adapted so that this reservoir can be maintained at a constant 
volume for longer periods by dispensing the formulation from a larger 
storage vessel. A potential complication is that freshly nebulised 
particulates may be electrically charged, influencing deposition in the 
respiratory tract (NRC, 2006). Although published technical guidelines 
do not state an acceptable pH range for inhalation exposure of animals 
to aqueous formulations, it is common ethical practice for laboratories 
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to ensure formulations are neither too acidic nor alkaline; local 
practices vary but an accepted range of pH 3 to 9 is not uncommon. 
Exposure system 
Non-clinical inhalation exposure systems are ultimately designed to 
present a test atmosphere to the snouts of animals. There are three 
fundamental concepts for presentation of a test atmosphere to animals: 
static (no airflow in chamber), dynamic single-pass exposure system 
and a dynamic recirculating exposure system (Cheng and Moss, 1995). 
Prima facie, static and recirculating exposure systems appear to offer 
advantages for reducing the mass of test article required to sustain the 
target aerosol concentration. However, static atmospheres present 
challenges for simultaneous exposure of animals due to the depletion 
of oxygen, accumulation of CO2 (limiting the exposure period) and 
homogenous mixing of particles inside the chamber. With recirculation 
of a test atmosphere, exposure of animals can be sustained if CO2 is 
removed by passing the atmosphere through quicklime (CaO) or soda 
lime (Ca(OH)2) and supplementing the atmosphere with oxygen. 
However, recirculating chambers are better suited for exposing animals 
to gases or vapour atmospheres since particulates impact or sediment 
within the exposure system and are removed by the CO2 scrubber. In 
addition, the presentation of pharmaceuticals to animals should be 
consistent with that intended for humans. Recycling of an aerosol that 
has been partially inhaled, exhaled and mixed with a supplementary 
aerosol supply is almost certainly not representative of the formulated 
drug product emitted from a clinical inhaler. 
Conventional inhalation exposure systems commonly used for 
presentation of pharmaceutical aerosols to animals are thus of the 
dynamic single-pass design, in which the test atmosphere is 
continuously delivered and exhausted from the ‘breathing zone’. The 
oxygen in the exposure system must be maintained at a minimum of 
19% (v/v) and CO2 must not increase excessively so as not to effect 
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animal physiology. This is achieved using an appropriate airflow to 
replenish the air within the ‘breathing zone’. However, for test 
atmospheres containing a saturated vapour or gas, it may be 
necessary to supplement the atmosphere with oxygen to mitigate 
against the displacement of air by the test article and prevent the onset 
of hypoxia. 
Inhalation exposure systems can also be broadly categorised as 
whole-body chambers and snout-only systems. Endotracheal tubes 
can also be used to expose larger species such as dogs and 
non-human primates individually for limited periods of time; this 
technique is analogous to oral inhalation of pMDI formulations in 
humans. Given the single-pass approach required for presentation of 
aerosols to animals, a proportion of particulate is inhaled by animals. 
Larger particulates dispersed from the aerosol generator impact or 
sediment within the exposure system and much of the finer particles 
are exhausted to waste. Inhaled administration of drugs to laboratory 
animals thus consumes a large mass of drug relative to other exposure 
routes for a given dose, which increases considerably with whole-body 
exposure. 
Whole-body chambers are used primarily to expose rodents to 
industrial or agrochemicals and fumigants requiring exposure periods 
of six hours (US-EPA[3645], 1998, OECD[TG413], 2017, 
OECD[TG412], 2017). Animals are housed individually in cages within 
the chamber to minimise crowding and maximise exposure to the test 
atmosphere. The chamber must be well designed with a plenum to 
ensure even distribution of the test article within the chamber 
environment and hence uniform exposure of the animals. An 
advantage of this technique is that observation of animal behaviour 
during exposure is possible for those animals within view. However, 
individually housed animals may curl up and press their external nares 
against their body, filtering an aerosol through their fur, and particulates 
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are ingested orally when the animals groom themselves post exposure 
(Holländer, 1988, Princi et al., 1949). 
Snout-only inhalation exposure is most commonly used for both small 
and large species in pharmaceutical research. The potential for dermal 
and oral exposure is reduced by presenting an aerosol to an animal’s 
nares. The internal volume of a snout-only system is considerably 
smaller than a whole-body chamber used to accommodate a given 
number of animals and the mass of test article required to maintain the 
target concentration in air is therefore considerably reduced.  
Configurations of animal exposure systems are varied and are best 
considered in relation to the size of the test species, rodents and 
non-rodents (historically dogs and non-human primates). An exposure 
system consists of apparatus for dispersing the test article in air 
(aerosol generator, vaporiser or gas cylinder), a ‘breathing zone’ for 
exposure of animals and an exhaust system for the safe removal of 
waste atmosphere. For snout-only exposure of rats, animals are 
restrained in tubes and attached to a chamber through which the test 
atmosphere is directed (Figures 1.7A and 1.8A). Dogs and non-human 
primates are normally exposed using a mask attached to a breathing 
circuit conducting the test aerosol (Figure 1.7B); a rubber diaphragm 
(dogs) or foam edging may be used to achieve a seal around the snout 
of the animal to contain the test atmosphere during exposure. Provision 
(access ports and apparatus) must also be made for characterisation of 
the concentration in air and the particle size distribution if appropriate. 
The duration of exposure may vary for local practices, but an exposure 
period of 30 to 60 minutes is common for snout-only administration of 
candidate drugs to both rodents and non-rodents. 
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1.7A: 
 
1.7B: 
 
 
Figure 1.7: Dynamic single-pass exposure systems for the non-clinical 
administration of aerosols. 1.7A: snout-only inhalation chamber for 
exposure of rats in restraint tubes. A dust generator is mounted on top of the 
chamber and a vacuum attached at the base to vent the chamber. 
1.7B: mask-based snout-only exposure system for dogs. Two nebulisers are 
seen attached to an expansion tank. The resultant aerosol is conducted via 
tubing to the masks or sampling port and returned to an exhaust manifold. 
Before undertaking aerosol administration, animals are acclimatised to 
the restraint and inhalation exposure procedures during which they are 
attached to the exposure system and exposed to air only. Local 
practices vary but this training typically takes approximately two days 
for rodents and two weeks for non-rodents. Pauluhn and Mohr (2000) 
described the need for tight-fitting masks and effective restraint of large 
species as a cause of stress that may alter breathing patterns and 
possibly make characterisation of the test atmosphere difficult or even 
impossible. Experience shows that, with sufficient pre-study training, 
dogs require minimal restraint during aerosol administration 
(Figure 1.8B). In fact, dogs have been observed sleeping during 
administration of drugs devoid of sedative activity. Nevertheless, it is 
important to frequently observe each animal during snout-only 
exposure to ensure it is inhaling the aerosol and that its condition is not 
compromised. For example, a rat may turn its head within a restraint 
tube presenting the risk of asphyxiation and necessitating intervention 
to reposition the rat. Tube restraint may also compromise a rodent’s 
condition if a drug inhibits thermoregulation; whole-body exposure may 
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be a more appropriate method of exposure in the latter scenario (Lewis 
and McKevitt, 2013). 
1.8A: 
 
1.8B: 
 
Figure 1.8: Restraint of animals for snout-only inhalation exposure. 
1.8A: conscious rats lying in restraint tubes. 1.8B: with sufficient pre-study 
training, dogs remain calm throughout inhalation exposure and require 
minimal restraint. A harness is attached to a pole towards the rear of the 
‘dosing table’ but the animal is otherwise able to move freely whilst wearing 
the mask. 
Particle size distribution and exposure of animals 
Solid particulates are often of irregular shape and the density of 
materials may vary greatly. Aerodynamic equivalent diameter is a 
means of expressing particle size in terms of the diameter of a sphere 
of unit density that has the same settling velocity as the particle being 
studied (NRC, 2006). This relative measurement is a function of an 
airborne particle’s shape, density and geometric size and thus provides 
a means of comparing a diverse range of airborne materials. 
As the potentially most harmful particle size or most responsive region 
of the respiratory tract cannot be predicted for the species in question, 
non-clinical exposure systems designed to test chemicals are normally 
designed to administer polydisperse aerosols (particles of varied sizes) 
to animals to ensure exposure of the entire respiratory tract to generate 
general toxicology data suitable for risk assessment (Pauluhn, 2008). 
For the testing of chemicals in rodents, regulatory technical guidance 
first issued in the early 1980s stipulated particulate size requirements 
of a mass median aerodynamic diameter (MMAD) of 1 to 3 μm and 
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geometric standard deviation (σg) of 1.5 to 3, although the regulatory 
guidance acknowledged that extenuating circumstances related to the 
physico-chemical properties of a test material may result in these 
ranges being exceeded (OECD[413], 2009, OECD[412], 2009, US-
EPA[3645], 1998). In October 2017, the OECD revised its guidance 
primarily to accommodate the testing of nanomaterials. However, 
criteria revised for MMAD ≤2 μm and σg of 1 to 3 were stipulated for all 
aerosol forms (OECD[TG413], 2017, OECD[TG412], 2017). 
To date, pharmaceutical regulatory agencies have not issued technical 
guidance or expectations for aerosols administered to animals in 
non-clinical studies. This is perhaps because pharmaceutical 
development is focused on optimising drug delivery to humans and not 
laboratory species. Orally inhaled particles of ≤5 µm diameter and 
nasally inhaled particles of ≤3 µm diameter are thought to deposit in 
the lower airways of humans (NRC, 2006) and the optimal therapeutic 
response is reported to occur for a MMAD of 0.5 to 5 µm (Tayab and 
Hochhaus, 2005). The test article supplied for non-clinical safety 
studies is representative of that subsequently administered to humans 
in clinical trials. This therefore presents practicing inhalation 
toxicologists with a dilemma insofar as the MMAD/σg of a 
pharmaceutical aerosol will be driven by the particle size range in the 
input material, which is optimised for humans. Whilst reasonable 
attempts are made to generate aerosols in line with the MMAD 
stipulated by regulators of the chemical industry, a smaller MMAD may 
not be technically feasible for exposure of rodents. The technical 
guidance issued by regulators of the chemical industry are therefore, in 
effect, reference documents for testing pharmaceuticals in rodent and 
non-rodent species. 
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1.4.5. Animal exposure and understanding dosimetry 
When administering test articles to animals by inhalation, it is important 
to appreciate the technical limitations and implications for the achieved 
dose. Laboratory species are not dosed per se, but are exposed to an 
atmosphere containing test material mixed with air. Animals breathe 
passively from the test atmosphere; some material is retained in the 
respiratory tract but most is not. Although a breath-activated device 
may be employed to optimise dose delivery to larger species, this is 
impractical for smaller species such as rodents given the small volume 
of air inhaled relative to the internal volume of the ‘dosing apparatus’. 
The administered dose is thus unknown but is commonly calculated on 
a mass per unit body weight basis using the following equation: 
𝐼𝐷𝑒 =
𝐶×𝑅𝑀𝑉×𝑇
𝐵𝑊
  …………………………… Equation 1 
Where IDe = estimated inhaled dose (mg/kg), C = aerosol 
concentration (mg/L), RMV = respired minute volume (L/min), 
T = duration of inhalation exposure (30 minutes) and BW = body weight 
(kg; animals weighed pre-exposure).  
The respired minute volume was historically estimated from various 
published algorithms (Guyton, 1947, McMahon et al., 1975, Bide et al., 
2000) or occasionally measured directly. In 2008, the Association of 
Inhalation Toxicologists published an algorithm based on data collated 
from 10 laboratories constituting a total of 1983 observations in four 
species commonly used for inhalation toxicology studies at the time 
(rats, dogs, mice and cynomolgus monkeys). The working group 
recommended their algorithm be used for estimating doses to facilitate 
comparison of data generated at different research facilities.  
Inhaled doses stated in this thesis are thus based on the respired 
minute volume estimated (eRMV) from body weight data using the 
published equation of Alexander et al. (2008) as follows: 
𝑒𝑅𝑀𝑉 = 0.608 × 𝐵𝑊0.852 ……………… Equation 2 
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However, use of such algorithms overlooks the potential for 
physiological or toxicological effects on lung function that can be 
induced by the test article’s properties (Nirogi et al., 2012, 
Vijayaraghavan et al., 1993). Furthermore, predicted lung function does 
not permit correlation of data with other parameters such as the drug 
concentration in lung/plasma or animal behaviour. 
Deposition of inhaled droplets or dust within the respiratory tract is 
dependent upon the aerodynamic properties of the particulate (a 
function of particle shape, mass and density), electrostatic charge (and 
hence potential for aggregation), the anatomy of the respiratory tract 
and the breathing pattern of the test subject (Snipes, 1989). 
Differences in the angle of bend in the pharynx of animals of 
pronograde (horizontal) and orthograde (upright) postures influence the 
proportion of particulate impacting against the wall of the airway. The 
nature of breathing also greatly influences the site of deposition. For 
example, rodents are obligate nasal breathing animals, which results in 
humidification of aerosols and filters out larger particles. However, 
human patients not only have larger airways but often inhale medicines 
orally, bypassing the nasal cavity and increasing the lung deposited 
dose 1.6-fold for particles of 2 µm in aerodynamic diameter (Table 1.1). 
Approximately 85% of particles of aerodynamic diameter 2 µm are 
‘inhalable’ to rats (Miller, 2000) and Snipes (1989) reported that 7% of 
such particles are deposited in rat lung. Results of non-clinical studies 
must therefore consider the achieved particle size distribution and 
mass of drug likely to be retained by the animal. The US-FDA assumes 
lung deposition factors of 10% in rats, 25% in dogs and 100% in 
humans (Forbes et al., 2011, Jones and Baldrick, 2013, Owen, 2013) 
based on the seminal publication of Snipes (1989). This article 
referenced historical data for industrial materials such as inorganic 
nuisance materials and radioactive particulates, which differ to the 
small organic molecules and biopharmaceuticals in drug development. 
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Table 1.1: Proportion of particles deposited in the lungs and respiratory 
tract of mice, rats, guinea pigs, dogs, monkeys and humansA 
Species 
Aerodynamic diameter 
0.2 µm 0.5 µm 1 µm 2 µm 5 µm 
Total Lung Total Lung Total Lung B Total Lung Total Lung 
Rat - - 0.10 0.10 NS 0.10 0.60 0.07 - - 
Guinea pig 0.50 0.35 0.50 0.35 NS 0.20 0.90 0.30 - - 
Dog 0.40 0.25 0.30 0.25 NS 0.25 0.60 0.20 - - 
Monkey - - 0.50 0.40 NS 0.30 0.75 0.20 0.90 0.10 
Human C           
Nose 0.30 - 0.25 0.20 
NS 0.25 D 
0.80 0.25 1.00 0.10 
Mouth 0.20 0.20 0.15 0.15 0.50 0.40 0.90 0.30 
Notes and references: 
A Adapted by Snipes (1989) from Schlesinger (1985); “total” deposition equals 
the fraction of inhaled particles that deposit in the respiratory tract; “lung” 
deposition equals the fraction of inhaled particles that deposit in the lung. 
B Reproduced from Snipes (1989) table of “Respiratory Parameters for Selected 
Laboratory Animal Species and Humans”; total deposition not stated (NS). 
C Human data presented for nose breathing and mouth breathing. 
D Human exposure route not stated; adapted by Snipes (1989) from Schlesinger 
(1985) and from Snyder et al. (1975), data for adult man, “light activity”. 
1.4.6. Fate of molecules post inhalation exposure 
During inhalation of a polydisperse aerosol, larger particles are 
deposited predominantly in the upper respiratory tract (nasal cavity 
and/or pharynx) and are typically swallowed or may be expectorated. 
Finer particles will be drawn deeper into the lungs, a proportion of 
which will be deposited in the fluid or mucous lining the respiratory 
tract, and additional airborne particles will be deposited in the 
respiratory tract as the aerosol is exhaled (Figure 1.1). Once a particle 
has been deposited in the lung, there are initially two competing 
processes that govern the drug’s fate: 
• Solvation and dissolution of the drug into the epithelial lung fluid, 
followed by transmembrane absorption into epithelial cells. 
• Removal of particles by mucociliary clearance in the upper lung 
or endocytosis by macrophages in the alveolar region.  
Absorption 
Solid particles must undergo dissolution prior to transepithelial 
absorption. Dissolution can be described as a three-stage process. 
Firstly, the crystalline lattice (hydrogen bonds) of a solute must be 
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disrupted and, secondly, cavitation of the solvent must occur to ‘host’ 
dissolved molecules; both processes are endothermic. Thirdly, 
solvation or hydration of the molecules occurs (exothermic) in which 
the ‘dissolved solute molecules’ integrate with the ‘solvent cavities’ 
(Van den Mooter, 2012). The organization of molecules in an 
amorphous particle is random and the material is thus more soluble 
than the crystalline form because less energy is required to facilitate 
cavitation of the solvent alone. It is also reasonable to hypothesise that 
a drug presented as droplets of a nebulised aqueous solution will be 
absorbed even faster that its solid form because dissolution of the drug 
has already been achieved. 
The rate at which a drug particle dissolves is influenced by the 
physicochemical properties of the drug molecule and the solvent, in 
this case epithelial lung fluid which is a complex mixture including 
water, salts, surfactant lipid and proteins. In the airways and alveoli, the 
epithelial lung liquid is also coated with a monolayer of lung surfactant 
in which the fatty acid chains of phospholipid molecules project towards 
the lumen (Patton, 1996). The rate of dissolution is also dependent 
upon the surface area of drug presented to the solvent, the degree to 
which the ‘microclimate’ around the particle becomes saturated with 
the drug, and the rate of transepithelial and then systemic absorption. 
The depth of epithelial lung fluid lining the respiratory tract becomes 
progressively thinner with progression from the upper to lower 
respiratory tract. In humans, the depth of fluid is 8 µm at the bronchi, 
3 µm at terminal bronchioles and 0.07 µm at the alveoli (Figure 1.3). 
Consequently, the surface area of a spherical particle of 2 µm in 
diameter presented to the epithelial lung fluid will be significantly less in 
the alveoli than in the upper airways. Particle morphology may also 
potentially influence a particle’s absorption or macrophage-mediated 
clearance from the lung and it is therefore likely that dissolution kinetics 
of aerosol particles on the lung surface are different to those of bulk 
material in aqueous media (Patton et al., 2010). 
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Once dissolved in the epithelial lung fluid, a drug may then cross the 
epithelium via mechanisms influenced by the size of the molecule and 
its physicochemical properties (Figure 1.9). There are essentially two 
key mechanisms for the transepithelial absorption of small molecules: 
diffusion (transcellular and paracellular) and transcytosis (adsorption or 
receptor-mediated). Absorption may also occur through a compromised 
epithelium such as via apoptotic cells (Patton, 1996). In practice, 
transepithelial permeability will be a combination of these mechanisms. 
 
Figure 1.9: Mechanisms of transmembrane absorption of molecules. 
Adapted from Veiseh et al. (2015) and reproduced with permission of the 
Nature Publishing Group. 
Diffusion, the non-specific net movement of molecules from an area of 
high concentration to an area of low concentration, occurs across 
cellular membranes (transcellular) or between adjacent cells by 
crossing tight junctions. Most aqueously soluble small molecules are 
absorbed form the lungs. Molecules that are more lipophilic are 
absorbed faster (within seconds or a few minutes), most likely across 
the cellular membrane. More hydrophilic molecules are absorbed at a 
Chapter One 
43 
 
slower rate (within minutes to tens of minutes) and most likely via 
aqueous pores in the intercellular tight junctions (Patton et al., 2004).  
Transcytosis is a mechanism by which cells transport macromolecules 
from one membrane surface to another by formation of vesicles that 
maintain the membrane integrity or disrupt the electrochemical 
potential across a membrane. The movement of drugs can be 
receptor-mediated or non-specific if charged molecules adsorbed onto 
the membrane surface are captured during formation of the vesicles. 
Molecules may also potentially undergo non-specific migration if 
associated with fluid captured during vesicle formation, a process 
known as fluid phase transcytosis, although electron microscopy 
evidence for this was weak (Patton, 1996).  
The transport of molecules across a membrane against a concentration 
gradient requires active transport, an ATP-dependent process 
facilitated by transmembrane proteins called ATP-binding cassette 
(ABC) transporters (Cole, 2014). Active transport can be competitively 
inhibited by common substrates for the binding site of the carrier 
protein, or inhibited non-competitively by binding elsewhere and 
altering the structure of the carrier protein (Alberts et al., 2002). Whilst 
the absorption of drugs is normally considered from the apical to the 
basal surfaces of the respiratory epithelial membrane, the efflux 
transporter P-glycoprotein 1 (Pgp) antagonises this process. Often 
described as a “multidrug resistance protein pump”, Pgp is associated 
with the poor efficacy of glucocorticosteroids in some patients treated 
for inflammatory diseases (Barnes and Adcock, 2009). Pgp is generally 
restricted to the apical surface of cells in many tissues including the 
lung (Bellamy, 1996). Pgp appears to be well defined at the luminal 
surface of the bronchiolar epithelium (air interface), bronchial 
capillaries (blood interface) and alveolar macrophages, but evidence 
regarding the presence or absence of Pgp in alveolar epthelium is 
contradictory (Patton et al., 2010). Substrates of Pgp crossing the 
apical membrane of epithelial cells are therefore pumped back into the 
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lumen of the airway, potentially impeding transepithelial migration of a 
drug on the one hand, and/or pumped into the capillaries expediting 
clearance from lung tissue into the systemic circulation. 
Microfold cell (M-cell) antigen sampling is a mechanism for presenting 
particulates in the lumen to systemically circulating cells of the immune 
system, thereby effecting an immunological tolerance or suppression of 
the foreign material. M-cells are specialised epithelial cells that 
facilitate transcytosis of small particles, soluble macromolecules and 
microorganisms (Gebert et al., 1996). The reduced efficacy and/or 
toxicity of biopharmaceuticals with repeated exposure may sometimes 
be attributable to the generation of anti-drug antibodies (ADAs). 
However ADAs may also illicit their own toxicity by cross-reacting with 
endogenous molecules in laboratory species (Koren et al., 2008). 
Macrophage and mucociliary clearance 
Endocytic uptake of particles by macrophages is the primary 
mechanism for clearance of micron-sized particles at the lung 
epithelium. Macrophages may then leave the lung via transepithelial 
migration into the interstitium and subsequently the lymphatic system. 
However, the mucociliary escalator is the principal pathway for 
clearance of macrophage-associated particles (Geiser, 2010), which 
are conveyed to the larynx and swallowed. A proportion of an inhaled 
‘dose’ may therefore be absorbed from the gastrointestinal tract and 
become systemically available depending upon its bioavailability 
(subject to the extent of hepatic first-pass metabolism). Tayab and 
Hochhaus (2005) claimed 10% to 60% of an orally inhaled drug 
entered the lungs, and 40% to 90% of the drug was swallowed when 
mucociliary clearance was considered. Whilst these ranges are broad, 
Bennett et al. (1999) showed that orally ingested Salmeterol accounted 
for approximately 28% and 36% of the increases in heart rate and 
plasma glucose concentration following an inhaled dose of 400mg 
(Salmeterol concentrations in plasma not presented). 
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1.5. Chronic Obstructive Pulmonary Disease 
COPD is a ‘generic disease’ encompassing several inflammatory 
pulmonary conditions that impair lung function. These include 
emphysema and chronic bronchitis which affect the alveolar sacs and 
airways respectively (NHS, 2017). COPD is a debilitating disease in 
which patients present symptoms of dyspnoea (breathlessness), 
coughing, wheezing, sputum production and frequent chest infections 
(Celli et al., 2004). COPD is most commonly found in smokers and 
administration of cigarette smoke to animals is used to induce an 
emphysema-like disease model (Wright and Churg, 2002, Churg et al., 
2008, Armstrong et al., 2015, Shapiro, 2000). COPD is less commonly 
associated with exposure to irritant dusts, fumes and air pollution 
particles including the burning of biomass fuels (Churg et al., 2008). 
Progression of COPD has also been reported in populations of workers 
in mining and construction (concrete) industries, in potato sorters 
exposed to diatomaceous earth (a soft, siliceous sedimentary rock) and 
in pottery workers (Hnizdo and Vallyathan, 2003). However, a genetic 
predisposition to COPD is also implicated, since 90% of COPD is 
associated with cigarette smoking but only 15% to 20% of heavy 
smokers develop this disease (Turato et al., 2001). 
The Global Initiative for Chronic Obstructive Lung Disease (GI-GOLD, 
2006) defined COPD as: 
“a preventable and treatable disease with some significant 
extrapulmonary effects that may contribute to the severity in 
individual patients. Its pulmonary component is characterized by 
airflow limitation that is not fully reversible. The airflow limitation 
is usually progressive and associated with an abnormal 
inflammatory response of the lung to noxious particles or 
gases.” 
Diagnosis of COPD was historically based on clinical impairment of 
lung function using spirometry measurements, which does not capture 
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the aetiology of disease conditions resulting in the functional changes. 
COPD is characterised by the permanent destructive enlargement of 
air spaces in the lung parenchyma with fibrosis (emphysema) and 
inflammation of the distal airways (bronchiolitis) and central/proximal 
airways (chronic bronchitis). The structural changes include increased 
airway wall thickness (due to inflammation) and remodelling (fibrosis 
and smooth muscle hypertrophy) that collectively narrow or constrict 
the airways. In addition, emphysema results in a loss of elastic recoil of 
the airways (Turato et al., 2001, Saetta et al., 2001). T-lymphocytes 
(positive for CD4 and CD8 glycoproteins; clusters of differentiation at 
the cellular membrane of helper and killer immune cells), neutrophils 
and macrophages are implicated in the remodelling of airways and 
parenchymal destruction (Hnizdo and Vallyathan, 2003). 
Glucocorticosteroids are the most effective anti-inflammatory drugs 
available to treat inflammatory and autoimmune diseases. However, 
some patients exhibit poor efficacy for treatment of asthma (1% of 
patients require oral steroids to supplement inhaled doses) and 90% of 
COPD patients do not respond to inhaled glucocorticosteroids (Barnes 
and Adcock, 2009). Activation of the mitogen-activated protein kinase 
(MAPK) pathways is one of the molecular mechanisms implicated in 
glucocorticoid resistance. 
1.5.1. p38 mitogen-activated protein kinase inhibitors  
Mitogen-activated protein kinases (MAPKs) are part of conserved 
signalling pathways that facilitate relaying of extracellular stimulations 
to intracellular responses. p38 MAPK is more responsive to stress 
stimuli including ionizing radiation, osmotic shock and cytokine stimuli 
(Roux and Blenis, 2004). Located in the cytoplasm and nucleus 
(Cuenda and Rousseau, 2007), p38 MAPK performs a central 
regulatory function in a signal cascade that results in the synthesis and 
modulation of proinflammatory mediators. Consequently, inhibition of 
this mechanism represents a ubiquitous target for inflammatory 
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diseases including rheumatoid arthritis, Crohn’s disease, psoriasis, 
COPD and asthma (Millan et al., 2011, Mayer and Callahan, 2006). 
Research into potential mechanisms to inhibit inflammatory disease 
has focused on protein kinases, which are widely expressed in 
inflammatory cells and are activated by a variety of stresses. Activation 
(by phosphorylation) of the p38 MAPK pathways leads to changes in 
cell cycle or expression of key genes, including cytokines, chemokines, 
and growth factors (Chung, 2011). The alpha-isoform of p38 MAPK is 
expressed in airway smooth muscle cells, epithelial cells, and immune 
cells, and research into using p38 MAPK inhibitors to elicit an 
anti-inflammatory effect for treatment of COPD have focused on this 
isoform (Williams et al., 2008, Mayer and Callahan, 2006). 
To this end, GSK258899B, a p38 mitogen-activated protein kinase 
(MAPK) inhibitor of relatively low aqueous solubility, was initially 
developed as an anti-inflammatory drug designed to have a longer 
duration of action. Development of the candidate drug was terminated 
primarily due to inflammatory changes seen in the lungs of dogs after 
28 days of treatment. However, an infiltration of inflammatory cells was 
also seen concurrently with accumulation of alveolar macrophages in 
the lungs of rats after 28 days (Freke, 2010). Prima facie, the 
inflammatory findings observed histopathologically appeared to be 
contradictory to the anticipated pharmacology for a p38 MAPK inhibitor. 
GSK258899B therefore represented a tool compound for investigation 
of inflammation and its potential modulation with a change in aerosol 
form. Selection of additional compounds of the same pharmacological 
class but with different physicochemical properties, such as higher 
solubility and/or membrane permeability, provided an opportunity to 
investigate the potential relevance of such parameters in drug design.  
Blood concentrations of drugs following inhaled administration are 
often cited but the persistence or location of a drug within the lung is 
rarely characterised (Patton et al., 2010). Pauluhn (2008) stated 
differences in the toxic potency of relatively inert materials may be 
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associated with differences in particle clearance, dissolution rate in 
lung fluid or initiation of a self-perpetuating inflammation. Whilst 
potential therapeutic indications for p38 MAPK inhibitors in 
inflammatory diseases and rodent models for investigating 
mechanisms of inhibiting acute lung inflammation have been discussed 
in the literature (Banerjee et al., 2012, Chung, 2011, Haddad et al., 
2001, Nick et al., 2002, Underwood et al., 2000, Williams et al., 2008), 
little has been published about the toxicology of these biologically 
active organic molecules.  
1.6. Thesis aims and objectives 
Pharmaceutical companies are under increasing pressure to reduce 
the time and cost of developing new medicines. Expediting strategies 
for preclinical development of respiratory drugs include use of 
surrogate formulations or administration routes (different to intended 
clinical regimen) to facilitate in vivo experiments earlier in development, 
when candidate drugs are synthesised in small quantities. This 
research was undertaken to investigate potential implications of such 
expediting strategies. Accepted in vivo endpoints and methods for 
non-clinical assessment of efficacy and pulmonary toxicopathology 
were selected to profile the response of rats to dry powder or nebulised 
aerosols of three drugs of common pharmacology. The experimental 
objectives of this thesis were to: 
• Select anti-inflammatory drugs of the same pharmacological 
class but with differing physicochemical properties, and to 
measure the systemic (plasma) and lung exposure in rats 
administered a dry powder aerosol or nebulised solution of each 
test article (Chapter 2). 
• Evaluate the potential for environmental factors during inhalation 
exposure procedures to influence lung function and dosimetry of 
inhaled compounds (Chapter 3). 
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• Determine the median effective dose (ED50) of three compounds 
presented as dry powder and nebulised aqueous aerosols using 
a rat model to assess prophylactic inhibition of acute lung 
inflammation (Chapter 4). 
• Determine the toxicopathology of three compounds presented 
as dry powder and nebulised aqueous aerosols for 28 days 
(Chapter 5). 
Results of experimental objectives will be used to test the following key 
hypotheses: 
• The physicochemical properties of a drug influence its lung or 
systemic exposure in vivo, and hence the resultant efficacy 
and/or toxicopathology. 
• Changing the presentation of a drug to rats will affect its 
absorption and hence alter the resultant efficacy and/or 
toxicopathology in vivo. 
Although the systemic and lung exposure of drugs are known to 
change for different formulations, less is currently known about the 
implications for potential changes in efficacy, toxicopathology and 
hence the therapeutic index between these endpoints. If is anticipated 
that the results of this thesis will indicate the potential opportunities or 
risks of administering surrogate formulations to animals in early 
respiratory drug development and identify key factors for drug design.
  
 
CHAPTER TWO 
Multivariate-based selection of p38 
mitogen-activated protein kinase 
inhibitors and investigation of 
pharmacokinetics in rats following 
a single inhalation exposure
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2.1. Introduction 
With just one in 40,000 compounds tested in animals eventually reaching 
the market (Kapetanovic, 2008), there is an ethical obligation and a 
compelling commercial argument for pharmaceutical companies to 
employ effective computational (“in silico”) models for lead optimisation 
and preselection of candidate drugs. In silico techniques are increasingly 
important in predicting chemical properties of new molecules and 
facilitating computer-aided drug design, considerably reducing the time 
and resources required for chemical synthesis and biological screening 
of new drugs (Kapetanovic, 2008). In 2015, a workshop of the American 
Association of Pharmaceutical Scientists (AAPS), US Pharmacopeia (USP) 
and Food and Drug Administration (FDA) identified a need to classify inhaled 
drugs using a model for physicochemical properties specific to lung physiology 
and drug delivery, similar to the Biopharmaceutics Classification System (BCS) 
developed in the 1990s for orally ingested drugs. However, participants of this 
workshop acknowledged that deriving inhalation BCS classifications would not 
be simple (Hastedt et al., 2016). 
With a desire to extend the duration of pharmacological action for 
treatment of chronic pulmonary diseases (Buhl et al., 2003, RNS-LSE#1, 
2017), candidate drugs have been designed with relatively low aqueous 
solubility or high lipophilicity. However, strategies to slow absorption or 
prolong lung retention may have implications for safety as accumulation 
of insoluble material at the respiratory epithelium may impair lung 
function (Fröhlich, 2017). Aerosols are characterised for their particle 
size distribution, morphology and dissolution rate in vitro. Whilst much is 
also learnt from in vitro models used in high throughput screening of 
candidate drugs, for example with regards to the mechanisms and 
pharmacokinetics of absorption (including membrane permeability), 
receptor binding and occupancy, the most complete assessments of 
pulmonary drug delivery, efficacy and toxicity are determined in vivo 
using intact organisms (Fernandes and Vanbever, 2009). 
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The pharmacokinetics of an inhaled drug can have profound implications 
for its efficacy and adverse effects, both locally and systemically. For 
example, the extent of systemic exposure to inhaled corticosteroids has 
implications for their pharmacodynamic effect of hypothalamic-pituitary-
adrenal axis and cortisol suppression, which are associated with chronic 
adverse side effects such as thinning and bruising of skin, and reduced 
growth rate and bone density leading to fractures (Derendorf et al., 
2006). An understanding of the drug-lung concentration time profile 
following inhaled administration of a drug to animals immediately post 
exposure can provide an indication of the ‘achieved lung dose’ and the 
potential for accumulation in lungs with repeated administration. The 
pharmacokinetic parameters of selected p38 mitogen-activated protein 
kinase (MAPK) inhibitors in plasma and lung tissue and the pattern of 
lung deposition determined in this chapter will thus provide a context for 
investigation of efficacy and pulmonary toxicology in animal models 
described in subsequent chapters. 
2.1.1. Principal component analysis of physicochemical 
properties of compounds 
Principal component analysis (PCA), also known as multivariate analysis 
(MVA), is a statistical method for evaluating complex multivariate data in 
which observations are described by several inter-correlated quantitative 
dependent variables (Abdi and Williams, 2010[A]). PCA was first 
outlined by Pearson in 1901 as an analysis for finding “lines and planes 
of closest fit to systems of points in space” and was introduced into 
chemistry by Malinowski in the 1960s (Wold et al., 1987). Today, PCA is 
widely used by the pharmaceutical industry in conjunction with the 
concept of ‘drug-like chemical space’, a function of various 
physicochemical parameters calculated from a chemical structure or 
measured, to shortlist candidate drugs for high throughput screening 
(Mirza et al., 2009). Three variables can be clearly represented using a 
three-dimensional plot. However, it is difficult for people to comprehend 
a greater number of variables represented mathematically. Multivariate 
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analysis provides a means of reducing the ‘dimensionality’ of large 
datasets to facilitate more manageable visualisation and interpretation 
of the information (Wheelock and Wheelock, 2013). This is achieved by 
representing data as a set of new orthogonal (perpendicular) variables 
called principal components used to project a pattern of similarity of the 
observations or variables as points in a two dimensional plot or map 
(Abdi and Williams, 2010[A]). The concept of multivariate analysis is 
illustrated in Figure 2.1. 
2.1A: 
 
2.1B: 
 
Figure 2.1: Illustration of principal component analysis (Umetrics, 
2013). 2.1A: A dataset of 22 observations are plotted for three variables 
(axes X1, X2 and X3). A line of best fit is plotted, representing the direction of 
maximum variation (principal component: PC1). A second axis, 
perpendicular to PC1, is plotted representing the next best line of fit (PC2). 
2.1B: The observations are projected onto a plane defined by the principal 
components (PC1 and PC2) to create score plot depicting separation of the 
observations in two dimensions. 
By summarising the physicochemical properties of p38 MAPK inhibitors 
and plotting the relative similarities and differences of these molecules 
in the ‘physchem space’, PCA provides a means for selecting tool 
compounds of contrasting properties to investigate the systemic 
exposure, efficacy and toxicopathology, arising in vivo following inhaled 
administration to animals. 
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2.1.2. Aims and objectives 
The experimental aims of this chapter are to: 
• Select three p38 MAPK inhibitors of differing physicochemical 
properties by principal component analysis of predicted (in silico) and 
measured in vitro parameters. 
• Characterise the particle forms for particulate aerosols of the p38 
MAPK inhibitors selected for further investigation. 
• Determine systemic (plasma) and lung exposure of the selected p38 
MAPK inhibitors in rats after a single inhaled dose by chemical 
analysis of blood/plasma and lung homogenate samples taken up to 
24 hours post exposure. 
• Investigate drug-lung deposition of the selected p38 MAPK inhibitors 
in rats following a single inhaled dose, by matrix assisted laser 
desorption/ionization with mass spectrometry imaging (MALDI-MSI) 
analysis of lung sections. 
Apparatus and procedures for inhalation exposure of rats described in 
this chapter will form the basis of core methodology in subsequent 
chapters. In addition, the following hypotheses will be tested: 
• Compounds of faster dissolution in vitro are likely to be cleared 
more quickly in vivo, from the lungs of rats exposed to an aerosol 
of the test article. 
• Presentation of the test article to rats as a nebulised solution will 
facilitate a quicker clearance from the lungs since dissolution of 
the particles is achieved prior to inhaled drug administration. 
Results for the testing of these hypotheses will provide a context for 
investigations described in subsequent chapters. For example, the 
dissolution rate of a drug in simulated lung fluid (in vitro) may not 
necessarily translate to the in vivo model if dissolution in epithelial lung 
fluid was impeded by the layer of surfactant lining the respiratory tract. It 
is anticipated that the efficacy or incidence/severity of pulmonary 
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toxicopathology of a nebulised solution or compounds quickly cleared 
from the lungs will be less than for drugs persisting in lung tissue. 
. 
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2.2. Materials and methods 
2.2.1. Principal component analysis of the physico-
chemical properties of six p38 MAPK inhibitors 
A shortlist of p38 MAPK inhibitors was compiled for further consideration. 
GSK development programmes associated with these compounds had 
been terminated but just six of these compounds (Figure 2.2) were 
available in sufficient quantity to support conduct of single exposure in 
vivo inhalation studies. Physicochemical data of preselected compounds 
were collated for PCA. Two datasets of parameters were selected for 
data mining with reference to panels commonly assessed during lead 
optimisation of compounds in early drug development by the sponsor 
(GSK). The parameters were interrelated but generally influenced 
lipophilicity, solubility and/or protein binding by molecules. Examples of 
general grouping for in silico parameters included: 
• Lipophilicity: high number of aromatic rings and fluorine groups; 
LogD (distribution coefficient between organic and aqueous 
media) and Log P (partition coefficient); membrane permeability. 
• Solubility: high acid or base class (acidity/basicity), Abraham’s 
hydrogen bond acidity/basicity; charge, number of positively 
ionisable groups; rotatable bonds, single bonds (sp3) and 
aliphatic rings (i.e. a lack of unsaturated bonds). 
• Protein binding: high number of aromatic rings and double bonds 
(i.e. unsaturated bonds); higher proportion of oxygen, nitrogen 
and sulphur atoms versus carbon atoms (‘hetero atoms’). 
These groupings are not mutually exclusive: basicity is associated with 
solubility and binding to alpha-1 acid glycoprotein (Urien et al., 1993), a 
carrier of basic and neutral lipophilic compounds); acidity is associated 
with solubility and binding to human serum albumen via anionic or 
electronegative drug moieties (Simard et al., 2006); aromatic rings are 
associated with lipophilicity and protein binding (Ritchie and Macdonald, 
2009). 
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A: GSK258899A (GSK-899) 
 
B: GSK610677A (GSK-677) 
 
C: GSK678361A (GSK-361) 
 
D: GSK719340A (GSK-340)
 
E: SB-681323 (SB-323) 
 
F: SB-731445 (SB-445) 
 
Figure 2.2: Chemical structures of six p38 MAPK inhibitors shortlisted 
for potential investigation of in vivo endpoints. Figures 2.2A to 2.2F show 
chemical structures for the parent compounds (free base). A criterion for 
compound selection was that all drug development programmes had been 
terminated. 
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The first data set consisted of 34 parameters calculated or derived 
(modelled in silico) from the molecular structure of each compound using 
Adamantis, an in-house web-based tool developed by GSK for the 
prediction of physicochemical properties and accessing ADME 
(absorption, distribution, metabolism and excretion) models (Ritchie et 
al., 2009). The parameters included the following: 
• Acid (pKa) and base (pKb) dissociation constants, ranked by 
range thresholds e.g. 0 = no acidic group; 1 = pKa>8.5 etc.  
• Log P: partition coefficient of non-ionised compound between 
aqueous and organic phases (indication of lipophilicity). 
• Log D: distribution coefficient of ionised plus non-ionised forms 
between aqueous and organic phases (indication of lipophilicity). 
• Number of aromatic and non-aromatic rings in a molecule. 
• The number of negatively ionisable groups and the number of 
positively ionisable groups in a molecule. 
• The number of hydrogen bond donors and acceptors in a 
molecule. 
• The number of rotatable bonds in a molecule. 
• Average binding energy: derived for 10 common functional 
groups, where present, and used as an indicator of potential 
drug-receptor affinity (Andrews et al., 1984). 
• Polar surface area: calculated by the method of Ertl et al. (2000); 
only nitrogen and oxygen were considered as polar atoms. 
The second data set consisted of 17 measured physicochemical 
parameters including but not limited to the following: 
• Chromatographic Log P at pH 7.4: the partition coefficient of 
non-ionised compound between aqueous and organic phases 
(indication of lipophilicity). 
• Chromatographic Log D at pH 7.4: the distribution coefficient of 
ionised plus non-ionised forms between aqueous and organic 
phases (indication of lipophilicity). 
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• Chromatographic hydrophobicity index (CHI), a rapid 
reverse-phase high performance liquid chromatography (HPLC) 
method used for measuring lipophilicity (Valkó et al., 1997); 
CHI-values for Log P, Log D and the immobilised artificial 
membrane column (IAM) were determined. 
• Logarithms of the steady state volume of distribution (VDSS) and 
estimated unbound volume of distribution (VDUSS). 
• Estimated proportion of plasma protein-drug binding. 
• Membrane permeability. 
• Solubility after 0.5, 4 and 24 hours in simulated lung fluid; 
compounds were considered of low solubility for concentrations 
of <0.05 mg/mL and high solubility for >1 mg/mL. Simulated lung 
fluid consisted of 0.59 mg/mL lecithin and 1 mg/mL bovine serum 
albumin in aqueous 0.78% (w/v) sodium dihydrogen ortho-
phosphate and 0.4% (w/v) sodium chloride, buffered to pH 6.9. 
Although Log P and Log D were modelled (in silico) and measured (in 
vitro), these parameters were analysed separately by PCA, one dataset 
for Log P and Log D, and did not supersede one another. 
Each dataset (X-matrix) was formatted as a table with the six p38 MAPK 
inhibitors (N=6 observations) and parameters (K=35 or 17 variables for 
the in silico and measured data respectively). Multivariate data analysis 
was performed using SIMCA software (version 13.0.3.0; Umetrics). The 
software extracted data from the “X-matrix” and the position of the 
compounds in the multidimensional space was visualised (multivariate 
projection) by drawing a new co-ordinate axis (t[1]) representing the line 
of best fit through the data points. This is known as the first principal 
component and all observations (compounds) were projected onto this 
new axis and the values scored. The programme then added a second 
principal component (t[2]), orthogonal to the first principal component, to 
define the next best direction for approximating the data. The 
compounds were projected onto a plane defined by the two principal 
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components to create a score plot representing the optimal 
two-dimensional view of the original multidimensional data. The new 
axes (first and second principal components) can be related back to 
each original variable (axis) by measuring the angles between them and 
the principal components. A small angle indicates a variable has a large 
impact because it is almost aligned with the principal component; 
conversely, a large angle indicates less influence. The influence of 
variables is summarised in the loadings plot, which can be superimposed 
on the score plot; the further a variable is from the origin of the loadings 
plot, the greater its influence on an observation appearing in the same 
quadrant of the score plot (Umetrics, 2013). 
For each dataset, the scores and loadings plots were then compared to 
assess the relative distribution and separation of the compounds within 
the ‘t[1]/t[2] space’ for each model. Statistical parameters for the PCA were 
also summarised as follows: 
• Component index (1 or 2 for respective principal components). 
• R2X: fraction of X variation modelled by the component. 
• R2X (cum): cumulative R2X score for the stated component(s). 
• Eigenvalue: the number of variables (K) multiplied by R2X. 
• NIPALS iterations: number of Nonlinear Iterative PArtial Least 
Squares iterations until convergence, i.e. the point at which 
further iterations of the algorithm do not refine the outcome. 
2.2.2. Test articles 
The p38 MAPK inhibitors were supplied by GSK as micronised crystals 
(all compounds) and stored at ambient temperature, protected from light 
and moisture (Table 2.1). 
Amorphous GSK-899 was produced by spray drying a saturated solution 
of GSK-899 (prepared from micronised crystals) in methanol. Harsh 
drying conditions were used in conjunction with atomisation to produce 
amorphous particles of a respirable size. Rapidly drying the droplets 
achieved a similar effect to rapidly cooling molten compounds, which 
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prevents adequate mobility of molecules to assume lattice positions 
(Telko and Hickey, 2005). The physical state of particles was confirmed 
using X-ray powder diffraction (XRPD), using crystalline GSK-899 as a 
reference material. 
Table 2.1: Salt form and purity of p38 MAPK inhibitors used for 
dissolution testing (in vitro) and inhalation exposure of rats (in vivo)  
Test article Salt form Purity 
In vivo 
study 
number 
GSK258899B mesylate 95.4% 
R30573N 
SB-731445T tosylate 99.9% 
GSK610677B hydrochloride 98.5% R30988N 
GSK678361A parent 99.7% R31225N 
SB-681323T tosylate 99.6% n/a 
2.2.3. Dissolution rates of p38 MAPK inhibitors in 
simulated lung fluid 
Prior to conducting experiments with animals, the in vitro dissolution of 
the crystalline forms of p38 MAPK inhibitors and amorphous GSK-899 
were evaluated in simulated lung fluid using a flow-through apparatus. 
2.2.3.1. Sample preparation for dissolution testing 
A filtrete (Figure 2.3A) was prepared for powder sample collection, 
placed on a wire support mesh at Stage 3 of a Next Generation Impactor 
(NGI) and clamped in place using an O-ring seal. The filtrete is a custom 
made total trap filter consisting of spun bound polypropylene in a 
cover-web design (3M, UK). 
Approximately 1.5 mg of the test article was weighed into a size 3 
capsule and loaded into a Cyclohaler® (Teva Pharmaceutical Industries, 
Israel). The powder was dispersed in air as two consecutive four-second 
bursts from the inhaler, at a flow rate of 60 L/min, and the respirable 
particles of the resultant aerosol (aerodynamic diameter ≤4.46 µm 
(Marple et al., 2003)) were collected onto the filtrete. 
The NGI was dismantled and the filtrete removed and positioned on the 
lower half of a stainless steel filter holder with the powder orientated 
downwards, towards the inlet port (Figure 2.3B). A polyvinyldifluoride 
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(PVDF) 0.22 µm filter and then a stainless steel support were placed 
over the filtrete. The top of the filter holder was then screwed into place 
to form a tight seal, and the dissolution cell connected to HPLC tubing in 
an oven maintained at 37°C.  
2.2.3.2. Preparation of simulated lung fluid 
Simulated lung fluid (0.59 mg/mL lecithin and 1 mg/mL bovine serum 
albumin in aqueous 0.78 % (w/v) sodium dihydrogen orthophosphate 
and 0.4% (w/v) sodium chloride, buffered to pH 6.9) was prepared the 
day before the dissolution experiment. 
A phosphate buffer was first prepared by dissolving sodium dihydrogen 
orthophosphate (3.90g) and sodium chloride (2.0g) in deionised water 
(475 mL), adjusting the pH 6.9 ±0.1 using 5M sodium hydroxide and 
made up to volume (500 mL) with deionised water. Simulated lung fluid 
was then formulated by dissolving lyophilised bovine serum albumin in 
the phosphate buffer at room temperature, and dispersing lecithin in the 
solution at 60°C over a period of two hours with constant stirring. The 
formulation was cooled to room temperature overnight. 
2.2.3.3. Evaluation of dissolution 
The flow-through design of apparatus used to perform dissolution 
experiments (Figure 2.3C) was based on a modified HPLC instrument. 
Simulated lung fluid was drawn at a constant flow of 1 mL/min from a 
reservoir of the media using an HPLC pump. The media was warmed 
via a coil and applied in an upward direction to the filtrete (clamped in an 
HPLC filter holder), both of which were accommodated in an oven 
maintained at 37ºC. The dissolved test article which passed through the 
filtrete and the PVDF filter were collected for HPLC analysis with 
ultraviolet detection as a series of samples of 1.5 mL (i.e. over periods 
of 1.5 minutes) for up to three hours. On completion of the experiment, 
the filtrete was removed from the dissolution cell and any remaining test 
article was dissolved in 20 mL of 50:50 (v/v) acetonitrile in water.  
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The mass of analyte measured in each sample was used to calculate 
the cumulative percentage of test article recovered over the time course; 
the total mass of test article was calculated from the sum of analyte in 
each sample. 
2.3A 
 
2.3B 
 
2.3C 
 
Figure 2.3: Schematic of apparatus used to evaluate dissolution of p38 
MAPK inhibitors in simulated lung fluid. 2.3A: filtrete (electrostatically 
charged polypropylene in spun bound cover-web design) used for presentation 
of respirable particles (aerodynamic diameter of <4.46µm). 2.3B: schematic 
of the dissolution cell showing the direction of media flow. Top to bottom: upper 
half of a stainless steel filter holder (A); stainless steel porous filter support (B); 
polyvinyldifluoride (PVDF) 0.22 µm filter (C); filtrete (D) with loaded powder 
orientated towards the cell inlet; lower half of the stainless steel filter holder. 
2.3C: a constant flow (1 mL/min) of simulated lung fluid was drawn from a 
reservoir of the media using an HPLC pump, warmed to 37ºC (via a heated 
coil) and applied to the filtrete in an upward direction. Serial samples (1.5 mL) 
were collected for HPLC-UV analysis over 3 hours. 
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2.2.4. Investigating the pharmacokinetics of p38 MAPK 
inhibitors in rats after a single inhaled dose 
Rats were administered a p38 MAPK inhibitor, by inhalation, and then 
sampled for blood and/or lung tissue for chemical analysis by high 
performance liquid chromatography with mass spectrometry detection 
(HPLC-MS/MS) or assessment of drug-lung distribution by matrix 
assisted laser desorption/ionization with mass spectrometry imaging 
(MALDI-MSI) analysis (Figure 2.4). A target dose of 0.6 mg/kg was 
selected for single exposure of rats, which represents a 10-fold overage 
for a nominal clinical dose of 1 mg when a conservative scaling factor 
for inter-species differences in lung deposition is applied (Degeorge et 
al., 1997, Jones and Baldrick, 2013).  
 
Figure 2.4: Design to investigate plasma and lung concentrations and 
lung distribution of p38 MAPK inhibitors in rats after a single inhaled 
dose. Rats were acclimatised to restraint tubes for 20 minutes (Day -1). The 
next day, rats were exposed to an aerosol for 30 minutes (target dose of 
0.6 mg/kg) and sampled for plasma and lungs (n=3/time point) up to 24 hours 
post exposure. Additional rats (n=1/time point) were sampled for matrix 
assisted laser desorption/ionization (MALDI) analysis of drug-lung distribution. 
2.2.4.1. Test system and animal husbandry 
Male Crl:WI(Han) rats (Charles River UK Ltd, Margate, Kent) were 
accommodated under standard laboratory conditions (Home Office, 
2014) including room temperature of 21±2°C and relative humidity of 
55±10% (excesses in relative humidity and temperatures of 18 to 24°C 
were acceptable for less than two consecutive days); a lighting cycle of 
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approximately 12 hours light to 12 hours dark was implemented. The 
animals were group housed (3/cage if practicable; same treatment 
group) in plastic solid bottom cages containing Aspen 4H bedding 
(Datesand Ltd, Manchester, UK) and given environmental enrichment 
including a fun tube and wood-chew (Lillico, Betchworth, UK) in each 
holding cage. Rats were accommodated for at least five days before 
undertaking the first licensed procedure (tube restraint) and were 
approximately 10 weeks old on the day of inhalation exposure (Day 1). 
Rats had access to Purina Mills International (PMI) 5LF2 EURodent Diet 
and filtered mains water (Veolia Water plc, UK) ad libitum, except during 
inhalation exposure or blood sampling procedures. 
For each experiment, animals were randomly allocated to treatment 
groups through arbitrary placement of the required number in each cage 
whilst unpacking the animals following delivery to the laboratory. 
Animals were identified by a number written in indelible ink on the tail. 
2.2.5. Aerosol Generation and formulation details 
Groups of rats were administered a single dose of a p38 MAPK inhibitor, 
by snout-only inhalation exposure, presented as a dry powder 
formulation (all compounds) or as a nebulised aqueous solution 
(GSK-361, GSK-677 or GSK-899).  
Aerosols were generated using commercially available aerosol 
generators for dry powder formulations (Section 2.2.5.2) or aqueous 
solutions (Section 2.2.5.4). Regulated airflow conducted the resultant 
aerosol from the apparatus into the top of a snout-only inhalation 
exposure chamber; volumetric flow of the compressed air supply and 
chamber exhaust (vacuum) were calibrated using a Bios Defender 510H 
airflow meter before initiating aerosol generation. 
A target aerosol concentration of 0.028 mg/L was selected for exposure 
of animals and was calculated using the following equation: 
𝐶𝑡 =
𝐼𝐷𝑡×𝐵𝑊
𝑅𝑀𝑉×𝑇
  ……………………………… Equation 3 
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Where Ct = target aerosol concentration (mg/L); IDt = target inhaled dose 
(mg/kg); BW = predicted body weight (0.35 kg, based on unpublished 
historical data); RMV = respired minute volume (L/min) estimated using 
Equation 2 (Alexander et al., 2008); T = duration of inhalation exposure 
(30 minutes). 
‘Pre-study’ aerosol characterisation work was conducted without 
animals to establish the operating conditions needed to generate target 
aerosol concentrations and to ensure that the airborne particles or 
droplets were of a size suitable for exposure of rodents. 
2.2.5.1. Dry powder formulations of p38 MAPK inhibitors 
Each p38 MAPK inhibitor was blended nominally 5% (w/w) with 
‘inhalation grade lactose’, which consisted mainly of large carrier 
particles but also included a small proportion of fine lactose particles; the 
mass median particle size of the lactose excipient was 66 µm, with 
approximately 6% (w/w) of particles less than 4.5 µm. The large lactose 
carrier particles are non-respirable and readily sediment out of the 
aerosol. These particles provide bulk to formulations for controlled 
dispersal of the drug(s) and minimise aggregations by reducing drug 
cohesiveness (Telko and Hickey, 2005). 
For each of the blends of crystalline GSK-899, GSK-677 or GSK-361, 
the required masses of test article and lactose excipient were weighed 
into a suitable container and mixed using a bladed mixer (Donsmark 
QMM/I Mixing System; Donsmark Process Technology, Denmark) for 10 
minutes at 600 revolutions per minute (RPM). For blends of amorphous 
GSK-899 or 5% (w/w) SB-445 (Study R31035N), the test article and 
excipient were mixed for four hours (GSK-899) or one hour (SB-445) 
respectively using a non-bladed inversion mixer (Turbula®; design 
similar to the contemporary T2F model by Glen Mills Inc, Clifton NJ, 
USA) at a nominal speed of 60 RPM. The resultant mixture was left to 
stand for one hour before samples were taken for chemical analysis. 
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Chemical analysis of dry powder formulations 
The concentration and homogeneity of each p38 MAPK inhibitor in its 
respective formulation were confirmed by chemical analysis. Six 
aliquots, each of 250 mg, were taken from each blend (2 samples from 
each of the top, middle and bottom) and dissolved in an appropriate 
diluent. The concentration of test article was measured using high 
performance liquid chromatography with ultraviolet detection 
(HPLC-UV), with reference to results of calibration standards and quality 
control (QC) samples that were prepared from independently prepared 
stock solutions of the reference material.  
Dry powder formulations were packed into a canister (internal volume of 
5 cm3) ready for aerosol generation. This was performed by compressing 
small aliquots of powder into the cylindrical canister using a bench press 
(applied force of 6 MPa) to build up thin layers of compressed powder of 
even density. 
2.2.5.2. Generation of dry powder aerosols of p38 MAPK 
inhibitors 
Aerosols were generated from the dry powder formulations using a Mk II 
Wright Dust Feed mechanism (Figure 2.5). The Wright dust feed (Wright, 
1950) was designed to produce and maintain dust atmospheres by 
suspending material scraped from the surface of a compressed powder 
in a stream of dry air. A canister containing the powder was advanced 
along a screw thread so the formulation was presented to a radial blade 
at a consistent rate. The concentration of analyte in air can be altered by 
changing the cross-sectional area of powder presented to the blade 
(canisters of internal volume 1.3, 5 or 40 cm3 are commercially 
available), the speed at which the radial section of powder is presented 
to the blade, and by varying the dilution of analyte in excipient. A 
regulated flow of compressed air (14 L/min) was used to disperse the 
powder into the exposure chamber. 
The operational settings for the Wright dust feed were selected to 
facilitate controlled delivery of each p38 MAPK inhibitor at the required 
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powder feed rates to achieve the indicated dose. Speed settings were 
selected with reference to pre-study aerosol generation trials performed 
without rats. Operating conditions were adjusted as necessary during 
each experiment to target the aerosol concentrations for each dose. 
2.5A 
 
2.5B 
 
Figure 2.5: Aerosol generator for dispersal of dry powder formulations. 
2.5A: Schematic of a Wright dust feed (Wright, 1950) adapted from 
www.researchgate.net. 2.5B: Mark II model used for generation of aerosols 
from p38 MAPK inhibitors blended with lactose vehicle. A blade (B) scrapes 
compressed powder (D), which is then suspended in a compressed air supply 
(AI) and dispersed downwards (AO) into the chamber. The motor (M) speed is 
adjusted by a variable rheostat (C). 
2.2.5.3. Liquid formulations of p38 MAPK inhibitors 
For exposure of animals to aqueous solutions of the p38 MAPK 
inhibitors, each micronised crystalline test article was dissolved in a 
vehicle to achieve a concentration (Table 2.2) anticipated to achieve an 
inhaled dose of 0.6 mg/kg. All mixtures were stirred magnetically 
throughout preparation and sonicated as required to aid formation of a 
solution. Solutol HS 15 is a non-ionic surfactant that inhibits 
P-glycoprotein 1 (Alani et al., 2010), a multidrug resistance protein pump 
typically restricted to the apical surface of cells in many tissues including 
the lung (Bellamy, 1996). Solutol HS 15 has been shown to inhibit 
P-glycoprotein 1 (Pgp) and enhance membrane permeability (Alani et 
al., 2010, Komarov et al., 1996). Systemic absorption of the p38 MAPK 
inhibitors, as substrates of Pgp, may therefore be enhanced by Solutol 
HS 15 by inhibiting the active reflux of compounds back into the lumen. 
AO 
AI 
B 
D 
D 
B 
AI 
AO 
M 
C 
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Table 2.2: Aqueous solutions of p38 MAPK inhibitors  
nebulised for single inhalation exposure of rats 
Study 
No. 
Test 
article 
Concentration 
in vehicle 
Vehicle for nebulisation 
R30573N GSK-899 1.50 mg/mL 
3% (v/v) Solutol HS 15 in 10% (w/v) 
aqueous 
2-hydroxypropyl-beta-cyclodextrin 
R30988N GSK-677 2.50 mg/mL 
3% (v/v) Solutol HS 15 in 0.9% (w/v) 
aqueous sodium chloride (pH 5.9) 
R31225N GSK-361 1.50 mg/mL 
20:20:60 (v/v/v) Solutol HS 15, ethanol 
and 60 mM phosphate buffer (pH 7) 
Cyclodextrins consist of a hydrophilic outer surface and a central 
lipophilic cavity. They form complexes with organic compounds via 
non-covalent bonds and are used to solubilise drugs of low solubility. 
Cyclodextrins improve the bioavailability of a drug by making it available 
at a biological interface such as a mucosa, from where the drug molecule 
transfers into the membrane without disrupting it (Challa et al., 2005). 
Hydrophillic cyclodextrins including 2-hydroxypropyl-beta-cyclodextrin 
(HPβCD) are unable to significantly permeate biological membranes but 
nevertheless enhance permeation of lipophilic drugs in aqueous 
environments (Loftsson et al., 2007) by solubilising the molecule and 
facilitating its presentation at a membrane. Inclusion of HPβCD could 
potentially enhance uptake of GSK-899 into the respiratory epithelium 
but may not necessarily promote its transfer into the systemic circulation. 
Ethanol is the most commonly used alcohol for enhancement of 
transdermal penetration of drugs (Sinha and Kaur, 2000). Kim and Chien 
(1996) demonstrated that skin permeation of three drugs increased with 
an increase in the proportion of ethanol in two cosolvent systems, 
achieving maximum skin permeability for 50% to 60% (v/v) ethanol. 
Gurtovenko and Anwar (2009) showed that insertion of ethanol into a 
lipid bilayer results in expansion and thinning of a membrane. Potential 
disruption of the membrane in concert with Solutol HS 15 may enhance 
the absorption of GSK-361, although the significance of enhanced 
absorption ascribed to ethanol in the nebulised formulation is uncertain, 
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given that volatile formulation components preferentially evaporate 
during aerosol generation, changing the composition of the droplets. 
Solutol HS 15, HPβCD and ethanol were used to solubilise p38 MAPK 
inhibitors of low solubility (GSK-899 and GSK-361). Solutol HS 15 was 
also formulated with GSK-677 for consistency with investigations 
comparing the toxicopathology of GSK-899 and GSK-677 described in 
Chapter 5. Whilst the potential for these vehicle components to enhance 
membrane permeability or systemic absorption of the p38 MAPK 
inhibitors in the lungs complicates elucidation of mechanisms for 
pulmonary absorption of nebulised test articles, this does not undermine 
the fundamental hypothesis that changing the aerosol form of a drug 
changes the kinetics of exposure and concomitant efficacy or 
toxicopathology. 
Preparation of GSK-899 in 3% (v/v) Solutol HS 15 in 10% (w/v) aqueous 
2-hydroxypropyl-beta-cyclodextrin 
The required mass of GSK-899 for a given concentration and volume 
was weighed into a container and Solutol HS 15 (3% of final volume) 
was added. The resultant mixture was stirred and minimal heat applied 
using a stir/hot plate. The required volume (80% of final volume) of 10% 
(w/v) aqueous 2-hydroxypropyl-beta-cyclodextrin was added and the 
resultant mixture acidified using 11.6M hydrochloric acid to achieve a 
solution. The pH was adjusted to within a range pH 4 to 6 using 10M 
sodium hydroxide, and the solution was made up to the final volume 
using additional 10% (w/v) aqueous 2-hydroxypropyl-beta-cyclodextrin. 
Preparation of GSK-677 in 3% (v/v) Solutol HS 15 in 0.9% (w/v) aqueous 
sodium chloride 
The required mass of GSK-677 for a given concentration and volume 
was weighed into a container and Solutol HS 15 (3% of final volume) 
was added. The required volume of 0.9% (w/v) aqueous sodium chloride 
was then added and the resultant mixture stirred until a solution formed. 
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Preparation of GSK-361 in 20:20:60 (v/v/v) Solutol HS 15, ethanol and 
60 mM phosphate buffer 
The required mass of GSK-361 for a given concentration and volume 
was weighed into a container and ethanol (20% of final volume) added. 
The resultant mixture was stirred and minimal heat applied using a 
stir/hot plate until a solution formed. Solutol HS 15 (20% of final volume) 
was added and the resultant mixture was stirred, maintaining a solution. 
The solution was made up to the final volume with addition of 60 mM 
phosphate buffer (pH 7) and the resultant mixture stirred. 
Evaluating physical stability of nebulised solutions 
In order to minimise the potential for each test article to precipitate out 
of solution during dose administration or in vivo, its solubility in the 
vehicle was checked after a period of nebulisation and also after dilution 
in simulated lung fluid (0.59 mg/mL lecithin and 1 mg/mL bovine serum 
albumin in aqueous 0.78 % (w/v) sodium dihydrogen orthophosphate 
and 0.4% (w/v) sodium chloride, buffered to pH 6.9). Visual appraisal of 
nebulised formulations confirmed the test articles remained in solution. 
In addition, formulations were visually checked after dilution of the test 
solution 1:1 and 1:10 (v/v) in simulated lung fluid; absence of a 
precipitate was interpreted as an indication the p38 MAPK inhibitor 
would remain in solution after deposition of droplets in the epithelial lung 
fluid of rats exposed to the nebulised drug. 
The concentration of each test article in solution was selected to facilitate 
controlled delivery of nebulised p38 MAPK inhibitor at the required feed 
rates to achieve the indicated dose. Formulation concentrations were 
selected with reference to pre-study aerosol generation trials performed 
without animals. 
2.2.5.4. Nebulisation of droplet aerosols 
Liquid aerosols were generated from aqueous solutions of each p38 
MAPK inhibitor using the Pari LC® Sprint (Figure 2.6), a commercially 
available nebuliser used for clinical applications. Air jet nebulisers were 
designed to atomise liquids by directing compressed air at high velocity, 
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via a nozzle, through a reservoir of liquid. A baffle traps larger droplets, 
which return under gravity to the reservoir; smaller droplets are emitted 
from the device for presentation to the patient or test subject(s). 
2.6A 
 
2.6B 
 
Figure 2.6: Air jet nebuliser used to disperse solutions or suspensions. 
2.6A: Schematic of a Pari LC Sprint adapted from www.pari.com. The 
compressed air (AI1) supplied to the nebuliser base passes through a nozzle 
(N), dispersing the liquid formulation (D1); small droplets are emitted from the 
aerosol outlet (AO). Ambient room air (AI2) can be drawn into the nebuliser via 
the nozzle insert (NI) during inspiration by a patient. 2.6B: twin air jet nebulisers 
adapted for presentation of aqueous solutions of p38 MAPK inhibitors to rats. 
Tubing (D2) and a peristaltic pump were used to maintain the liquid formulation 
at a constant volume in the device during nebulisation.  
The concentration of analyte in air was altered by varying its 
concentration in the solution or suspension used for atomisation. The 
Pari LC Sprints were modified to incorporate a tube for topping up the 
formulation from a bottle of the solution (using a peristaltic pump) and 
thus maintaining a constant volume of formulation in the device 
throughout the nebulisation period. 
A single nebuliser was used for dispersal of GSK-677 and twin 
nebulisers for dispersal of the less soluble GSK-361 and GSK-899 to 
achieve the target dose. Calibrated flows of compressed air (nominally 
6 to 7 L/min/nebuliser) supplemented with diluent air to deliver a total 
airflow of 14 L/min to the inhalation exposure chamber. 
2.2.5.5. Rodent inhalation exposure system 
Aerosols were generated using the appropriate apparatus and directed 
into the top of a rodent snout-only inhalation exposure chamber 
(Figure 2.7). The chambers (ADG Developments Ltd, Holbeach, 
AI1 
AI D2 
AO 
AO 
D1 
N 
NI 
AI2 
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Lincolnshire, UK) were of simple flow-through design (Figure 2.7C) and 
modular construction, consisting of a top section, three animal exposure 
sections (each accommodating two rows each of six animal exposure 
ports, and a single aerosol sampling port) and a base section to form a 
chamber with an internal diameter of four inches and volume of 7.5 litres. 
The chambers were operated under conditions of dynamic airflow such 
that animals could be sustained without compromising their physiology, 
i.e. to ensure oxygen was not depleted and carbon dioxide did not 
become excessive. The chamber exhaust (vacuum attached to the base 
section) was calibrated for airflow 16 L/min, which was slightly greater 
than the airflow emitted from the aerosol generation system (14 L/min). 
The diluent port in the chamber top section remained open to permit a 
draw of room air to balance airflow and maintain the chamber at near 
ambient pressure whilst ensuring airflow through the chamber. The 
chamber exhaust air was drawn through a filtration unit to remove 
particulates before the air was vented to atmosphere. For dry powder 
formulations, this consisted of two cartridges in series containing filters 
with cut-points of 5 µm followed by 0.5 µm. 
For nebulised aerosols, the exhaust line upstream of the particle filters 
also incorporated a droplet trap (cartridge containing glass bumping 
granules and water) followed by an empty cartridge (to capture 
percolating fluid emitted from the droplet trap) and then a moisture trap 
(typically two cartridges filled with silica gel) to dry the air before it passed 
through the particle filters. 
Acclimatisation of rats to inhalation exposure procedures 
Rats were restrained in polycarbonate tubes for inhalation exposure 
procedures. On the day prior to aerosol administration, rats were placed 
into the restraint tubes, attached to the chamber and exposed to air only 
for 20 minutes (airflows were calibrated for a supply of 14 L/min supply 
and exhaust of 16 L/min). 
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2.7A 
 
2.7B 
 
2.7C 
 
2.7D 
 
Figure 2.7: Snout-only inhalation exposure system incorporating a 
flow-through chamber for administration of aerosols to rats. 2.7A: 
snout-only inhalation exposure system, which was operated dynamically (air 
constantly supplied to and extracted from the chamber). 2.7B: schematic 
overlay of photograph showing a regulated air supply (1) connected to an 
aerosol generator (2), which dispersed test formulation into a chamber 
consisting of a mixing zone (3) and a ‘dosing zone’ (4) for presentation of the 
aerosol to rats restrained in tubes (5). Exhaled and waste aerosol were 
extracted from the base of the chamber and drawn through an exhaust filtration 
system (6) to remove particulate before being vented to atmosphere. 2.7C: 
view down the centre of the flow-through design of exposure chamber. 2.7D: 
presentation of a rat snout to the chamber, viewed through an open exposure 
port on the opposite side of the chamber. 
Inhalation exposure of animals 
Prior to exposure of animals, the aerosol generator was primed with the 
formulation. Rats were placed into the restraint tubes and attached to 
.6. 
.5. .5. 
.4. 
.3. .1. 
.2. 
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the chamber; the vertical position (chamber level) of each animal on the 
chamber was documented. 
It is not uncommon for an aerosol concentration gradient to form down 
an inhalation exposure chamber of flow-through design, as animals 
recycle the exhaled aerosol into the chamber atmosphere as it passes 
down the chamber (personal observations of unpublished data). This is 
less pronounced in chambers of narrower internal diameter, since the air 
velocity is faster for a given volumetric airflow. Nevertheless, in order to 
minimise a potential bias in achieved lung dose for animals sampled for 
blood and lung tissue (6 time points, each of 3 rats), one animal per time 
point was attached to each of the three chamber levels used. Unused 
animal exposure or sampling ports were closed using blanking plugs. 
Aerosol generation was started by connection of the power supply to the 
Wright dust feed (powder formulations) or connection of the compressed 
air supply to the nebuliser (aqueous formulations), and the time was 
documented. Animals were exposed to the aerosol for a period of 
30 minutes during which time operational settings (airflow and aerosol 
generation) and the animals were formally checked and documented at 
10-minute intervals. Also for animal welfare purposes, an electronic 
probe (Rotronic HygroFlex HF53 transmitter and HC2-C05 probe) was 
used to monitor chamber air temperature during inhalation exposures 
(data not presented). 
On completion of the 30-minute inhalation exposure period, aerosol 
generation was stopped (Wright dust feed power supply switched off or 
nebuliser air supply disconnected) and the time documented. The 
chamber was allowed to clear of aerosol and the condition of each 
animal was checked as it was returned to its holding cage. 
2.2.5.6. Aerosol characterisation 
‘Pre-study’ aerosol characterisation work was conducted without 
animals to establish the operating conditions needed to generate the 
aerosols at the target concentration, to confirm airborne particulates 
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were of suitable size for exposure of rats, and to select appropriate air 
sampling volumes for aerosol concentration and particle size analysis. 
Aerosol samples were taken during exposure of rats to determine the 
aerosol concentration for estimation of inhaled doses, and particle size 
analysis to confirm administered aerosols were comparable for the test 
articles and appropriate for exposure of rats. Aerosol characterisation 
data are summarised (Table 2.10) for discussion in Section 2.3.6.1. 
Additional samples of the test article and dry powder aerosols were 
taken during pre-study aerosol generation trials for imaging by scanning 
electron microscopy. 
Aerosol concentration 
The chamber aerosol concentration of each p38 MAPK inhibitor was 
determined twice during exposure of animals. The aerosol was sampled 
by drawing a measured volume of chamber air (6 litres for almost all 
aerosols; 4 litres for nebulised GSK-899 due to saturation of the filter 
with moisture) at a calibrated rate of 2.0 L/min through a glass fibre filter 
(Whatman GF/C). The filter was accommodated in an open-faced 
sampler (Figure 2.8A) that was attached to a sampling port adjacent to 
the rats (Figure 2.8B). 
After sampling, each filter was transferred to a labelled glass vial and 
transferred to a laboratory for processing and analysis. A measured 
volume of diluent (solvent) was added for extraction of the analyte for 
chemical analysis using a validated method for high performance liquid 
chromatography with ultraviolet detection (HPLC-UV). The test article 
was used as reference material for preparation of analytical standards 
and QC samples. 
Aerosol concentrations were calculated from the mass of analyte 
determined for each filter and the volume of chamber air sampled. 
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2.8A 
 
2.8B 
 
Figure 2.8: Apparatus for sampling the chamber atmosphere for 
measurement of aerosol concentration of drug analyte. 2.8A: open-faced 
filter holder (FH) connected to a pump used for drawing a known volume of air 
(sampling rate of 2 L/min) through a glass fibre filter (F). Filters were processed 
for HPLC-MS/MS analysis of a test article. 2.8B: filter holder (FH) attached to 
a chamber sampling port; sampled air was returned to the chamber exhaust to 
balance airflow during aerosol sampling. 
Particulate Size Distribution 
The size distribution of each p38 MAPK inhibitor was determined once 
during exposure of animals. A measured volume of air (6 litres for 
GSK-899 and SB-445; 20 litres for GSK-677 and GSK-361) was drawn 
from the exposure chamber, at a calibrated airflow of 2.0 L/min, through 
a Marple Personal Cascade Impactor (model 296) attached to a 
sampling port adjacent to the animals. 
A Marple 296 cascade impactor (Figure 2.9) consists of six stages with 
cut-points of decreasing aerodynamic diameter (orifices of decreasing 
size) that are off-set from one stage to the next. An aerosol is 
fractionated into sub-populations of decreasing particle size by 
accelerating the particles through each orifice such that the larger 
particles with sufficient momentum are unable to follow a change in 
airflow direction and consequently impact upon a collection surface. 
OFH FH 
FH 
F 
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2.9A 
 
 
 
 
2.9B 
 
2.9C 
 
Figure 2.9: Sampling chamber air using a cascade impactor to determine 
the particle size distribution of drug analyte. 2.9A: schematic of a cascade 
impactor illustrating key design features, airflow (red) and deposition of 
particulate (blue) into fractions of decreasing size as the sampled aerosol is 
drawn through progressively smaller apertures. 2.9B: Marple cascade impactor 
(Model No. 296) attached to a chamber port for aerosol sampling (airflow of 2 
L/min) for HPLC-MS/MS analysis of the drug-analyte and determination of 
particle size distribution. 2.9C: unassembled view of Marple cascade impactor 
showing the inlet cowl (1), slotted stages (2) and collection substrates (stainless 
steel (3) or glass-fibre (4) for powder or liquid aerosols respectively), a final 
glass fibre filter (5) which was supported on a wire mesh in the base section (6). 
Dry powder aerosols were collected onto stainless steel plates and 
nebulised aerosols were collected onto glass fibre substrates (Whatman 
GF/A), with a final glass fibre filter (Whatman GF/A) for both aerosol 
forms. After sampling, each substrate was visually assessed to confirm 
Vacuum 
Aerosol 
Large particulate 
Small particulate 
Fine particulate 
Stage and jet 
o-ring 
Filter 
Substrate 
.1. 
.2. 
.3. 
.4. 
.5. 
.6. 
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the presence or absence of a deposit and was transferred to an 
individually labelled glass vial. A measured volume of diluent was added 
to each vial to wash the stainless steel plate (dry powder aerosol) or 
extract the analyte from the glass fibre substrate. The washing or extract 
of the analyte was subjected to chemical analysis using a validated 
method for high performance liquid chromatography with ultraviolet 
detection (HPLC-UV) using the test article as reference material for 
preparation of analytical standards and quality control (QC) samples. 
Analysis of particle size data  
The percentage deposition on each stage was determined and used to 
calculate the cumulative percentage of particulate, by mass, smaller 
than each cut point (cumulative percentage undersize a stage).  
Regression analysis of the probit of cumulative percentage undersize a 
stage versus the Log10 of the cut-point of the stage indicated that the 
log-transformed data were non-linear. Consequently, the mass median 
aerodynamic diameter (MMAD) was determined using a pragmatic 
method (Christopher et al., 2010) by interpolation of the two central data 
points encompassing the median point of the distribution; the four central 
data points were used to estimate the geometric standard deviation (σg), 
excluding the most outlying data points. 
The European Medicines Agency Committee for Medicinal Products for 
Human Use define “fine particle mass” as the “particle size distribution 
of less than 5 µm” (EMA-3, 2006). Although this is described in a clinical 
context, it nevertheless provides another benchmark for comparing 
particle size. The fine particle fraction (percentage of mass <5µm 
aerodynamic diameter) was estimated by plotting the probit (probability 
function) of the cumulative proportion of aerosol mass less than each 
cut-point against Log10 of the cut-point. For each aerosol, the probit at 
Log10(x)=0.70 (aerodynamic diameter of 5 µm) was determined and 
back-transformed to a percentage using a probit table (Finney, 1952). 
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Theoretical cut-points for the Marple 296 at an airflow of 2.0 L/min 
(Rubow et al., 1987) are reproduced for reference (Table 2.3). For 
determination of MMAD, σg and the fine particle fraction, the dynamically 
calibrated ‘effective cut-point diameter’ (ECD) for each individual device 
and stage were used to process data for each impactor sample. 
Table 2.3: Theoretical effective cut-off diameter  
cut-points (ECDs) for a Marple 296 cascade impactor 
 Marple 296 cascade impactor Stages and cut points 
Stage No. 3 4 5 6 7 8 Filter 
ECD (m) 9.8 6.0 3.5 1.55 0.93 0.52 0 
Scanning electron microscopy of particles 
Dry powder samples of lactose excipient, amorphous GSK-899 and 
crystalline GSK-899, GSK-677 and GSK-361 were sampled from the 
stock material and also from aerosols generated using the excipient 
alone or in combination with the p38 MAPK inhibitor (nominally 5% w/w) 
for imaging by scanning electron microscopy. 
Aerosol samples were obtained by drawing a measured volume (1 litre) 
of the chamber atmosphere at a calibrated rate (1.0 L/min) through a 
polycarbonate isopore membrane filter (pore size 0.2 μm; 37 mm 
diameter; Millipore™), which was mounted in an open-face sampler and 
attached to the sampling port of the chamber. Following aerosol 
sampling, the filters were stuck to the lid of a petri dish or glass jar (to 
prevent contamination of the sampled aerosol) and stored at ambient 
temperature, protected from light and moisture pending image analysis. 
Reference (stock) material was deposited onto self-adhesive carbon 
discs using a brush; each carbon disc was mounted on an aluminium 
stub to facilitate manipulation of the sample and electron microscopy. 
Excess powder was carefully blown from the carbon disc.  
For each aerosol sample, a square of approximately 50 mm length and 
width was excised from the centre of the filter and mounted onto a 
self-adhesive carbon disc, which was mounted on a stub. 
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The mounted samples were then coated with platinum for a total of 60 
seconds (coating applied from three different angles each for 20 
seconds). 
2.2.5.7. Calculation of the estimated inhaled dose 
Estimated inhaled doses were calculated using Equations 1 and 2 
(Chapter 1, Section 1.3.4) for an exposure period of 30 minutes. 
2.2.5.8. Pharmacokinetic profiling of p38 MAPK inhibitors in 
blood/plasma and lung 
For logistical reasons, single dose experiments with GSK-899 and 
SB-445 were conducted first using analytical methods for blood samples 
diluted 1:1 in water. All subsequent experiments were performed using 
analytical methods established for plasma samples. 
Sampling of blood for chemical analysis of GSK-899 or SB-445  
A series of blood samples (60μL) were taken from groups of rats 
(3/dose/time point) immediately post exposure (30 minutes) and at 1.5, 
3.5, 7.5, 12.5 and 24 hours relative to the start of inhalation exposure. 
Blood was sampled by jugular venepuncture or caudal venepuncture if 
further sampling from the jugular vein was not feasible; animals were 
warmed for up to 10 minutes at approximately 39ºC to induce 
vasodilation in the tail for caudal venepuncture. Blood samples were 
taken into heparin (anticoagulant), mixed gently and placed on crushed 
wet-ice. As soon as practicable, duplicate aliquots (25 μL) of the blood 
sample were mixed 1:1 with sterile water in a micronic tube. Samples 
were then frozen over solid carbon dioxide and stored in a freezer at 
approximately -20°C or below pending analysis. 
Historically in drug development studies performed with GSK-899, 
sodium fluoride was used to inhibit endogenous esterases (Peirce, 
1913) in plasma, which may otherwise hydrolyse an amide bond (Fukami 
and Yokoi, 2012) in the analyte (Figure 2.2A). The method of analysis 
using blood/water was developed by a second analytical group without 
inclusion of sodium fluoride. Retrospective work (aligned to study 
R30662N) using blood taken from GSK-899 treated rats demonstrated 
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that, under the experimental conditions, there was no difference in 
measured concentrations of GSK-899 in blood diluted 1:1 in water or 1:1 
in aqueous sodium fluoride solution. 
Sampling of plasma for chemical analysis of GSK-677 or GSK-361 
Blood samples (400 μL) were taken from groups of rats (3/dose/time 
point) immediately post exposure (30 minutes) and at 1.5, 3.5, 7.5, 12.5 
and 24 hours relative to the start of inhalation exposure. Blood was 
sampled by jugular venepuncture (immediately post exposure) or from 
the abdominal aorta, i.e. as a terminal sample taken during 
exsanguination of the animal under isoflurane anaesthesia. Blood 
samples were taken into EDTA (anticoagulant), mixed gently and placed 
on crushed wet-ice. As soon as practicable, duplicate aliquots (25 μL) of 
the blood sample were mixed 1:1 with sterile water in a micronic tube. 
Samples were then frozen over solid carbon dioxide and stored in a 
freezer at approximately -80°C or below pending analysis. 
Sampling of lung for homogenisation and chemical analysis of p38 
MAPK inhibitors  
Groups of rats (3/dose/time point) were euthanized (deep anaesthesia 
under isoflurane followed by exsanguination) as soon as possible after 
exposure and at 1.5, 3.5, 7.5, 12.5 and 24 hours relative to the start of 
inhalation exposure. The relative time of lung sampling for rats 
euthanized as soon as possible post exposure was approximately 
50 minutes, i.e. 20 minutes after completion of the 30-minute inhalation 
exposure period, due to the logistics of transferring rats to the necropsy 
facility and the time taken for euthanasia and then isolation of lungs. 
The lungs were exposed by excision of the sternum. The heart and 
thymus were removed and the lungs then isolated from the carcass and 
freed of as much connective tissue as possible. The trachea was 
removed and the lung lobes weighed. Right lung lobes were placed into 
a megacassette (GSK-899 or SB-445 treated rat lungs) or 7mL Precellys 
tube (GSK-677 or GSK-361 treated rat lungs) and snap frozen in liquid 
nitrogen. Samples were stored at -80°C pending homogenisation. 
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Lung tissue presented in a megacassette (Fisher scientific, Reference 
No. 38VSP59042) was transferred to a 7mL Precellys tube (Precellys 
tissue homogenising CK28-7mL, Cat No. 0904-01). A volume of water 
was added to the lung tissue (one part water to one part lung tissue for 
GSK-361 and GSK-677; five parts water to one part lung tissue for 
GSK-899 and SB-445). At least two homogenisation cycles 
(15 seconds) were performed using a Precellys Tissue Homogenizer 24. 
The resultant tissue homogenate was centrifuged at 5500 RPM for 
10 minutes and the supernatant transferred to a vial and stored at -80°C 
pending chemical analysis. 
Chemical analysis of p38 MAPK inhibitors in lung homogenate and blood 
or plasma 
Concentrations of GSK-899 or SB-445 in blood-water, GSK-677 or 
GSK-361 in plasma and all compounds in lung homogenate were 
quantified using a validated method for high performance liquid 
chromatography with mass spectroscopy detection (HPLC-MS/MS) 
using the respective p38 MAPK inhibitor and an internal standard as 
reference materials.  
Results for analysis of blood-water samples were initially corrected for 
the 1:1 dilution to express concentrations in terms of GSK-899 in blood. 
Blood values were then converted to plasma-based values using a 
blood:plasma ratio of 2.10 for GSK-899 and 0.683 for SB-445 
(unpublished data) to facilitate consistency of presentation for plasma 
data across all of the p38 MAPK inhibitors. 
Determination of pharmacokinetic parameters 
For each p38 MAPK inhibitor, statistical analysis of the 
drug-concentration profiles in lung and plasma was performed 
(Statistica, version 12.0.1133.40) using two-way analysis of variance 
(ANOVA), with post hoc analysis using Tukey’s honestly significant 
difference test (Abdi and Williams, 2010[B]) to determine degrees of 
statistical significance between aerosol forms (crystals versus aqueous 
solution, and amorphous GSK-899). 
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Pharmacokinetic evaluations of plasma and lung concentration data for 
each p38 MAPK inhibitor were performed using a non-compartmental 
method to estimate the maximum observed concentration (Cmax), time to 
Cmax (Tmax) and the area under the concentration-time curve (AUC) 
approximated using the trapezoid rule (linear-up, log-down method). 
Statistical analysis was not performed for pharmacokinetic parameters 
because they were calculated from composite data and not for each 
animal individually. 
2.2.5.9. Analysis of drug-lung distribution by matrix assisted 
laser desorption/ionization (MALDI) 
For each p38 MAPK inhibitor, a rat was euthanized (deep anaesthesia 
under isoflurane followed by exsanguination) as soon as possible after 
the 30-minute inhalation exposure period (i.e. at 50 minutes) and at 
3.5 hours relative to the start of inhalation exposure. 
The lungs were exposed by excision of the sternum. The heart and 
thymus were removed and the lungs then isolated from the carcass and 
freed of as much connective tissue as possible. The lungs were carefully 
spread out on foil, with the trachea at the top and the front of the lungs 
uppermost, to permit identification of the individual lobes. The lungs were 
then placed in a megacassette, and frozen over solid carbon dioxide and 
stored at approximately -80°C pending analysis. 
Frozen lung samples were mounted onto a cryostat chuck and sections 
of nominally 12 µm thickness were cut (LEICA CM3050S Cryostat) and 
thaw mounted onto indium tin oxide coated glass slides. Typically, five 
sections per lung were processed for matrix assisted laser 
desorption/ionization with mass spectrometry imaging (MALDI-MSI) 
including, where possible, a section selected for each lobe to include the 
main airway. Lung sections were coated with matrix, which consisted of 
approximately 2 mL of α-cyano-4-hydroxycinnamic acid (CHCA; 
7 mg/mL) matrix solution in 70:30 (v/v) methanol with 0.2% aqueous 
trifluoroacetic acid. 
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For GSK-899, GSK-677 and GSK-361, a Bruker UltrafleXtreme 
TOF-TOF mass spectrometer was used to construct an ion intensity map 
of the lung section by systematically vaporising focal points of the lung 
section and detecting the ionised analyte fragments by mass 
spectrometry. MALDI-MSI analysis of SB-445 was precluded by poor 
ionisation of the molecule. 
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2.3. Results and discussion 
2.3.1. Principal component analysis of the physico-
chemical parameters of six p38 MAPK inhibitors 
Two datasets (X matrices) of physicochemical data were collated for 
principal component analysis. The first dataset (Tables 2.4 and 2.5) 
consisted of in silico parameters derived from molecular structures 
(Figure 2.2) and the second data set (Table 2.6) consisted of parameters 
measured in vitro. 
Table 2.4: ‘In silico’ physicochemical parameters for principal 
component analysis of six p38 MAPK inhibitors 
Physicochemical 
parameter 
Test article 
GSK-899 GSK-677 GSK-361 GSK-340 SB-323 SB-445 
Pgp_v31.Pgp_Score A 
(sponsor’s parameter; 
negative score indicates 
drug is Pgp substrate) 
-1.57 -2.02 -0.23 -2.64 -0.54 -0.35 
Chromatic distribution 
coefficient B 
(ChromLogD_v6.value) 
3.77 2.29 4.84 2.85 3.87 3.52 
Chromatic partition 
coefficient 
(ChromLogP_v1.value) 
4.01 5.94 4.91 3.88 5.16 5.15 
Property forecast index 
(PFI_v2.PFI_score) 
9.77 5.29 7.84 5.85 7.87 7.52 
perm_chrom_v4.perm_ 
score (function of 
ChromLogD vs cmr) C 
-0.22 -0.64 0.5 -0.67 0.2 0.17 
CXN_pKa.acid class;  1 1 2 1 1 1 
CXN_pKa.base class 
See Table 2.5 for class 
score definition (CXN is 
software abbreviation) 
2 7 1 6 1 1 
Notes 
A Pgp (P-glycoprotein 1), a multidrug resistance protein pump often restricted to 
apical cell surface in tissues including lung (Bellamy, 1996). Model constructed 
from in silico data (LogD, charge, cLogP; Abraham’s bond acidity and basicity) 
and validated for 442 non-substrates and 1201 substrates of Pgp (flux ratio of 
membrane permeability: basolateral to apical versus apical to basolateral). 
B Parameter used to derive Pgp_v31.Pgp_Score using an in-house in silico model. 
C Permeation model of ChromLogD plotted against CMR using a linear discriminant 
function. Compounds of larger positive values are more likely to be well absorbed; 
very large and lipophilic molecules (mw >500 and clogP >5) are likely to be poorly 
absorbed due to low solubility. Negative values indicate poor absorption. 
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Physicochemical 
parameter 
Test article 
GSK-899 GSK-677 GSK-361 GSK-340 SB-323 SB-445 
Andrew’s binding energy 
(abe); (Andrews et al., 
1984) 
23.1 31.05 13.2 47.05 16.8 18.6 
Net charge (charge) B 
sum of positive/negative 
0 0 0 0 0 0 
Calculated log partition 
coefficient (cLogP) B 
3.750 5.287 3.746 2.063 
3.758 
3.847 
Calculated molar 
refraction (cmr) 
15.013 15.551 11.037 16.956 11.555 11.123 
Ratio of rotatable to total 
bonds (flex) 
15 27 15 12 16 16 
Molecular weight (mw) 570.57 565.66 410.44 618.72 456.42 478.37 
Molar volume (mv) 518 602 423.5 637 423.5 409.5 
Polar surface area 
(tpsa); (Ertl et al., 2000) 
130.48 102.49 97.12 96.94 100.27 100.27 
Number of listed items in molecule 
Aromatic rings (aring) 6 3 3 3 4 4 
Halogen groups 
(halgrps) 
1 1 0.5 1 1.5 2.5 
Hydrogen bond 
acceptors (hba) 
6 4 4 4 5 5 
Hydrogen bond donors 
(hbd) 
3 3 2 2 3 3 
Non-hydrogen atoms 
(heavy) 
41 41 30 45 33 34 
Hetero atoms (hetrat); 
ratio of O, N and S vs C 
0.39 0.30 0.32 0.30 0.30 0.32 
Hydrogen bond acceptor 
(liphba); (Lipinski et al., 
1997) 
10 9 7 10 7 7 
Hydrogen bond donor 
(liphbd); (Lipinski et al., 
1997) 
3 3 2 2 3 3 
Aliphatic rings (naring) 0 1 0 3 0 0 
Negatively ionisable 
groups (neg) 
0 0 0 0 0 0 
Positively ionisable 
groups (pos) 
0 1 0 1 0 0 
Rotatable bonds (rb) 7 12 5 6 6 6 
sp2 carbons (sp2); 
aromatic or double bond 
35 22 21 22 23 23 
sp3 carbons (sp3); 
saturated bonds 
6 19 9 23 10 11 
Notes 
B Parameter used to derive Pgp_v31.Pgp_Score using an in-house in silico model. 
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Physicochemical 
parameter 
Test article 
GSK-899 GSK-677 GSK-361 GSK-340 SB-323 SB-445 
Abraham’s descriptors (Abraham, 1993) 
Hydrogen bond acidity 
(alpha) B 
1.0841 0.7658 0.8446 0.572 0.3989 0.3989 
Hydrogen bond basicity 
(betah) B 
2.6653 2.9075 1.7470 3.4886 2.1699 2.0209 
Dipolarity/ polarizability 
(pi) 
5.2771 3.6982 3.5739 4.078 3.3452 3.3558 
Excess molar refraction 
(r2) 
4.8492 3.6563 2.2754 4.2079 3.5091 3.2663 
McGowan characteristic 
scaled molar volume 
(vx2); (McGowan, 1978) 
3.8289 4.2796 3.0456 4.5849 3.0703 2.9648 
Notes 
B Parameter used to derive Pgp_v31.Pgp_Score using an in-house in silico model. 
Table 2.5: Scoring system used for pKa acid and base  
class definitions for in silico parameters listed in Table 2.4 
Value Acid class Base class 
0 No acidic group No basic group 
1 pKa >8.5 pKa ≤6.0 
2 pKa 7.5 - 8.5 pKa 6.0 - 7.0 
3 pKa 7.0 - 7.49 pKa 7.01 - 7.5 
4 pKa 6.5 - 6.99 pKa 7.51 - 8.0 
5 pKa 6.0 - 6.49 pKa 8.01 - 8.5 
6 pKa 5.5 - 5.99 pKa 8.51 - 9.0 
7 pKa <5.5 pKa >9.0 
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Table 2.6: Measured physicochemical parameters for  
principal component analysis of six p38 MAPK inhibitors 
Physicochemical 
parameter 
Test article 
GSK-899 GSK-677 GSK-361 GSK-340 SB-323 SB-445 
Apparent membrane 
permeability of compound 
in MDCKII-MDR1 cells A 
(Cmpd_Papp nm/sec) 
97.2 71.4 350.1 13.348 146.605 209.62 
Solubility in SLF (µg/mL)       
0.5 hours 3 878 29 100 347 280 
4 hours 4 957 9 130 352 294 
24 hours 6 865 14 220 393 314 
Acid or Base 
Weak 
Base 
Basic Neutral Basic Neutral Neutral 
Property forecast index 
(PFI); sum of the number 
of aromatic rings and 
ChromLogD 
9.29 4.90 7.96 5.83 7.57 7.90 
Artificial membrane 
permeability B 
(PERM_NUM) at pH 7.05 
160 6.33 540 31 470 - 
% human serum albumin 
protein binding 
(HSA_PCT_BIND) 
94.8 81.0 88.8 90.3 88.8 91.2 
Alpha-1-acid glycoprotein 
binding (AGP_PCT_BIND) 
90.2 79.4 76.0 86.2 74.6 77.0 
% plasma protein binding 
(PCT_PPB) 
99.5 96.1 96.3 99.0 - 96.5 
VDSS (steady state 
volume of distribution) 
1.19 2.86 1.89 3.20 1.04 0.758 
LogVDSS 0.0767 0.456 0.276 0.506 0.0152 -0.12 
LogVDUSS (log of 
unbound volume of 
distribution at steady state) 
1.53 1.18 1.28 1.58 1.03 1.04 
Chromatographic 
(CHROM) LogD at pH 7.4 
3.29 1.9 4.96 2.83 3.57 3.90 
CHI_LogD at pH 7.4 1.77 0.92 2.80 1.48 1.95 2.15 
CHI_LogP 1.77 2.48 2.81 2.30 2.00 2.15 
CHI_IAM 39.7 39.7 39.06 43.7 33.7 32.2 
Notes 
A MDCKII-MDR1: cell line of Madin-Darby canine kidney cells transfected with 
human Pgp (Agarwal et al., 2007). For measurement of passive membrane 
permeability, Pgp was inhibited by GF120918 (Ward and Azzarano, 2004). 
B Passive permeability across lipid bilayer of egg phosphatidyl choline (1.8%) 
and cholesterol (1%) in n-decane; buffer (50mM Na2HPO4 with 0.5% HPβCD; 
pH 7.05) of donor (bottom) and acceptor (top) compartments analysed for drug 
concentration at 3 hours of incubation (Kansy et al., 1998, Veber et al., 2002). 
SLF simulated lung fluid 
LogD distribution coefficient in organic-aqueous phases 
LogP partition coefficient in organic-aqueous phases 
CHI chromatographic hydrophobicity index (data obtained from HPLC method) 
IAM immobilised artificial membrane (HPLC column for phospholipidotic potential) 
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Principal component analysis of the in silico data generated a score plot 
(Figure 2.10) in which the compounds formed three equidistant groups 
within the ‘t[1]/t[2] space’. GSK-899 lay close to the t[1] axis, with a dual 
cluster (GSK-677 and GSK-340) in the lower left quadrant and a second 
cluster (SB-323, SB-445 and GSK-361) in the lower right quadrant. The 
two principal components accounted for 74% of the data variability in the 
dataset (Table 2.7). The influence of parameters (variables) on the 
distribution of the compounds is summarised in the loading plot 
(Figure 2.11); variables with a narrow angle to an axis have a more 
predominant relationship with that principal component (t[1] or t[2]), and 
the further a variable is from the origin of the loading plot, the greater its 
significance for a compound (observation) appearing in the same 
quadrant of the score plot (Umetrics, 2013).  
The loading plot (Figure 2.11) indicated the in silico parameters most 
influencing the relative distribution of the three groups of compounds 
from one another included the following: 
1. GSK-899: number of aromatic rings, sp2 hybridised carbons 
(double or aromatic bonds) and hydrogen bond acceptors, a 
higher proportion of oxygen, nitrogen and sulphur atoms relative 
to carbon (“heterat”) and polar surface area (“tpsa”); 
2. GSK-677 and GSK-340: pKa base class, hydrogen bond basicity 
(“betah”), Andrew’s average binding energy (“abe”), molar 
volume, number of aliphatic rings (“naring”) and positively 
ionisable groups, hydrogen bond basicity (“betah”) and 
McGowan’s scaled molar volume (“vx2”); 
3. GSK-361, SB-323 and SB-445: Pgp score (the smaller negative 
scores suggested these three compounds were less likely to be 
substrates of P-glycoprotein 1 and would not be actively returned 
to the lumen); positive scores for the permeation model of 
ChromLogD plotted against calculated molar refraction 
(“perm_chrom_v4.perm_score”) indicated the compounds may 
be better absorbed. 
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Principal component analysis of the measured physicochemical data 
(Table 2.6) produced a similar distribution of compounds in the ‘t[1]/t[2] 
space’ (Figure 2.12) suggesting the information embedded within the in 
silico model was reasonably well aligned to experimental data. There 
was limited separation of the three compounds clustered in the lower 
right quadrant (SB-323, SB-445 and GSK-361) but a clear separation of 
the other three compounds, with GSK-340 plotted in the upper left 
quadrant between GSK-677 and GSK-899. The variances of the two 
principal components (R2X[1] and R2X[2]) accounted for 80% of the 
variance in the dataset (Table 2.7). 
The distribution of variables in the loading plot (Figure 2.13) indicated 
the in vitro parameters most influencing the relative distribution of the 
compounds from one another in the score plot included the following: 
1. GSK-899: binding of plasma protein (“Pct_PPB”) and 
alpha-1-acid glycoprotein (“AGP_Pct_Bind”) and log of the 
unbound volume of distribution at steady state (“LogVDUSS”); 
2. GSK-677: solubility in simulated lung fluid; 
3. GSK-361, SB-445 and SB-323: apparent (passive) membrane 
permeability (“Cmpd_Papp_nm_sec”), artificial membrane 
permeability (“Perm_Num_pH7.05”) and chromatographic LogD 
(“Chrom_LogD_pH7.4”). 
4. GSK-340: chromatographic hydrophobicity index for the 
immobilised artificial membrane column (“CHI-IAM”). 
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Figure 2.10: Score plot for principal component analysis of estimated 
ADME and physicochemical properties for six p38 MAPK inhibitors: 34 
parameters were derived for each molecular structure shown in Figure 2.2 
using Adamantis, a predictive web-based tool for characterising compounds. 
 
Figure 2.11: Loading plot for principal component analysis of calculated 
ADME and physicochemical properties for six p38 MAPK inhibitors. Most 
noteworthy parameters appear furthest from the origin and, in terms of its 
contribution to a principal component, has the narrowest angle from the 
respective axis (p[1] or p[2]). 
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Figure 2.12: Score plot for principal component analysis of the measured 
physicochemical properties for six p38 MAPK inhibitors: 14 in vitro 
parameters and solubility (0.5, 4 and 24 hours in simulated lung fluid) were 
measured for each molecular structure shown in Figure 2.2. 
 
Figure 2.13: Loading plot for principal component analysis of measured 
physicochemical parameters of six p38 MAPK inhibitors. Most noteworthy 
parameters appear furthest from the origin and, in terms of its contribution to a 
principal component, has the narrowest angle from the respective axis (p[1] or 
p[2]). 
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Table 2.7: Statistical summary data for principal component analysis  
of measured physicochemical parameters of six p38 MAPK inhibitors 
Dataset Component R2X R2X(cum) Eigenvalue Iterations 
In silico 1 0.466 0.466 2.8 20 
 2 0.272 0.738 A 1.63 19 
In vitro 1 0.505 0.505 3.03 20 
 2 0.294 0.799 B 1.77 19 
Notes 
A In silico data: cumulative R2X value of 0.738 indicates the two principal 
components (R2X[1] and R2X[2]) account for 74% of variance in the data set. 
B In vitro data: cumulative R2X value of 0.799 indicates the two principal 
components (R2X[1] and R2X[2]) account for 80% of variance in the data set. 
2.3.2. X-ray powder diffraction of amorphous GSK-899  
Before conducting in vitro dissolution testing and in vivo experiments, 
and again following completion of most in vivo experiments, samples of 
spray dried GSK-899 were analysed by X-ray powder diffraction (XRPD) 
to confirm the material was amorphous and had not reverted to the more 
stable crystalline state. The characteristic diffraction pattern for 
crystalline GSK-899 (Figure 2.14A) was not evident for amorphous 
GSK-899 (Figure 2.14B), which exhibited a broad baseline characteristic 
of randomly orientated molecules (Bates et al., 2006). 
2.14A 
 
2.14B 
 
Figure 2.14: X-ray powder diffraction of amorphous and crystalline 
GSK-899. Replicate scans (red, blue and green) shown with a total scan (pink) 
as a plot of signal intensity (counts) against scattering angle (2ɵ). 
2.14A: GSK-899 crystals (Lot 051087156) exhibit a reproducible peak 
‘signature’ for diffracted X-rays consistent with atomic spacing in 
crystals. 2.14B: amorphous GSK-899 (batch EE666025D) shows a broad 
baseline devoid of peaks indicative of randomly orientated molecules. 
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2.3.3. In vitro dissolution of p38 MAPK inhibitors 
The cumulative mass of dissolved drug, expressed as a percentage of 
total mass, plotted against time (Figure 2.15) showed dissolution of 
crystalline GSK-899 and GSK-361 in simulated lung fluid was 
considerably slower than crystalline GSK-677, SB-323 or SB-445. The 
dissolution-time curve for amorphous GSK-899 was sigmoid but the rate 
from 12 minutes was much faster than for crystalline GSK-899, which is 
consistent with the findings of Hancock and Parks (2000). 
Dissolution rates expressed as the percentage of dissolved mass 
against time (%/min) were calculated for the steepest approximately 
linear portion of each compound profile (Table 2.8). The ranking of 
dissolution rates for the crystalline compounds was broadly in line with 
measured solubility data. The dissolution rate for amorphous GSK-899 
was faster than that of crystalline GSK-899 but slower than crystalline 
GSK-677, SB-323 and SB-445. 
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Figure 2.15: In vitro dissolution of five crystalline p38 MAPK inhibitors 
and amorphous GSK-899 in simulated lung fluid. The cumulative 
proportion of each test article dissolved plotted against time (individual data). 
GSK performs dissolution testing of respirable aerosols on a risk-benefit 
basis. Experiments for investigative purposes, including this thesis, are 
performed once given the observed robustness of the test methodology and 
chemical analyses (unpublished data; duplicate data for crystalline GSK-899 
were consistent with this assertion). Data in support of strategic decisions for 
commercial assets (drug development) and regulatory submissions are 
generated in triplicate for reporting mean dissolution and standard deviation. 
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Table 2.8: In vitro dissolution rates of five crystalline p38 MAPK 
inhibitors and amorphous GSK-899 in simulated lung fluid 
PCA 
group A 
Test article 
Particle 
form 
Dissolution 
rate (%/min) 
Period of 
analysis 
(min)B 
Measured 
solubility 
(µg/mL)C 
1 GSK258899B crystalline 0.0459  1.5 - 180 
4.33 
  amorphous 1.47  15 - 60 
2 GSK610677B crystalline 2.85  1.5 - 19.5 900 
3 GSK678361A crystalline 0.0783  1.5 - 180 17.3 
 SB-681323T crystalline 2.13  1.5 - 19.5 364 
 SB-731445T crystalline 3.17  1.5 - 19.5 296 
Notes 
A Nominal grouping identified in PCA score plots in Figures 2.10 and 2.12. 
B Period selected for initial linear portion of the curve before slowing of rate. 
C Mean for 0.5, 4 and 24 hours (values for timepoints presented in Table 2.6). 
2.3.4. Selection of p38 MAPK inhibitors for in vivo 
investigation of pharmacokinetics 
The aim of PCA was to select three from six p38 MAPK inhibitors with 
contrasting physicochemical properties within the ‘t[1]/t[2] space’. For both 
in silico and in vitro data, PCA clearly separated GSK-899 from the other 
compounds and can be considered a more aromatic molecule 
(Figure 2.11) with a propensity for protein binding (Figure 2.13). 
Although GSK-677 and GSK-340 were clustered in the in silico ‘t[1]/t[2] 
space’, a clear separation of these compounds was evident for the in 
vitro dataset and GSK-677 was selected as a readily soluble, more polar 
and basic molecule. 
For both PCA analyses, SB-323, SB-445 and GSK-361 were clustered 
with high passive membrane permeability (Figure 2.13). SB-323 and 
SB-445 were indistinguishable in the score plot for in silico data, with 
GSK-361 plotted slightly towards the periphery from these compounds. 
In vitro dissolution rates in simulated lung fluid separated these 
compounds, with GSK-361 exhibiting a slow rate and SB-323 and 
SB-445 faster rates. GSK-361 was selected as a membrane permeable 
molecule of low solubility and high lipophilicity. Given its limited supply, 
SB-445 (high solubility, high lipophilicity and high membrane 
Chapter Two 
98 
 
permeability) was only included in the single dose study described in this 
chapter to investigate its pharmacokinetics after inhaled administration. 
A plot of the solubility versus dose in conducting airways for marketed 
pulmonary drugs was considered at a workshop of the AAPS, US-FDA 
and USP, with a view to considering development of an inhalation 
Biopharmaceutics Classification System (iBCS). The plot included a 
threshold representing critical solubility of small molecule drugs for a 
given dose above which drugs had sufficient solubility to be dissolved 
and below which drugs were dissolution limited; most of the marketed 
drugs plotted were not dissolution limited (Hastedt et al., 2016). Key in 
vitro measurements and descriptors for selected p38 MAPK inhibitors in 
keeping with this convention included solubility in simulated lung fluid 
and passive membrane permeability (Table 2.9). 
Table 2.9: Key in vitro physicochemical parameters of p38 MAPK 
inhibitors selected for in vivo evaluation of lung exposure in rats 
Test 
article 
Physicochemical parameter 
Key descriptors 
Solubility in 
SLF at 4 
hours 
(µg/mL) 
Apparent membrane 
permeability of drug in 
MDCKII-MDR1 cells A 
(nm/sec) 
% plasma 
protein 
binding 
(PCT_PPB) 
GSK-899 4 97.2 99.5 
Low solubility; 
low membrane 
permeability 
GSK-677 957 71.4 96.1 
High solubility; 
low membrane 
permeability 
GSK-361 9 350.1 96.3 
Low solubility: 
high membrane 
permeability 
SB-445 294 209.62 96.5 
High solubility; 
high membrane 
permeability 
Notes 
A MDCKII-MDR1: cell line of Madin-Darby canine kidney cells transfected with 
human Pgp (Agarwal et al., 2007). For measurement of passive membrane 
permeability, Pgp was inhibited by GF120918 (Ward and Azzarano, 2004). 
SLF simulated lung fluid 
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2.3.5. Scanning electron microscopy of particles 
Aerosols generated from lactose excipient alone or in combination with 
nominally 5% (w/w) p38 MAPK inhibitor were sampled for scanning 
electron microscopy, with reference to the input materials (indexed in 
Table 2.10). 
Table 2.10: Index of figures showing scanning electron  
microscopy (SEM) of input materials and aerosol samples 
Input material Figure number 
Lactose n/a 2.16 
GSK-899 
crystalline 2.17 
amorphous 2.18 
GSK-677 crystalline 2.19 
GSK-361 crystalline 2.20 
Notes 
P38 MAPK inhibitors used for investigation of efficacy (Chapter 4) and repeat 
dose toxicity (Chapter 5) were sampled; SB-445 not sampled for SEM. 
Particles of the excipient, “inhalation grade lactose”, were irregular in 
shape with both angular and smooth edges (Figure 2.16). The lactose 
excipient was supplied as a mixture of mainly large carrier particles with 
6% (w/w) fine particles (<4.5 µm aerodynamic diameter). Large carrier 
particles (50 to 100 µm aerodynamic diameter) are commonly used as 
excipient in dry powder inhaler formulations to facilitate manipulation of 
small clinical doses and to improve dispersal of the drug in air (Healy et 
al., 2014). 
Comparison of supplied excipient (Figure 2.16A) with sampled aerosol 
(Figure 2.16B) shows enrichment of the fine particles of lactose during 
aerosol generation, with primary particles and agglomerates evident on 
the isopore membrane filter. Enrichment of fine lactose particles (and a 
respirable drug if present) in aerosols generated from dry powder 
formulations occurs as the large lactose particles impact or sediment 
within the exposure system. 
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2.16A: 
 
2.16B:  
 
Figure 2.16: Scanning electron microscopy of ‘inhalation grade lactose’ 
used as excipient in dry powder formulations of p38 MAPK inhibitors. 
2.16A: excipient supplied for preparation of drug-lactose blends. Particles were 
irregular in shape, with angular and smooth edges. Large particles (L1) are 
visible, with smaller particles of lactose (L2) adhered to their surface. 2.16B: 
lactose particles sampled from an aerosol onto an isopore filter; the pores are 
visible as black spots on the membrane. 
Crystalline drugs manufactured for non-clinical (in vitro and in vivo) and 
clinical (human) development are commonly micronised using a jet mill 
to reduce particle size for inhaled delivery. Micronised crystals of the p38 
MAPK inhibitors were angular and irregular in appearance with GSK-899 
(Figure 2.17A) and GSK-361 (Figure 2.20A) of columnar appearance 
with elongated crystals of medium aspect ratio; crystals of GSK-361 
appeared more slender than GSK-899. Micronised crystals of GSK-677 
(Figure 2.19A) were more plate-like and less distinct from lactose. 
2.17A: 
 
2.17B:  
 
Figure 2.17: Scanning electron microscopy (SEM) of crystalline GSK-899. 
2.17A: jet milled (micronised) crystals of angular and irregular appearance. 
2.17B: particles sampled from an aerosol generated from 5% (w/w) crystalline 
GSK-899 in lactose onto an isopore filter. A large lactose particle (L1) is clearly 
visible but the irregular angular appearance of crystalline GSK-899 (C) and 
small lactose particles (L2) makes differentiation of species by SEM uncertain. 
L1 
L1 
L2 
C 
L2 
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Amorphous GSK-899 was produced by spray drying a saturated solution 
of the drug in methanol, a volatile solvent that rapidly evaporated to 
produce particles of randomly orientated GSK-899 molecules. Particles 
resembled shrunken spheres of dimpled appearance (Figure 2.18A). 
2.18A 
 
2.18B 
 
Figure 2.18: Scanning electron microscopy of amorphous GSK-899. 
2.18A: amorphous powder was produced by spray drying a saturated solution 
of GSK-899 in methanol to produce ‘dimpled spheres’. 2.18B: particles 
sampled from an aerosol generated from 4% (w/w) amorphous GSK-899 in 
lactose onto an isopore filter. A larger lactose particle (L1) and primary 
amorphous particles (A) are distinct. A drusy agglomeration (DA) of particles 
represents a large lactose particle coated with small lactose particles and 
amorphous GSK-899. 
L2 A 
DA 
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Aerosols generated from powder formulations of p38 MAPK inhibitors 
showed the drug and lactose as primary particles and also as drusy 
agglomerations, i.e. large particle (lactose) coated with fine particulates. 
Given the particle shapes for the input materials, distinction of the p38 
MAPK inhibitor from lactose was readily apparent for amorphous 
GSK-899 (Figure 2.18B) and, to a lesser extent, crystalline GSK-361 
(Figure 2.20B) but was indistinguishable for crystalline GSK-677. 
2.19A: 
 
2.19B:  
 
Figure 2.19: Scanning electron microscopy (SEM) of crystalline GSK-677. 
2.19A: crystals were micronised using a jet mill, producing smaller crystals of 
an angular and irregular or plate-like (P) appearance. 2.19B: particles sampled 
from an aerosol generated from 5% (w/w) crystalline GSK-677 in lactose onto 
an isopore filter. A large lactose particle (L1) is distinct but the irregular and 
plate-like appearance of crystalline GSK-677 and small lactose particles 
precludes differentiation of these two species by SEM. 
2.20A: 
 
2.20B:  
 
Figure 2.20: Scanning electronic microscopy of crystalline GSK-361. 
2.20A: crystals were micronised using a jet mill, producing smaller crystals of 
an angular and irregular or columnar (Col) appearance. 2.20B: particles 
sampled from an aerosol generated from 5% (w/w) crystalline GSK-361 in 
lactose onto an isopore filter. Plate-like lactose particles (L1) and columnar 
GSK-361 crystals (C) can be distinguished in the image. 
 
L1 
P 
L1 Col 
 C 
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SEM of aerosols revealed no indication that fine particles had fused to 
form larger aggregates in the aerosol and that compression of dry 
powder formulations to facilitate aerosol generation would not 
compromise presentation of the p38 MAPK inhibitors to animals. 
2.3.6. Pharmacokinetics of p38 MAPK inhibitors in rats 
following a single inhaled dose 
It was anticipated the rate of clearance of p38 MAPK inhibitors from rat 
lungs after inhalation exposure would be driven by high solubility and 
lipophilicity, facilitating transmembrane migration of the molecules and 
uptake into the systemic circulation (blood). Compounds presenting a 
faster dissolution rate were expected to achieve higher plasma 
concentrations immediately after inhalation exposure, and for lung 
concentrations to be significantly reduced at 24 hours post exposure.  
Based on the results of PCA and in vitro dissolution, it was hypothesised 
that exposure in terms of area under the drug-concentration time curve 
may be ranked as follows:  
• Plasma: SB-445 > GSK-678 > GSK-361 > GSK-899 
• Lung: GSK-899 > GSK-361 > GSK-678 > SB-445 
It was also hypothesised that: 
• Nebulised solutions of p38 MAPK inhibitors would be cleared from 
the lungs quicker than for the corresponding crystalline aerosol 
form, as crystalline particles must first undergo dissolution prior to 
transmembrane absorption. 
• Presentation of GSK-899 as amorphous powder would achieve 
higher plasma concentrations and show faster lung clearance 
than for the crystalline form of GSK-899. 
2.3.6.1. Inhalation exposure of rats to p38 MAPK inhibitors 
and estimation of the inhaled dose 
Generally, achieved mean aerosol concentrations were in good 
agreement with target (±10% of 24 µg/L), with crystalline GSK-899 and 
nebulised GSK-361 slightly higher (±15% of target). Mean estimated 
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inhaled doses for each p38 MAPK inhibitor and aerosol form were 
generally ±15% of the target dose of 0.6 mg/kg (0.51 to 0.69 mg/kg), with 
GSK-677 doses below this range (Table 2.11). This was primarily due to 
lower body weights for rats exposed to GSK-677 (target dose assumed 
a mean body weight of 350g) and depletion of the GSK-677 solution in 
the nebuliser reservoir resulting in a reduced aerosol concentration for 
the latter period of animal exposure. 
Table 2.11: Estimated inhaled doses in rats and  
aerosol characterisation data for p38 MAPK inhibitors 
Study 
number 
Test article 
Aerosol form 
and test article 
concentration 
in vehicle 
Estimated 
inhaled 
dose A 
(mg/kg) 
Mean (n=2) 
drug aerosol 
concentration 
(µg/L) 
Particle size 
distribution 
MMAD 
(µm) 
σg 
R30573N 
GSK-899 
Crystalline 
(4.9% w/w) 
0.681 31.6 2.4 1.9 
Amorphous 
(4.0% w/w) 
0.527 24.4 2.7 2.1 
Nebulised 
solution 
(1.5 mg/mL) 
0.529 24.4 4.2 1.8 
SB-455 
Crystalline 
(4.9% w/w) 
0.517 23.9 2.7 2.0 
R30988N GSK-677 
Crystalline 
(4.4% w/w) 
0.490 22.2 2.8 2.0 
Nebulised 
solution 
(2.5 mg/mL) 
0.422 19.1 1.3 2.2 
R31225N GSK-361 
Crystalline 
(4.8% w/w) 
0.554 26.0 2.0 2.4 
Nebulised 
solution 
(1.5 mg/mL) 
0.570 27.0 2.5 2.4 
Notes 
MMAD mass median aerodynamic diameter 
σg geometric standard deviation 
A Estimated inhaled doses calculated for a 30-minute exposure period using 
mean data (body weight and aerosol concentration) and a body-weight 
derived estimate of respired minute volume (Alexander et al., 2008). 
The mass median aerodynamic diameter (MMAD) for nebulised 
GSK-899 (4.2 µm) was on the cusp of the range 1 to 4 µm recommended 
for acute (single exposure) inhalation toxicity testing (US-EPA[1300], 
1998, OECD[403], 2009). Otherwise, the MMAD and estimated 
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geometric standard deviation (σg) for all aerosols were within ranges 
stipulated to ensure exposure of the respiratory tract of rodents during 
repeat exposure studies, i.e. MMAD of 1 to 3 μm and σg of 1.5 to 3.0 
(OECD[412], 2009, OECD[413], 2009, US-EPA[3645], 1998). The 
MMAD for nebulised GSK-899 and GSK-361 was higher than for powder 
aerosols of the respective compounds, and also nebulised GSK-677. 
This is at least in part due to utilisation of two nebulisers to disperse the 
solution into the chamber to achieve the target aerosol concentration, 
which was necessitated by low aqueous solubility of the compounds. 
Significant differences between droplet or particle size distributions will 
have implications for the mass of an aerosol deposited in the lower 
respiratory tract. However, the MMAD is a median value of particle size 
and not an absolute threshold of respirability, with a proportion of larger 
particulates being inhaled by animals. Miller (2000) reported the 
probability of rats inhaling particles of 4 µm aerodynamic diameter was 
71%, and of inhaling particles of 7 µm aerodynamic diameter was 55%. 
The fine particle fraction (percentage mass less than 5 µm aerodynamic 
equivalent diameter (EMA-3, 2006)) was determined for each compound 
and aerosol form (Figure 2.21). Values (Table 2.12) were similar for 
most of the aerosols (81% to 87%), lower for nebulised GSK-899 (62%) 
and higher for nebulised GSK-677 (>99.9%). 
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2.21C: GSK-677 and GSK-361 
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Figure 2.21: Estimation of fine particle fraction (% mass <5µm 
aerodynamic diameter) by interpolation of particulate size data. 
2.21A: probit (probability function) of cumulative mass less than a cut-point 
plotted against Log10(cut-point). The probit at x=0.70 (aerodynamic diameter of 
5 µm) was determined for back-transformation of the fine particle fraction 
(Table 2.12). 2.21B: GSK-899 and SB-445. 2.21C: GSK-677 and GSK-361.  
Table 2.12: Estimation of fine particle fraction of aerosols of 
p38 MAPK inhibitors by interpolation of particulate size data 
Study 
number 
P38 MAPK inhibitor 
and particle form 
Probit at 
Log10(5µm) 
Fine particle fraction 
(%<5µm) A 
R30573N 
GSK-899 
crystalline 6.15 87% 
amorphous 6.08 86% 
nebulised 5.30 62% 
SB-445 crystalline 6.20 88% 
R30988N GSK-677 
crystalline 5.90 81% 
nebulised 11.1 >99.9% 
R31225N GSK-361 
crystalline 6.00 84% 
nebulised 6.05 85% 
Notes 
A Probit at x=0.70 (equating to 5µm effective cut-point aerodynamic diameter) 
transformed to probability (percentage mass less than cut-point) using 
Finney’s table (Finney, 1952). 
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2.3.6.2. Systemic and pulmonary pharmacokinetics and lung 
distribution of p38 MAPK inhibitors in rats 
Lung and plasma concentration profiles and representative MALDI-MSI 
images for drug-lung deposition are presented for each p38 MAPK 
inhibitor (Table 2.13). Summary pharmacokinetic parameters for lung 
and plasma data are tabulated together following the figures 
(Tables 2.16 and 2.17). 
Table 2.13: Index of figures presenting concentrations of p38 MAPK 
inhibitors in lung and plasma, and relative lung distribution 
Study 
number 
p38 MAPK inhibitor 
and particle form 
Figure number 
Concentration (HPLC-MS/MS) Lung distribution 
(MALDI-MSI) Lung  Plasma  
R30573N 
GSK-899 
crystalline   2.24 
amorphous 2.22 2.23 2.25 
nebulised   2.26 
SB-445 crystalline 2.35 2.36 n/a 
R30988N GSK-677 
crystalline 
2.27 2.28 
2.29 
nebulised 2.30 
R31225N GSK-361 
crystalline 
2.31 2.32 
2.33 
nebulised 2.34 
Although rats were exsanguinated before isolation of lung samples, the 
mass of p38 MAPK inhibitor measured in lung homogenate would be a 
combination of drug associated with lung tissue per se and residual 
blood in the vasculature of the lungs post mortem. Triplett et al. (1985) 
reported that blood accounted for 30% of the mass of wet lung. However, 
the Sprague Dawley rats used for these investigations were euthanized 
under urethane anaesthesia (at a dose not expected to affect blood 
pressure (Field and Lang, 1988)) by injection of potassium chloride, 
which is used to induce cardiac arrest in murine models (Abella et al., 
2004). The lung weights of the exsanguinated animals used for 
investigations described in this chapter were similar to the published 
mean value but body weights were higher than the published range 
(Triplett et al., 1985). Estimation of the circulating blood volume from 
body weights using a published conversion factor (Diehl et al., 2001) and 
comparison of the ratio of lung weight to circulating blood volume 
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suggested there was 33% less blood residing in the lung tissue of the 
exsanguinated rats (Table 2.14).  
Table 2.14: Lung weights and estimated circulating blood volume of rats  
Compound and  
aerosol form 
No. 
rats 
(n) 
Lung weight 
(g) 
Body weight 
(g) 
Circulating 
blood 
volume A 
(mL) 
Ratio 
LWT:CBV Mean 
(total) 
sd Mean sd 
GSK-899 
 
crystalline 18 1.126 0.079 321.8 16.2 20.6 0.055 
amorphous 18 1.096 0.065 320.4 13.6 20.5 0.053 
nebulised 18 1.114 0.066 316.0 14.1 20.2 0.055 
GSK-677 
 
crystalline 18 1.000 0.056 272.8 16.4 17.5 0.057 
nebulised 18 1.013 0.062 271.6 16.2 17.4 0.058 
GSK-361 
crystalline 18 1.176 0.092 348.8 15.6 22.3 0.053 
nebulised 18 1.369 0.104 378.5 26.9 24.2 0.057 
SB-445 crystalline 18 1.159 0.084 320.2 11.9 20.5 0.057 
All groups combined 
(p38 MAPK inhibitors) 
144 1.132 0.131 318.7 37.2 20.4 0.056 
Triplett et al. (1985) 40 1.32 0.92 250 B n/a 16.0 0.083 
Notes 
LWT Lung weight 
A Circulating blood volume (CBV) calculated from body weight using value of 
64 mL/kg for rats (Diehl et al., 2001) 
B Body weight: median value of published range (225 to 275g) used for 
calculation of CBV 
In order to determine the potential distribution of p38 MAPK inhibitors 
between lung tissue and blood residing in the lung vasculature, lung and 
blood concentrations of each p38 MAPK inhibitor were used to estimate 
the proportion of analyte associated with the tissue per se. Results 
indicate that, when quantifiable, ≥99% of the p38 MAPK inhibitor was 
associated with lung tissue for most aerosols. For GSK-361, it was 
estimated ≤20% of the analyte was associated with residual blood in the 
wet lung sample (Table 2.15). Given the general prevalence of p38 
MAPK inhibitors in the lung tissue following inhaled administration, 
correction of lung concentration data for residual blood was considered 
unnecessary for evaluation of lung pharmacokinetics. 
The mean GSK-899 concentration in lungs sampled as soon as 
practicable after inhaled administration of crystals to rats was 
approximately three-fold higher than that of animals administered 
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amorphous powder and 15-fold higher than for the nebulised solution 
(Figure 2.22), achieving statistical significance for all comparisons of 
aerosol form (p<0.01). Although the MMAD for nebulised GSK-899 was 
higher than for crystalline and amorphous particulates, the observed 
differences in lung concentration cannot be ascribed to differences in the 
fine particle fraction alone (Table 2.12) or a difference in estimated 
inhaled doses for crystalline and nebulised GSK-899 (Table 2.11). 
Table 2.15: Distribution of drug between lung tissue and blood  
residing in vasculature, and indexing of appendices for individual data 
Compound 
Aerosol 
form 
No. 
rats (n) 
Proportion of drug 
associated with lung tissue 
Maximum 
proportion of 
drug in blood A mean A sd 
GSK-899 crystalline 13 100% 0% 0% 
 amorphous 16 100% 0% 1% 
 nebulised 15 100% 0% 1% 
GSK-677 crystalline 14 100% 0% 0% 
 nebulised 13 100% 0% 0% 
GSK-361 crystalline 15 92% 5% 18% 
 nebulised 13 88% 7% 20% 
SB-445 crystalline 18 99% 1% 3% 
Notes 
A Assumes 20% of lung weight is attributable to residual blood, based on 
differences between the ratio of lung weight to circulating blood volume for 
exsanguinated and non-exsanguinated rats (Table 2.14) 
It is worth noting isolation of lungs at the first timepoint occurred 
approximately 20 minutes after the end of the 30-minute inhalation 
exposure period. This was due to logistics for transferring animals to a 
necropsy facility, euthanasia (exsanguination under anaesthesia) and 
removal of lungs from the carcass. A drug-lung residence period of 20 
to 50 minutes thus elapsed before lungs were isolated, during which time 
particles underwent dissolution and absorption. Systemic uptake and 
elimination of drug in plasma normally achieves steady state during 
aerosol administration (personal observation of unpublished 
pharmacokinetic data), with a decline in plasma concentration seen post 
exposure. For low solubility drugs, the 20-minute period elapsing post 
exposure may, at least in part, account for differences in lung dose 
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measured after cessation of aerosol generation. For nebulised solutions, 
a drug would be available for absorption after deposition but this would 
be delayed for crystals of relatively low solubility first undergoing 
dissolution. 
The drug-lung concentration profiles show a persistence of crystalline 
GSK-899 in rat lung after single exposure, with mean concentrations at 
24 hours just 74% of the post exposure mean for rats administered 
crystals, 10% for amorphous powder and 3% for the nebulised solution. 
This shows a potential for drug accumulation with repeated once daily 
administration of crystalline and perhaps amorphous GSK-899. 
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Figure 2.22: GSK-899 concentrations in lung homogenate sampled 
from rats after a single inhaled dose. Rats inhaled crystalline, amorphous 
or aqueous (nebulised) GSK-899 for 30 minutes (target dose of 0.6 mg/kg). 
Mean GSK-899 concentrations in lungs are shown with standard deviations 
(error bars; n=3) up to 24 hours from the start of exposure. Statistical analysis 
(2-way ANOVA with post hoc analysis using Tukey’s honestly significant 
difference test (Abdi and Williams, 2010[B])) of log10-transformed data 
indicated each aerosol was significantly different from one another (p<0.01). 
Drug-plasma concentrations of GSK-899 following inhalation exposure 
were highest in rats administered amorphous or nebulised GSK-899 
(Figure 2.23). Although the profiles appeared similar for these aerosol 
forms, differences achieved statistical significance (p<0.05). The profile 
following exposure of rats to crystalline GSK-899 was more variable with 
a time of peak concentration (Tmax) at 7.5 hours. This profile was 
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significantly different (p<0.01) to the profiles following exposure of rats 
to amorphous or nebulised aerosol forms. Plasma concentrations after 
a 30-minute intravenous infusion of GSK-899 (Petri, 2004) showed an 
initial distribution phase characterized by a steep gradient (Shargel et 
al., 2005) that was not seen after inhalation exposure of rats. 
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Figure 2.23: GSK-899 concentrations in plasma sampled from rats after 
a single inhaled or intravenous dose. Rats inhaled crystalline, amorphous 
or aqueous (nebulised) GSK-899 for 30 minutes (target dose of 0.6 mg/kg). 
Data (in red) also plotted for rats administered GSK-899 by a 30-minute 
intravenous infusion (Petri, 2004). Mean GSK-899 plasma concentrations 
shown with standard deviations (error bars; n=3) up to 24 hours from start of 
exposure. Statistical analysis (2-way ANOVA with post hoc analysis using 
Tukey’s honestly significant difference test (Abdi and Williams, 2010[B])) of 
concentrations indicated each aerosol form was significantly different from 
one another (p<0.01 for crystalline versus amorphous/nebulised GSK-899; 
p<0.05 for amorphous versus nebulised GSK-899). No result for samples at 
1.5 hours (1/3 crystalline), 7.5 hours (1/3 crystalline, 1/3 amorphous and 2/3 
nebulised) and 12.5 hours (2/3 crystalline) due to no response for internal 
standard; insufficient sample for re-analysis. 
MALDI-MSI analysis of lung sections from rats administered crystalline 
GSK-899 showed foci of peak concentrations distributed relatively 
evenly across the tissue as soon as practicable post exposure and three 
hours later (Figure 2.24). The signal intensity of GSK-899 for rats 
administered amorphous powder was less pronounced than for 
crystalline GSK-899 post exposure, but also showed no obvious drug 
localisation within the lung section (Figure 2.25A). GSK-899 was barely 
perceptible after nebulised administration (Figure 2.26A), relative to the 
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amorphous and crystalline aerosol forms. Imaged sections at three 
hours post exposure indicated drug clearance of the amorphous 
(Figure 2.25B) and nebulised (Figure 2.26B) aerosol forms. 
2.24A: immediately post exposure 
 
(R30573N; Rat 055, Section 11) 
2.24B: 3 hours post exposure 
 
(R30573N; Rat 056, Section 16) 
Figure 2.24: GSK-899 in lungs of rats inhaling crystalline drug imaged by 
matrix assisted laser desorption/ionization with mass spectrometry 
imaging (MALDI-MSI). Rats inhaled crystalline GSK-899 for 30 minutes 
(target dose of 0.6 mg/kg). A matrix was applied to frozen sections of tissue (12 
µm thick) for MALDI-MSI; coloured scaling of the relative amount of GSK-899 
is shown (arbitrary units). 2.24A: rat lung taken as soon as possible (20 
minutes) after a single exposure. 2.24B: rat lung taken 3 hours post exposure. 
2.25A: immediately post exposure 
 
(R30573N; Rat 057, Section 9) 
2.25B: 3 hours post exposure 
 
(R30573N; Rat 058, Section 10) 
Figure 2.25: GSK-899 in lungs of rats inhaling amorphous drug imaged 
by matrix assisted laser desorption/ionization with mass spectrometry 
imaging (MALDI-MSI). Rats inhaled amorphous GSK-899 for 30 minutes 
(target dose of 0.6 mg/kg). A matrix was applied to frozen sections of tissue (12 
µm thick) for MALDI-MSI; coloured scaling of the relative amount of GSK-899 
is shown (arbitrary units). 2.25A: rat lung taken as soon as possible (20 
minutes) after exposure. 2.25B: rat lung taken 3 hours post exposure. 
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2.26A: immediately post exposure 
 
(R30573N; Rat 059, Section 9) 
2.26B: 3 hours post exposure 
 
(R30573N; Rat 060, Section 17) 
Figure 2.26: GSK-899 in lungs of rats inhaling nebulised drug imaged by 
matrix assisted laser desorption/ionization with mass spectrometry 
imaging (MALDI-MSI). Rats inhaled aqueous (nebulised) GSK-899 for 
30 minutes (target dose of 0.6 mg/kg). A matrix was applied to frozen sections 
of tissue (12 µm thick) for MALDI-MSI; coloured scaling of the relative amount 
of GSK-899 is shown (arbitrary units). 2.26A: rat lung taken as soon as possible 
(20 minutes) after exposure. 2.26B: rat lung taken 3 hours post exposure. 
These observations correlate with the drug-lung concentration profiles. 
GSK-899 persistence after inhalation of micronised crystals and 
depletion of amorphous GSK-899 was consistent with the hypothesis 
that materials exhibiting a faster dissolution rate in vitro are likely to be 
cleared more quickly in vivo following inhalation exposure of rats. 
Solubilisation of crystalline solutes first requires disruption of the crystal 
lattice (Van den Mooter, 2012). A faster dissolution rate for amorphous 
powder may thus occur due to the disrupted, random organisation of 
molecules in the inhaled particles, making GSK-899 more available for 
solvation and subsequent absorption from the lung surface. Nebulised 
GSK-899 was presented in solution, facilitating absorption from lungs. 
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GSK-677 concentration profiles in lung tissue (Figure 2.27) and plasma 
(Figure 2.28) were indistinguishable for the crystalline and nebulised 
aerosols forms. Mean lung concentrations of GSK-677 following 
exposure were similar to that of nebulised GSK-899 (Figure 2.22) and 
GSK-677 plasma concentrations were initially higher than those of 
GSK-899 (Figure 2.23) but had decreased by at least one order of 
magnitude within one hour post exposure. This supports the hypothesis 
that a faster in vitro dissolution rate would lead to faster absorption and 
systemic exposure after inhaled administration of GSK-677 to rats and 
that dissolution of crystalline GSK-677 was not rate limiting. Plasma 
concentrations after a 30-minute intravenous infusion of GSK-677 
followed a similar profile to those evident after inhalation exposure, 
indicating an initial distribution phase characterized by a steep gradient 
followed by a slower elimination phase (Shargel et al., 2005). 
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Figure 2.27: GSK-677 concentrations in lung homogenate sampled 
from rats after a single inhaled dose. Rats inhaled an aerosol of crystalline 
or aqueous (nebulised) GSK-677 for 30 minutes (target dose of 0.6 mg/kg). 
Mean GSK-677 concentrations are shown with standard deviations (error 
bars; n=3) up to 24 hours from the start of exposure. Lung concentrations at 
24 hours post exposure (*) were below the limit of quantification (<40 ng/g 
lung tissue). No differences of statistical difference (2-way ANOVA with post 
hoc analysis using Tukey’s honestly significant difference test (Abdi and 
Williams, 2010[B])) for log10-transformed data. 
Chapter Two 
115 
 
0 5 1 0 1 5 2 0
1 0 -2
1 0 -1
1 0 0
1 0 1
1 0 2
1 0 3
G S K 6 1 0 6 7 7 B  in  ra t  p la s m a
T im e  (h o u r s )  a f te r  s ta r t  o f  1 -h o u r  e x p o s u r e
P
la
s
m
a
 c
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/m
L
)
C ry s ta llin e  (0 .4 9  m g /k g )
N e b u lis e d  (0 .4 2  m g /k g )
In tra v e n o u s  (1 .1  m g /k g ;
3 0  m in u te  in fu s io n )
**
 
Figure 2.28: GSK-677 concentrations in plasma of rats after a single 
inhaled or intravenous dose. Rats inhaled an aerosol of crystalline or 
aqueous (nebulised) GSK-677 for 30 minutes (target dose of 0.6 mg/kg). 
Data (in red) also plotted for rats administered GSK-677 a 30-minute 
intravenous infusion (Umbrecht, 2007); plasma concentrations at ≥8 hours 
(*) were not quantifiable (<5 ng/mL). Mean GSK-677 concentrations in 
plasma are shown with standard deviations (error bars; n=3) up to 24 hours 
from the start of exposure. No differences of statistical difference (2-way 
ANOVA with post hoc analysis using Tukey’s honestly significant difference 
test (Abdi and Williams, 2010[B])) for log10-transformed data. 
MALDI-MSI analysis of rat lung sections showed ‘hot areas’ of GSK-677 
in the main airways, with relatively even distribution of foci corresponding 
to peak drug concentrations across peripheral tissue (Figures 2.29A and 
2.30A). For each aerosol form, a decreased signal intensity of GSK-677 
was seen three hours post exposure (Figures 2.29B and 2.30B) but it 
was difficult to draw conclusions regarding relative differences in signal 
intensity for crystalline or nebulised GSK-677 given differences in the 
coloured scaling applied for image analysis in each experiment. 
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2.29A: immediately post exposure 
 
(R30988N; Rat 037, Section 14) 
2.29B: 3 hours post exposure 
 
(R30988N; Rat 038, Section 7) 
Figure 2.29: GSK-677 in lungs of rats inhaling crystalline drug imaged by 
matrix assisted laser desorption/ionization with mass spectrometry 
imaging (MALDI-MSI). Rats inhaled crystalline GSK-677 for 30 minutes (target 
dose of 0.6 mg/kg). A matrix was applied to frozen sections of tissue (12 µm 
thick) for MALDI-MSI; coloured scaling of the amount of GSK-677 is shown 
(arbitrary units). 2.29A: rat lung taken as soon as possible (20 minutes) after a 
single exposure. 2.29B: rat lung taken 3 hours post exposure. 
2.30A: immediately post exposure 
 
(R30988N; Rat 039, Section 22) 
2.30B: 3 hours post exposure 
 
(R30988N; Rat 040, Section 23) 
Figure 2.30: GSK-677 in lungs of rats inhaling nebulised drug imaged by 
matrix assisted laser desorption/ionization with mass spectrometry 
imaging (MALDI-MSI). Rats inhaled aqueous (nebulised) GSK-677 for 30 
minutes (target dose of 0.6 mg/kg). A matrix was applied to frozen sections of 
tissue (12 µm thick) for MALDI-MSI; coloured scaling of the amount of GSK-677 
is shown (arbitrary units). 2.30A: rat lung taken as soon as possible (20 
minutes) after a single exposure. 2.30B: rat lung taken 3 hours post exposure. 
GSK-361 lung concentrations were higher in rats following inhaled 
administration of crystals than for the nebulised solution (Figure 2.31), 
achieving statistical significance (p<0.01), and were similar to 
concentrations of GSK-899 in rats administered the amorphous powder 
(Figure 2.22). Plasma concentrations were variable and, although mean 
values for crystalline GSK-361 appeared higher than nebulised 
GSK-361 (Figure 2.32), no statistical significance was achieved. 
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As with GSK-899, a particle-lung residence time of 20 to 50 minutes 
occurred and a slow dissolution rate may have given rise to short-term 
formation of a lung depot of micron-sized GSK-361 crystals, accounting 
for the difference in drug-lung concentration evident at the first time point 
(Figure 2.31). Plasma concentrations following inhaled administration of 
GSK-361 initially increased, indicating an absorption phase. Thereafter, 
plasma concentration profiles were similar to an essentially linear profile 
seen after administration of an intravenous bolus of GSK-361 (Ioannou, 
2005) indicating the distribution phase was rapid (Shargel et al., 2005).  
MALDI-MSI of the lungs of rats administered GSK-361 showed even 
distribution of foci corresponding to peak drug concentrations across 
lung sections, with a greater signal intensity in rats administered crystals 
(Figure 2.33A) than nebulised GSK-361 (Figure 2.34A). This finding 
correlated with the lung concentration data (Figure 2.31). A decreased 
signal intensity was evident for both aerosol forms of GSK-361 at three 
hours post exposure (Figures 2.33B and 2.34B). 
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Figure 2.31: GSK-361 concentrations in lung homogenate sampled from 
rats after a single inhaled dose. Rats inhaled an aerosol of crystalline or 
aqueous (nebulised) GSK-361 for 30 minutes (target dose of 0.6 mg/kg). Mean 
GSK-361 concentrations are shown with standard deviations (error bars; n=3) 
up to 24 hours from the start of exposure. Statistical analysis (2-way ANOVA 
with post hoc analysis using Tukey’s honestly significant difference test (Abdi 
and Williams, 2010[B])) of log10-transformed data indicated a significant 
difference between crystalline and nebulised aerosols (p<0.01). 
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Figure 2.32: GSK-361 concentrations in plasma of rats after a single 
inhaled or intravenous dose. Rats inhaled an aerosol of crystalline or 
aqueous (nebulised) GSK-361 for 30 minutes (target dose of 0.6 mg/kg). Data 
(in blue) also plotted for rats administered GSK-677 as an intravenous bolus 
(Ioannou, 2005). Mean GSK-361 concentrations in plasma are shown with 
standard deviations (error bars; n=3) up to 24 hours from the start of exposure. 
Plasma concentrations at 24 hours (*) were not quantifiable (<5 ng/mL). No 
differences of statistical difference (2-way ANOVA with post hoc analysis using 
Tukey’s honestly significant difference test (Abdi and Williams, 2010[B])) for 
log10-transformed data. 
2.33A: immediately post exposure 
 
(R31225N; Rat 019, Section 25) 
2.33B: 3 hours post exposure 
 
(R31225N; Rat 020, Section 19) 
Figure 2.33: GSK-361 in lungs of rats inhaling crystalline drug imaged by 
matrix assisted laser desorption/ionization with mass spectrometry 
imaging (MALDI-MSI). Rats inhaled crystalline GSK-361 for 30 minutes 
(target dose of 0.6 mg/kg). A matrix was applied to frozen sections of tissue 
(12 µm thick) for MALDI-MSI; coloured scaling of the amount of GSK-361 is 
shown (arbitrary units). 2.33A: rat lung taken as soon as possible (20 minutes) 
after a single exposure. 2.33B: rat lung taken 3 hours post exposure. 
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2.34A: immediately post exposure 
 
(R31225N; Rat 039, Section 9) 
2.34B: 3 hours post exposure 
   
(R31225N; Rat 040, Section 16) 
Figure 2.34: GSK-361 in lungs of rats inhaling nebulised drug imaged by 
matrix assisted laser desorption/ionization with mass spectrometry 
imaging (MALDI-MSI). Rats inhaled aqueous (nebulised) GSK-361 for 30 
minutes (target dose of 0.6 mg/kg). A matrix was applied to frozen sections of 
tissue (12 µm thick) for MALDI-MSI; coloured scaling of the amount of GSK-361 
is shown (arbitrary units). 2.34A: rat lung taken as soon as possible (20 
minutes) after a single exposure. 2.34B: rat lung taken 3 hours post exposure. 
Lung concentrations of SB-445 (Figure 2.35) were similar to values for 
respective analytes after administration of GSK-677 (Figure 2.27) or 
nebulised GSK-899 (Figure 2.22). SB-445 in plasma followed a similar 
profile to SB-445 in lung, with peak values at 1.5 hours and quantifiable 
values persisting at 24 hours (Figure 2.36). MALDI-MSI was not possible 
due to poor ionisation of SB-445. 
Pharmacokinetic parameters for p38 MAPK inhibitors, i.e. area under the 
drug concentration-time curve (AUC), the maximum concentration 
(Cmax), time to Cmax (Tmax) and half-life, are summarised for lung 
(Table 2.16) and plasma (Table 2.17). 
Generally, lung exposure (AUC and Cmax) in rats administered the 
crystalline aerosol form of each p38 MAPK inhibitor was higher than for 
the corresponding nebulised form (Table 2.16). This was marked for 
GSK-899, reflecting the persistence of crystals in rat lungs post 
exposure, with an AUC that was three-fold higher than for amorphous 
powder and 127-fold higher than for the nebulised solution. AUC for 
crystalline GSK-361 was 10-fold higher than the nebulised form and 
AUCs for crystalline and nebulised GSK-677 were essentially the same. 
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Figure 2.35: SB-445 concentrations in lung homogenate sampled from 
rats after a single inhaled dose. Rats inhaled crystalline SB-445 for 30 
minutes (target dose of 0.6 mg/kg). Mean concentrations are shown with 
standard deviations (error bars; n=3) up to 24 hours from the start of 
exposure. 
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Figure 2.36: SB-445 concentrations in plasma sampled from rats after 
a single inhaled or intravenous dose. Rats inhaled crystalline SB-445 for 
30 minutes (target dose of 0.6 mg/kg). Data (in red) also plotted for rats 
administered SB-445 by a 30-minute intravenous infusion (Zhang, 2003). 
Mean concentrations in plasma are shown with standard deviations (error 
bars; n=3) up to 24 hours from the start of exposure. 
Generally, Cmax was observed at the end of the inhalation exposure 
period but crystalline SB-445 showed a slight peak at 1.5 hours (one 
hour after cessation of aerosol generation) and crystalline GSK-899 
peaked at 3.5 hours. The later Tmax for crystalline SB-445 and GSK-899 
are likely to be associated with inter-animal variability, a relatively flat 
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concentration profile shortly after inhalation exposure and, especially for 
GSK-899, formation of a depot of test article in the lungs. Plasma 
concentrations following inhaled and intravenous administration of 
GSK-361 (Zhang, 2003) initially increased indicating a fast absorption 
phase followed by elimination (Shargel et al., 2005). 
Systemic exposure (AUC and Cmax) was highest in rats inhaling 
crystalline SB-445, followed by GSK-361. The ranking of the third and 
fourth compounds showed differences in parameters, with a higher Cmax 
for GSK-677 compared with GSK-899 and lower AUC for a given aerosol 
form (Table 2.18). Relative differences between the crystalline and 
nebulised aerosol forms were evident. For GSK-677, systemic exposure 
was similar following inhalation of crystalline and nebulised aerosols and 
is consistent with the hypothesis that an onset of systemic absorption is 
dependent upon dissolution. For GSK-899, systemic exposure was 
lowest in rats administered the crystalline form, higher for the nebulised 
solution but highest for amorphous powder. This is again consistent with 
the hypothesis regarding the relationship between dissolution and 
absorption; the low solubility for crystalline GSK-899 impedes disruption 
of the crystal lattice (Van den Mooter, 2012). Dissolution of amorphous 
powder was quicker given the disrupted, random organisation of 
molecules in the inhaled particles. Systemic exposure of GSK-361 in 
plasma, as with lungs, appeared to be higher in rats administered the 
crystals than nebulised solution. However the apparent difference in 
AUC is influenced by the mean values at 12.5 hours post exposure used 
for the calculation. For rats administered nebulised GSK-677, 2/3 
plasma concentrations were below the limit of quantification (<5 ng/mL) 
and values of zero were used for calculation of a mean value, 
exaggerating the apparent difference to the mean value for rats inhaling 
crystalline GSK-677; there were no differences of statistical significance 
between the concentration profiles (Figure 2.32). 
Although the partition of p38 MAPK inhibitors in plasma or cellular 
components of blood differs for each compound, their ranking was not 
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affected when AUC and Cmax were converted to values in terms of whole 
blood using rat blood:plasma concentration ratios (Table 2.17). 
Table 2.16: Pharmacokinetics of mean p38 MAPK inhibitor 
concentrations in lung after single exposure of rats to test articles 
Study No. Aerosol form 
Inhaled 
Dose 
(mg/kg/day) 
Toxicokinetic parameter (lung) 
AUC0-t 
(h.ng/g) 
Cmax 
(ng/g) 
Tmax 
(h) A 
T½ 
(h) A 
GSK-899 
Crystalline 0.680 678000 38390 3.5 74.7 
Amorphous 0.528 22100 9527 0.8 5.0 
Nebulised 0.521 5340 1592 0.8 7.5 
GSK-677 
Crystalline 0.490 3770 1410 0.8 3.0 
Nebulised 0.421 3690 1320 0.8 2.3 
GSK-361 
Crystalline 0.554 6250 6250 0.8 8.4 
Nebulised 0.570 633 193 0.8 7.8 
SB-445 Crystalline 0.516 9680 1530 1.5 7.6 
Notes 
A T½ and median Tmax relative to the start of the 30-minute exposure period; time 
point at 0.8h includes a 20-minute period post exposure to isolate lungs. 
CV  Coefficient of variation (%) = sd/mean 
There were differences in the relationship between half-lives in lung 
tissue and plasma and between aerosol forms of the p38 MAPK 
inhibitors (Tables 2.16 and 2.17). The half-life of crystalline GSK-899 in 
lung was at least 10-fold longer than for the other aerosol forms reflecting 
previous discussion about its low solubility and persistence in lung 
tissue. The half-life of GSK-899 in plasma following intravenous infusion 
was approximately half that following aerosol administration which was 
consistent with slower systemic absorption associated with a pulmonary 
depot of GSK-899. Half-lives of GSK-361 in lung were also longer than 
for plasma following inhaled administration. However, half-lives in 
plasma were similar after inhaled or bolus intravenous administration. 
The half-lives of GSK-677 in lung were lower than for plasma following 
aerosol administration, and lower again in plasma following intravenous 
infusion. The plasma profiles of GSK-677 (Figure 2.27) indicated an 
initial distribution phase, which may account for a shorter half-life in lung 
tissue with a longer elimination phase from plasma. The half-lives of 
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crystalline SB-445 in lung and plasma were similar following inhaled 
administration and slightly lower in plasma following intravenous infusion 
suggesting that the soluble membrane permeable SB-445 was not 
retained in tissues. 
Table 2.17: Pharmacokinetics of mean p38 MAPK inhibitor  
concentrations in plasma after single exposure to test articles 
Study No. Aerosol form 
Dose 
(mg/kg/day) 
Toxicokinetic parameter (plasma) 
AUC0-t 
(h.ng/mL) 
Cmax 
(ng/mL) 
Tmax 
(h) A 
T½ 
(h) A 
GSK-899 
Crystalline 0.680  19.0 B  2.4 B 7.5 9.5 
Amorphous 0.528  48.1 B  8.0 B 0.5 9.0 
Nebulised 0.521  38.1 B  4.6 B 0.5 10.2 
Intravenous 1.0 (infus) C 455 807 0.25 4.7 
GSK-677 
Crystalline 0.490 15.4 18.6 0.5 6.0 
Nebulised 0.421 18.5 27.4 0.5 10.1 
Intravenous 1.1 (infus) C 166 256 0.25 1.5 
GSK-361 
Crystalline 0.554 760 200 1.5 3.5 
Nebulised 0.570 387 131 0.8 1.9 
Intravenous 1 (bolus) C 4877 1620 0.083 3.0 
SB-445 
Crystalline 0.516  977 D  250 D 1.5 6.3 
Intravenous 1.91 (infus) C 463 1902 0.58 4.0 
Notes 
A T½ and median Tmax relative to the start of the 30-minute exposure period. 
B GSK-899: blood in water (1:1 w/w) was analysed; parameters converted to 
plasma using blood:plasma ratio of 2.1 (unpublished data). 
C Intravenous administration as a bolus or 30-minute infusion. 
D SB-445: blood in water (1:1 w/w) was analysed; parameters converted to 
plasma using blood:plasma ratio of 0.683 (unpublished data). 
CV  Coefficient of variation (%) = sd/mean 
Whilst ranking of lung exposure for the three lead compounds (GSK-899, 
GSK-361 and GSK-677) following inhaled administration of the 
crystalline aerosol form supported the hypothesis that a faster 
dissolution rate would facilitate depletion of lung concentration, it did not 
necessarily follow that the observed systemic exposure would be 
relatively higher (Table 2.18). In addition, SB-455 (high solubility, high 
lipophilicity) ranked second highest for lung exposure and highest for 
systemic exposure. However, the volume of distribution was highest for 
GSK-677 and lowest for SB-445 (Table 2.6) indicating that GSK-677 was 
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distributed more into the tissues and this may account for the lower 
systemic exposure observed following inhaled administration. The 
biphasic kinetics of GSK-677 in plasma (Figure 2.27) also indicates 
distribution of the compound in secondary tissues following systemic 
absorption (Rowland and Tozer, 1995). 
Table 2.18: Ranking of p38 MAPK inhibitors and  
aerosol forms for systemic and lung exposure 
Sample 
medium 
Particulate 
category 
AUC 
or Cmax 
Ranking of p38 MAPK inhibitors  
and aerosol form 
Lung 
Crystalline both GSK-899 > SB-445 > GSK-361 > GSK-677 
Nebulised both GSK-899 > GSK-677 > GSK-361 
GSK-899 both crystalline > amorphous > nebulised 
GSK-677 both crystalline ≈ nebulised 
GSK-361 both crystalline > nebulised 
Plasma 
Crystalline 
AUC SB-445 > GSK-361 > GSK-899A ≥ GSK-677A 
Cmax SB-445 > GSK-361 > GSK-677 > GSK-899 
Nebulised 
AUC GSK-361 > GSK-899 > GSK-677 
Cmax GSK-361 > GSK-677 > GSK-899 
GSK-899 both amorphous > nebulised > crystalline 
GSK-677 both nebulised ≈ crystalline 
GSK-361 both crystalline > nebulised  
Notes 
A Ranking of compounds for plasma AUC and Cmax was not changed with 
transformation to blood-based valuesB; an equivocal difference for two 
crystalline forms was more distinct in AUCblood (GSK-899 > GSK-677)  
B Blood:plasma concentration ratios (unpublished data) used to estimate Cmax 
and AUC: GSK-899 (2.10), GSK-677 (1.02), GSK-361 (1.30) SB-445 (0.683) 
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2.4. Conclusion 
Principal component analysis (PCA) was used to select p38 MAPK 
inhibitors of differing physicochemical properties, using datasets of 
predicted (in silico) parameters derived from molecular structures or 
measured in vitro parameters. The score plot for each model grouped 
six p38 MAPK inhibitors into three distinct populations. The ranking of in 
vitro dissolution rates for five crystalline (cr) p38 MAPK inhibitors and 
amorphous (am) GSK-899 was as follows: SB-445(cr) > GSK-677(cr) > 
SB-323(cr) > GSK-899(am) > GSK-361(cr) > GSK-899(cr). A compound 
from each of the populations defined by PCA was selected for in vivo 
evaluation of exposure (lung and plasma) in rats, with GSK-899 (low 
solubility, aromatic and protein bound), GSK-677 (soluble, polar and 
basic) and GSK-361 (low solubility and high lipophilicity) representing 
the most diverse compounds within the ‘physicochemical space’. 
SB-445 (high solubility and lipophilicity) was included to contrast with the 
low solubility and dissolution of GSK-361. 
Ranking of lung exposure for the three lead compounds following inhaled 
administration of crystals (GSK-899 > GSK-361 > GSK-677) supported 
the hypothesis that a faster dissolution rate would facilitate quicker lung 
clearance. However, this did not necessarily translate to a higher 
systemic exposure observed post dose (GSK-361 > GSK-899 ≥ 
GSK-677), most likely due to differences in distribution and elimination 
of the compounds from plasma. Differences in relative exposure 
between the aerosol forms were evident, with GSK-899 lung exposure 
ranked crystalline > amorphous > nebulised. This was again consistent 
with the hypothesis regarding the relationship between dissolution and 
absorption. Systemic exposure of GSK-677, and GSK-361 
(notwithstanding data variability at 12.5 hours and the analytical limit of 
quantification), were more similar for the two aerosol forms. Although 
fast dissolution may account for similarity of concentration profiles for 
GSK-677, the lipophilicity of GSK-361 may explain the higher systemic 
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exposure in vivo versus comparable aerosol forms of GSK-899. Particles 
deposited in the lung must first dissolve into the epithelial lung fluid, 
which may become locally saturated with drug if clearance from this 
‘compartment’ is slower than the rate of dissolution. This local effect may 
be exacerbated by extreme variations in regional deposition that can 
affect pharmacokinetics of the inhaled drug (Gray, 2015). This contrasts 
with the in vitro dissolution test in which a continuous flow of simulated 
fluid is applied to the powder preventing saturation of the local fluid 
environment, maintaining the undissolved test article in sink conditions. 
Secondly, the principal fluid lining the conducting airways is mucous 
(85% water) but surfactant (85% phospholipid, 5% cholesterol and 10% 
surfactant proteins) is predominant in the respiratory region (Eixarch et 
al., 2010), varying solubility of particles throughout the respiratory tract. 
In vivo, a lipophilic compound will cross a cell membrane, maintaining 
sink conditions and facilitating further dissolution of the particle into the 
fluid. Measurement of drug concentrations in plasma during inhalation 
exposure of rats and more rapid isolation of lungs on cessation of 
aerosol generation would present technical challenges. However, future 
work in this area would refine characterisation of drug concentration 
profiles in lung and plasma during inhaled administration of the p38 
MAPK inhibitors and improve understanding of the relationship between 
the kinetics of exposure for these two compartments. 
In addition to transfer of ‘free drug’ from the epithelial lung fluid to lung 
tissue to blood, which are in equilibrium between these compartments, 
there are other mechanisms influencing the fate of particles deposited in 
the lungs. All compounds are likely to be, to a greater or lesser extent 
(GSK-677 > GSK-899 > GSK-361 > SB-445) substrates for 
P-glycoprotein 1, an efflux pump found on apical membranes that is 
involved in the energy (ATP) dependent expulsion of xenobiotics as a 
multidrug resistance mechanism against cytotoxicity (Bellamy, 1996). 
Lysosomes play a key role in autophagy, the breakdown of endogenous 
molecules such as phospholipids and waste products. Amphiphilic drugs 
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(containing both lipophilic and hydrophilic moieties) are prone to 
lysosomal trapping (Kazmi et al., 2013). Alveolar macrophages are rich 
in lysosomes and lung surfactant, and their presence in lung accounts 
for high uptake of basic lipophilic drugs. Values for lysosomal trapping in 
lungs vary for drugs, with 25% reported for the anti-depressant Perazine 
(Daniel and Wójcikowski, 1999) and 60% to 90% for psychotropic drugs 
also investigated by Daniel and Wöjcikowski (1997). Macrophages also 
play a key role in clearance of particles from the lungs. Geiser (2010) 
stated that typically 50% to 75% of micron-sized particles are 
phagocytosed after two to three hours, ≥90% of particles by 10 hours 
and almost all particles phagocytosed by 24 hours. The macrophages 
are in turn cleared from the conducting airways via the mucociliary 
escalator within 24 to 48 hours, and may take weeks or months to clear 
from alveoli (Geiser, 2010). Under the conditions of the in vivo 
experiments, it is likely GSK-899 crystals would have been endocytosed 
by macrophages but did not have sufficient time to facilitate muciliary 
clearance. 
Drug-lung concentration profiles were consistent with the hypothesis that 
GSK-361 (low solubility; high passive membrane permeability) is 
maintained under sink conditions in vivo but GSK-899 (low solubility; low 
passive membrane permeability) becomes saturated in epithelial lung 
fluid due to a slower rate of transmembrane clearance. However, 
relatively little is known about transporter systems and efflux pumps in 
the lung (Patton et al., 2010) and such mechanisms could also play a 
role in the pulmonary pharmacokinetics of GSK-899 and/or GSK-361 
resulting in the observed differences in drug-lung concentration profiles. 
Quantification of drug concentrations in various lung compartments, 
such as epithelial lung fluid, epithelial cells and macrophages throughout 
the distal respiratory region of rat lung may elucidate key mechanisms 
pertinent to the pulmonary pharmacokinetics of the p38 MAPK inhibitors. 
MALDI-MSI showed a concentration of GSK-677 in the main airways and 
a relatively even distribution of GSK-361 and GSK-899 across lung 
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sections immediately post exposure and at three hours where still 
present, irrespective of aerosol form. Chaurand et al. (2007) described 
use of MALDI-MSI capable of achieving irradiation areas down to 7 µm. 
However, this lacks the lateral resolution required to differentiate 
between compartments within the lung section such as the epithelium 
and fluid (<0.2 µm and 0.07 µm thick at alveoli; 10 µm and 3 µm thick at 
terminal bronchioles; (Patton and Byron, 2007)) and macrophages 
(13 µm diameter; (Krombach et al., 1997)). Secondary ion mass 
spectrometry (SIMS), is capable of lateral resolution down to 50 nm for 
elemental ions (Benabdellah et al., 2010) and a resolution of 80 to 
100 nm was reported for imaging of melanin stained using iodine-125 
labelled iodobenzamide (Guerquin-Kern et al., 2004). SIMS may 
therefore provide an opportunity for ultrastructural investigations in 
concert with MALDI-MSI to determine the location of p38 MAPK 
inhibitors within cell types or fluid compartments of the lung sections. 
This chapter characterised the lung and systemic exposure following 
administration of a single inhaled dose of p38 MAPK inhibitors to rats. 
The observed differences in exposure and a potential for accumulation 
in lungs with repeated daily administration will be considered for 
investigations of efficacy following a single dose (Chapter 4) and for 
toxicopathology evident after 28 days of treatment (Chapter 5). 
  
 
 
 
CHAPTER THREE 
Estimation of inhaled doses in rats 
from lung function data and 
refinement of tube restraint in 
scientific procedures
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3.1. Introduction 
Inhaled administration of substances to animals is technically 
challenging for quantitative dosimetry. Animals are not “dosed” per se 
but are exposed to an atmosphere containing a test substance or 
formulation mixed with air. Non-clinical “doses” reported for animals 
inhaling such atmospheres are commonly calculated using the 
following equation: 
𝐼𝐷𝑒 =
𝐶×𝑅𝑀𝑉×𝑇
𝐵𝑊
  ……………………… Equation 1 
Where IDe = estimated inhaled dose (mg/kg), C = aerosol 
concentration (mg/L), RMV = respired minute volume (L/min) 
T = duration of inhalation exposure and BW = body weight (kg). The 
minute volume (MV) can be measured but is more commonly 
estimated by calculation from body weight using a published algorithm. 
Various algorithms (Guyton, 1947, McMahon et al., 1975, Bide et al., 
2000) or minute volume data for a variety of species (Snipes, 1989) 
have been published. Given a lack of consensus within the regulatory 
toxicology and research communities for the method of estimating 
inhaled doses in drug safety studies, a working party (Alexander et al., 
2008) reviewed 18 datasets generated by 10 contributing laboratories 
in conscious animals of species used in non-clinical research (mice, 
rats, beagle dogs and cynomolgus monkeys) and published the 
following algorithm: 
𝑒𝑅𝑀𝑉 = 0.608 × 𝐵𝑊0.852 ……...……… Equation 2 
Where eRMV = estimated respired minute volume (L/min) and 
BW = body weight (kg). This equation is commonly used in respiratory 
drug development as it was derived from a larger volume of data in 
toxicologically relevant species. However, use of such an algorithm 
overlooks the physiological effects on lung function that can be induced 
by a substance’s properties (Nirogi et al., 2012, Vijayaraghavan et al., 
1993). Furthermore, variability in MV measurements may have 
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occurred between datasets due to differences in habituation of animals 
to the restraint procedures between species and protocols used by the 
10 participating laboratories (Alexander et al., 2008). 
Lung-homogenate concentration data for small groups of rats (typically 
n=3) attached to adjacent ports on a snout-only inhalation exposure 
chamber, and thus breathing from the same aerosol, sometimes vary 
up to three-fold (personal observation of unpublished data). Little is 
known about the ways environmental factors may affect lung function 
and hence the inhaled dosimetry for individual animals subjected to 
“standard procedures” during non-clinical studies. For example, 
manipulation or disturbance of animals may excite them to varying 
degrees and the implications of this for lung dose are uncertain. In 
addition, rats are insensitive to red light (Szél and Röhlich, 1992). 
Amber or red-coloured transparent polycarbonate shelters for rodents 
are marketed with the claim that they “provide security and shelter for 
the animal by reducing the level of perceived light” (Datesand, 2017, 
Scanbur, 2017), although the efficacy of such products do not appear 
to have been determined independently (Burn, 2008). It was 
hypothesised that conducting snout-only inhalation exposure 
procedures under red-filtered lighting may maintain rats in a calmer 
state during the tube restraint procedure.  
Plethysmography is a technique used for measuring changes in the 
volume of an organ or body, typically due to changes in the volume of 
blood (Pointel et al., 1981) or air (Pennock et al., 1979) contained 
therein. A head-out plethysmograph (Vijayaraghavan et al., 1993, 
Glaab et al., 2001) is a vessel that encloses the body of a subject to 
facilitate lung function measurements derived from changes in ambient 
pressure due to changes in body volume as the subject breathes. 
Since the head of an animal is outside this compartment, its snout or 
head can be presented simultaneously to an atmosphere for inhaled 
administration of a test substance, e.g., aerosol, vapour or smoke. 
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Protocols for acclimatisation of animals to tube restraint vary between 
laboratories, and may also vary within institutions depending upon the 
species and experimental objectives. Nirogi et al. (2012) described 
acclimatisation of rats to plethysmograph chambers for two hours, 
twice daily over three days before investigating the effect of respiratory 
stimulants or depressants on lung function. Renninger (2006) 
described acclimatisation of rats for up to 15 minutes on three 
consecutive days in preparation for safety pharmacology (single dose) 
investigations, whilst other laboratories acclimatise rodents daily and 
progressively increase the tube residence time up to the required 
duration over five days (Hoymann, 2012) or a week. In addition, the 
tube acclimatisation protocols applied in toxicology studies employing 
inhaled administration or intravenous infusion also varies considerably. 
This has implications for dosimetry and the translation of results 
between studies, such as respiratory pharmacology and toxicology. 
3.1.1. Aims and objectives 
The experimental aims of this chapter are to measure breath frequency 
(BF) and minute volume (MV) in conscious rats using head-out 
plethysmography to test the following hypotheses: 
• lighting colour (red or white) and duration of restraint tube 
acclimatisation protocols influence BF and MV of rats; 
• the degree of restraint (use of neck seal) during a repeat dose 
study artefactually affects the BF and MV measurements of rats; 
• measured MV is consistent with the pre-dose body weight 
derived estimate (eRMV) calculated using the algorithm of 
Alexander et al. (2008). 
On the basis of lung function data generated to test these hypotheses, 
which can be interpreted as a surrogate indicator of activity or stress 
(Williams et al., 1988, Barone et al., 1990), the influence of conditioning 
rats on their welfare and dosimetry of inhaled drugs will be considered. 
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3.2. Materials and methods 
3.2.1. Head-out plethysmography and data capture of 
lung function measurements 
Minute volume and breath frequency of conscious rats were measured 
non-invasively using a body plethysmograph (Model PLY22L; Electro-
Medical Measurement Systems (EMMS), UK), a restraint tube 
designed to accommodate rats and facilitate measurement of lung 
function parameters. The plethysmograph was similar to that described 
by Glaab et al. (2001) but differing insofar as only the snout of a rat 
would be presented to a test atmosphere contained within an exposure 
chamber. The animal’s body was enclosed in the tube, using a rubber 
diaphragm to form a seal around its neck (Figure 3.1A). Two 
diaphragms were used during capture of lung function data, with holes 
pre-cut at the centre of each disc to allow the animal’s head to pass 
through (holes of 20 mm or 25 mm diameter were typically cut for rats 
of 240 g to 270 g). A thin latex diaphragm (0.25 mm thick) was used to 
form the seal around the neck of the rat facilitating lung function 
measurement. A second latex diaphragm was thicker (0.63 mm thick) 
and used as a support for the thinner diaphragm. A sensor 
(pneumotach and pressure transducer) facilitated detection of changes 
in air pressure inside the tube as the animal breathes. 
Using Boyle’s law (absolute pressure and the volume of a fixed mass 
of gas are inversely proportional at constant temperature), lung 
function parameters derived from the changes in pressure inside the 
body plethysmograph were captured using software (eDacq version 
1.8.4b; EMMS) that facilitated rejection of anomalous breath-wave 
signals ascribed to a compromised neck seal, typically associated with 
an animal’s movement in the plethysmograph; approximately 700 to 
1,000 breaths per hour were captured for each animal. During data 
capture, the breath wave, tidal volume and minute volume for each 
animal were displayed on a monitor (Figure 3.1B). Each 
plethysmograph containing a rat was attached to a simple, flow-through 
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design of a snout-only inhalation exposure chamber to facilitate 
exposure of the animals to air only or in combination with an aerosol of 
a p38 MAPK inhibitor as described in Chapter 2 (Section 2.2.5.5).  
3.1A 
 
3.1B 
 
Figure 3.1: Head-out plethysmography in rats. 3.1A: restraint of a rat in a 
plethysmograph. 3.1B: real-time monitoring of breath waves for four rats and 
monitoring of tidal volume (TV) and minute volume (MV) for each rat (1 to 4). 
3.2.2. Investigating lung function and dosimetry in rats  
Four experiments were conducted during which procedures for 
acclimatisation of rats to the plethysmographs and data capture were 
refined. Given an ethical obligation to minimise the degree of restraint 
applied to rats repeatedly undergoing inhalation exposure procedures, 
consideration was given to inclusion or omission of the neck seal on 
days when lung function data were not recorded. The protocol for 
acclimatising rats to plethysmographs evolved from one experiment to 
the next and key features or refinements for lung function 
measurements introduced for subsequent experiments included 
improvements in data quality by allowing rats to settle in the 
plethysmographs before aerosol generation, and reducing potential 
stimuli by limiting nearby activities or incursions into the area 
surrounding the chamber (Figure 3.2). For Designs 2 to 4, rats were 
exposed to an aerosol of a p38 MAPK inhibitor; the pharmacology was 
not expected to affect the lung function measurements. Key outcomes 
for each experimental design are summarised in the methods 
(Section 3.2) for clarity of the evolving methodology but are 
TV MV 
2 
4 3 
1 
4 
3 
2 1 
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subsequently described in detail in the results and discussion 
(Section 3.3). 
 
Figure 3.2: Evolution of study designs for investigation of light, duration 
of tube acclimatisation and conditioning of rats on lung function. 
3.2.2.1. Preliminary analysis of lung function data 
In order to facilitate analysis of group trends for the continuous data 
(≤1000 breaths/hour for each animal), mean minute volume (MV) and 
breath frequency (BF) were calculated for each rat for 5-minute periods 
at intervals throughout each data capture period. 
3.2.3. Test system and animal husbandry 
Male rats (Charles River UK Ltd, Margate, Kent) were randomly 
allocated to groups and accommodated under standard laboratory 
conditions (Home Office, 2014) with access to food and water as 
described in Chapter 2 (Section 2.2.4.1). Rats were accommodated for 
at least five days before undertaking the first licensed procedure (tube 
restraint) and were approximately 10 or 11 weeks old on the (first) day 
of aerosol administration and/or observation as applicable (Day 1). 
Two strains of rat were used to investigate lung function. The 
Crl:WI(Han) rat is currently the sponsors strain of choice for non-clinical 
safety studies, and was used for the first three experiments (Designs 1 
to 3). The Crl:CD(SD) rat was formerly used for non-clinical safety 
studies including the first toxicity studies performed using p38 MAPK 
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inhibitors before termination of the respective drug development 
programmes. For logistical reasons, investigation of lung function in the 
fourth experiment (Design 4) was performed using the same animals 
designated for the toxicokinetic investigations described in Chapter 5, 
for which the Crl:CD(SD) rat was selected for continuity with and 
reference to historical pathology data for p38 MAPK inhibitors. 
3.2.4. Method acquisition (Design 1) 
A preliminary study was performed to implement methodology and 
confirm satisfactory data capture by head-out plethysmography. Rats 
(2 groups; n=4) were acclimatised to plethysmographs over a six-day 
period, using a protocol similar to those adopted by other laboratories 
preparing rodents for respiratory pharmacology investigations using 
head-out plethysmography (Hoymann, 2012). Rats were restrained in 
tubes each day for progressively longer periods of time and were first 
restrained using a latex neck seal from the fourth day of acclimatisation 
(Table 3.1). Rats were then maintained for a 31-day observation period 
(Days 1 to 31). Rats were restrained in plethysmographs, attached to 
the inhalation chamber and exposed to air only, once daily, throughout 
the acclimatisation and 31-day observation periods. For lung function 
measurements, rats were restrained in plethysmographs for 90 minutes 
with the neck seal incorporated. 
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Table 3.1: Tube restraint protocol for acclimatisation of rats to  
plethysmographs and a 31-day observation period (Design 1) 
Days of 
observation 
period A 
Tube 
Group A Group B Comment or 
figure number 
for presentation 
of BF / MV 
Neck 
seal 
present 
Time 
in tube 
(min) 
Neck 
seal 
present 
Time 
in tube 
(min) 
Acclimatisation to tube restraint 
-6 PLY22L No n/a No n/a Rat ‘run up’ tube 
 -6 B PLY22L No 20 No 20  
-5 PLY22L No 45 No 45  
-4 PLY22L No 60 No 60  
-3 PLY22L Yes  30 C Yes  30 C 3.7A / 3.9A 
-2 PLY22L Yes 60 Yes 60 3.7B / 3.9B 
-1 PLY22L Yes 90 Yes 90 3.7C / 3.9C 
Observation period 
1 PLY22L Yes 90 Yes 90 3.7D / 3.9D 
2 to 6 PLY22L No 60 No 60  
7 PLY22L Yes  90 D No 60  
8 PLY22L Yes 90 Yes 90 3.7E / 3.9E 
9 to 13 PLY22L No 60 No 60  
14 PLY22L Yes 90 No 60  
15 PLY22L Yes  90 D Yes 90 3.7F / 3.9F 
16 to 26 PLY22L No 60 No 60  
27 PLY22L Yes  90 D No 60  
28 PLY22L Yes 90 Yes 90 3.8A / 3.10A 
29 PLY22L No 60 No 60  
30 PLY22L Yes 90 Yes 90 3.8B / 3.10B 
31 PLY22L Yes 90 Yes 90 3.8C / 3.10C 
Notes 
BF/MV Breath frequency; minute volume 
A Days of acclimatisation to tube restraint, conventionally preceding the first 
aerosol administration, are designated by a negative number. 
B 20-minute restraint period performed during afternoon (all other procedures 
were conducted during the morning). 
C 30-minute acclimatisation performed with tubes on non-slip table surface (15 
minutes) followed by attachment of tubes to chamber (15 minutes). 
D Lung function data were captured on Days 7, 14 and 27 for Group A only. 
These profiles (not reported) were very similar to those presented for Days 8, 
15 and 28, for which data are also available for Group B. 
In order to consider the potential influence of infrequent restraint using 
the neck seal after Day 1, rats allocated to Group B were subjected to 
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the neck seal for single occasions (Days 8, 15 and 28) and rats of 
Group A were subjected to restraint with the neck seal for two 
consecutive days (Days 7/8, 14/15 and 27/28). On days when data 
capture was not performed, rats were restrained in the 
plethysmographs for 60 minutes without a neck seal (Table 3.1; 
Figure 3.3). 
Design 1 
 
Figure 3.3: Design of a preliminary study to measure lung function over 
four weeks and consider the impact of lighting conditions. Rats (n=4; two 
groups designated A and B) were acclimatised to plethysmograph tubes over 
six days and maintained under normal fluorescent lighting for 17 days. From 
Days 18 to 29, rats were restrained under red-filtered lighting and a cross-
over design for red and white lighting was implemented on Days 30 and 31. 
3.2.4.1. Investigating lighting colour during tube restraint 
Tube restraint of animals during the acclimatisation period (Day -6 to 
Day -1) and Days 1 to 17 of the observation period were performed 
under normal fluorescent (‘white’) lighting. The potential influence of 
lighting colour on activity and hence breathing of rats during inhalation 
exposure procedures was first considered during this experiment. From 
Days 18 to 29, restraint procedures were performed under red-filtered 
lighting (λ ≥ 600 nm) and a cross-over design was implemented with 
half of the rats (n=2/group) subjected to white light and the other half to 
red light on Day 30, and vice versa on Day 31 (Figure 3.3). 
Group A 
Group B 
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3.2.4.2. Statistical analysis of lung function data 
Multivariate analysis of variance (MANOVA) was conducted (Statistica, 
version 12.0.1133.40) using pooled data (n=8 for Groups A/B and 
Days 30/31) with post hoc analysis using Tukey’s honestly significant 
difference test (Abdi and Williams, 2010[B]). 
3.2.4.3. Methodological outcomes of Design 1 
Variability in MV and BF values indicated a need to minimise 
disturbances adjacent to rats undergoing plethysmography data 
capture. Anecdotal observations in activity and the presence of faeces 
suggested rats may be calmer under red light, although these apparent 
observations may have been a consequence of repeated conditioning 
of the rats from Day 19, irrespective of lighting colour. 
3.2.5. Colour of lighting and duration of acclimatisation 
protocols for tube restraint (Design 2) 
In Design 1, animals were acclimatised to the plethysmographs over 
six days, in line with the practices of other laboratories investigating 
respiratory pharmacology in rodents. For inhaled administration of 
candidate drugs for pharmacokinetics and/or toxicopathology 
investigations, rodents are typically acclimatised to the restraint tubes 
over shorter periods. At the sponsor’s laboratory, rodents were 
commonly acclimatised for 20 minutes and then 45 minutes over the 
two days preceding the first 60-minute inhalation exposure, or for 
20 minutes the day before the first 30-minute inhalation exposure. This 
raised a question regarding the implications for breathing patterns of 
animals prepared specifically for pharmacology investigations versus 
routine administration of inhaled drugs in non-clinical studies, and 
potential differences in the resultant lung deposited doses of a drug. In 
addition, anecdotal observations for Design 1 suggested red lighting 
may maintain animals in a calmer state when restrained for head-out 
plethysmography. However, this needed to be evaluated more robustly. 
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Design 2 
 
Figure 3.4: Latin square design of study to investigate effects of lighting 
and duration of tube acclimatisation on lung function and dose. Groups 
of rats (n=8) were acclimatised to plethysmograph tubes over two or six days 
and under normal fluorescent (‘white’) or red-filtered lighting. All rats (32 in 
total) were exposed to crystalline GSK-899 for 60 minutes concurrently with 
lung function measurements, euthanized and lungs taken for analysis of 
GSK-899. For logistical reasons (limited capacity for respiratory data capture), 
acclimatisation and inhalation exposures were conducted over four weeks 
using two sub-groups of rats (n=4/treatment), duplicating the outlined design. 
A Latin square design was used to investigate the potential influence of 
lighting colour and duration of pre-treatment acclimatisation protocols 
on MV and BF during inhalation exposure of rats to an aerosol 
(Figure 3.4).  
Rats (4 groups; n=8/group) were acclimatised to plethysmographs 
under either normal fluorescent (white) lighting or red-filtered lighting 
(λ ≥ 600 nm) by progressively extending restraint periods over two or 
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six days (Table 3.2). BF and MV were measured during inhaled 
administration of crystalline GSK-899 (600 µg/kg; 60 minutes) under 
white or red light. Rats were restrained in plethysmographs, attached to 
the snout only chamber and exposed to 5% GSK-899 (w/w) in lactose 
for 60 minutes as summarised in Section 3.2.8.  
Table 3.2: Tube restraint protocol for acclimatisation of rats to  
plethysmographs and aerosol administration (Design 2) 
Days of 
observation 
period 
Tube 
2-day protocol 6-day protocol 
Neck seal 
present 
Time in 
tube (min) 
Neck seal 
present 
Time in 
tube (min) 
Acclimatisation to tube restraint 
-6 ADG B - - No 20 
-5 ADG B - - No 45 
-4 ADG B - - No 60 
-3 PLY22L - - Yes 30 
-2 PLY22L Yes 20 Yes 60 
-1 PLY22L Yes 45 Yes 60 
Treatment (aerosol administration) 
1 PLY22L Yes 60 Yes 60 
Notes 
A Days of acclimatisation to tube restraint are designated by a negative number 
B “Standard” restraint tube (ADG Developments Ltd, UK) routinely used for 
inhalation exposure of rats 
Rats were euthanized (exsanguination under isoflurane anaesthesia) 
as soon as practicable post exposure and the lungs removed (right and 
intermediate lobes pooled) and homogenised for analysis of GSK-899 
using a validated HPLC-MS/MS method as described in Chapter 2 
(Section 2.2.5.8), but with addition of an equal volume of 10 mg/mL 
aqueous sodium fluoride added to the tissue to prevent potential 
hydrolysis of an amide bond in GSK-899. Results of Chapter 2 showed 
the crystalline form of GSK-899 was of relatively low solubility in vitro 
and there was no appreciable decrease in drug-lung concentrations up 
to 24 hours post exposure. Crystalline GSK-899 was therefore selected 
for this experiment to enable investigation of lung dose post exposure 
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whilst minimising the potential for drug-lung clearance prior to isolation 
of lung tissue for analysis by HPLC-MS/MS. 
The plethysmography apparatus permitted simultaneous data capture 
from four subjects. Consequently, for Design 2, a group size of n = 8 
for each of four treatments (white versus red light; two versus six days 
of acclimatisation) necessitated inhalation exposure of animals as two 
sub-groups. In order to reduce potential bias, the experiment was 
performed over four weeks with the first sub-group of each treatment 
conducted first (Figure 3.4) before repeating the cycle of treatments 
and inhalation exposure procedures for the second sub-groups. 
3.2.5.1. Data analysis of measured and body weight derived 
estimates of minute volume 
The inhaled dose is proportional to the minute volume (Equation 1). 
There is potential for differences between measured MV and the body 
weight derived estimate (eRMV), and hence potential discrepancies in 
dose estimation, were investigated by comparing the mean measured 
minute volumes for the 60-minute inhalation exposure period with 
eRMV values calculated from the corresponding pre-dose body weight 
for each animal using Equation 2 (Alexander et al., 2008). 
3.2.5.2. Data analysis of estimated lung deposited dose and 
measured drug-lung concentrations 
Drug-lung concentrations measured by HPLC-MS/MS were compared 
with estimates of the lung deposited dose. The lung dose was 
calculated from the estimated inhaled dose (Equation 1), calculated 
using MV (measured) or eRMV (Equation 2), and assuming 7% of 
inhaled GSK-899 was deposited in the rat lung (Snipes, 1989). 
3.2.5.3. Statistical analysis of lung function data and drug-
lung concentration in lung tissue 
Statistical analysis of lung function and concentration data were 
performed using Statistica software (version 12.0.1133.40) as follows: 
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MV and BF: comparison of acclimatisation protocols  
MANOVA was conducted using pooled data (n=16 for duration of 
acclimatisation or lighting colour) with post hoc analysis using Tukey’s 
honestly significant difference test (Abdi and Williams, 2010[B]). 
Comparison of measured MV and body weight-derived eRMV when 
plotted against body weight 
One-way analysis of variance (ANOVA) was conducted using pooled 
animal-specific mean data for the 60-minute inhalation exposure 
period. Data were pooled for both the duration of acclimatisation and 
lighting colour (n=32). 
Lung concentrations for measured (HPLC-MS/MS) or estimated (MV or 
eRMV) data 
MANOVA was conducted using pooled data (n=16 for duration of 
acclimatisation or lighting colour) with post hoc analysis using Tukey’s 
honestly significant difference test (Abdi and Williams, 2010[B]). 
3.2.5.4 Methodological outcomes of Design 2 
A shorter acclimatisation period, with inclusion of the neck seal 
throughout, was sufficient provided animals were allowed to settle in 
the restraint tubes for 15 minutes before the start of aerosol generation. 
MV and BF for rats maintained under red or white light were similar and 
normal fluorescent lighting was acceptable for further experiments. 
3.2.6. Settling rats before aerosol administration 
(Design 3) 
In Design 2, the MV and BF of rats acclimatised over two days 
appeared to settle during the first 15 minutes of inhalation exposure.  
The design of two single dose experiments performed to investigate 
the pharmacokinetics of inhaled GSK-677 or GSK-361 (Figure 3.5; 
Chapter 2) were adapted such that rats were allowed to settle in their 
restraint tubes before aerosol generation was initiated (Table 3.3) and 
selected rats were used to capture lung function measurements.  
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Design 3 
 
Figure 3.5: Simple study design to investigate lung function 
measurements and drug-lung concentrations after a single inhaled dose 
of GSK-361 or GSK-677. Groups of rats (n=3) were acclimatised to 
plethysmograph tubes for 20 minutes (Day -1). The following day, lung 
function was measured whilst rats settled in the tubes for 15 minutes and then 
during aerosol administration for 30 minutes. Rats were euthanized as soon 
as possible after exposure and the lungs taken for drug analysis.  
The day before aerosol administration, rats (4 groups; n=3/group) were 
acclimatised to tube restraint for 20 minutes using plethysmographs 
fitted with the neck seal. The following day, rats were restrained in 
plethysmographs, attached to the snout only chamber and allowed to 
settle for 15 minutes before exposure to crystalline or aqueous 
nebulised aerosols of GSK-677 or GSK-361 for 30 minutes (see 
Section 3.2.8). Lung function data were captured throughout the 
pre-exposure and aerosol administration periods, with the erroneous 
exception of a period preceding administration of crystalline GSK 361. 
All procedures were performed under normal fluorescent lighting. 
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Table 3.3: Tube restraint protocol for acclimatisation of rats  
to plethysmographs and aerosol administration (Design 3) 
Days of 
observation 
period A 
Tube 
model 
2-day protocol 
Neck seal 
present 
Time in 
tube (min) 
Acclimatisation to tube restraint 
-1 PLY22L Yes 20 
Treatment (aerosol administration) 
1 PLY22L Yes 15B +30 
Notes 
A Day of acclimatisation to tube restraint is designated by a negative number. 
B Rats allowed to settle in restraint tubes before starting aerosol generation. 
Rats were euthanized (exsanguination under isoflurane anaesthesia) 
as soon as practicable post exposure and the lungs removed (right and 
intermediate lobes pooled) and homogenised for analysis using a 
validated HPLC-MS/MS method for GSK-677 or GSK-361 as described 
in Chapter 2 (Section 2.2.5.8). 
3.2.6.1. Statistical analysis of lung function data and drug-
lung concentration in lung tissue 
Statistical analysis of lung function and concentration data were 
performed using Statistica software (version 12.0.1133.40) as follows: 
MV and BF: comparison of aerosol forms  
Two-way ANOVA was applied to the animal specific mean data for 
each time point, and also for the 30-minute inhalation exposure period. 
Comparison of measured MV and body weight-derived eRMV when 
plotted against body weight 
One-way ANOVA was conducted using pooled animal-specific mean 
data for the 30-minute inhalation exposure period. Data were pooled 
for both the aerosol form and test articles (n=12). 
Lung concentrations for measured (HPLC-MS/MS) or estimated (MV or 
eRMV) data 
MANOVA was conducted using pooled data (n=6 for aerosol form or 
compound) with post hoc analysis using Tukey’s honestly significant 
difference test (Abdi and Williams, 2010[B]). 
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3.2.6.2. Methodological outcomes of Design 3 
It was confirmed a shorter acclimatisation period, with application of the 
neck seal, was sufficient when animals were allowed to settle in the 
restraint tubes for 15 minutes before the start of aerosol generation.  
3.2.7. Incorporation of lung function measurements into 
repeat-dose inhalation studies (Design 4) 
The fourth experiment was designed to consider technical implications 
for incorporating lung function measurements into repeated exposure 
inhalation toxicology studies. Given the degree of restraint required to 
facilitate data capture using the design of head-out plethysmograph, a 
28-day experiment was conducted to investigate the effect on lung 
function measurements when the neck seal was included or omitted 
during inhalation exposure procedures on days preceding data capture. 
For logistical reasons, MV and BF were measured using animals 
assigned to two inhalation toxicology studies, one administering 
crystalline GSK-361 and the other aqueous nebulised GSK-361. 
Rats (2 groups; n=3/group) were acclimatised to the plethysmographs 
for 20 minutes, then 45 minutes and finally 60 minutes over three 
consecutive days preceding the first aerosol administration (Table 3.4). 
Rats were then restrained in plethysmographs, attached to the snout 
only chamber and allowed to settle for 15 minutes before exposure to a 
crystalline or aqueous nebulised aerosol of GSK-361 for 60 minutes 
once daily for 28 days (see Section 3.2.8). Lung function data were 
captured throughout the pre-exposure and aerosol administration 
periods on Day -1 (acclimatisation) and Days 1, 4, 14 and 26 to 28 of 
treatment. On Days 5 to 13 and 15 to 25, rats were restrained without a 
neck seal and exposed to the aerosol for 60 minutes (Figure 3.6). All 
procedures were performed under normal fluorescent lighting. 
After the last administration of GSK-361 (Day 28), rats were sampled 
for plasma up to 24 hours post exposure and then euthanized (by 
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exsanguination under isoflurane anaesthesia) and the lungs taken for 
toxicokinetic investigations described in Chapter 5. 
Table 3.4: Tube restraint protocol for acclimatisation of rats to  
head-out plethysmography and aerosol administration (Design 4) 
Days of 
observation 
period A 
Tube 
model 
Group A 
Figure number 
for presentation 
of BF / MV 
Comment Neck 
seal 
present 
Time in 
tube 
(min) 
Acclimatisation to tube restraint 
-3 PLY22L Yes  20   
-2 PLY22L Yes  45   
-1 PLY22L Yes  60  3.15A / 3.17A  
Treatment period (aerosol administration) 
1 PLY22L Yes 15B +60  3.15B / 3.17B 
First day of aerosol 
administration 
2 to 3 PLY22L Yes 15B +60   
4 PLY22L Yes 15B +60  3.15C / 3.17C  
5 to 13  No  60   
14 PLY22L Yes 15B +60  3.15D / 3.17D  
15 to 25 PLY22L No  60   
26 to 28 PLY22L Yes 15B +60 
 3.16 (3.15E) / 
  3.18 (3.17E) 
 
Notes 
BF/MV Breath frequency; Minute volume 
A Days of acclimatisation to tube restraint designated by a negative number. 
B Rats allowed to settle in restraint tubes before starting aerosol generation. 
3.2.7.1 Statistical analysis of lung function data 
Statistical analysis of lung function data was performed using Statistica 
software (version 12.0.1133.40) as follows: 
Comparison of the measured and body weight derived estimates of 
minute volume 
The potential for differences between measured MV and the body 
weight derived estimate (eRMV), and hence potential discrepancies in 
dose estimation, were investigated by comparing the mean measured 
minute volumes for the 60-minute inhalation exposure period with 
eRMV values calculated from the corresponding pre-dose body weight 
for each animal using Equation 2 (Alexander et al., 2008). 
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Design 4 
 
Figure 3.6: Experimental design to investigate lung function of rats 
during a 28-day inhalation study. Rats (n=3) were acclimatised to 
plethysmograph tubes (with neck seals) over three days and exposed 
(60 minutes/day) to crystalline or nebulised GSK-361 for 28 days. Lung 
function data were captured on the last day of acclimatisation (Day -1) and 
during inhalation exposures on Days 1, 4, 14 and 26 to 28 of treatment. Neck 
seals were omitted from plethysmograph tubes for exposure of rats on Days 5 
to 13 and 15 to 25 of treatment (shown as blue rectangles). 
Comparison of BF for two aerosol forms 
Two-way ANOVA was applied to the animal specific mean data for the 
60-minute inhalation exposure period (n=3). 
Comparison of measured MV and body weight-derived eRMV for two 
aerosol forms 
MANOVA was conducted using pooled data (n=6) with post hoc 
analysis using Tukey’s honestly significant difference test (Abdi and 
Williams, 2010[B]). 
3.2.8. Aerosol generation of p38 MAPK inhibitors and 
inhalation exposure of rats 
For experiments requiring aerosol administration to rats (Designs 2 to 
4), aerosols were generated and directed into the top of the snout-only 
inhalation exposure chamber as described in Chapter 2 (Section 2.2.5).  
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3.2.8.1. Test articles 
The p38 MAPK inhibitors were supplied as micronised crystals and 
stored at ambient temperature, protected from light and moisture. 
Dry powder formulations of p38 MAPK inhibitors  
For aerosol administration of crystalline p38 MAPK inhibitors, aliquots 
of dry powder formulations prepared for use in Chapter 2 (nominally 
5% drug (w/w) in lactose) were packed into the dust feed canisters 
(internal volume of 5 cm3). These methods were described in Chapter 2 
(Section 2.2.5.1). 
Liquid formulations of GSK-677 and GSK-361 
For nebulisation of aqueous solutions of GSK-677 or GSK-361, each 
micronised crystalline test article was dissolved in a vehicle to achieve 
a concentration (Table 3.5) anticipated to achieve the target inhaled 
dose. Methods for preparation of the formulations are stated in 
Chapter 2 (Section 2.2.5.3). 
Table 3.5: Aqueous solutions of p38 MAPK inhibitors  
nebulised for single inhalation exposure of rats 
Test 
article 
Study 
No. 
Concentration 
in vehicle 
Vehicle for nebulisation 
GSK-677 R30988N 2.50 mg/mL 
3% (v/v) Solutol HS 15 in 0.9% (w/v) 
aqueous sodium chloride (pH 5.9) 
GSK-361 
R31225N 1.50 mg/mL 
20:20:60 (v/v/v) Solutol HS 15, ethanol 
and 60 mM phosphate buffer (pH 7) R31036N 
1.60, 1.70 or 
1.75 mg/mL 
3.2.8.2. Aerosol Generation and formulation details 
Groups of rats were administered an aerosol of the p38 MAPK inhibitor 
once (Designs 2 and 3) or repeatedly (Design 4), by snout-only 
inhalation exposure, as a dry powder aerosol or nebulised solution as 
appropriate (Chapter 2, Sections 2.2.5.2 and 2.2.5.4 respectively). The 
same design of apparatus was used for both single and repeated 
exposure of rats to nebulised GSK-361 (Designs 3 and 4), i.e. with the 
output of two nebulisers directed into a common exposure chamber. 
For single inhalation exposure of rats (Designs 2 and 3), a target dose 
of 0.6 mg/kg was selected in line with non-clinical studies representing 
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a 10-fold overage for a nominal clinical dose of 1 mg when a 
conservative scaling factor for inter-species differences in lung 
deposition is applied (Degeorge et al., 1997, Jones and Baldrick, 
2013). Rats undergoing repeated inhalation exposure to GSK-361 
(Design 4) were administered the target dose of 1 mg/kg/day selected 
for toxicopathology investigations described in Chapter 5. 
Target aerosol concentrations (Table 3.6) for exposure of animals were 
calculated from the required doses using Equation 2 (Chapter 1, 
Section 1.3.4) and Equation 3 (Chapter 2, Section 2.2.5), assuming a 
predicted body weight of 350g (unpublished data) and an inhalation 
exposure period of 30 or 60 minutes as appropriate. 
Table 3.6: Duration of exposure, target doses and aerosol 
concentrations of p38 MAPK inhibitors for exposure of rats 
Test 
article 
Study 
No. 
Experimental 
design for 
lung function 
Target 
dose 
(mg/kg) 
Duration of 
exposure period 
(minutes) 
Target aerosol 
concentration 
(mg/L) 
GSK-899 R31125N 2 0.6 60 0.014 
GSK-677 R30988N 3 0.6 30 0.028 
GSK-361 
R31225N 3 0.6 30 0.028 
R31035N 4 1 60 0.024 
R31036N 4 1 60 0.024 
3.2.8.3. Aerosol characterisation 
‘Pre-study’ aerosol characterisation work was conducted without 
animals to establish the operating conditions needed to generate target 
aerosol concentrations and to ensure aerosols were in line with 
particulate size criteria for exposure of rodents (OECD[412], 2009, 
OECD[413], 2009, US-EPA[3645], 1998). For repeat exposure studies, 
the operating conditions of the dust generator (speed of canister 
advancement) or concentration of GSK-361 in the nebulised solution 
were adjusted as necessary during the course of the study, with 
reference to HPLC-UV analysis results of aerosol concentration, to 
maintain the desired aerosol concentration on target.  
Aerosols were also taken during exposure of animals using the stated 
air sampling volumes (Table 3.7) to determine aerosol concentrations 
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of the p38 MAPK inhibitors for dose estimation using Equation 1, and 
to determine particle size parameters, as described in Chapter 2 
(Section 2.2.5.6). For repeat exposure studies, aerosol concentration 
was determined for representative days (approximately half of the 
exposure occasions) and particle size distribution was determined once 
in Weeks 1 and 3 of treatment. 
Table 3.7: Aerosol sampling volumes for aerosol  
concentration and particle size analysis  
Test article 
Aerosol 
form 
Study No. 
Air sampling volume (L) 
Aerosol 
concentration 
Particle size 
distribution 
GSK-899 A crystalline R31125N 4 8 
GSK-677 B 
crystalline 
R30988N 
6 20 
nebulised 6 24 
 GSK-361 C 
crystalline 
R31225N 6 20 
nebulised 
crystalline R31035N 6 6 
nebulised R31036N 6 6 
Notes 
A Diluent for HPLC-UV analysis (Appendix 28): methanol: 0.1% formic acid 
(50:50 v/v) 
B Diluent for HPLC-UV analysis (Appendix 31): acetonitrile: 0.1% formic acid 
(50:50 v/v) 
C Diluent for HPLC-UV analysis (Appendix 33): acetonitrile: methanol: water 
(40:40:20 v/v/v) 
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3.3. Results and discussion 
Lung function data (breath frequency and minute volume) and 
dosimetry (inhaled dose and lung concentration) are presented for 
each experimental design (Table 3.8) and discussed in the context of 
lung function, effect of animal handling, correlation of lung function with 
body weight-derived predictions and implications for lung deposition. 
Table 3.8: Index of figures and tables summarising lung function data, 
inhaled doses and lung concentrations of p38 MAPK inhibitors in rats 
Experiment 
design 
Study 
number 
 
Figure/table number 
Breath 
frequency 
Minute 
volume 
Inhaled 
doses 
Lung 
concentration 
1 R30657N Figures 3.7, 3.9 3.8, 3.10 - - 
2 R31125N 
Figures 3.11 3.12, 3.21 - 3.24 
Tables 3.9 3.10, 3.13 3.15 3.16 
3 
R30988N 
R31225N 
Figures 3.13 3.14, 3.22 - 3.25 
Tables 3.11 3.12, 3.14 3.17 - 
4 
R31035N 
R31036N 
Figures 
3.15, 3.16, 
3.19 
3.17, 3.18, 
3.20, 3.23 
- - 
3.3.1. Breath frequency and minute volume of rats 
restrained in tubes 
Mean breath frequency (BF) and minute volume (MV) of rats generally 
decreased over the first 15 minutes of restraint for all experiments. 
In the preliminary study, Design 1, transient increases in BF 
(Figure 3.7) and MV (Figure 3.8) were likely to be associated with 
stimulation of the animals during the observation period. It is common 
practice during non-clinical studies to perform visual checks on the 
condition of restrained animals for animal welfare reasons. It is likely 
the transient increases in BF and MV coincided with visual checks on 
the restrained animals and operational parameters such as chamber 
airflow and temperature, or when repositioning animals with a 
compromised neck seal (e.g. to remove an animal’s forepaw from 
between its neck and the latex diaphragm).  
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Design 1: breath frequency 
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3.7C: Day -1 (white light) 
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3.7D: Day 1 (white light) 
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3.7E: Day 8 (white light) 
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3.7F: Day 15 (white light) 
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Figure 3.7: Breath frequency of rats restrained in tubes once daily for 28 
days. Mean data plotted with standard deviations (n=4). Rats were 
acclimatised to plethysmographs with neck seals (30, 60 and 90 minutes) and 
monitored for an additional 17 days under normal fluorescent light (see 
Figure 3.3 for study design); all rats (Groups A and B) were restrained with 
neck seals on days of BF measurement and Group A were also subjected to 
neck seals on Days 7 and 14. The same rats were used for Group A (blue 
solid line) and Group B (green dotted line) throughout the experiment. 
Generally, breath frequency decreased during the first 15 minutes of restraint 
suggesting that animals were calmer after a settling period. Time courses on 
each day of observation nevertheless showed transient increases, with no 
obvious improvement (i.e. reduced variability) of data for Group A. 
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Design 1: minute volume 
3.8A: Day -3 (white light) 
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3.8B: Day -2: (white light) 
0 1 5 3 0 4 5 6 0 7 5 9 0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
6 0 0
T im e  (m in u te s )
M
in
u
te
 v
o
lu
m
e
 (
m
L
)
 
3.8C: Day -1 (white light) 
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3.8D: Day 1 (white light) 
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3.8E: Day 8 (white light) 
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3.8F: Day 15 (white light) 
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Figure 3.8: Minute volume of rats restrained in tubes once daily for 28 
days. Mean data plotted with standard deviations (n=4). Rats were 
acclimatised to plethysmographs with neck seals (30, 60 and 90 minutes) and 
monitored for an additional 17 days under normal fluorescent light (see 
Figure 3.3 for details of design); all rats (Groups A and B) were restrained 
with neck seals on days of BF measurement and Group A were also 
subjected to neck seals on Days 7 and 14. The same rats were used for 
Group A (blue solid line) and Group B (green dotted line) throughout the 
experiment. Generally, minute volume decreased during the first 15 minutes 
of restraint suggesting animals were calmer after a settling period. Time 
courses on each day of observation nevertheless showed transient increases, 
with no obvious improvement (i.e. reduced variability) of data for Group A. 
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Under the conditions of this experiment, no improvement (reduced 
variability) in the BF or MV was evident on Days 8 and 15 of the 
observation period for rats also restrained with neck seals on the day 
preceding each data capture period (Group A), relative to comparator 
rats (Group B) not subjected to the neck seal on Days 7 and 14. 
Design 1: breath frequency 
3.9A: Day 28 (red-filtered light) 
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Design 1: derived from Fig.3.3 
 
3.9B: Day 30 (cross-over) 
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3.9C: Day 31(cross-over) 
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Figure 3.9: Breath frequency of rats restrained in tubes under red or 
white lighting. Mean data plotted with standard deviations (n=4). Rats were 
restrained under red light (Days 18 to 29) and then under red or white light 
according to a cross-over design as extension to the experiment in Figure 3.7. 
3.9A: Day 28; Group A (red solid line) and Group B (brown dotted line) were 
subjected to restraint under red light for 10 days. Breath frequency appeared 
less variable than for the same rats maintained under white light (Figure 3.7). 
3.9B: Day 30; half of Groups A and B restrained under white light and half 
under red light. 3.9C: Day 31; repetition with light colour switched for sub-
groups. Statistical analysis (MANOVA with post hoc analysis using Tukey’s 
honestly significant difference test (Abdi and Williams, 2010[B]); n=8 with 
pooling of data) indicated a significant difference (p<0.01) between rats under 
red and white light, and between Days 30 and 31. No differences of statistical 
significance between time points during the 90-minute observation period. 
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Fewer faecal pellets were seen in plethysmographs when rats were 
restrained under red light from Day 18, suggesting rats may be calmer 
(Williams et al., 1988, Barone et al., 1990) than under white light. This 
subjective observation was apparently consistent with less variable BF 
(Figure 3.9A) and MV (Figure 3.10A) data on Day 28. 
Design 1: minute volume 
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Design 1: derived from Fig.3.3 
 
3.10B: Day 30 
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3.10C: Day 31 
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Figure 3.10: Minute volume of rats restrained in tubes under red or white 
lighting. Mean data plotted with standard deviations (n=4). Rats were 
restrained under red light (Days 18 to 29) and then according to a cross-over 
design or red and white light as an extension to the experiment shown in 
Figure 3.8. 3.10A: Day 28; Group A (red solid line) and Group B (brown 
dotted line) were subjected to tube restraint under red light for 10 days. 
Minute volume appeared less variable than that observed for the same rats 
when maintained under white light (Figure 3.9). 3.10B: Day 30; half of Groups 
A and B restrained under white light and the other half of Groups A and B 
under red light. 3.10C: Day 31; repetition with lighting colour switched for 
cohorts of Groups A and B. Statistical analysis (MANOVA with post hoc 
analysis using Tukey’s honestly significant difference test (Abdi and Williams, 
2010[B]); n=8 with pooling of data) indicated no differences of significant 
difference between red or white light, day or time of measurement. 
Statistical analysis of data pooled for investigation of light colour on 
Days 30 and 31 suggested BF (Figure 3.9B/C) of rats under red light 
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was lower than for white light (p<0.01). However, significant differences 
were also evident between Days 30 and 31 suggesting data variability. 
There were no significant differences in MV (Figure 3.10B/C) for rats 
under red or white light nor between Days 30 or 31. The error bars 
(standard deviations) indicated data for Days 30 and 31 were more 
variable than for the same animals on Day 28 of the observation 
period. Furthermore, apparent differences in measurements taken 
under white and then red light may also have been attributable to 
further procedural conditioning of rats as the observation period 
progressed. A more robust experimental design was thus required to 
further investigate these preliminary observations. 
3.3.1.1. Influence of lighting colour and duration of tube 
acclimatisation on breath frequency and minute 
volume of rats 
BF and MV measurements for the preliminary study (Design 1) showed 
a potential for interventions or activities near rats undergoing 
plethysmography data capture to induce erratic increases in BF and 
MV. Checks made on the condition of restrained rats for Designs 2 to 4 
were performed less intrusively to limit the potential for excitation of 
animals during data capture, achieving a more stable baseline with 
fewer transient increases in BF and/or MV during the plethysmography 
data capture periods (Figures 3.11 to 3.18). 
When considering the potential for lighting colour to affect the 
excitability of animals during restraint, measurements of BF in Design 1 
were equivocal. In a more robust study (Design 2), BF (Figure 3.11A) 
or MV (Figure 3.12A) measurements for rats restrained under red or 
white light were similar during inhalation exposure, with no significant 
difference between mean values for the 60-minute exposure period 
(Table 3.9 for BF; Table 3.10 for MV). The profile for BF showed a 
trend for a gradual reduction throughout the 60-minute exposure period 
and MV appeared to decrease from five minutes of exposure, 
establishing a baseline thereafter. 
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Investigation of the duration of the acclimatisation protocol showed no 
significant differences in mean BF (Table 3.9) or MV (Table 3.10) for 
animals acclimatised to restraint tubes over two or six days. 
Nevertheless, transient but statistically significant elevations in BF 
(Figure 3.11B; p<0.01) and MV (Figure 3.12B; p<0.05) were evident for 
rats acclimatised over two days compared with rats acclimatised over 
six days. BF and MV for rats acclimatised over six days followed a 
stable baseline with no elevation at the start of the exposure period.  
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3.11B: acclimatisation period 
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Figure 3.11: Breath frequency of rats exposed to GSK-899 for 60 
minutes after a tube acclimatisation protocol of two or six days and 
under red or white lighting. Latin square design (n=8 rats/group) used for 
statistical analyses (MANOVA with post hoc analysis using Tukey’s honestly 
significant difference test (Abdi and Williams, 2010[B]); mean data with 
standard deviations (n=16) are plotted against time of inhalation exposure. 
Breath frequencies at 5 minutes (p<0.01) and 15 minutes (p<0.05) were 
significantly different to those at 60 minutes. 3.11A: light colour used during 
restraint for acclimatisation and inhalation exposure (2-day and 6-day 
acclimatisation data pooled); no differences of statistical significance. 
3.11B: duration of acclimatisation period (red and white light data pooled); no 
differences of statistical significance.  
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Table 3.9: Breath frequency (breaths per minute) of rats  
during a 60-minute inhalation exposure period 
Design 2 
(R31125N) 
Lighting conditions A Tube acclimatisation A 
White Red 2 days 6 days 
Mean (bpm) 169.2 170.3  168.3  169.0 
sd 15.7 5.93  17.9  19.2 
CV 9% 10%  11%  11% 
n 16 16  16 16 
Notes 
sd standard deviation 
CV coefficient of variation (ratio of standard deviation to mean) 
n number of animals/group in statistical comparison 
A No differences of statistical difference (2-way ANOVA); Latin square design 
(n=8 rats/group) for statistical analyses of acclimatisation period (red and white 
light data pooled) and lighting (2-day and 6-day acclimatisation data pooled). 
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3.12B: acclimatisation period 
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Figure 3.12: Minute volume of rats exposed to GSK-899 for 60 minutes 
after a tube acclimatisation protocol of two or six days and under red or 
white lighting. Latin square design (n=8 rats/group) used for statistical 
analyses (MANOVA with post hoc analysis using Tukey’s honestly significant 
difference test (Abdi and Williams, 2010[B]); mean data with standard 
deviations (n=16) are plotted against time of inhalation exposure. Minute 
volumes at 5 minutes were significantly different to the rest of the profile 
(p<0.05 relative to 15 minutes; p<0.01 relative to 30, 45 and 60 minutes). 
3.12A: light colour used during restraint for acclimatisation and inhalation 
exposure (2-day and 6-day acclimatisation data pooled); no differences of 
statistical significance. 3.12B: duration of acclimatisation period (red and 
white light data pooled); no differences of statistical significance.  
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Table 3.10: Minute volume of rats during a  
60-minute inhalation exposure period 
Design 2 
Lighting conditions A Tube acclimatisation A 
White Red 2 days 6 days 
MV (mL) 262.0 254.6 258.1 253.8 
sd 22.2 25.2 18.4 25.2 
CV 8% 10% 7% 10% 
n 16 16 16 16 
Notes 
A No differences of statistical difference (2-way ANOVA); Latin square design 
(n=8 rats/group) for statistical analyses of acclimatisation period (red and white 
light data pooled) and lighting (2-day and 6-day acclimatisation data pooled). 
These data indicated the red filtration of light did not reduce BF or MV 
and, by inference, did not induce a calmer state for animals undergoing 
inhalation exposure to a dry powder aerosol. A shorter acclimatisation 
protocol (two days) did not significantly affect mean respiratory 
parameters for the 60-minute period. However, reductions in BF and 
MV early in the exposure period suggests modification of the procedure 
to allow rats to settle in the restraint tubes before aerosol generation 
may facilitate a more consistent exposure of rats to the test aerosol. 
3.3.1.2. Breath frequency and minute volume of rats 
allowed to settle before aerosol administration 
Procedures including checks on animal condition and aerosol sampling 
were performed less intrusively, where practicable, to limit the potential 
for excitation of animals during plethysmography data capture. A 
pre-exposure period of nominally 15 minutes was also applied for rats 
to settle in plethysmographs before aerosol administration. Statistically 
significant (p<0.01) reductions in BF (Figure 3.13; Table 3.11) and MV 
(Figure 3.14; Table 3.12) were evident after the pre-exposure period. 
Statistical analysis of the time courses indicated the BF of rats inhaling 
crystalline p38 MAPK inhibitors was significantly higher than for the 
nebulised aerosol forms, but with no significant difference between 
compounds. However, there was no significant difference in mean 
values for the 30-minute exposure period (Table 3.11). This apparent 
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difference was driven by generally higher BF values for rats 
administered crystalline GSK-361 (Figure 3.13B) and the time profiles 
were similar for crystalline and nebulised GSK-677 (Figure 3.13A). 
Similarly, the MV of rats administered GSK-361 was significantly higher 
than for GSK-677 but there was no significant difference between 
aerosol forms (Figure 3.14; Table 3.12). 
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3.13B: GSK-361 
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Figure 3.13: Breath frequency (BF) of rats exposed to crystalline or 
nebulised aerosols for 30 minutes. Mean BF with standard deviations (n=3) 
against time of inhalation exposure (30 minutes). 3.13A: GSK-677 treated 
rats settled for 20 minutes before exposure. 3.13B: GSK-361 treated rats 
settled for 15 minutes before exposure (data not captured before exposure to 
crystalline GSK-361). Statistical analysis (MANOVA with post hoc analysis 
using Tukey’s honestly significant difference test (Abdi and Williams, 2010[B]) 
indicated significant differences (p<0.01) between pre-exposure (-10 minutes) 
data and during exposure, and between crystalline and nebulised aerosols; 
no significant difference between GSK-677 and GSK-361. 
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Table 3.11: Breath frequency (breaths per minute) of rats  
during a 30-minute inhalation exposure period 
Design 3 
Period A 
Summary 
parameters 
Compound A Aerosol form A 
GSK-677 GSK-361 Crystalline Nebulised 
Pre-exposure 
(-10 min) 
Mean (bpm) 214.4 195.3 225.2 199.5 
sd 29.9 12.4 43.0 9.9 
CV 14% 6% 19% 5% 
n 6 3 B 3 B 6 
Aerosol 
administration ** 
(0 to 30 min)  
Mean (bpm) 156.4 150.8 163.9 143.3 
sd 17.2 29.3 25.6 16.2 
CV 11% 19% 16% 11% 
n 6 6 6 6 
Notes 
sd standard deviation 
CV coefficient of variation (ratio of standard deviation to mean) 
n number of animals/group in statistical comparison 
A Statistical analysis (MANOVA with post hoc analysis using Tukey’s honestly 
significant difference test (Abdi and Williams, 2010[B]) indicated reduced MV 
from pre-exposure to aerosol exposure periods (** p<0.01; drug and aerosol 
form data pooled); no significant difference between drugs or aerosol forms. 
B Data for nebulised GSK-361 treated rats only (data not captured in error before 
administration of crystalline GSK-361). 
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3.14B: GSK-361 
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Figure 3.14: Minute volume (MV) of rats exposed to crystalline or 
nebulised aerosols for 30 minutes. Mean MV with standard deviations 
(n=3) against time of inhalation exposure (30 minutes). 3.14A: GSK-677 
treated rats settled for 20 minutes before exposure. 3.14B: GSK-361 treated 
rats settled for 15 minutes before exposure (data not captured before 
exposure to crystalline GSK-361). Statistical analysis (MANOVA with post hoc 
analysis using Tukey’s honestly significant difference test (Abdi and Williams, 
2010[B])) indicated significant differences (p<0.01) between MV pre-exposure 
(-10 minutes) and during exposure, and between GSK-677 and GSK-361; no 
significant difference between crystalline and nebulised aerosol forms. 
Chapter Three 
163 
 
Table 3.12: Minute volume of rats during a  
30-minute inhalation exposure period 
Design 3 
Period A 
Summary 
parameters 
Compound A Aerosol form A 
GSK-677 GSK-361 Crystalline Nebulised 
Pre-exposure 
(-10 min) 
MV (mL) 341.9 484.5 346.0 411.1 
sd 44.1 143.7 44.2 126.0 
CV 13% 30% 13% 31% 
n 6 3 B 3 B 6 
Aerosol 
administration ** 
(0 to 30 min) 
MV (mL) 224.7 295.0 * 265.2 254.4 
sd 18.3 71.2 43.3 80.2 
CV 8% 24% 16% 32% 
n 6 6 6 6 
Notes 
A Statistical analysis (MANOVA with post hoc analysis using Tukey’s honestly 
significant difference test (Abdi and Williams, 2010[B]) indicated reduced MV 
from pre-exposure to aerosol administration periods (** p<0.01; aerosol form 
and drug data pooled) and significant difference between GSK-677 and 
GSK-361 treated rats (* p<0.05; aerosol form data pooled); no significant 
difference between aerosol forms (drug data pooled). 
B Data for nebulised GSK-361 treated rats only (data not captured in error before 
administration of crystalline GSK-361). 
3.3.2.3. Effect of neck restraint on breath frequency and 
minute volume of rats during repeat dose studies  
Procedures including checks on animal condition and aerosol sampling 
were performed less intrusively, where practicable, to limit the potential 
for excitation of animals during plethysmography data capture. 
Generally, BF (Figures 3.15 and 3.16) and MV (Figures 3.17 and 3.18) 
decreased during the pre-exposure settling period but remained 
elevated for rats administered crystalline GSK-361 on Day 1, the first 
day that animals inhaled an aerosol. This finding appears consistent 
with the apparent elevation observed for rats administered a single 
dose of GSK-361 (Figures 3.13 and 3.14). BF and MV data appeared 
less variable on Day 4 (Figures 3.15C and 3.17C respectively) and 
Day 28 (Figures 3.16C and 3.18C respectively), which followed 
repeated administration of aerosols concurrent with conditioning of the 
rats with neck seals incorporated into the plethysmographs. 
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Design 4: breath frequency 
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3.15B: Day 1 
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3.15C: Day 4 
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3.15D: Day 14 
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3.15E: Day 26 
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Design 4: derived from Fig.3.6 
 
Figure 3.15: Breath frequency of rats administered GSK-361 for 28 days. 
Mean data with standard deviations (n=3). Rats were allowed to settle for 15 
minutes before aerosol administration (60 minutes). 3.15A: Day -1; third and 
final day of tube acclimatisation. 3.15B: Day 1; first inhaled dose. Variability of 
data was greater for rats administered the nebulised aerosol. 3.15C: Day 4; 
data less variable than for Day 1. 3.15D: Day 14 (neck seal omitted from 
tubes on Days 5 to 13); data are more variable than for Day 4. 3.15E: Day 26 
(neck seal omitted from tubes on Days 15 to 25); data variability similar to 
Day 14, when data were also captured after a routine of tube restraint without 
the neck seal present. 
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Design 4: breath frequency 
3.16A: Day 26 
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3.16B: Day 27 
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3.16C: Day 28 
0 1 5 3 0 4 5 6 0
1 0 0
1 5 0
2 0 0
2 5 0
3 0 0
T im e  (m in u te s )
B
r
e
a
th
 f
r
e
q
u
e
n
c
y
 (
b
r
e
a
th
s
/m
in
u
te
)
C rys ta lline
N e b u lis e d
 
Design 4: derived from Fig.3.6  
 
Figure 3.16: Breath frequency of rats administered GSK-361 for 28 days. 
Mean data with standard deviations (n=3). Rats were allowed to settle for 15 
minutes before aerosol administration (60 minutes). 3.16A: Day 26 (neck seal 
omitted from tubes on Days 15 to 25); Figure 3.15E reproduced for reference. 
3.16B: Day 27. 3.16C: Day 28; a progressive reduction in data variability was 
apparent over three days with reintroduction of the neck seal from Day 26. 
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Design 4: minute volume 
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3.17B: Day 1 
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3.17C: Day 4 
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3.17D: Day 14 
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3.17E: Day 26 
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Design 4: derived from Fig.3.6  
 
Figure 3.17: Minute volume of rats administered GSK-361 for 28 days. 
Mean data with standard deviations (n=3). Rats were allowed to settle for 15 
minutes before aerosol administration (60 minutes). 3.17A: Day -1; third and 
final day of tube acclimatisation. 3.17B: Day 1; first inhaled dose. A transient 
reduction appeared pronounced for rats administered the nebulised aerosol. 
3.17C: Day 4; data less variable than for Day 1. 3.17D: Day 14 (neck seal 
omitted from tubes on Days 5 to 13). 3.17E: Day 26 (neck seal omitted from 
tubes on Days 15 to 25); data variability similar to Day 14, when data were 
also captured after a routine of tube restraint without the neck seal present. 
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Design 4: minute volume 
3.18A: Day 26 
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3.18B: Day 27 
0 1 5 3 0 4 5 6 0
2 0 0
3 0 0
4 0 0
T im e  (m in u te s )
M
in
u
te
 v
o
lu
m
e
 (
m
L
)
C ry s ta llin e
N e b u lis e d
 
3.18C: Day 28 
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Design 4: derived from Fig.3.6  
 
Figure 3.18: Minute volume of rats administered GSK-361 for 28 days. 
Mean data with standard deviations (n=3). Rats were allowed to settle for 15 
minutes before aerosol administration (60 minutes). 3.18A: Day 26 (neck seal 
omitted from tubes on Days 15 to 25); Figure 3.17E reproduced for reference. 
3.18B: Day 27. 3.18C: Day 28; a slight reduction in data variability was 
apparent over three days with reintroduction of the neck seal from Day 26. 
Mean BF (Figure 3.19) and MV (Figure 3.20) values for the 60-minute 
exposure period were most variable on Day 1, when rats were first 
exposed to an aerosol, and on Days 14 and 26 following a treatment 
period in which the neck seal was omitted from the body 
plethysmograph for aerosol administration. It is noteworthy that mean 
MV was similar to or slightly greater than the body weight-derived 
estimate (eRMV) when the neck seal was used during days of restraint 
preceding data capture on Days 1, 4 and 28. However, with omission 
of the neck seal from Day 5 (excluding days of data capture), the mean 
MV decreased with an increase in eRMV (Days 14 and 26). With 
reintroduction of the neck seal from Day 26, the variability in measured 
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BF and MV progressively reduced and mean MV attained parity with 
eRMV on Day 28, suggesting rats may require at least two days of 
reacclimatisation to the neck seal before the mean measured MV is 
representative of eRMV.  
Design 4: breath frequency 
 
Figure 3.19: Breath frequency (breaths per minute) in rats over a 28-day 
treatment period. Mean data points (n=6) are joined by a blue line. There 
was no obvious difference for rats administered a crystalline or nebulised 
aerosol of GSK-361. Statistical analysis (2-way ANOVA) indicated no 
significant differences between crystalline and nebulised aerosol forms, or 
days of measurement. 
Alternatively, this raises the possibility of an observer effect, i.e. that 
minute volume may change as a consequence of using the neck seal 
to facilitate measurement of this parameter. Nirogi et al. (2012) 
published baseline minute volumes for male Wistar rats (body weight 
range of 250 g to 300 g) of 173 ± 15.7 mL when measured by whole 
body plethysmography of ‘unrestrained’ rats and 228 ± 14.8 mL when 
measured by head-out plethysmography, suggesting a potential for 
procedural-related differences in lung function measurements between 
techniques with differing degrees of animal restraint. 
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Design 4: minute volume 
 
Figure 3.20: Measured minute volume (MV) and the body weight derived 
estimate (eRMV) in rats over a 28-day treatment period. Measured MV 
data are shown in blue, with corresponding body weight derived eRMV data 
in red. Mean data points are joined by a blue or red line, respectively. 
Statistical analysis (MANOVA with post hoc analysis using Tukey’s honestly 
significant difference test (Abdi and Williams, 2010[B])) for Days 1, 4, 14/15, 
26/25 and 28 indicated no significant differences between MV and eRMV or 
crystalline and nebulised aerosol forms; MV and eRMV values were 
significantly higher on Day 28 (p<0.05) compared with Day 1. 
3.3.2. Relationship between measured minute volume and 
pre-exposure body weight 
In Design 2, rats were acclimatised to tube restraint over two or six 
days, and plethysmography data were captured during administration 
of crystalline GSK-899 for 60 minutes; no settling period was applied 
before starting aerosol generation. Figure 3.21 indicates there was no 
clear proportional relationship between the body weight-derived and 
measured MV of rats under the conditions of this experiment. The 
measured MV data were considerably more variable than the body 
weight-derived estimates but also generally and significantly (p<0.01) 
higher; mean MV ≈ 1.17x eRMV (Table 3.13). 
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Design 2: minute volume 
2 5 0 2 7 5 3 0 0 3 2 5 3 5 0
1 5 0
2 0 0
2 5 0
3 0 0
3 5 0
B o d y  w e ig h t  (g ) ;  p re -d o s e
M
in
u
te
 v
o
lu
m
e
 (
m
L
)
M V : 6  d a y s ; w h ite  lig h t
M V : 2  d a y s ; re d  lig h t
M V : 6  d a y s ; re d  lig h t
e R M V  (re s p ire d  m in u te  v o lu m e
c a lc u la te d  fro m  b o d y  w e ig h t)
M V : 2  d a y s ; w h ite  lig h t
K e y  to  d u ra t io n  a n d  lig h t in g
o f  a c c lim a t is a t io n  p ro to c o ls
Figure 3.21: Measured minute volume (MV) and the body weight derived 
estimate (eRMV) against body weight of rats during a single exposure. 
Rats were administered GSK-899 for 60 minutes, starting immediately after 
their attachment to the chamber. Data plotted against pre-dose body weights. 
Table 3.13: Measured and body weight-derived estimates of minute 
volume (mL) of rats during a single 60-minute exposure period 
Design 2 
(R31125N) 
Respired minute volume  
(body weight derived estimate) 
Minute volume 
(measured) 
Mean 221  260** 
sd 15.9  24.8  
CV 7%  10%  
n 32 32 
Notes 
** indicates statistical difference (p<0.01 using 1-way ANOVA) for measured 
minute volume versus the body weight-derived estimate (eRMV). 
In contrast, when rats were allowed to settle in the plethysmographs for 
15 minutes before the start of aerosol generation, the MV and eRMV 
for a given body weight were generally similar (Figure 3.22) although 
3/6 rats administered GSK-361 were outliers and increased the overall 
mean (Table 3.14) in line with rats that did not settle before exposure 
(Table 3.13). In addition, when rats were acclimatised to the neck seal 
in days preceding data capture during the repeat dose study, the MV 
and eRMV for a given body weight were also generally similar and a 
change in MV (23% increase) was in line with the body weight 
development (30% gain) of rats from Days 1 to 28 of treatment 
(Figure 3.23). This finding supports use of an algorithm for estimating 
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the inhaled dose of a test article in healthy rats provided animals are 
adequately conditioned to the procedure and allowed to settle in 
restraint tubes before initiating aerosol generation. However, the rats 
used for MV measurements were not adversely affected by repeated 
administration of GSK-361 and, consequently, the potential relationship 
between MV and adverse body weight changes (reduced gain or loss) 
was not addressed in this experiment. Nevertheless, it is reasonable to 
hypothesize that MV and body weight may not be proportional for a 
compromised animal. For example, depletion of adipose tissue is 
unlikely to influence lung architecture and lung function may be 
affected by the onset of inhalation toxicity (Sung et al., 2008). 
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Figure 3.22: Measured minute volume (MV) and the body weight derived 
estimate (eRMV) against body weight of rats during a single exposure. 
Rats were allowed to settle in plethysmographs for 15 minutes and then 
administered GSK-677 or GSK-361 for 30 minutes. Data plotted against 
pre-exposure body weights. 
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Table 3.14: Measured and body weight-derived estimates of minute 
volume (mL) of rats during a single 30-minute exposure period 
Design 3 
(R30988N and 
R31225N) 
Respired minute volume  
(body weight derived estimate) 
Minute volume 
(measured) 
Mean 229.7 259.8 
sd 21.9 61.7 
CV 10% 24% 
n 12 12 
Notes 
 No differences of statistical difference (1-way ANOVA) for measured minute 
volume versus the body weight-derived estimate (eRMV). 
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 Figure 3.23: Measured minute volume (MV) and the body weight derived 
estimate (eRMV) against body weight of rats over 28 days. Rats were 
administered GSK-361 for 60 minutes, starting 15 minutes after attachment of 
rats to the chamber. Minute volumes for Days 1, 4, 14 and 28 of the study 
data are plotted against pre-dose body weights for each rat (Day 14 MV data 
plotted against the Day 15 body weight). 
3.3.3. Comparison of measured lung concentrations and 
estimated pulmonary doses 
For logistical reasons in Design 2, rats were administered GSK-899 as 
sub-groups (n=4) for each of the four treatments. Mean aerosol 
concentrations for the second cycle of inhalation exposures were at 
least 30% higher than for the first corresponding sub-group, with a 
consequent difference in estimated inhaled doses between each of the 
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paired sub-groups. The particle size distributions were similar between 
treatment groups and the two cycles (Table 3.15). 
Table 3.15: Estimated inhaled doses in rats and  
aerosol characterisation data for crystalline GSK-899 
Design 2 
Study 
number 
Acclimatisation 
duration and 
lighting colour  
Estimated inhaled 
dose A (mg/kg) 
Mean (n=2) 
aerosol 
concentration 
of GSK-899 
(µg/L) 
Particle size 
distribution 
MMAD 
(µm) 
σg 
sub-group group 
R31125N 
2 days; white 
0.741 
0.843 
16.7 2.0 2.0 
0.944 21.9 2.3 2.0 
6 days; white 
0.717 
0.876 
16.2 1.9 2.1 
1.034 24.1 1.9 2.0 
2 days; red 
0.813 
0.997 
18.5 1.7 2.0 
1.181 27.3 2.3 1.9 
6 days; red 
0.744 
0.972 
17.2 2.4 2.0 
1.201 29.4 2.3 1.9 
Notes 
MMAD mass median aerodynamic diameter 
σg geometric standard deviation 
A Estimated inhaled doses calculated for a 60-minute exposure period using 
mean data (aerosol concentration and body weight) and a body-weight 
derived estimate of respired minute volume (Alexander et al., 2008). 
Drug concentrations for lungs taken immediately post-exposure 
(Table 3.16) appeared to be slightly more variable than MV measured 
in the same animals (Table 3.10). This was attributable, at least in part, 
to differences in aerosol concentration achieved for the two sub-groups 
for each treatment (light colour and duration of acclimatisation 
protocol). With pooling of group data to investigate the light colour or 
duration of acclimatisation as appropriate (Figure 3.24), an apparent 
difference in lung-homogenate concentrations for red versus white 
lighting was evident and in contrast to trends observed in BF and MV, 
and hence the “achieved lung dose.” Although the variability observed 
in lung-homogenate concentrations was not unexpected (personal 
observation of unpublished data), the apparent differences between 
these data types suggest the reason for a difference in lung 
concentrations between the treatment groups cannot be ascribed to 
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differences in aerosol concentration alone or inter-animal differences of 
MV and thus the deposited lung dose per se.  
Table 3.16: GSK-899 concentration in rat lung homogenate (µg/g)  
after a single inhalation exposure (breakdown of groups) 
Design 2 (R31125N) 
GSK-899 concentration in lung homogenate 
immediately post exposure  
Lighting and duration  
of tube acclimatisation  
White light; 
2 days 
Red light; 
2 days 
White light; 
6 days 
Red light; 
6 days 
Mean (µg/g) 33.3 44.6 33.7 36.8 
sd 6.46 5.38 2.55 5.93 
CV 19% 12% 8% 16% 
n 8 8 8 8 
Notes 
sd standard deviation 
CV coefficient of variation (ratio of standard deviation to mean) 
n number of animals/group in statistical comparison 
Design 2: drug-lung concentrations 
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3.24B: lighting conditions 
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Figure 3.24: Measured and predicted lung concentrations in rats after a 
single inhaled dose of GSK-899 and tube acclimatisation for two or six 
days under red or white light. Latin square design (n=8 rats/group) used for 
statistical analyses (MANOVA with post hoc analysis using Tukey’s honestly 
significant difference test (Abdi and Williams, 2010[B]); n=16; data pooled). 
Means with standard deviations shown for GSK-899 lung concentrations and 
predicted from measured minute volume (MV) and body weight (eRMV). Post 
hoc statistical analysis indicated all methods of drug-lung determinations were 
significantly different (p<0.0101). 3.24A:  no significant difference between 
two or six days of acclimatisation (data pooled for light colour). 3.24B: lighting 
colour during tube acclimatisation and inhalation exposure (data pooled for 
acclimatisation periods); ** statistical significance (p<0.01) for light colour. 
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Possible explanations for discrepancies or imprecision in drug-lung 
homogenate concentrations include processing of lung-homogenate 
samples for HPLC-UV analysis e.g. non-uniform drug-lung deposition 
in conjunction with pooling of selected lung lobes, the degree of 
homogenization and incomplete solvent extraction of the drug. 
Statistical analysis of GSK-899 lung concentrations measured by 
HPLC-MS/MS or estimated from minute volume indicated that all 
methods were significantly different from one another, with mean 
values ranked HPLC-MS/MS > MV > eRMV. 
Estimated inhaled doses and aerosol characterisation data for 
GSK-677 and GSK-361 (Table 3.17) were discussed in Chapter 2 
(Section 2.3.6.1). The estimated doses for these compounds achieved 
over a 30-minute exposure were lower than the estimated inhaled 
doses of GSK-899 achieved over 60 minutes (Table 3.15). 
Table 3.17: Estimated inhaled doses in rats and  
aerosol characterisation data for GSK-677 and GSK-361  
Design 3 
Study 
number 
Test 
article 
Aerosol form 
and test article 
concentration 
in vehicle 
Estimated 
inhaled 
dose A 
(mg/kg) 
Mean (n=2) 
drug aerosol 
concentration 
(µg/L) 
Particle size 
distribution 
MMAD 
(µm) 
σg 
R30988N GSK-677 
Crystalline 
(4.4% w/w) 
0.487 22.2 2.8 2.0 
  
Nebulised 
solution 
(2.5 mg/mL) 
0.418 19.1 1.3 2.2 
R31225N GSK-361 
Crystalline 
(4.8% w/w) 
0.555 26.0 2.0 2.4 
  
Nebulised 
solution 
(1.5 mg/mL) 
0.574 27.0 2.5 2.4 
Notes 
MMAD mass median aerodynamic diameter 
σg geometric standard deviation 
A Estimated inhaled doses calculated for a 30-minute exposure period using 
mean data (aerosol concentration and body weight) and a body-weight 
derived estimate of respired minute volume (Alexander et al., 2008). 
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Statistical analysis of GSK-677 and GSK-361 lung concentrations 
(Figure 3.25) measured by HPLC-MS/MS or estimated from minute 
volume indicated that measured values were significantly lower 
(p<0.01) than estimated values. There were no significant differences 
between estimates derived from measured MV or body weight-derived 
estimates (eRMV), which was consistent with the change in procedure 
allowing rats to settle in the plethysmographs for approximately 
15 minutes prior to the start of aerosol administration. 
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Figure 3.25: Measured and predicted lung concentrations in rats after a 
single inhaled dose of GSK-677 or GSK-361. Mean data with standard 
deviations (n=3) are shown for dug concentrations in lung homogenate 
(analysis by HPLC-MS/MS) and estimated from the measured minute volume 
(MV) and body weight-derived estimate (eRMV). Statistical analysis 
(MANOVA with post hoc analysis using Tukey’s honestly significant difference 
test (Abdi and Williams, 2010[B]); n=6 with pooling of data) indicated 
significant differences between lung concentrations measured by 
HPLC-MS/MS and those estimated from MV or eRMV (p<0.01), with no 
significant difference between MV or eRMV-derived values. Lung 
concentrations after exposure to crystalline or nebulised aerosol forms were 
also significantly different (p<0.01). There was no significant difference 
between GSK-361 or GSK-677. 
The persistence of GSK-899 in lung tissue up to 24 hours post 
exposure and comparatively fast reduction in drug-lung concentrations 
of GSK-677 or GSK-361 post exposure were described in Chapter 2 
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(Section 2.6.3.2). The discrepancy between lung concentrations of 
GSK-677 or GSK-361 and the higher estimates based on MV are 
attributable to the kinetics of dissolution/absorption and systemic 
distribution of the analyte during exposure (30 minutes) and the 
off-dose period before isolation of lungs (approximately 20 minutes). 
Mean measured lung concentrations of GSK-899 were approximately 
20% higher than the estimated lung deposited doses derived from 
measured MV. Since no appreciable change in GSK-899 concentration 
is evident immediately post exposure, these data indicate that 
approximately 12% of GSK-899 administered as an aerosol of mass 
median aerodynamic diameter (MMAD) 2 µm was deposited in the 
lungs of exposed rats (Figure 3.26). 
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Figure 3.26: Measured lung concentrations of GSK-899 as a proportion 
of the estimated inhaled dose (IDe) in rats after a single exposure. Lung 
deposition (n=32) was calculated as the measured mass of GSK-899 in lung 
(by HPLC-MS/MS) as a percentage of the lung dose predicted from the 
inhaled dose calculated from measured minute volume (MV) or body 
weight-derived estimate (eRMV). Rat lung deposition fractions reported by 
Snipes (1989) and applied by US-FDA (Lewis and McKevitt, 2013, Owen, 
2013, Forbes et al., 2011, Jones and Baldrick, 2013) are also shown. 
Chapter Three 
178 
 
This is slightly higher than the pulmonary deposition value of 7% 
published by Snipes (1989) and similar to the deposition factor of 10% 
in rats applied by the US Food and Drug Administration when 
evaluating regulatory submissions for the clinical approval of inhaled 
drugs (Lewis and McKevitt, 2013, Owen, 2013, Forbes et al., 2011, 
Jones and Baldrick, 2013). 
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3.4. Conclusion 
This work illustrated the importance of considering the experimental 
design and procedural conduct for acclimatising animals to restraint 
procedures and data acquisition by head-out plethysmography, a 
technique used for assessing lung function and estimating doses in 
non-clinical inhalation studies. 
The plethysmography data indicated 15 minutes was sufficient for rats 
to achieve a settled state, in terms of BF or MV measurements with 
little change in these parameters thereafter. On the basis of these data, 
which were interpreted as a surrogate indicator of activity or stress 
(Williams et al., 1988, Barone et al., 1990), procedures were 
harmonised for routine non-clinical studies performed by the sponsor, 
with rodents acclimatised to restraint tubes for 30 minutes on each of 
two consecutive days preceding the first dose, irrespective of the dose 
route (typically intravenous infusion or inhalation exposure) or the 
duration of treatment (single or repeated administrations). This 
represented refinement of procedures on two fronts:  
• Firstly, by considerably reducing the duration and frequency of 
pre-treatment tube acclimatisation applied to rats before the first 
dose. The need to subject rats to progressively longer restraint 
periods up to four hours to match the intravenous infusion period 
was subsequently proven unnecessary (personal observation of 
unpublished data). 
• Secondly, by extending the tube restraint period to 30 minutes 
and applying this on each of two pre-treatment occasions to 
ensure rats achieved a settled state before being returned to 
their holding cages. 
Key conclusions of work described in this chapter were: 
• Two days of acclimatisation of rats (or reacclimatisation after a 
reduced level of restraint) to plethysmographs was sufficient to 
achieve parity of mean MV (measured) with mean eRMV (body 
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weight-derived estimate) when rats were allowed to settle for 
15 minutes before initiating aerosol generation. 
• Changes in MV were in line with the normal body weight gain of 
rats over a 28-day period supporting use of an algorithm for 
estimating the inhaled dose of a drug in healthy rats. However, 
the relationship between MV and body weight following an 
adverse effect of treatment, i.e. weight loss or reduced gain due 
to toxicity, is uncertain. 
• There were no differences in BF or MV for rats illuminated by 
red or white light during acclimatisation and inhalation exposure 
procedures. 
• MV measurements were more variable than corresponding body 
weight-derived estimates (eRMV), especially when animals were 
exposed to an aerosol for the first time. 
• The lung deposited fraction of GSK-899 (12%) was consistent 
with the fraction applied by US-FDA regulators (10%) for drug 
safety assessment (Lewis and McKevitt, 2013, Owen, 2013, 
Forbes et al., 2011, Jones and Baldrick, 2013). 
Although rats were successfully acclimatised for a 60-minute exposure 
period over two days, experiments requiring detection of subtle 
changes in lung function (e.g. a dose response in respiratory 
pharmacology) may require a modified and possibly more prolonged 
approach for acclimatisation. An ethical desire to minimise the degree 
of restraint applied to animals during repeated inhalation exposure 
studies must be weighed against a potentially deleterious effect on the 
precision and accuracy of lung function measurements. 
These conclusions are limited by the small group sizes, which were 
nevertheless typical of those used during non-clinical studies in early 
drug development. Given the desire and ethical obligation to minimise 
the number of animals used in non-clinical research, measurement of 
lung function may therefore provide a tool for understanding anomalies 
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in quantitative lung doses and potential effects on inhaled dosimetry 
associated with the properties of a test substance, but also for refining 
procedures for inhaled administration of test articles or other 
procedures requiring tube restraint. 
  
 
CHAPTER FOUR 
Suppression of 
lipopolysaccharide-induced acute 
lung inflammation in rats by single 
prophylactic doses of p38 mitogen 
activated protein kinase inhibitors
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4.1. Introduction 
Signalling pathways activated during acute lung inflammation are also 
activated by acute lung injury and acute respiratory distress syndrome 
(Figure 4.1), a diffuse but critical lung injury resulting in 40% mortality for 
affected patients (Matthay and Zemans, 2011). p38 mitogen activated 
protein kinase (MAPK) performs a central regulatory function in the 
synthesis and modulation of proinflammatory mediators. p38α MAPK is 
expressed in the cytoplasm and nucleus of cells (Cuenda and Rousseau, 
2007) in the airway smooth muscle, respiratory epithelium and immune 
system (Williams et al., 2008, Mayer and Callahan, 2006), thus 
representing a ubiquitous target in the respiratory tract for suppressed 
expression of cytokines, chemokines and growth factors. 
Bacterial lipopolysaccharide (LPS) provokes a potent immunological 
response resulting in local or systemic inflammation (Van Helden et al., 
1997, Ulich et al., 1994). In the late 1980s, a series of small molecules 
were found to inhibit LPS-induced production of interleukin-1 (IL-1) and 
tumour necrosis factor (TNF) in human monocytes, and were 
subsequently shown to selectively inhibit p38 MAPK (Lee et al., 1999). 
Beardmore et al. (2005) demonstrated normal LPS-induced cytokine 
release in a p38β MAPK knockout murine model, indicating the p38α 
MAPK isoform was a major component of the pathway and hence a 
principal target for inhibition (Mayer and Callahan, 2006). 
Bronchoalveolar lavage (flushing of lungs with isotonic fluid), was 
developed in the early 1980s as a method for investigating pulmonary 
toxicity. The application of this technique is based on the premise that 
exposure of the respiratory epithelium to inhaled toxicants will result in 
the release of markers including cellular contents (such as enzymes or 
total protein) from injured cells, inflammatory mediators and subsequent 
recruitment of inflammatory cells to the epithelial-air surface and 
associated fluid. 
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Figure 4.1: Normal alveolus (left) and injured alveolus in the acute phase 
of acute lung injury and acute respiratory distress syndrome (right). 
Neutrophils adhere to the injured capillary endothelium and migrate through the 
interstitium into the air space filled with protein-rich oedema fluid. Alveolar 
macrophages secrete cytokines (IL-1, 6, 8 and 10) and TNFα that locally 
stimulate chemotaxis and activate neutrophils, which release proinflammatory 
molecules (oxidants, proteases, leukotrienes and platelet-activating factor 
(PAF)). Anti-inflammatory mediators in the alveolus include IL-1 receptor 
antagonist, anti-IL-8 autoantibodies, soluble TNF receptor and cytokines (such 
as IL-10 and IL-11). With the syndrome (diffuse, critical lung injury), sloughing 
of bronchial and alveolar epithelial cells also occurs and protein-rich hyaline 
membranes form on the basement membrane; IL-1 stimulates production of 
extracellular matrix by fibroblasts. The influx of protein-rich oedema fluid into 
the alveolus leads to inactivation of surfactant. Matthay and Zemans (2011) 
reproduced with permission of Annual Reviews, USA. 
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These inflammatory markers in the epithelial lung fluid or lumen can be 
sampled for analysis by flushing the lung with an isotonic salt solution 
(Henderson, 1984, Henderson et al., 1985); an influx of neutrophils is 
the most sensitive indicator of inflammation (Henderson, 2005). 
Conversely, a reduction or suppression of these markers in animals with 
prophylactic treatment of a drug provides a non-clinical model for 
assessing the efficacy of a drug (Underwood et al., 2000, Mayer and 
Callahan, 2006, Haddad et al., 2001). 
Efficacy models used for the screening of drugs need to be consistent; 
the biological response of animals to LPS and its suppression by a 
prophylactic dose of a drug should both be reproducible, without high 
inter-animal variability and not susceptible to temporal or genetic drift. 
The nature of the bronchoalveolar lavage (BAL) sampling process 
(flushing of lungs with saline) has the potential to exacerbate 
experimental error due to partial recovery of the lavageate and the 
efficiency of harvesting cells in the airways and alveoli. Ettensohn et al. 
(1988) reported the proportion of lavageate recovered from human lung 
with each sample was generally consistent (64.8 ±9.8%, with 3/16 
subjects presenting high variability) but considerable variability was 
evident in leukocyte counts between individuals (inter-subject variability) 
and between successive lavages recovered from each subject (intra-
subject variability). Work described by Hoshino et al. (1999) indicated no 
significant difference in the proportion of lavageate recovered for groups 
of rats (variability of leukocyte counts not specified) but unpublished data 
(GSK) suggested a potential for variability in rat leukocyte counts and 
pro-inflammatory mediators harvested in bronchoalveolar lavage fluid 
(BALF). 
Biomarkers for quantifying acute lung inflammation and the application 
of alternative techniques may present opportunities for adapting and 
developing non-clinical efficacy models. Quantification of inflammatory 
cell infiltration cannot be done easily using routine histological sections 
and stains; the phenotype of inflammatory cells must be determined and 
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representative areas of lung tissue cannot be surveyed and readily 
quantified without automation. Cell counting could be performed 
following digestion of lung tissue with collagenase but this technique is 
also labour intensive and time consuming. Quantification of cell 
infiltration by gamma-counting leukocytes (radiolabelled ex vivo) also 
carries the risk that in vitro manipulation of cells (purification and 
radiolabelling) may activate cells and compromise the experiment 
(Schneider et al., 1997). Schneider and Issekutz (1996) described a 
method for assaying the activity of myeloperoxidase (MPO; a biomarker 
for neutrophils) in extracts of lung tissue sampled from Brown Norway 
rats challenged with ovalbumin. Sugiyama et al. (2001) described the 
immunostaining of MPO in histological sections of human arteries. 
Image analysis has potential applications for the automation and 
standardisation of high throughput screening of cell morphology or 
phenotypes in samples (such as tissue biopsies, cell swabs or blood) for 
the diagnosis of diseases (Loukas et al., 2003, Ross et al., 2006), 
although some reviews suggest further research is required before 
automated image analysis systems can be recommend for healthcare 
screening (Willis et al., 2005). Nevertheless, image analysis could 
potentially facilitate quantification of LPS-induced inflammation in rat 
lung sections provided neutrophils can be distinguished from the lung 
tissue and other cells in section. 
Factors influencing the biological response of a subject to an inhaled 
drug include the achieved dose, location of the pharmacological target 
receptor within the respiratory tract and cross-reactivity with ‘off-target 
receptors’. Since the p38 MAPK receptor is expressed throughout the 
respiratory tract and in inflammatory cells migrating to the site of insult, 
efficacy of this pharmacological class can be investigated by determining 
the degree of prophylactic inhibition of the infiltration of neutrophils 
following a pulmonary challenge by LPS. Given the ubiquitous nature of 
the target, inhaled administration and/or intratracheal instillation of the 
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drug and LPS can be performed without the need to target a specific 
region of the respiratory tract. 
Administration of LPS in acute lung models is often performed via 
intratracheal administration (Van Helden et al., 1997, Ulich et al., 1994, 
Spond et al., 2004, Shanley et al., 1995) and is a technique that can be 
performed under light anaesthesia without the technical infrastructure 
and engineering required to support inhalation exposure systems. Non-
clinical evaluation of the efficacy of drugs is normally conducted early in 
drug development, when candidate drugs are initially produced in small 
quantities. Drugs eventually intended for inhaled administration to 
humans are therefore often administered to non-clinical models using a 
surrogate exposure route, typically intratracheal instillation. However, 
intratracheal instillation is not a clinical route of exposure and the pattern 
of particle lung deposition is different to that achieved following inhalation 
exposure to aerosols (Osier and Oberörster, 1997). Whilst aerosol 
generators have been designed to expose individual or small groups of 
rodents using small quantities of test article (Paul et al., 2012, Gerde, 
1999), intratracheal instillation is commonly used in non-clinical 
research.  
4.1.1 Aims and objectives 
Using three p38 MAPK inhibitors of differing physicochemical properties, 
the experimental aims of this chapter are to: 
• Determine the utility of biomarkers of inflammation in BALF 
(neutrophils and TNFα) or image analysis (neutrophil infiltration 
evident in lung sections) to evaluate a dose response for the 
prophylactic inhibition of LPS-induced acute lung inflammation. 
• For each of three p38 MAPK inhibitors, determine the median 
effective dose (ED50) in rats for prophylactic inhibition of 
LPS-induced acute lung inflammation. 
• Determine the systemic and/or lung exposure of each p38 MAPK 
inhibitor in rats after a single inhalation exposure to contextualise 
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the dose responses for inhibition of LPS-induced acute lung 
inflammation. 
By comparing the data generated following administration of the p38 
MAPK inhibitors as nebulised solutions or dry powder aerosols, the 
following hypotheses will be tested: 
• Changes in the presentation of a drug to rats may affect lung 
exposure and consequently the drug concentration at the 
pharmacological target, resulting in modulation of dose response 
for efficacy (ED50). 
• Differences in physicochemical properties may affect the 
compartmentalisation of a drug in cells or fluid compartments 
within the respiratory tract, affecting the drug concentration at the 
pharmacological target, influencing the dose response for 
efficacy (ED50). 
Although the systemic and lung exposure of drugs are known to change 
for different formulations, less has been published about the potential 
implications for efficacy. It is anticipated that results of these 
investigations will permit ranking of p38 MAPK inhibitors and/or aerosol 
forms for their relative efficacy. Identification of potential limitations or 
opportunities for modulating efficacy may also have implications for 
experimental design in early non-clinical development of inhaled drugs.  
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4.2. Materials and methods 
4.2.1. Test articles 
The p38 MAPK inhibitors were supplied by GSK as micronised crystals 
and stored at ambient temperature, protected from light and moisture. 
(Table 4.1). 
Table 4.1: Purity of crystalline p38 MAPK  
inhibitors used for inhalation exposure of rats  
Test article Salt form Purity 
In vivo study 
number 
GSK258899B mesylate 95.4% 
R30820N 
R31763N 
GSK610677B hydrochloride 98.5% R31400N 
GSK678361A parent 99.7% R31675N 
Two batches of amorphous GSK-899 were produced by spray drying a 
saturated solution of GSK-899 (prepared from micronised crystals) in 
methanol. The amorphous state of the resultant material was confirmed 
by X-ray powder diffraction analysis (XRPD; Chapter 2, Section 2.3.2). 
One batch (amorphous-2) was used for single exposure experiments 
described in Chapter 2. A larger batch (amorphous-1) was supplied for 
repeat exposure experiments described in Chapter 5 and was of slightly 
larger particle size (Table 4.2). Both batches were selected for 
experiments described in this chapter to investigate the potential 
influence of particle size on achieved lung dose and efficacy. 
Table 4.2: Summary of aerosol particle sizes for amorphous GSK-899  
Test article 
Batch 
identification 
Aerosol 
concentration  
(µg/L) 
Particle size 
In vivo study number MMAD 
(µm) 
σg 
GSK-899 
Amorphous-2 24.4 2.7 2.1 R30573N (Chapter 2) 
Amorphous-1 
0.592 3.9 2.0 
R30662N (Chapter 5) 26.9 4.2 1.9 
380 3.7 2.3 
Notes 
MMAD mass median aerodynamic diameter 
σg geometric standard deviation 
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4.2.2. Investigating efficacy and exposure of inhaled p38 
MAPK inhibitors in rats 
For investigating the efficacy of p38 MAPK inhibitors in the respiratory 
tract of rats and to put potential findings in context with concomitant 
pharmacokinetics, groups of rats were administered a single 
prophylactic ‘dose’ of the test aerosol, by snout-only inhalation exposure. 
Rats were then challenged with LPS and evaluated for inhibition of acute 
lung inflammation (Figure 4.2). Additional animals (satellite groups) were 
concurrently administered an inhaled dose of the p38 MAPK inhibitor 
and sampled for plasma and lung tissue for HPLC-MS/MS analysis of 
the drug. Blood and tissue samples were thus obtained for three key 
investigations as follows: 
• Assessment of biomarkers for the inflammatory cell infiltration in 
lungs of rats challenged with LPS, with reference to a vehicle 
control for the drug (n=6 rats/treatment). 
• Drug concentration measured in rat plasma sampled post 
exposure (n=3 rats/timepoint). 
• Drug concentrations in lungs sampled post exposure 
(n=3 rats/timepoint). 
Following optimisation of the LPS challenge (Appendix 1), four large 
experiments were performed to determine the median effective dose 
(ED50) of each MAPK inhibitor in each aerosol form. Experimental 
Design A, the first of four principal experiments, was based on a protocol 
developed and validated at GSK (unpublished data) in which neutrophils 
are evaluated in BALF four hours after a single challenge with LPS 
(2 µg/rat); other research facilities also implement a four-hour interval 
between the LPS challenge and sampling of BALF for analysis of 
cytokines and/or neutrophils (CRL, 2017, Eutamene et al., 2005). The 
design evolved from one experiment to the next, mainly simplifying 
technical logistics for experimental conduct (data comparisons were not 
compromised). Additional parameters were considered following review 
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of the dose response data for the inflammatory responses. The rationale 
for dose selections and experimental design features are summarised 
with methodological outcomes for each experiment (Sections 4.2.2.1 to 
4.2.2.4). Details of the biomarkers for inflammation and associated 
methodology are described in Section 4.2.6. 
 
Figure 4.2: Study design used for investigating inhibition of 
lipopolysaccharide induced lung inflammation after a single dose of an 
inhaled p38 MAPK inhibitor. Rats (n=6/dose) inhaled an aerosol of the p38 
MAPK inhibitor (dry powder or aqueous formulations) or vehicle (control) for 30 
minutes and were immediately challenged by intratracheal instillation of 
lipopolysaccharide (LPS); a ‘negative’ control group for baseline data was 
instilled with phosphate buffered saline. Four hours post challenge, rats were 
euthanized and the lungs removed to evaluate markers for inflammation: 
histological staining of lung sections for myeloperoxidsase (MPO) and/or 
chloroacetate esterase (CAE), or bronchoalveolar lavage (BAL) using saline to 
facilitate measurement of TNFα (GSK-677 study only) and neutrophils in lung. 
Serum was sampled 1.5 and 4 hours after administration of GSK-677 and LPS 
for analysis of TNFα (* n=2x 6/dose; lung histology and lavage groups). 
Additional rats (n=3/dose) were sampled immediately post exposure (all p38 
MAPK inhibitors) and after four hours (GSK-899 only) for analysis of drug 
concentrations in plasma and lung homogenate. 
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4.2.2.1. Efficacy of GSK-899 determined using neutrophil 
counts in BALF (Design A) 
This study was performed in two phases. Firstly, blends of GSK-899 
micronised crystals or amorphous powders (‘batches’ 1 and 2) in lactose 
were administered a target dose of 30 µg/kg. This dose was based on 
unpublished data (Figure 4.3) indicating an ED50 of 3 µg/kg GSK-899 
when administered as an aqueous suspension by intratracheal 
instillation, adjusted to allow for 10% deposition of an aerosol in rat lungs 
(Forbes et al., 2011, Jones and Baldrick, 2013, Owen, 2013).  
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Figure 4.3: Inhibition of lipopolysaccharide induced lung inflammation in 
rats after prophylactic administration of GSK-899 (unpublished data). 
Rats were administered micronised GSK-899 by intratracheal instillation before 
whole body inhalation exposure to a nebulised aerosol of lipopolysaccharide 
(LPS; 15 minutes). Lungs were lavaged four hours after LPS challenge and the 
harvested neutrophils counted (expressed as a percentage of total cell count). 
4.3A: dry powder formulations dosed four hours before LPS challenge. 
4.3B: aqueous suspension of GSK-889A (parent) dosed 30 minutes before 
LPS challenge. A median effective dose (ED50) of 3 µg/kg was cited (data circa 
2004; method of calculation not stated). 
Subsequently, one dose for each particle form of GSK-899 was selected 
following review of the neutrophil counts in BALF for the previously 
administered dose. Nebulised doses of GSK-899 were administered in 
a second experimental phase with a concurrent vehicle control; doses 
were selected with reference to neutrophil counts for rats administered 
dry powder formulations. An additional dose (maximum practicable for 
solubility) was subsequently administered with a concurrent control. 
Methodological outcomes of Design A 
Although progressive selection of doses for each aerosol form was 
expected to achieve a dose range that encompassed the ED50, an 
Chapter Four 
194 
 
observed day to day variability in the neutrophil cell counts in BALF 
sampled from the LPS-dosed control animals complicated data analysis 
(dose response expressed relative to the concurrent LPS controls). 
Further experiments would administer a range of doses for one aerosol 
form on a given day, with duplicate cohorts (if necessary) and alternative 
aerosol forms administered on separate days.  
4.2.2.2. Evaluation of endpoints used to determine inhibition 
of lung inflammation by GSK-677 (Design B) 
Given the temporal variability in neutrophil counts noted in BALF 
samples during Design A, additional endpoints were evaluated 
concurrently with the BAL neutrophil count following LPS challenge as 
follows:  
• Leukocytes and neutrophils in BALF 
• TNFα in serum and BALF 
• Image analysis of biomarkers for neutrophils in lung sections: 
myeloperoxidase (MPO) and chloroacetate esterase (CAE).  
Inhaled target doses (1, 10, 100 and 1000 µg/kg) were selected as a 
logarithmic progression based on unpublished data (Figure 4.4) 
indicating an ED50 of 5 µg/kg GSK-677 when administered as an 
aqueous suspension by intratracheal instillation. The selected doses 
were adjusted for 10% lung deposition in rats (Forbes et al., 2011, Jones 
and Baldrick, 2013, Owen, 2013) and the dose range was anticipated to 
encompass the inhaled ED50. 
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Figure 4.4: Inhibition of lipopolysaccharide induced inflammation in rat 
lungs after prophylactic administration of GSK-677 (unpublished data). 
Rats were dosed micronised GSK-677 in lactose or aqueous suspension (drug 
in 0.5% Tween 80 in phosphate buffered saline) by intratracheal instillation. 
Animals were challenged with a nebulised aerosol of lipopolysaccharide (LPS; 
15 minutes; whole body inhalation exposure) four hours after instillation of dry 
powder formulations or 30 minutes after instillation of aqueous suspensions. 
Lungs were lavaged four hours post LPS-challenge and harvested neutrophils 
counted (expressed as a percentage of total cell count); linear regression 
analysis of the dose response was used to determine a median effective dose 
(ED50) of 5 µg/kg as aqueous suspension. 
Methodological outcomes of Design B 
TNFα concentrations in serum and BALF were more variable than for 
neutrophils in BALF. Image analysis of rat lung sections indicated MPO 
lacked the specificity for neutrophils required to assess LPS-induced 
inflammation in the non-clinical model. Further experiments would 
evaluate neutrophils in BALF (Design D) and/or lung image analysis of 
CAE-stained sections (Designs C and D). 
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4.2.2.3. Efficacy of GSK-899 measured using lung image 
analysis (Design C) 
Inhaled target doses (3, 30, 300 and 1000 µg/kg) were selected as a 
logarithmic progression anticipated to encompass the ED50. 
Experimental design was standardized for each of the aerosol forms 
based on results for Design A (Figures 4.16 to 4.18). This experiment 
was performed to evaluate inhibition of LPS-induced acute lung 
inflammation in rats by GSK-899 using image analysis of CAE-stained 
lung sections. 
4.2.2.4. Efficacy of GSK-361 using neutrophil counts in BALF 
and lung image analysis (Design D) 
Inhaled target doses (3, 30, 300 and 1000 µg/kg) were selected as a 
logarithmic progression in line with Design C. Unpublished data 
(Table 4.3) indicated in vitro potency for inhibition of p38 MAPK was 
similar for GSK-899, GSK-677 and GSK-361. This experiment was 
performed to evaluate inhibition of LPS-induced acute lung inflammation 
in rats by GSK-361, as determined by neutrophil counts in BALF and 
image analysis of CAE-stained lung sections. In addition, histology 
sections of lungs subjected to BAL sampling were prepared for image 
analysis to assess the extent to which the BAL sampling procedure 
depleted neutrophils from the lungs. 
Methodological outcomes of Designs C and D 
A series of artefacts were observed during preparation of lung sections 
that compromised image analysis; the aetiology of the artefacts, which 
were not evident in Design B, were investigated (Appendix 2). Although 
methodology was modified and lung sections were successfully 
scanned, the significant delays prevented completion of image analysis 
for the assessment of lung inflammation at the time of thesis submission. 
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Table 4.3: In vitro binding and potency of p38 MAPK inhibitors 
p38 MAPK 
isoform  
Parameter 
(pKi) 
GSK-899 GSK-677 GSK-361 
p38 Binding 8.8  0.2 8.6 ± 0.1 8.6 ± 0.2 
 Inhibition 8.9  0.2 8.3 ± 0. 2 8.8 ± 0.2 
 Competition 8.7 pKi = 8.7 pKi = 8.7 
   - pKi' = 8.1 pKi' = 8.1 
 Reversibility  NS A  NS A “rapid” 
p38 Binding 8.2  NS  NS 
 Inhibition 8.3  0.3 7.8 7.4 
 Competition 8.7  NS  NS 
 Reversibility  NS  NS  NS 
Comments p38 and p38 
p38 400-fold 
more potent 
p38 >2000-fold 
more potent 
p38 1000-fold 
more potent 
Notes 
Ki dissociation constant for inhibitor binding 
Ki' dissociation constant for inhibitor binding to a site distinct from the 
substrate binding site 
NS not stated or determined 
A no significant return in enzymatic activity observed 
4.2.3. Test system and animal husbandry 
Male Crl:WI(Han) rats (Charles River UK Ltd, Margate, Kent) were 
randomly allocated to groups and accommodated under standard 
laboratory conditions (Home Office, 2014) with access to food and water 
as described in Chapter 2 (Section 2.2.4.1). Rats were identified by a 
number written in indelible ink on the tail.  
Rats were accommodated for at least five days before undertaking the 
first licensed procedure (tube restraint) and were approximately 
10 weeks old on the day of aerosol administration (Day 1). 
Clinical observations and body weight measurements were maintained 
for all animals to ensure their general wellbeing during the experiment 
and to facilitate key procedures or investigations such as dosing. 
4.2.4. Aerosol generation of p38 MAPK inhibitors and 
inhalation exposure of rats 
Groups of rats were administered an aerosol of the p38 MAPK inhibitor 
for 30 minutes by snout-only inhalation exposure. Aerosols were 
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generated from dry powder formulations or aqueous solutions and 
directed into the top of the snout-only inhalation exposure chamber as 
described in Chapter 2 (Section 2.2.5). Target aerosol concentrations 
(Tables 4.4 and 4.6) for the exposure of animals were calculated from 
the required doses using Equation 3 (Chapter 2, Section 2.2.5). 
4.2.4.1. Dry powder formulations of p38 MAPK inhibitors  
Aliquots of dry powder formulations used for prophylactic exposure of 
rats to crystalline p38 MAPK inhibitors or amorphous GSK-899 were 
packed into the dust feed canisters (Table 4.4) using the method 
described in Chapter 2 (Section 2.2.5.1). 
Table 4.4: Dry powder formulations of p38 MAPK inhibitors, canister 
volumes, target doses and aerosol concentrations for exposure of rats  
Study 
number 
Test article 
Target 
dose 
(mg/kg) 
Test article in 
lactose 
(% w/w) 
Aerosol 
generator 
canister 
size (cm3) 
Target aerosol 
concentration 
(µg/L) A 
R30820N 
GSK-899 
(crystalline) 
3 0.1% 5 0.14 
30 0.1% 5 1.4 
300 1% 5 14 
1000 1% 40 45 
GSK-899 
(amorphous-1) 
3 0.5% 1.3 0.14 
30 0.5% 1.3 1.4 
300 5% 5 14 
1000 5% 40 45 
R30820N 
GSK-899 
(amorphous-2) 
0.3 0.4% 1.3 0.014 
3 0.4% 5 0.14 
30 0.4% 5 1.4 
300 4% 5 14 
R31763N 
GSK-899 
(crystalline) 
3 0.05% 5 0.15 
30 1% 5 1.5 
300 1% 5 15 
1000 5% 5 50 
GSK-899 
(amorphous-1) 
3 0.05% 5 0.15 
30 0.5% 5 1.5 
300 5% 5 15 
1000 5% 5 50 
GSK-899 
(amorphous-2) 
3 0.08% 5 0.15 
30 0.08% 5 1.5 
300 2.6% 5 15 
1000 2.6% 5 50 
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Study 
number 
Test article 
Target 
dose 
(mg/kg) 
Test article in 
lactose 
(% w/w) 
Aerosol 
generator 
canister 
size (cm3) 
Target aerosol 
concentration 
(µg/L) A 
R31400N 
GSK-677 
(crystalline) 
1 0.01% 5 0.047 
10 0.1% 5 0.47 
100 1% 5 4.7 
1000 10% 5 47 
R31765N 
GSK-361 
(crystalline) 
3 0.05% 5 0.15 
30 1% 5 1.5 
300 1% 5 15 
1000 5% 5 50 
Notes 
A Calculation of target aerosol concentration: R30820N assumed body weight of 
240g; R31763N, R31400N and R31765N assumed body weight of 350g 
4.2.4.2. Liquid formulations of p38 MAPK inhibitors 
For nebulisation of aqueous solutions, each p38 MAPK inhibitor was 
dissolved in the vehicle (Table 4.5) to prepare concentrations anticipated 
to achieve target aerosol concentrations and inhaled doses (Table 4.6). 
Methods of preparing solutions are stated in Chapter 2 (Section 2.2.5.3). 
Table 4.5: Vehicles used for nebulisation of p38 MAPK  
inhibitors and repeated inhalation exposure of rats 
Test article Study No. Vehicle for nebulisation 
GSK-899 
R30820N 
3% (v/v) Solutol HS 15 in 10% (w/v) 
aqueous 2-hydroxypropyl-B-cyclodextrin 
R31763N 
3% (v/v) Solutol HS 15 in 0.9% (w/v) 
aqueous sodium chloride (pH 5.9) 
GSK-677 R31400N 
3% (v/v) Solutol HS 15 in 0.9% (w/v) 
aqueous sodium chloride (pH 5.9) 
GSK-361 R31765N 
20:20:60 (v/v/v) Solutol HS 15, ethanol 
and 60 mM phosphate buffer (pH 7) 
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Table 4.6: Formulation concentrations, target doses and aerosol 
concentrations for exposure of rats to p38 MAPK inhibitors 
Test 
article 
Study 
number 
Target 
dose 
(mg/kg) 
Concentration 
in vehicle 
(mg/mL) 
Number of 
nebulisers 
per system 
Target aerosol 
concentration 
(µg/L) 
GSK-899 
R30820N 
3 0.01 1 0.14 
30 0.15 1 1.4 
300 2.0 1 14 
MP 3.0 1 MP 
R31763N 
3 0.025 1 0.15 
30 0.25 1 1.5 
300 1.5 1 15 
1000 4.0 2 50 
GSK-677 R31400N 
1 0.0049 1 0.047 
10 0.044 1 0.47 
100 0.40 1 4.7 
1000 4.0 1 47 
GSK-361 R31765N 
3 0.027 1 0.15 
30 0.15 1 1.5 
300 2.0 1 15 
1000 2.0 2 50 
Notes 
MP Maximum practicable dose based on limited solubility of GSK-899 in vehicle 
Solutol HS 15 and 2-hydroxypropyl-B-cyclodextrin or ethanol were used 
to solubilise p38 MAPK inhibitors of low solubility (GSK-899 and 
GSK-361). Solutol HS 15 was formulated with GSK-677 for exposure of 
rats to nebulised GSK-899 or GSK-677 for comparison of the efficacy for 
these compounds. Potential implications for the enhanced absorption of 
p38 MAPK inhibitors were discussed in Chapter 2 (Section 2.2.5.3) and 
inclusion of these reagents in the vehicle does not undermine the 
fundamental hypothesis that changing the aerosol form of a drug 
changes the kinetics of exposure and concomitant efficacy. 
Each experiment included a group of control rats that inhaled the vehicle 
of the p38 MAPK inhibitor (30 minutes) and was then challenged by 
intratracheal instillation of phosphate buffered saline (PBS; vehicle for 
LPS). Neutrophil counts in BALF for PBS-control s were approximately 
zero, confirming the nebulised vehicles did not cause inflammation. 
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4.2.4.3. Aerosol Generation and formulation details 
Groups of rats were administered an aerosol of the p38 MAPK inhibitor, 
by snout-only inhalation exposure, as a dry powder aerosol or nebulised 
solution (Chapter 2, Sections 2.2.5.2 and 2.2.5.4 respectively).  
Generally, a single nebuliser of nominal airflow 6 L/min was used to 
disperse each solution at the target aerosol concentration; a chamber 
exhaust of 16 L/min was applied to vent the test atmosphere. For the 
highest doses of GSK-899 and GSK-361 at the highest dose (studies 
R31763N and R31765N), dual nebulisers (6 L/min/nebuliser) were used 
to disperse the formulations and mitigate against limited solubility of the 
test article in its vehicle to achieve the target aerosol concentration. 
4.2.4.4. Inhalation exposure of rats 
Animals were exposed to test aerosols using the apparatus and methods 
described in Chapter 2 (Section 2.2.5.5). The chambers were operated 
under conditions of dynamic airflow, with a chamber exhaust flow of 
16 L/min. 
Rats were restrained for exposure in polycarbonate restraint tubes and 
attached to the chamber; the vertical position (chamber level) of each 
animal was documented. Unused animal exposure or sampling ports 
were closed using blanking plugs. 
Animals were exposed to the aerosol for 30 minutes, during which time 
operational settings (airflow and aerosol generation) and animals were 
formally checked and documented at 10-minute intervals. 
4.2.4.5. Aerosol characterisation 
‘Pre-study’ aerosol characterisation work was conducted without 
animals to establish the operating conditions needed to generate target 
aerosol concentrations and to ensure aerosols were in line with 
particulate size criteria for exposure of rodents (OECD[412], 2009, 
OECD[413], 2009, US-EPA[3645], 1998). For Design A (study 
R30820N), selection of chamber settings was based upon time of flight 
analysis (ToF) of particulates using a TSI Aerosol Particle Sizer; these 
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data were referenced against a calibration curve of particulate 
concentration (ToF analysis) against GSK-899 concentration (chemical 
analysis by HPLC-UV) generated for each dry powder formulation. 
Table 4.7: Target aerosol concentrations and aerosol sampling volumes  
Test 
article 
Study 
number 
Aerosol form 
Target aerosol 
concentration 
(µg/L) 
Sampling volume 
Aerosol 
concentration 
Particle size using 
cascade impactor 
Aerosol (L) 
Aerosol 
(L) 
Solvent 
(mL) 
GSK-899 
R30820N 
crystalline 
amorphous-1 
0.14 20 
[120] 3 
1.4 10 
14 4 4 3 
45 6 8 3 
amorphous-2 
0.014 60 
[120] 3 
0.14 10 
1.4 10 NS NS 
14 6 8 3 
nebulised 
0.14 10 [40] 5 
1.4 10 [10] 5 
14 6 10 5 
MP 6 8 5 
R31763N 
crystalline 
amorphous-1 
amorphous-2 
nebulised 
0.15 20 [120] A 5 
1.5 8 20 5 
15 4 8 5 
50 2 4 5 
GSK-677 R31400N 
crystalline 
nebulised 
0.047 40 NS NS 
0.47 8 [60] 5 
4.7 4 16 5 
47 4 6 5 
GSK-361 R31765N 
crystalline 
nebulised 
0.15 20 [120] 5 
1.5 8 20 5 
15 4 8 5 
50 2 4 5 
Notes 
MP Maximum practicable dose based on limited solubility of GSK-899 in vehicle 
NS Not sampled 
[ ] Particle size distribution sampled during pre-study trials (aerosol sampling 
period exceeded duration of inhalation exposure) 
[ ] A Aerosol sampling volume: 120 L for crystalline and amorphous-2 GSK-899 
aerosols; 24L for amorphous-1 aerosol (sampling pump stalled prematurely); 
72L for nebulised aerosol (sampling pump stalled prematurely) 
Aerosols were sampled using predefined air sampling volumes 
(Table 4.7) during exposure of rats to determine the aerosol 
concentration and particle size distribution of p38 MAPK inhibitors as 
described in Chapter 2 (Section 2.2.5.6). For aerosol concentration, filter 
samples were taken in duplicate when practicable. An additional sample 
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was taken, if practicable, using a cascade impactor for determination of 
the particle size distribution; cascade impactor samples were not taken 
during exposure of animals to the lower doses because the aerosol 
sampling period required to capture sufficient analyte for quantification 
exceed the duration of animal exposure. 
4.2.4.6. Calculation of the estimated inhaled dose 
Estimated inhaled doses were calculated using Equations 1 and 2 
(Chapter 1, Section 1.3.4) for an exposure period of 30 minutes. 
4.2.5. Antigen challenge of rats 
Immediately following inhalation exposure of the p38 MAPK inhibitor or 
vehicle alone, groups of rats (n=6/treatment) were challenged with LPS 
obtained from Escherichia coli 0127:B8 (product number L3129; Sigma 
Aldrich). Additional control rats (≤6) exposed to the inhalation formulation 
vehicle alone were challenged with phosphate buffered saline (vehicle 
for LPS) as a negative control for determination of baseline data. 
Methodology for LPS challenge of rats was optimised (Appendix 1). LPS 
was instilled into the trachea as a bolus (2 µg/rat; 0.2 mL/rat; 10 µg/mL 
LPS in phosphate buffered saline) using a Penn Century microsprayer 
(Figure 4.5A) with the device placed transorally under light anaesthesia; 
when practicable, all instillations were performed by the same operator. 
Rats anaesthetised with 5% (v/v) isoflurane in oxygen (2 L/min) were 
held supine and angled at approximately 45°C to enable visualisation of 
the pharynx via a cold light source placed over the animal’s throat 
(Figure 4.5B). A loop was placed over the upper incisors and used to 
hold the mouth open and maintain the rat’s head in a stable position. The 
tongue was manipulated to aid visualisation of the vocal chords. The 
cannula (Penn Century microsprayer) was inserted into the mouth 
parallel to the hard palate and guided towards the vocal folds. When the 
epiglottis was deemed to be open, the cannula was directed into the 
trachea through the vocal folds. Once in position, the dose was 
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dispensed and the device carefully removed. Post challenge, rats fully 
recovered from anaesthesia before being returned to the holding cages. 
4.5A 
 
4.5B 
 
Figure 4.5: Intratracheal instillation of a solution. 4.5A: Penn Century 
microsprayer (without syringe). 4.5B: intratracheal dosing of a rat under light 
anaesthesia; a cold light source was used to visualize the vocal folds to 
facilitate passage of the cannula into the trachea. 
4.2.6. Assessment of biomarkers for lung inflammation 
Design B (GSK-677): 0.6 mL of blood was sampled at 1.5 hours and 
4 hours post challenge. The blood was sampled by caudal venepuncture 
or from the abdominal aorta under deep isoflurane anaesthesia into a 
BD SST Serum Microtainer and allowed to stand for at least two hours 
before centrifugation (5250 rpm; 3 minutes) for separation of serum. 
Rats were euthanized four hours after the LPS challenge (4.5 hours after 
the start of aerosol generation) or post inhalation exposure to sample 
lungs for assessment of inflammation (Sections 4.2.6.1 or 4.2.6.2) or 
drug concentration (Section 4.2.7.2) respectively. Rats were euthanized 
by exsanguination via the abdominal aorta under isoflurane anaesthesia. 
Death was confirmed by cutting major blood vessels (cessation of 
circulation). 
4.2.6.1. Bronchoalveolar lavage of lungs for analysis of 
TNFα and/or cell counts (Designs A, B and D) 
The thoracic cavity was opened by excision of the sternum and the lungs 
removed. A cannula was inserted into the trachea and tied in place with 
thread. The lungs were gently lavaged with 3× 5 mL fresh ice cold 0.9% 
aqueous sodium chloride and the lobes gently massaged prior to 
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removal of each lavageate. Lavageates were pooled in a centrifuge tube 
for each rat and kept on ice pending analysis of TNFα or cell counting. 
BALF samples were centrifuged for five minutes at 1500 rpm 
(approximately 395×g), at approximately 4°C with no brake. The 
supernatant was transferred to a separate tube for analysis of TNFα 
(Design B) or discarded (Designs A and D). The cell pellet was 
resuspended in 1 mL fresh ice cold 0.9% sodium chloride and 
transferred to a 1.5 mL eppendorf tube. 
Cell counts (Designs A, B and D) 
An aliquot of the cell suspension was counted for leukocytes using an 
Advia 2120 analyser and reagents supplied by Siemens Diagnostics. 
A second aliquot (≤0.5 mL) was applied to the cytofunnel (filling port) of 
a Shandon Cytospin Cytocentrifuge for preparation of a cytospin slide. 
Approximately 5x104 cells in the cytospin chamber were air-dried and 
stained with Wright-Giemsa stain (Sigma Aldrich) using a Hematek 
stainer; the stain includes methylene blue and azure B to stain nuclei 
blue/purple and eosin to stain cytoplasm pink. The cells were viewed by 
light microscopy and the neutrophils and leukocytes counted manually. 
TNFα (Design B) 
BALF supernatant or serum was aliquoted (50 µL) into a 96-well plate. 
A duplicate plate was prepared as a contingency for repeat analysis. The 
plates were stored at -80ºC or colder pending quantification of TNFα 
using the multiplex Meso Scale Discovery (MSD) protocol supplied with 
the kit (Plate Catalogue Number N153A41). 
4.2.6.2. Lung sampling and processing for image analysis 
The thoracic cavity was opened by excision of the sternum and the lungs 
removed, inflated with 10% buffered formalin and preserved in this 
fixative for at least 24 hours before further processing was performed. 
After fixation, lungs were trimmed to expose areas of interest and placed 
into labelled cassettes according to a predefined pattern to orientate the 
lobes presented for examination; a total of seven sections were 
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organised into two cassettes to present representative sections of all 
lung lobes. The cassettes containing lung samples were stored in 10% 
buffered formalin until processed. 
Tissue processing for preparation of slides 
Tissues were processed using an automated schedule during which the 
tissues were immersed in a series of reagents, each for one hour. The 
tissues were first dehydrated by immersing the cassettes in 70% 
industrial methylated spirits (IMS; one cycle), 90% IMS (one cycle) and 
then absolute IMS (five cycles). The cassettes were immersed in xylene 
(three cycles). Xylene is miscible with paraffin wax and was used to 
“clear” the dehydrant (IMS) from the tissue. The tissues were then 
impregnated with molten paraffin wax maintained at ≤63ºC (four cycles). 
For embedding, a mould base was filled with molten paraffin wax in a 
working area (“embedding centre”) maintained at 60ºC. The trimmed 
tissues in a cassette were transferred to the mould and orientated in 
accordance with a blocking pattern with the surface of interest 
downwards. The mould was chilled on a cold plate, the position of the 
tissues adjusted if necessary, and the lid of the mould closed using the 
labelled cassette base. The mould was further cooled until the paraffin 
wax had set, and the mounted wax block removed from the mould. 
Preparation of slides for lung image analysis 
The wax blocks were mounted onto a microtome, coarse trimmed to 
expose the area of interest and cooled on ice. After removing any ‘coarse 
trimming artefacts’, sections of 3 to 5 µm thickness were cut and floated 
onto warm distilled water (47 to 50ºC), and picked up onto a clean glass 
slide pre-labelled with study, animal and block identification numbers. 
Design B (MPO and CD68): sections mounted on Colormark™ Plus 
microscope slides were immunohistochemically labelled for MPO 
(product number A0398; Dako) or CD68 (product number MCA341R; 
Serotec). Slides were processed using an automated sequence using a 
Ruo Discovery Multimer V2 protocol on a Discovery Ultra instrument with 
associated reagents (Ventana Medical Systems; VMS) as follows: slides 
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warmed in oven (60ºC; 8 minutes); deparaffinised in VMS solvent (65°C; 
12 minutes); incubated in “CC1 Pretreatment Solution” (95°C; 
52 minutes); incubated in primary antibody (MPO or CD68; 37°C; 
32 minutes); “CM inhibitor” applied (8 minutes); labelled with OMap 
anti-Rb HRP secondary antibody (16 minutes; anti-rabbit antibody linked 
to horseradish peroxidase). Staining of the immunolabelled cells was 
developed by incubation (4 minutes; room temperature) of sections with 
3,3'-diaminobenzidine, which is metabolised by HRP to produce a dark 
stain in the immunolabelled cells. Lung sections were counterstained 
with haematoxylin II, dehydrated in 70% IMS (2× 3 minutes) and cleared 
in xylene (3× 3 minutes). A coverslip was then applied and set using 
Entellan® rapid mounting medium (Sigma Aldrich). Extra sections cut 
from an arbitrarily selected block from the treated group were processed 
as an isotype negative (background labelling) control for the primary 
antibodies. 
Designs B to D (CAE): lung sections were stained for CAE (biomarker of 
neutrophils) and counterstained with haematoxylin (stains cell nuclei 
blue) to contrast definition of the lung tissue with the neutrophils. Slides 
with mounted lung sections were warmed in an oven (60ºC; 60 minutes) 
to melt the paraffin wax and then immersed in xylene, ethanol and then 
water (1 cycle; timings not specified) to deparaffinize the sections. Slides 
were rinsed in deionised water and stood in warmed deionised water 
(37°C) until required for further processing. Slides were fixed 
(30 seconds; room temperature) in a solution of formaldehyde, acetone 
and water (3:66:31 v/v/v) containing 7 mM citrate (catalogue 
number 915; Sigma Aldrich), rinsed in deionised water (2 changes) and 
stood in warmed deionised water (1×3 minutes; agitated at 30-second 
intervals). Slides were then incubated (37ºC; protected from light; 
15 minutes for Design B; 7 minutes for Designs C and D;) in Naphthol 
AS-D Chloroacetate staining solution (Product code 91C-1KT; Sigma 
Aldrich), rinsed in warmed deionised water (5 changes), and 
counterstained in 5% Harris’ Haematoxylin (1× 20 seconds), rinsed in 
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cold running tap water (15 seconds) followed by warm water 
(15 seconds) to develop the blue stain. The slides were briefly rinsed in 
deionised water and dried in an oven at 50°C. A coverslip was then 
applied and set using Entellan® rapid mounting medium (Design B: 
catalogue number 1079610100; Sigma Aldrich) or permanent aqueous 
mounting medium (Designs C and D: catalogue number BUF058B; Bio-
Rad). 
Lung image analysis 
Stained slides were wiped clean with tissue, loaded onto a ScanScope 
XT brightfield scanner (Leica, formerly Aperio) and digitalised (×40 
magnification) to produce 1020 pixel-wide strips that were automatically 
‘stiched together’ to form a single SVS-formatted image (ScanScope 
Virtual Slide). Any scans of “quality factor” less than 95% were rejected 
and the slide rescanned; scans passing this criterion were visually 
inspected to ensure no visible seams between the stitch stripes, variable 
illumination or poor focus were evident. 
Design B (MPO/CD68 and CAE): The digitalised images (Figure 4.6A) 
were imported into Architect XD Tissue Studio (version 2.1.1; Definiens). 
Lung sections were demarcated by manually drawing around their 
boundaries (bronchus associated lymphoid tissue excluded) and areas 
of stained tissue and cells delineated (Figure 4.6B). All pixels that 
represented the physical lung structure (such as alveolar/bronchiolar 
walls, bronchi and blood vessels) were segmented into a class for ‘lung 
structure’ and all pixels representing lumens of alveoli and airways etc 
were segmented into a second class for ‘air spaces’. All pixels 
representing the brown stain (MPO or CD68-positive) or red stain 
(CAE-positive) were segmented by adjusting the intensity (optical 
density) threshold for the detection of the biomarker area. The quality of 
segmentation was evaluated by inspecting the accuracy of coloured 
overlays representing each class: yellow for biomarker; blue for nuclei; 
green for cytoplasm (Figures 4.6C and 4.6D). If segmentation appeared 
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robust, the optimised settings (‘image analysis solution’) were saved for 
batch processing all scans for the experiment. 
Designs C and D (CAE): modified lung image analysis method not 
available at time of thesis submission. 
4.6A 
 
4.6B 
 
4.6C 
 
4.6D 
 
Figure 4.6: Example of image analysis of rat lungs for biomarkers of 
inflammation. Rats (n=6/treatment) were administered lipopolysaccharide in 
phosphate buffered saline by intratracheal instillation (2 g/rat; bolus). Lungs 
were taken four hours later, fixed in 10% buffered formalin and embedded in 
paraffin wax. Lung sections were stained for myeloperoxidase (MPO) or 
chloroacetate esterase (CAE), biomarkers of neutrophils, and the lung tissue 
counterstained with haematoxylin and eosin. 4.6A: lung section with 
neutrophils stained by CAE (N) and erythrocytes (E); cell nuclei counterstained 
blue by haematoxylin and cytoplasm pink by eosin. 4.6B: the lung was 
demarcated (not shown) and areas of stained tissue and cells delineated. 
4.6C: colour overlays were applied to the areas of interest: CAE-stained 
neutrophils (yellow), nuclei (blue) and lung tissue (green). 4.6D: another 
representative lung section showing CAE-stained neutrophils (yellow) distinct 
from lung tissue and nuclei. The ratio of CAE-stained area to the remaining 
tissue area is determined; air spaces are excluded. 
The area of MPO or CAE-positive staining in each scan was expressed 
as a proportion of the surface area of the lung structure. The area of ‘air 
spaces’ was omitted from this calculation to minimise artefactual 
inter-animal variation due to lung inflation on the calculation of the lung 
N N N N 
N N 
E 
E 
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area. Since MPO was stained in both neutrophils and macrophages, the 
CD68-positive area was also deducted from the MPO-positive area to 
improve the neutrophil specificity for evaluation of this biomarker. 
4.2.6.3. Determination of the 50% effective dose (ED50) for 
inhibition of LPS-induced lung inflammation 
For each biomarker of inflammation, the baseline value (mean for 
PBS-challenged rats) was deducted from the datum for each animal. 
This value was then expressed as a percentage of the similarly adjusted 
mean biomarker value for LPS-challenged rats. Relative biomarker 
values (% of LPS control) were plotted against Log10 of the estimated 
inhaled dose of the p38 MAPK inhibitor and a linear regression line was 
fitted. The regression line was then used to estimate the inhaled dose 
that gives a 50% response (ED50) along with the corresponding 95% 
confidence interval of this estimate. This analysis was conducted using 
SAS (version 9.3). 
4.2.7. Bioanalysis of p38 MAPK inhibitors in rat plasma 
and lung 
Groups of rats were sampled for plasma and lungs following exposure 
to the p38 MAPK inhibitor for HPLC-MS/MS analysis of the test article. 
4.2.7.1. Plasma sampling for analysis of p38 MAPK inhibitors 
Blood samples were taken from groups of rats (3/dose/timepoint) by 
jugular venepuncture or from the abdominal aorta under isoflurane 
anaesthesia for the final (terminal) sample at the following timepoints 
after inhalation exposure to a p38 MAPK inhibitor: 
• Design A: 60 μL immediately post exposure (0.5 hours) and at 1.5 
and 4.5 hours after the start of aerosol administration; blood was 
mixed 1:1 with sodium fluoride (10 mg/mL). 
• Designs B to D: 400 μL immediately post exposure (0.5 hours) 
and at euthanasia (0.8 hours following the start of aerosol 
administration). Blood was processed for preparation of plasma. 
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Blood/plasma was processed for chemical analysis by HPLC-MS/MS as 
described in Chapter 2 (Section 2.2.5.8); samples were stored in a 
freezer at approximately -20°C or below prior to analysis. 
GSK-899 concentrations in blood (Design A) were converted to plasma-
based values using a blood:plasma ratio of 2.10 (unpublished data). 
4.2.7.2. Lung sampling for homogenisation and analysis of 
p38 MAPK inhibitors 
Groups of rats (3/dose/timepoint) were euthanized as soon as 
practicable after a single exposure (all p38 MAPK inhibitors) or 4.5 hours 
relative to the start of a single inhalation exposure (GSK-899 only; study 
R30820N). The lungs were taken and processed for HPLC-MS/MS 
analysis of p38 MAPK inhibitor in lung homogenate as described in 
Chapter 2 (Section 2.2.5.8). 
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4.3. Results and discussion 
4.3.1. Inhalation exposure of rats to p38 MAPK inhibitors 
Achieved aerosol concentrations (Tables 4.8 to 4.11), and hence the 
estimated inhaled doses of p38 MAPK inhibitors, deviated from the 
respective targets but nevertheless achieved a series of doses suitable 
for evaluating the dose response of p38 MAPK inhibitors for inhibition of 
LPS-induced acute lung inflammation in rats. 
Table 4.8: Aerosol characterisation data and inhaled doses  
of GSK-899 in rats (single 30-minute exposure) 
Study 
number 
Aerosol form 
Formulation 
concentration 
in vehicle 
Estimated 
inhaled 
dose A 
(µg/kg) 
Mean (n=2) 
drug aerosol 
concentration 
(µg/L) 
Particle size 
distribution 
MMAD 
(µm) 
σg 
R30820N 
Crystalline 
0.89% (w/w) 1.07 0.0499 [2.6]B [2.5] 
0.89% (w/w)  18.4 0.846 NS NS 
1.0% (w/w) 305 14.0 2.2 2.2 
1.0% (w/w) 533 24.1 2.0 2.5 
amorphous-1 
0.50% (w/w) 2.58 0.120 [4.4]B [1.9] 
0.50% (w/w) 12.5 0.582 [5.3]B [1.9] 
5.0% (w/w) 210 9.65 3.8 2.3 
5.0% (w/w) 2349 106 7.2 NC C 
amorphous-2 
0.082% (w/w) 0.658 0.0288 (n=1) NS NS 
0.082% (w/w) 3.95 0.183 NS NS 
0.082% (w/w)  37.7 1.77 [2.0]B [2.1] 
4.0% (w/w) 366 16.7 [2.2]B [2.3] 
4.0% (w/w) 915 42.7 NS NS 
Nebulised 
solution 
0.01 mg/mL 1.28 0.0590 - - 
[0.02 mg/mL] - - [2.6]B NC D 
0.15 mg/mL 22.7 1.05 - - 
[0.20 mg/mL] - - [2.7]B [2.3] 
2.0 mg/mL 279 12.9 2.5 2.0 
3.0 mg/mL 845 38.1 1.8 2.1 
Notes 
MMAD mass median aerodynamic diameter 
σg geometric standard deviation 
A Estimated inhaled doses calculated for a 30-minute exposure period using 
mean data (aerosol concentration and body weight) and a body-weight 
derived estimate of respired minute volume (Alexander et al., 2008). 
[ ]B Aerosol sample taken during aerosol generation trial without rats (required 
aerosol sampling period at 2 L/min exceeded 30-minute exposure period). 
NC σg not calculable 
C MMAD between two largest cut-points of 6.1 and 8.2 µm 
D At least 3 of 7 stages below limit of quantification (insufficient data) 
NS Not sampled 
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Deviations from target were particularly evident for Design A (Table 4.8), 
in which exposure system settings were based upon time of flight 
analysis data for particulates (referenced against a calibration curve of 
particulate versus GSK-899 aerosol concentrations). For subsequent 
experiments (Tables 4.9 to 4.11), settings were based upon chemical 
analysis data measured in more extensive pre-study trials, in line with 
the approach used for experiments described in Chapters 2, 3 and 5. 
This more conservative approach achieved a greater proportion of 
achieved aerosol concentrations in line with the respective targets. 
Table 4.9: Aerosol characterisation data and inhaled doses  
of GSK-899 in rats (single 30-minute exposure) 
Study 
number 
Aerosol form 
Formulation 
concentration 
in vehicle 
Estimated 
inhaled 
dose A 
(µg/kg) 
Mean (n=2) 
drug aerosol 
concentration 
(µg/L) 
Particle size 
distribution 
MMAD 
(µm) 
σg 
R31763N 
Crystalline 
0.053% (w/w) 3.03 0.135 [4.0]B [2.9] 
0.95% (w/w) 28.9 1.34 2.1 2.2 
0.95% (w/w) 244 11.3 2.7 2.2 
4.9% (w/w) 1156 53.7 2.4 2.2 
amorphous-1 
0.045% (w/w) 3.01 0.135 [5.9]B [2.0] 
0.50% (w/w) 31.5 1.48 4.2 2.0 
5.0% (w/w) 259 11.9 3.2 2.2 
5.0% (w/w) 1038 48.8 3.2 2.2 
amorphous-2 
0.082% (w/w) 2.15 0.100 [3.3]B [2.1] 
0.082% (w/w) 30.5 1.41 3.7 2.4 
2.5% (w/w) 288 13.4 2.3 2.2 
2.5% (w/w) 1171 55.1 3.0 2.1 
Nebulised 
solution 
0.024 mg/mL 
0.24 mg/mL 
2.59 0.115 [0.9]B NC 
24.3 1.12 1.1 2.5 
1.5 mg/mL 304 14.2 2.7 2.3 
3.5 mg/mL 891 42.1 4.0 2.0 
Notes 
MMAD mass median aerodynamic diameter 
σg geometric standard deviation 
A Estimated inhaled doses calculated for a 30-minute exposure period using 
mean data (aerosol concentration and body weight) and a body-weight 
derived estimate of respired minute volume (Alexander et al., 2008). 
[ ]B Aerosol sample taken during aerosol generation trial without rats (required 
aerosol sampling period at 2 L/min exceeded 30-minute exposure period). 
NC σg not calculable (3 of 7 stages below limit of quantification) 
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Table 4.10: Aerosol characterisation data and inhaled doses  
of GSK-677 in rats (single 30-minute exposure) 
Study 
number 
Aerosol form 
Formulation 
concentration 
in vehicle 
Estimated 
inhaled 
dose A 
(mg/kg) 
Mean (n=2) 
drug aerosol 
concentration 
(µg/L) 
Particle size 
distribution 
MMAD 
(µm) 
σg 
R31400N 
Crystalline 
0.012% (w/w) 
1.00 0.0463 (n=1) 
NS NS 
1.11 0.0513 (n=1) 
0.11% (w/w) 
8.82 0.410 
[4.3]B [2.3] 
9.66 0.447 
1.1% (w/w) 
81.6 3.76 3.9 1.9 
306 14.3 4.9 2.0 
11 % (w/w) 
1034 48.3 3.6 2.5 
775 35.9 2.4 2.1 
Nebulised 
solution 
0.0050 mg/mL 
1.36 0.0638 (n=1) 
NS NS 
1.39 0.0650 (n=1) 
0.044 mg/mL 
14.3 0.699 
[2.6]B [2.1] 
13.7 0.641 
0.40 mg/mL 
144 6.71 2.7 2.3 
95.3 4.48 2.0 2.4 
3.9 mg/mL 
1249 58.4 2.2 2.5 
973 45.2 2.4 2.5 
Notes 
MMAD mass median aerodynamic diameter 
σg geometric standard deviation 
NS Not sampled  
A Estimated inhaled doses calculated for a 30-minute exposure period using 
mean data (aerosol concentration and body weight) and a body-weight 
derived estimate of respired minute volume (Alexander et al., 2008). 
[ ]B Aerosol sample taken during pre-study aerosol generation trial without rats 
(aerosol sampling period at 2 L/min exceeded 30-minute exposure period). 
Particle size distribution data were generally compliant with criteria 
stipulated in the contemporary guidance for testing chemicals in rodents: 
mass median aerodynamic diameter (MMAD) 1 to 3 µm and geometric 
standard deviation 1.5 to 3 (OECD[412], 2009, OECD[413], 2009, US-
EPA[3645], 1998). The MMAD for aerosols of GSK-899 amorphous-1 
were higher (Tables 4.8 and 4.9) but were generally in line with particle 
size data for aerosols administered to rats during a repeat dose study 
(Table 4.2). Although the anomalous MMAD (7.2 µm) determined for the 
amorphous-1 high dose (Table 4.8) was inconsistent with that achieved 
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in the subsequent experiment (Table 4.9) and during repeated 
administration (Table 4.2), the lung concentration data confirmed the 
lung deposited dose was relatively lower for rats administered 
2350 µg/kg (Figure 4.16A) than 1038 µg/kg (Figure 4.19). Although 
differences in MMAD were evident for GSK-899 amorphous-1 and 
amorphous-2 aerosols in the first experiment (Table 4.8), values 
determined for the higher doses in the second experiment performed to 
investigate the utility of lung image analysis (Table 4.9) were similar. 
Table 4.11: Aerosol characterisation data and inhaled doses  
of GSK-361 in rats (single 30 or 60-minute exposure) 
Study 
number 
Aerosol form 
Formulation 
concentration 
in vehicle 
Estimated 
inhaled 
dose A 
(mg/kg) 
Mean (n=2) 
drug aerosol 
concentration 
(µg/L) 
Particle size 
distribution 
MMAD 
(µm) 
σg 
R31765N 
Crystalline 
0.042% (w/w) 
3.52 0.155 
[1.7]C [3.8] 
4.61 0.205 
0.95% (w/w) 
31.1 1.41 1.7 3.4 
28.1 1.28 1.2 5.1 
0.95% (w/w) 
282 12.8 1.9 3.1 
283 12.9 2.2 2.8 
5.0% (w/w) 
883 40.2 1.7 2.6 
958 43.6 2.7 2.7 
Nebulised 
solution 
0.027 mg/mL 
3.51 0.155 
[1.8]C [2.3] 
4.17 0.193 
0.15 mg/mL 
36.1 1.65 2.6 2.2 
10.5 0.471 1.3 2.5 
1.9 mg/mL 
236 10.8 2.0 2.3 
100 4.58 1.4 2.7 
1.9 mg/mL 
1006 B 23.0 2.3 2.5 
1232 B 28.2 2.0 2.2 
Notes 
MMAD mass median aerodynamic diameter 
σg geometric standard deviation 
A Estimated inhaled doses calculated for a 30-minute exposure period using 
mean data (aerosol concentration and body weight) and a body-weight 
derived estimate of respired minute volume (Alexander et al., 2008). 
B Nebulised high dose: limited solubility of GSK-361 in vehicle necessitated 
exposure of rats for 60 minutes to achieve the target dose (all other groups 
were exposed for 30 minutes). 
[ ]C Aerosol sample taken during pre-study aerosol generation trial without rats 
(aerosol sampling period at 2 L/min exceeded 30-minute exposure period). 
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4.3.2. Temporal variability of rat neutrophils in BALF four 
hours after an LPS challenge 
Neutrophil counts in BALF obtained from control rats four hours after 
intratracheal instillation of LPS showed variability between sampling 
occasions (Figure 4.7). Relative mean neutrophil counts (Figure 4.8) 
expressed as a percentage of leukocytes were 75% with a range of 67% 
to 84% for lactose-control rats, and 66% with a range of 40% to 75% for 
control rats administered a nebulised vehicle; the mean for 14-Jan-2016 
(n=3; nebulised vehicle) was skewed by a low result (18%) for 1/3 rats. 
This day to day variability in control neutrophil counts complicated data 
analysis, since dose response was expressed relative to the response 
of control rats to the LPS challenge. The source of such variability has 
implications for the integrity of the p38 MAPK inhibitor dose responses. 
Ettensohn et al. (1988) reported recovery of 64.8 ±9.8% of BALF from 
humans with 3/16 outliers. A similar recovery of BALF was achieved from 
isolated lungs of the control rats challenged with LPS, with a mean 
recovery of 71 ±10% and 12/60 outliers. The total recovered volumes 
were consistent between sampling occasions with no obvious correlation 
between peak or trough neutrophil counts (Figures 4.7 and 4.8) and high 
or low BALF yields (Figure 4.9) respectively. It is therefore unlikely that 
variability in neutrophil counts is attributable to the recovery volumes per 
se. However, it is plausible the variability may be attributable, at least in 
part, to partial recovery of neutrophils from lungs during the flushing 
procedure. The potential for differential recovery of neutrophils in BALF 
was to be investigated further by image analysis of CAE-stained 
neutrophils in lungs that had undergone BAL sampling or were ‘naïve’ 
for this procedure (Design D).  
In addition, the day to day variability may be temporal and potentially 
influenced by differences in the sub-clinical immune status and/or 
antigen challenge responses for batches of animals. 
Chapter Four 
217 
 
4.7A: lactose vehicle control 
 
4.7B: nebulised vehicle control 
 
Figure 4.7: Neutrophil counts in bronchoalveolar lavage fluid (BALF) 
sampled from control animals four hours after intratracheal instillation of 
lipopolysaccharide (LPS). Rats inhaled an aerosol of lactose or the vehicle 
for nebulization of GSK-899 (Design A), GSK-677 (Design B) or GSK-361 
(Design D) for 30 minutes and challenged by intratracheal instillation of LPS. 
Four hours later, rats were euthanized and sampled for BALF to determine 
neutrophil counts (mean presented with standard deviation as error bars). 
4.7A: rats administered lactose before LPS challenge. 4.7B: rats administered 
a nebulised aqueous vehicle before LPS challenge. 
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4.8A: lactose vehicle control 
 
4.8B: nebulised vehicle control 
 
Figure 4.8: Neutrophils as a proportion of leukocytes in bronchoalveolar 
lavage fluid (BALF) sampled from control rats four hours after 
intratracheal instillation of lipopolysaccharide (LPS). Rats inhaled an 
aerosol of lactose or the vehicle for nebulization of GSK-899 (Design A), 
GSK-677 (Design B) or GSK-361 (Design D) for 30 minutes and challenged by 
intratracheal instillation of LPS. Four hours later, rats were euthanized and 
sampled for BALF to determine neutrophil counts (relative mean presented with 
standard deviation as error bars). 4.8A: rats administered lactose before LPS 
challenge. 4.8B: rats administered a nebulised aqueous vehicle before LPS 
challenge. 
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4.9A: lactose vehicle control 
 
4.9B: nebulised vehicle control 
 
Figure 4.9: Recovery of bronchoalveolar lavage fluid (BALF) sampled 
from control animals. Rats were euthanized, the lungs removed and a 
cannula inserted into the trachea and secured with thread. Lungs were gently 
lavaged with 3×5mL ice cold saline (0.9%); lobes were gently massaged prior 
to removal of each aliquot, which were pooled for each animal (mean yield 
presented with standard deviation as error bars). 4.9A: rats administered 
lactose before LPS challenge. 4.9B: rats administered a nebulised aqueous 
vehicle before LPS challenge. 
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4.3.3. Pulmonary and systemic exposure of rats to 
GSK-677 and endpoints for investigating inhibition 
of acute lung inflammation (Design B) 
Concentrations of GSK-677 in lungs (Figure 4.10) and plasma 
(Figure 4.11) after aerosol administration increased with dose and were 
similar for crystalline and nebulised aerosol forms, with clear separation 
of the doses. Lung and plasma concentrations at the low dose of 1 µg/kg 
were non-quantifiable (<120 ng/g lung tissue; <0.05 ng/mL plasma). 
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Figure 4.10: GSK-677 concentrations in lung homogenate sampled from 
rats after a single inhaled dose (Study R31400N). Rats inhaled an aerosol 
of crystalline or aqueous (nebulised) GSK-677 for 30 minutes. Mean GSK-677 
concentrations with standard deviations (error bars; n=3) are shown for lung 
homogenate samples taken as soon as practicable (approximately 20 minutes) 
after the inhalation exposure. * indicates concentrations were below the limit of 
quantification (<120 ng/g). 
A decrease in plasma concentration was evident during the 20-minute 
period elapsing between removal of the rats from the inhalation exposure 
chamber and their euthanasia for lung sampling (Figure 4.11). These 
data are consistent with the results described in Chapter 2. 
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Figure 4.11: GSK-677 concentrations in plasma sampled from rats after a 
single inhaled dose (Study R31400N). Rats inhaled an aerosol of crystalline 
or aqueous (nebulised) GSK-677 for 30 minutes. Mean GSK-677 
concentrations with standard deviations (error bars; n=3) are shown for plasma 
samples taken immediately after inhalation exposure and during 
exsanguination for lung tissue sampling (approximately 20 minutes later). 
* indicates concentrations were below the limit of quantification (<0.05 ng/mL). 
Plotted data and the linear regression lines for evaluated biomarkers 
showed a more pronounced suppression of LPS-induced inflammation 
with an increase in the inhaled dose of GSK-677. However, 
concentrations of TNFα in serum (n=12/dose) at 1.5 or 4 hours post 
challenge (Figure 4.12) or BALF (n=6/dose) at 4 hours post challenge 
(Figure 4.13) were most variable, with outliers particularly evident in 
serum at 1.5 hours (Figures 4.12A and 4.12B). Relative neutrophil 
counts in BALF (Figure 4.14) and the relative proportion of MPO or 
CAE-stained lung sections (Figure 4.15) appeared less variable than 
TNFα. However, the relative MPO data for rats administered GSK-677 
(especially nebulised aerosols) were higher than corresponding data for 
CAE, suggesting elevation of the baseline associated with a potential 
lack of specificity of the antibody for MPO in the rat lung sections. 
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4.12B: Nebulised (1.5 hours) 
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4.12C: Crystals (4 hours) 
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4.12D: Nebulised (4 hours) 
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Figure 4.12: Tumour necrosis factor-alpha (TNFα) in serum, relative to 
controls, sampled from an acute lung inflammation model in rats 
administered GSK-677 (Study R31400N). Rats (n=6/dose) were exposed to 
an aerosol of GSK-899 or vehicle (control) for 30 minutes and then challenged 
with lipopolysaccharide (LPS) by intratracheal instillation; a control group for 
baseline data was instilled with phosphate buffered saline (PBS; n=4). Serum 
samples were obtained at 1.5 and 4 hours post challenge. Net TNFα 
concentrations (individual value less the mean concentration for 
PBS-challenged controls) were expressed relative to LPS-challenged controls 
and plotted against log10 dose of GSK-677. Individual data, a linear regression 
line and the corresponding 95% confidence interval (dotted lines) are plotted 
for each aerosol form and time point. 4.12A: crystalline doses: 1.00-1.11, 
8.82-9.66, 81.6-306 and 775-1034 µg/kg; serum sampled at 1.5 hours post 
challenge. 4.12B: nebulised doses: 1.36-1.39, 13.7-14.3, 95.3-144 and 
973-1249 µg/kg; serum sampled at 4 hours post challenge. 4.12C: crystalline 
doses: 1.00-1.11, 8.82-9.66, 81.6-306 and 775-1034 µg/kg; serum sampled at 
4 hours post challenge.4.12D: nebulised doses: 1.36-1.39, 13.7-14.3, 
95.3-144 and 973-1249 µg/kg; serum sampled at 4 hours post challenge.  
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4.13A: Crystals (4 hours) 
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4.13B: Nebulised (4 hours) 
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Figure 4.13: Tumour necrosis factor-alpha (TNFα) in broncho-alveolar 
lavage fluid (BALF), relative to controls, sampled from an acute lung 
inflammation model in rats administered GSK-677 (Study R31400N). Rats 
(n=6/dose) were exposed to an aerosol of GSK-899 or vehicle (control) for 30 
minutes and then challenged with lipopolysaccharide (LPS) by intratracheal 
instillation; a control group for baseline data was instilled with phosphate 
buffered saline (PBS; n=4). Four hours post challenge, rats were euthanized 
and lungs lavaged with saline. Net TNFα concentrations (individual value less 
the mean concentration for PBS-challenged controls) were expressed relative 
to LPS-challenged controls and plotted against log10 dose of GSK-677. 
Individual data, a linear regression line and the corresponding 95% confidence 
interval (dotted lines) are plotted for each aerosol form and time point. 
4.13A: crystalline doses: 1.00-1.11, 8.82-9.66, 81.6-306 and 775-1034 µg/kg. 
4.13B: nebulised doses: 1.36-1.39, 13.7-14.3, 95.3-144 and 973-1249 µg/kg.  
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4.14B: Nebulised 
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Figure 4.14: Neutrophils in bronchoalveolar lavage fluid, relative to 
controls, harvested from an acute lung inflammation model in rats 
administered GSK-677 (Study R31400N). Rats (n=6/dose) were exposed to 
an aerosol of GSK-677 or vehicle (control) for 30 minutes and then challenged 
with lipopolysaccharide (LPS) by intratracheal instillation; a control group for 
baseline data was instilled with phosphate buffered saline (PBS; n=4). Four 
hours post challenge, rats were euthanized and lungs lavaged with saline to 
harvest neutrophils. Neutrophils (expressed as net proportion of leukocytes for 
each rat, i.e. less mean count for PBS-challenged controls, and relative to 
LPS-challenged controls) were plotted against log10 dose of GSK-677. 
Individual data, a linear regression line and the corresponding 95% confidence 
interval (dotted lines) are plotted for each aerosol form. 4.14A: crystalline 
doses: 1.00-1.11, 8.82-9.66, 81.6-306 and 775-1034 µg/kg. 4.14B: nebulised 
doses: 1.36-1.39, 13.7-14.3, 95.3-144 and 973-1249 µg/kg. 
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0 1 2 3
0
5 0
1 0 0
1 5 0
L o g 1 0  o f d o s e  ( g /k g )
N
e
t 
M
P
O
-A
b
 i
n
 l
u
n
g
 t
is
s
u
e
a
s
 %
 o
f 
L
P
S
 C
o
n
tr
o
l
 
4.15B: Nebulised (MPO) 
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4.15C: Crystals (CAE) 
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4.15D: Nebulised (CAE) 
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Figure 4.15: Proportion of lung tissue stained for myeloperoxidase (MPO) 
or chloroacetate esterase (CAE), relative to controls, in an acute lung 
inflammation model in rats administered GSK-677 (Study R31400N). Rats 
(n=6/dose) were exposed to an aerosol of GSK-899 or vehicle (control) for 30 
minutes and then challenged with lipopolysaccharide (LPS) by intratracheal 
instillation; a control group for baseline data was instilled with phosphate 
buffered saline (PBS; n=6). Four hours post challenge, rats were euthanized, 
lungs preserved for histology; sections 3 µm thick were stained for MPO or 
CAE and imaged. The proportion of lung tissue stained for MPO or CAE (less 
mean value for PBS-challenged controls) relative to LPS-challenged controls 
was plotted against log10 dose of GSK-677. Individual data, a linear regression 
line and the corresponding 95% confidence interval (dotted lines) are plotted 
for each aerosol form. 4.15A: crystalline doses: 1.00-1.11, 8.82-9.66, 81.6-306 
and 775-1034 µg/kg; lung stained for MPO. 4.15B: nebulised doses: 1.36-1.39, 
13.7-14.3, 95.3-144 and 973-1249 µg/kg; lung stained for MPO. 
4.15C: crystalline doses: 1.00-1.11, 8.82-9.66, 81.6-306 and 775-1034 µg/kg; 
lung stained for CAE. 4.15D: nebulised doses: 1.36-1.39, 13.7-14.3, 95.3-144 
and 973-1249 µg/kg; lung stained for CAE. 
The 95% confidence limits of the median effective dose (ED50) for each 
biomarker of inflammation reflected high variability in the datasets; 
confidence limits increased dramatically when the extrapolated ED50 
was outside the evaluated range of inhaled doses. Confidence limits for 
TNF-α measurements and lung image analysis of net MPO (MPO less 
CD68-positive areas) were particularly variable, together with the CAE 
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data for rats administered crystalline GSK-677, with estimated ED50 
values exceeding doses at which pulmonary toxicopathology was 
observed (Chapter 5). The ED50 was approximately 360 µg/kg for both 
aerosol forms based on neutrophil counts in BALF, and 126 µg/kg for 
nebulised GSK-677 CAE staining of lung sections. Both estimates are 
higher than that predicted from intratracheal instillation of an aqueous 
suspension of GSK-677 (ED50 = 5 µg/kg; Figure 4.4B) after a lung 
deposition fraction of 10% was considered (Forbes et al., 2011, Jones 
and Baldrick, 2013, Owen, 2013). 
Table 4.12: Estimated inhaled doses of GSK-677 to achieve 50% 
reduction (ED50) in inflammation endpoints evaluated using an  
acute lung inflammation model in rats 
Parameter 
and medium 
Presentation 
of GSK-677 
ED50 
estimate 
(µg/kg) A 
95% confidence 
interval (µg/kg)  
ED50 
outside 
dose 
range? B lower upper 
TNFα (1.5h) 
serum 
crystalline 1709 230 1.45 x106 Yes 
nebulised 863 153 1.94 x105 No 
TNFα (4h) 
serum 
crystalline 6525 701 7.17 x106 Yes 
nebulised 90101 1471 NC Yes 
TNFα (4h) 
BALF 
crystalline 17377 286 NC Yes 
nebulised 7389 685 7.55 x107 Yes 
Neutrophils 
(4h) BALF 
crystalline 366 95.5 5744 No 
nebulised 356 102 4356 No 
MPO stain 
(4h) lung 
crystalline 3893 569 6.32 x105 Yes 
nebulised 47044 2137 1 x1010 Yes 
CAE stain 
(4h) lung 
crystalline 42701 286 NC  Yes 
nebulised 126 40.4 714 No 
Notes 
A ED50 values extrapolated from net data (mean value for PBS control 
deducted from result for LPS-challenged animal) expressed relative to 
the mean of LPS-challenged controls (see Figures 4.12 to 4.15).  
B 95% confidence limits increase dramatically when the extrapolated 
ED50 was outside the evaluated range of estimated inhaled doses. 
NC Not calculable 
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4.3.4. Pulmonary and systemic exposure of rats to 
GSK-899 and inhibition of inflammation 
Design A: lung concentrations of GSK-899 after inhaled administration 
of crystals increased with dose ≤308 µg/kg. Concentrations were similar 
for crystalline doses of 308 and 531 µg/kg with no difference at 0.5 and 
4.5 hours (Figure 4.16). Lung concentrations for rats inhaling amorphous 
or nebulised GSK-899 were lower than those of rats administered the 
crystalline form at a given dose, with the amorphous-1 preparation 
achieving the lowest relative lung concentration when normalisation of 
dose was considered. This is consistent with the higher MMAD noted for 
the latter aerosol form (Table 4.8) and the trends in results described in 
Chapter 2. GSK-899 was not quantifiable at low doses (amorphous-1 
≤18.9 µg/kg; amorphous-2 at 0.653 µg/kg; nebulised at 1.30 µg/kg). 
GSK-899 concentrations in plasma evaluated at the two highest doses 
for each aerosol form showed an increase with dose, and declined from 
0.5 hours (immediately post inhalation exposure) to 1.5 and 4.5 hours 
(Figure 4.17). For comparable doses, amorphous-2 GSK-899 achieved 
the highest plasma concentration and crystalline GSK-899 the lowest. 
Suppression of LPS-induced inflammation was evident with an increase 
in inhaled dose for each of the aerosol forms of GSK-899 (Figure 4.18). 
Prima facie, the plotted data and linear regression lines for neutrophils 
in BALF showed a similar variability in data points for GSK-899 to that 
evident for GSK-677 (Figure 4.14). 
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Figure 4.16: GSK-899 concentrations in lung homogenate sampled from 
rats after a single inhaled dose (Study R30820N). Rats inhaled an aerosol 
of crystalline, amorphous or aqueous (nebulised) GSK-899 for 30 minutes. 
Mean GSK-899 concentrations with standard deviations (error bars; n=3) are 
shown for lung homogenate samples taken as soon as practicable 
(approximately 20 minutes) after inhalation exposure (0.5h) and for higher 
doses at 4.5 hours (4 hours post exposure). * indicates concentrations were 
below the limit of quantification (<120 ng/g). 4.16A: rats administered 
crystalline GSK-899 (1.07, 22.5, 308 and 531 µg/kg for low to high dose groups 
respectively) or amorphous-1 powder (2.60, 18.9, 213 and 2350 µg/kg 
respectively). 4.16B: rats administered amorphous-2 powder (0.653, 4.00, 
22.4, 36.3 and 364 µg/kg respectively) or nebulised GSK-899 (1.30, 22.6, 280 
and 844 µg/kg respectively; “intermediate dose” designation not applicable). 
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Figure 4.17: GSK-899 concentrations in plasma sampled from rats after a 
single inhaled dose (Study R30820N). Rats inhaled an aerosol of crystalline, 
amorphous or aqueous (nebulised) GSK-899 for 30 minutes. Mean GSK-899 
concentrations with standard deviations (error bars; n=3) are shown for plasma 
samples taken as soon as practicable (approximately 20 minutes) after 
inhalation exposure (0.5h) and at 1.5 and 4.5 hours (1 and 4 hours post 
exposure). * indicates concentrations were below the limit of quantification 
(<0.05 ng/mL). 4.17A: rats administered crystalline GSK-899 (308 and 
532 µg/kg for high-intermediate and high dose groups respectively) or 
amorphous-1 powder (215 and 2340 µg/kg respectively). 4.17B: rats 
administered amorphous-2 powder (34.6 and 363 µg/kg respectively) or 
nebulised GSK-899 (282 and 840 µg/kg respectively). 
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4.18B: Amorphous-1 
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4.18C: Amorphous-2 
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4.18D: Nebulised 
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Figure 4.18: Neutrophils in bronchoalveolar lavage fluid, relative to 
controls, harvested from an acute lung inflammation model in rats 
administered GSK-899 (Study R30820N). Rats (n=6/dose) were exposed to 
an aerosol of GSK-899 or vehicle (control) for 30 minutes and then challenged 
with lipopolysaccharide (LPS) by intratracheal instillation; a control group for 
baseline data was instilled with phosphate buffered saline (PBS; n=4). Four 
hours post challenge, rats were euthanized and lungs lavaged with saline to 
harvest neutrophils. Neutrophils (expressed as net proportion of leukocytes for 
each rat, i.e. less mean count for PBS-challenged controls, and relative to 
LPS-challenged controls) were plotted against log10 dose of GSK-899. 
Individual data, a linear regression line and the corresponding 95% confidence 
interval (dotted lines) are plotted for each aerosol form. 4.18A: crystalline 
doses: 1.07, 18.4, 305 and 533 µg/kg. 4.18B: amorphous-1 doses: 2.58, 12.5, 
210 and 2349 µg/kg. 4.18C: amorphous-2 doses: 0.658, 3.95, 37.7, 366 and 
915 µg/kg. 4.18D: nebulised doses: 1.28, 22.7, 279 and 845 µg/kg.  
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Design C: lung concentrations of GSK-899 after inhaled administration 
of each aerosol form increased with dose, with clear separation of the 
doses (Figure 4.19). Lung concentrations for rats inhaling amorphous or 
nebulised GSK-899 were generally similar for a given dose and lower 
than that for the corresponding dose of crystalline GSK-899. These 
findings are consistent with results described in Chapter 2. 
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Figure 4.19: GSK-899 concentrations in lung homogenate sampled from 
rats after a single inhaled dose (Study R31763N). Rats inhaled an aerosol 
of crystalline, amorphous or aqueous (nebulised) GSK-899 for 30 minutes. 
Mean GSK-899 concentrations with standard deviations (error bars; n=3) are 
shown for lung homogenate samples taken as soon as practicable 
(approximately 20 minutes) after the inhalation exposure. 
GSK-899 concentrations in plasma were only quantifiable (>0.05 ng/mL) 
in samples taken immediately following administration of amorphous or 
nebulised GSK-899 at the highest administered dose of 1000 µg/kg 
(Figure 4.20). GSK-899 was not quantifiable in plasma samples taken 
approximately 20 minutes later, during exsanguination of animals for 
lung sampling. Systemic exposure of rats to GSK-899 was therefore 
lower than that apparent for GSK-677. 
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Figure 4.20: GSK-899 concentrations in plasma sampled from rats after a 
single inhaled dose (Study R31763N). Rats inhaled an aerosol of crystalline, 
amorphous or aqueous (nebulised) GSK-899 for 30 minutes. Mean GSK-899 
concentrations with standard deviations (error bars; n=3) are shown for plasma 
samples taken immediately post inhalation exposure; all plasma samples taken 
during exsanguination (approximately 20 minutes later) were not quantifiable. 
* indicates concentrations below the limit of quantification (<0.05 ng/mL). 
The 95% confidence limits of ED50 determined from GSK-899 dose 
responses for reduction of neutrophils in BALF (Table 4.13) were 
considerably narrower than confidence limits for GSK-677 (Table 4.12). 
The ED50 values for GSK-899 aerosols were notably lower than for 
GSK-677 and outside the confidence limits for GSK-677 (and vice versa) 
indicating a significant difference between the two compounds. 
The ED50 for amorphous-1 GSK-899 was six-fold higher than for the 
amorphous-2 batch, with confidence limits also indicating a significant 
difference between aerosols generated from amorphous batches. This 
trend was anticipated given differences in the aerosol particle size 
distribution and hence a potential difference in lung deposited dose. The 
ED50 for nebulised amorphous-2 was also significantly lower than for 
nebulised GSK-899 but the confidence limits and ED50 values for each 
aerosol form overlapped sufficiently to preclude a clear ranking relative 
to crystalline GSK-899. 
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Table 4.13: Estimated inhaled dose of GSK-899 to achieve  
50% reduction (ED50) in inflammation endpoints evaluated  
using an acute lung inflammation model in rats 
Parameter 
and medium 
Presentation 
of GSK-677 
ED50 
estimate 
(µg/kg) A 
95% confidence 
interval (µg/kg)  
ED50 
outside 
dose 
range? lower upper 
Neutrophils 
(4h) BALF 
crystalline 23.38 3.54 95.28 No 
amorphous-1 65.88 15.23 292.8 No 
amorphous-2 10.08 0.86 44.52 No 
nebulised 44.66 15.79 114.6 No 
Notes 
A ED50 values extrapolated from net data (mean value for PBS control 
deducted from result for LPS-challenged animal) expressed relative to 
the mean of LPS-challenged controls (see Figures 4.18). 
4.3.5. Pulmonary and systemic exposure of rats to 
GSK-361 and inhibition of inflammation (Design D) 
Concentrations of GSK-361 in lungs (Figure 4.21) and plasma 
(Figure 4.22) after aerosol administration increased with dose. The lung 
concentrations measured in rats administered crystalline GSK-361 were 
higher than for the corresponding nebulised dose, in line with results 
described in Chapter 2. Separation of GSK-361 exposure in rats for the 
doses was less pronounced than for GSK-677 and GSK-899. GSK-361 
was not quantifiable in lung (<30 ng/g lung tissue) for nebulised doses 
≤30 µg/kg or plasma (<5 ng/mL) for either aerosol form at these doses. 
Where quantifiable (doses ≥300 µg/kg), plasma concentrations of 
GSK-361 for each aerosol form were similar at the time rats were 
removed from the inhalation exposure chamber and at euthanasia for 
lung sampling (Figure 4.22). 
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Figure 4.21: GSK-361 concentrations in lung homogenate sampled from 
rats after a single inhaled dose (Study R31765N). Rats inhaled an aerosol 
of crystalline or aqueous (nebulised) GSK-361 for 30 minutes. Mean GSK-361 
concentrations with standard deviations (error bars; n=3) are shown for lung 
homogenate samples taken as soon as practicable (approximately 20 minutes) 
after the inhalation exposure. * indicates concentrations were below the limit of 
quantification (<30 ng/g). 
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Figure 4.22: GSK-361 concentrations in plasma sampled from rats after a 
single inhaled dose (Study R31765N). Rats inhaled an aerosol of crystalline 
or aqueous (nebulised) GSK-361 for 30 minutes. Mean GSK-361 
concentrations with standard deviations (error bars; n=3) are shown for plasma 
samples taken immediately after inhalation exposure and during 
exsanguination for lung tissue sampling (approximately 20 minutes later). * 
indicates concentrations were below the limit of quantification (<5 ng/mL). 
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Suppression of LPS-induced inflammation was evident with an increase 
in inhaled dose for each of the aerosol forms of GSK-361 (Figure 4.23). 
Neutrophil counts were most variable at the lowest dose, when relative 
neutrophil counts were highest, and least variable at the highest dose. 
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Figure 4.23: Neutrophils in bronchoalveolar lavage fluid, relative to 
controls, harvested from an acute lung inflammation model in rats 
administered GSK-361 (Study R31765N). Rats (n=6/dose) were exposed to 
an aerosol of GSK-361 or vehicle (control) for 30 minutes and then challenged 
with lipopolysaccharide (LPS) by intratracheal instillation; a control group for 
baseline data was instilled with phosphate buffered saline (PBS; n=6). Four 
hours post challenge, rats were euthanized and lungs lavaged with saline to 
harvest neutrophils. Neutrophils (expressed as net proportion of leukocytes for 
each rat, i.e. less mean count for PBS-challenged controls, and relative to 
LPS-challenged controls) were plotted against log10 dose of GSK-361. 
Individual data, a linear regression line and the corresponding 95% confidence 
interval (dotted lines) are plotted for each aerosol form. 4.23A: Crystalline 
doses: 3.52-4.61, 28.1-31.1, 282-283 and 883-958 µg/kg. 4.23B: Nebulised 
doses: 3.51-4.17, 10.5-36.1, 236-100 and 1006-1232 µg/kg.  
The 95% confidence limits of ED50 determined from GSK-361 dose 
responses for reduction of neutrophils in BALF (Table 4.14) were 
narrower than the confidence limits for GSK-677 (Table 4.12) and 
broader than those for GSK-899 (Table 4.13). ED50 values determined 
for the two aerosol forms of GSK-361 were similar despite differences in 
the lung concentrations following inhaled administration of the crystalline 
and nebulised aerosols. The ED50 values for GSK-361 ranked between 
GSK-677 and GSK-899, with confidence intervals indicating a significant 
difference between GSK-361 and GSK-899. 
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Table 4.14: Estimated inhaled dose of GSK-361 to achieve  
50% reduction (ED50) in inflammation endpoints evaluated using an 
acute lung inflammation model in rats 
Parameter 
and medium 
Presentation 
of GSK-677 
ED50 
estimate 
(µg/kg) A 
95% confidence 
interval (µg/kg)  
ED50 
outside 
dose 
range? lower upper 
Neutrophils 
(4h) BALF 
Crystalline 172.2 79.4 476.5 No 
Nebulised 164.6 45.4 1595.7 No 
Notes 
A ED50 values extrapolated from net data (mean value for PBS control 
deducted from result for LPS-challenged animal) expressed relative to 
the mean of LPS-challenged controls (see Figure 4.23). 
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4.4. Conclusion 
The objectives of this chapter were to assess the efficacy of three p38 
MAPK inhibitors using a non-clinical model for the prophylactic inhibition 
of LPS-induced acute lung inflammation. Following review of preliminary 
data for neutrophil counts in BALF, additional biomarkers for 
inflammation were incorporated into experiments for evaluation. 
Optimisation of the exposure route used for LPS challenge using small 
numbers of rats (n=3/treatment) indicated that, for the administered 
doses, successful intratracheal instillation of the antigen achieved a 
higher and more consistent increase in neutrophils in BALF within a 
dosing session than for the more diffuse delivery achieved by inhalation 
exposure. However, a successful outcome was dependent upon the 
operator being able to ensure the catheter was placed within the trachea 
and not the oesophagus before dispensing the dose volume of LPS. 
Key experiments were designed to compare endpoints such as 
neutrophil counts in BALF versus biomarkers for neutrophils in lung 
sections. However, given the total number of animals required for each 
experiment and the time taken to perform the required procedures for 
each animal, it was necessary to design each experiment with 
sub-groups treated on consecutive days. Aerosol delivery and hence 
inhalation exposure procedures are more susceptible to day-to-day 
variability in delivered doses than exposure routes simply dispensing 
measured volumes of liquid (oral gavage or parenteral injection). Whilst 
temporal variability has little impact for assessing changes after 
repeated administration (changes related to mean doses), the potential 
for data variability is higher for cohorts of single inhaled doses. 
Experiments were therefore designed with sub-groups of animals for 
each treatment (BALF sampling or lung histology) administered a 
common aerosol on one of two days such that potential differences in 
lung deposited doses of p38 MAPK inhibitors would not bias the results 
for one of the principal endpoints under investigation. 
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Data variability was evident for the neutrophil counts in BALF taken from 
control rats challenged with LPS (Designs A, B and D). Experiments 
were modified (Designs C and D) to determine if lung image analysis of 
CAE-stained neutrophils in LPS-treated control rats showed a similar 
pattern of variability to that observed for neutrophil counts in BALF (data 
not available at thesis submission). If data variability had proven to be of 
a temporal nature then this would illustrate the importance of prioritising 
variables and minimising parameters to accommodate all procedures 
within a series of succinct experiments, each with its own control group. 
Results described in Chapter 2 were used to rank the systemic (plasma) 
and lung exposure of rats to p38 MAPK inhibitors in terms of the AUC 
over 24 hours and Cmax after a single inhalation exposure (Table 4.15). 
Drug-lung and plasma concentrations of p38 MAPK inhibitors measured 
in rats exposed concurrently with animals used to evaluate efficacy 
(challenged with LPS) were consistent with these rankings of Cmax. 
Table 4.15: Ranking of the exposure of rats to p38 MAPK inhibitors 
following a single inhaled administration 
Sample 
medium 
Pharmacokinetic 
parameter 
Ranking of p38 MAPK inhibitors 
Lungs AUC0-t GSK-899 > GSK-361 > GSK-677 
Cmax crystals GSK-899 > GSK-361 > GSK-677 
 nebulised GSK-899 > GSK-677 > GSK-361 
Plasma AUC0-t GSK-361 > GSK-899 > GSK-677 
Cmax GSK-361 > GSK-677 > GSK-899 
For a drug to be efficacious, it must be available at the target receptor or 
site of action. p38α MAPK is expressed in the cytoplasm and nucleus of 
cells (Cuenda and Rousseau, 2007) in the airway smooth muscle, 
respiratory epithelium and immune system (Williams et al., 2008, Mayer 
and Callahan, 2006). The median effective dose (ED50) extrapolated 
from the linear regression lines of dose responses for suppression of 
neutrophils in BALF ranked the compounds GSK-899 < GSK-361 < 
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GSK-677, with a significant difference between GSK-899 and the other 
compounds. This was consistent with the higher lung concentrations of 
GSK-899 measured post exposure, i.e. at the time of LPS challenge. 
However, similar lung concentrations of GSK-361 (crystalline) and 
GSK-677 (both forms) and their less significant ranking of ED50 allude to 
potential implications for physicochemical properties of a drug to 
enhance or impair access of a molecule to the pharmacological target. 
It could be hypothesised a receptor in the cytoplasm or nucleus (p38 
MAPK) is more accessible to a membrane permeable molecule 
(GSK-361) than a readily soluble molecule (GSK-677).  
Table 4.16: Estimated inhaled doses of p38 MAPK inhibitors to achieve 
50% reduction (ED50) in inflammation endpoints evaluated using an 
acute lung inflammation model in rats 
Parameter 
and medium 
Compound Aerosol form 
ED50 
estimate 
(µg/kg)  
95% confidence 
interval (µg/kg)  
lower upper 
Neutrophils 
(4h) BALF 
GSK-899 
crystalline 23.38 3.54 95.28 
amorphous-1 65.88 15.23 292.8 
amorphous-2 10.08 0.86 44.52 
nebulised 44.66 15.79 114.6 
GSK-677 
crystalline 366 95.5 5744 
nebulised 356 102 4356 
GSK-361 
crystalline 172 79.4 476.5 
nebulised 165 45.4 1596 
CAE stain 
(4h) lung 
GSK-677 
Crystalline 42701 AB 286 NC  
Nebulised 126 A 40.4 714 
Notes 
A ED50 values extrapolated from net data (mean value for PBS control 
deducted from result for LPS-challenged animal) expressed relative to 
the mean of LPS-challenged controls (see Figures 4.16 to 4.19).  
B 95% confidence limits increase dramatically when the extrapolated 
ED50 was outside the evaluated range of estimated inhaled doses. 
NC Not calculable 
A significant decrease in aerosol particle size (MMAD) with an increase 
in lung concentration for amorphous GSK-899 was consistent with an 
increase in ED50. However, the variability of data indicated by the 95% 
confidence limits precluded clear ranking of all aerosol forms of 
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GSK-899, and limited general conclusions with regards to ranking of the 
compounds. 
Measurements of TNFα in serum and BALF showed high variability and 
appeared unsuitable for evaluating a dose response for inhibition of 
acute lung inflammation in the rat model used. It is noteworthy that, for 
the three administered volumes of lavageate (5 mL/lavage), mean 
recoveries of 58%, 76% and 80% were achieved for successive cycles. 
Although the lung lobes were massaged prior to removal of each BALF 
volume, retention of fluid from the first lavage cycle in the distal lung may 
potentially impair access of successive volumes of lavageate to the distal 
lung and/or poor mixing of the administered and residual lavageates may 
give rise to incomplete sampling of TNFα and neutrophils from the lower 
respiratory tract. 
Schneider et al. (1997) described a method for determining neutrophil 
counts in BALF based upon the enzymatic activity of MPO. However, a 
high baseline achieved for immunostaining of MPO (even after redaction 
of CD68-positive areas, i.e. macrophages) indicated this biomarker 
lacked sufficient specificity for identifying neutrophils in rat lung sections 
without further method development. Standalone image analysis results 
for CAE-stained lung sections from rats exposed to GSK-677 were 
equivocal. However, results for rats exposed to GSK-899 or GSK-361 
(Appendix 10) subsequently confirmed CAE also lacked sufficient 
specificity to identify neutrophils in rat lung sections (no obvious 
inhibitory dose response; 95% confidence limits not calculable). 
This chapter describes experiments undertaken to characterised the 
efficacy of three p38 MAPK inhibitors using a rat model for acute lung 
inflammation, when administered as nebulised solutions, amorphous 
(GSK-899) or crystalline dry powder formulations. Key conclusions of 
experiments described in this chapter are: 
• The observed variability in biomarkers limited the conclusions that 
could be drawn from the data. Nevertheless, attempts to stain 
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histology sections of lung for biomarkers of neutrophils produced 
insufficient contrast for quantitative image analysis. Assessment 
of acute lung inflammation by counting neutrophils in BALF, 
although variable, was thus the best of the biomarkers evaluated. 
• A larger particle size of amorphous GSK-899 (MMAD ≥3.8 µm 
versus 2.1 µm) and hence a less respirable aerosol resulted in a 
less effective dose (higher ED50). Differences in drug particle size 
and hence the lung deposited dose therefore modulated drug 
efficacy for inhibition of acute lung inflammation. 
• The median effective dose (ED50) for suppression of neutrophils 
in BALF ranked compounds GSK-899 < GSK-361 < GSK-677, 
with confidence limits indicating a significant difference between 
GSK-899 and the other compounds. 
• ED50 values were similar for respective nebulised and crystalline 
aerosol forms of GSK-361 (high passive membrane permeability) 
and GSK-677 (high solubility). However, dry powder formulations 
of GSK-899 were more effective at four hours post LPS-challenge 
(ED50 values lower) than for a nebulised solution consistent with 
an increased lung residence time (Hastedt et al., 2016). 
• GSK-899, a drug of relatively low solubility and consequently 
more persistent in lung tissue, inhibited LPS-induced lung 
inflammation more effectively than GSK-361 (low solubility; high 
passive membrane permeability) and GSK-677 (high solubility). 
Image analysis could potentially facilitate quantification of LPS-induced 
acute lung inflammation in histological sections but identification of a 
robust biomarker of neutrophils and development of histology methods 
is required to achieve the tighter confidence limits necessary for a more 
robust ranking of p38 MAPK inhibitors and aerosol forms for efficacy. In 
addition, comparison of lung sections stained for such a biomarker of 
neutrophils from rats administered a p38 MAPK inhibitor with or without 
being sampled for BALF four hours post LPS-challenge would indicate 
the efficiency with which neutrophils are harvested from lungs by lavage. 
  
 
CHAPTER FIVE 
Toxicopathology of p38 mitogen-
activated protein kinase inhibitors 
in rats after inhalation of fixed 
doses for 28 days
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5.1. Introduction 
Non-clinical studies performed to characterise the general toxicology of 
candidate drugs typically administer compounds via the clinically 
relevant route, i.e. the anticipated exposure route for dosing humans. 
However, inhaled administration of drugs to laboratory animals 
consumes large masses of test material, relative to other exposure 
routes. This is especially true of conventional inhalation exposure 
systems used for presentation of dry powder aerosols, in which airflow 
is normally operated dynamically without recycling the test aerosol. A 
proportion of the particulate impacts or sediments within the exposure 
system. Furthermore, published estimates of the lung deposited dose 
indicate that only 7% to 10% of an inhaled aerosol of 2 µm 
aerodynamic diameter is deposited in the lungs of rats (Snipes, 1989, 
Jones and Baldrick, 2013). This is in stark contrast to the 
straightforward administration of drugs orally or via parental routes 
involving injection, which permits precise delivery of dose volumes with 
little wastage of the liquid formulation. 
The pharmaceutical industry is coming under increasing pressure to 
reduce the cost of developing new drugs and, by implication, 
minimising expenditure associated with early development of candidate 
drugs that subsequently fail to achieve regulatory approval. In early 
drug development, synthesis of a candidate drug is performed on a 
small scale at relatively high cost. In 2016, it took 6 to 9 months and a 
cost of £200,000 to £300,000 to synthesise approximately 30g of drug 
to support doses of ≤2.3 mg/kg/day for the first inhalation toxicity 
studies of a respiratory drug in rats (28 days treatment) and dogs 
(14 days treatment). Less than 4% of this amount of drug would have 
been required to dose these animals orally (conservative estimate from 
unpublished data). The use of surrogate exposure routes and/or 
formulations (differing from intended clinical presentation) to reduce 
compound usage and thereby expedite preliminary evaluation of drugs 
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to “first time in humans” (FTIH) would thus be attractive if effective. 
However, such strategies defer de-risking potentially altered tolerability 
or toxicopathology of the final formulation and dose route until later in 
development. 
The requirement for pre-market testing of pharmaceuticals as evidence 
of safety for new drugs was enacted in US legislation in 1938 (Kille, 
2013) and was formally instigated in the United Kingdom following 
outcry over birth defects following the prescription of thalidomide to 
pregnant mothers in the late 1950s and early 1960s (MHRA, 2012). 
Today, the International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH) maintains 
oversight of its safety guidelines outlining investigations to generate 
comprehensive datasets to satisfy regulatory requirements for market 
approval of drugs. Experimental designs based on such guidance 
continue to evolve within pharmaceutical and contract research 
organisations. 
The principals of reduction, refinement and replacement of the use of 
animals in scientific research (3Rs) are fundamental to the ethical 
review process and regulation of in vivo experiments (Festing and 
Wilkinson, 2007). However, the most complete assessments of 
pulmonary drug delivery, efficacy and toxicity are still provided by in 
vivo investigations (Fernandes and Vanbever, 2009). Understanding 
the relationship between endpoints for in vitro and in vivo experiments 
and the extent to which the former can predict the latter are thus key to 
implementation of the 3Rs. 
Haematoxylin (Titford, 2005) and eosin (Bancroft and Cook, 1994) 
were first used for dying fabrics in the early 1500s and 1875 
respectively. Amateur microscopists started using these dyes in the 
mid-1800s to stain cellular components, which was a milestone in 
medical research because the two stains have become the main 
diagnostic technique for histopathologists today (Bancroft and Cook, 
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1994); haematoxylin stains basophilic substances blue (e.g. calcified 
structures, DNA in the nucleus and RNA in the endoplasmic reticulum) 
and eosin is a pink counter stain that binds to acidophilic moieties such 
as lysine or arginine side chains in proteins, which are prevalent in 
tissue fibres and the cytoplasm. Other histological stains or techniques 
such as immunohistochemical staining of clusters of differentiation may 
be used to determine the phenotypes of inflammatory cells seen in 
section (Saetta et al., 1999, Fehrenbach et al., 2003). 
Although histopathology evaluation of tissues is the ‘gold standard’ for 
evaluating toxicopathology, an understanding of dosimetry, exposure 
and fate of a test article are also key to understanding the context for 
toxicopathology findings, particularly when comparing formulations or 
compounds. For example, the severity or potential absence of a lesion 
observed histopathologically could be a function of differences in the 
achieved dose, systemic exposure and/or the rate of elimination of a 
compound from the affected tissue. 
Experiments described in this chapter were designed with reference to 
a generic protocol designed to investigate the general toxicity of 
pre-candidate drugs in rodents. Unpublished toxicopathology data in 
rats administered crystalline GSK-899 (Freke, 2010) or GSK-677 
(Freke, 2007) were used to select suitable doses for the in vivo toxicity 
studies. 
5.1.1 Aims and objectives 
Using three p38 MAPK inhibitors of differing physicochemical 
properties, the experimental aims of this chapter are to: 
• Investigate the potential cellular toxicity, release of inflammatory 
cell mediators and particle uptake by macrophages in vitro. 
• Determine histopathological changes in the respiratory tract of 
rats administered one of three p38 MAPK inhibitors for 28 days. 
• Determine the systemic (plasma) and lung exposure of each 
p38 MAPK inhibitor in rats after single and repeated exposure. 
Chapter Five 
245 
 
• Investigate the particle uptake of macrophages in vivo, following 
inhaled administration of three p38 MAPK inhibitors for 28 days 
By comparing the data generated following administration of the p38 
MAPK inhibitors as nebulised solutions or dry powder aerosols, the 
following hypotheses will be tested: 
• Changes in aerosol presentation to rats will affect exposure of 
tissues and systemic absorption of the drug, resulting in 
modulation of toxicopathology after repeated administration due 
to pulmonary drug clearance or persistence/accumulation.  
• Differences in physicochemical properties between compounds 
may affect drug-lung clearance or compartmentalisation of a 
drug in cells or fluid compartments within the respiratory tract, 
which in turn influence adaptive changes (e.g. lung clearance) 
and/or toxicopathology following repeated administration. 
It is anticipated that results of these investigations will contrast the 
toxicopathology of molecules with differing physicochemical properties 
and illustrate potential limitations of using surrogate formulations. 
Increased understanding of such limitations could optimise 
experimental design in early non-clinical development of inhaled drugs.  
Chapter Five 
246 
 
5.2. Materials and methods 
5.2.1. Test articles 
The p38 MAPK inhibitors were supplied by GSK as micronised crystals 
and stored at ambient temperature, protected from light and moisture 
(Table 5.1). 
Table 5.1: Purity of p38 MAPK inhibitors used for repeated 
administration to rats 
Test article Salt form Purity In vivo study numbers 
GSK258899B mesylate 
95.4%, 98.7% R29413 
98.7% R29739 
95.4% 
R30353N, R30662N, R31038N, 
R31039N 
95.5% R31697N, R31711N 
GSK610677B hydrochloride 98.5% R31037N, R31038N 
GSK678361A parent 99.7% R31034N, R31035N, R31036N 
SB-681323T tosylate 99.6% n/a 
Amorphous GSK-899 was produced by spray drying a saturated 
solution of GSK-899 (prepared from micronised crystals) in methanol. 
The amorphous state of the resultant material was confirmed by X-ray 
powder diffraction analysis (XRPD; Chapter 2, Section 2.3.2). 
5.2.2. In vitro cytotoxicity and morphology of NR8383 rat 
macrophage cells incubated with particles 
The NR8383 cell line was established from normal alveolar 
macrophages obtained from Sprague Dawley rats by bronchoalveolar 
lavage (Helmke et al., 1987, Helmke et al., 1989) and obtained from 
American Type Culture Collection (ATCC, Manassas, USA) care of 
LGC (Middlesex, UK).  
The NR8383 cells were grown in Kaighn’s modification of Ham’s F12 
medium (Kaighn et al., 1981) with 2mM glutamine, supplemented with 
15% heat-inactivated foetal bovine serum (Invitrogen catalogue 
number 10108-157) and 100 units/mL penicillin and 100 µg/mL 
streptomycin serum (Invitrogen catalogue number 15140-122). The 
cells were incubated in T75 cm2 (20 mL) or T175 cm2 (50 mL) tissue 
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culture flasks, which were maintained at 37ºC in a humidified 
atmosphere containing 5% CO2; cell culture media was changed twice 
weekly. Approximately 0.5 ×105 cells/mL were seeded (40 mL into a 
T175 cm2 flask), of which approximately half adhered to the flask and 
half remained as a floating population of cells.  
5.2.2.1. Treatment of cells to investigate cytotoxicity and 
release of inflammatory cell mediators 
Cytotoxicity was assessed by measurement of the enzymatic activity of 
lactate dehydrogenase (LDH) in the extracellular medium. LDH is a 
cytosolic enzyme and leakage of the enzyme into the medium is an 
indication of cell membrane damage (Fotakis and Timbrell, 2006). All 
treatments (p38 MAPK inhibitor concentrations and controls) were 
performed in triplicate. 
Cells were seeded into wells (48-well tissue culture plates (Costar™ 
3548); 6 ×104 cells in 125 µL), incubated for two to four hours. An equal 
volume of medium containing p38 MAPK inhibitor was added (typically 
six concentrations to cover a range of 6.25 to 400 µg/mL) and the 
treated cells were incubated for 72 hours.  
Controls were similarly treated, by addition of an equal volume of 
media alone (negative control) or appropriate reagent in media 
(positive control) as follows: 
• Untreated control (addition of media only at 0 hours). 
• Triton X-100 (catalogue number T9284; Sigma Aldrich, Dorset, 
UK): positive control for LDH (cytotoxicity). Triton X-100 was 
added to cells at 71.5 hours to achieve a final concentration of 
0.1% (v/v), to solubilise cellular membranes and release 
intracellular lactate dehydrogenase into the media. 
• Lipopolysaccharide (catalogue number L2654-1MG; Sigma 
Aldrich, Dorset, UK): positive control for cytokine/chemokine 
release. Lipopolysaccharide was added to cells at 0 hours to 
achieve final concentrations of 5 and 10 ng/mL. 
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On completion of the 72-hour treatment period, the 48-well plates were 
centrifuged (805×g for 10 minutes) and aliquots of 50 µL supernatant 
were transferred to flat-bottomed 96-well plates for LDH analysis. 
Remaining supernatant (approximately 200 µL) was transferred to 
wells in a ‘v-bottomed’ 96-well plate for analysis of cytokines. The 
pelleted cells were lysed at room temperature with addition of 250 µL of 
cell lysis agent (CelLytic™ Sigma C2978) for 15 minutes. The 48-well 
plates were then centrifuged (805×g for 10 minutes) and aliquots of 
50 µL supernatant were transferred to flat-bottomed 96-well plates for 
measurement of total LDH from the lysed cells. 
5.2.2.2. Analysis of cytotoxicity by measurement of lactate 
dehydrogenase leakage from treated cells 
LDH in the media supernatant was analysed using a colourimetric 
technique. A reaction mixture was prepared in accordance with the 
protocol supplied with the Cytotoxicity Detection Kit (Roche, 2016) and 
50 µL transferred to each well. The media-reaction mixture stood for 
30 minutes at room temperature, protected from light, and was then 
transferred to a cuvette and the absorbance of the sample was 
measured at wavelength 490 nm using a Spectramax absorbance plate 
reader (wavelength correction applied at 650 nm). 
The proportion of LDH leaking from the NR8383 cells was calculated 
using the following equation: 
𝐿𝑒𝑎𝑘𝑒𝑑 𝐿𝐷𝐻 (%) = [
𝐿𝐷𝐻 − 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
100 − 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
] × 100 …… Equation 4 
The median effective concentration (EC50) was extrapolated from the 
dose response curve, which was scaled for a maximum response value 
of 100% relative to the total LDH value determined for the lysed cells.  
p38 MAPK inhibitors were categorised for their potential cellular toxicity 
as low risk (EC50 >100 µg/mL), medium risk (EC50 of 10 to 100 µg/mL) 
or high risk (EC50 <10 µg/mL). Categorisation of compounds as low or 
medium risk was made with reference to a threshold of 100 µg/mL, 
representing a maximum theoretical drug concentration in rat epithelial 
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lung fluid to cover a clinical dose of 1 mg. This was derived from a 
published estimate of the volume of epithelial lung fluid in rats (Cheng 
et al., 1995), an assumed body weight of 350 g and reference dose of 
0.6 mg/kg to cover a nominal clinical dose of 1 mg/kg (rationale defined 
in Chapter 2, Section 2.2.4). The “high risk” category was based upon 
unpublished in vivo data indicating foamy macrophages are more likely 
to occur in animals retaining more than 10% of the lung deposited dose 
at 24 hours post exposure. 
5.2.2.3. Analysis of inflammatory cell mediators 
The remaining supernatant prepared at 72 hours was centrifuged 
(340×g for 5 minutes) to remove debris, and the resultant supernatant 
aliquoted into a 96-well plate. A duplicate plate was prepared as a 
contingency for repeat analysis. The plates were stored at -80ºC or 
colder pending quantification of cytokines/chemokines using the 
multiplex Meso Scale Discovery (MSD) protocol supplied with the kit 
(Plate Catalogue Number N75CA-1) for the following parameters: 
• Interleukins: IL-1α and IL-1β 
• Tumour necrosis factor (TNF) 
• Chemokine: CXCL1 (C-X-C motif, ligand 1) otherwise known as 
keratinocyte chemoattractant (KC) or growth-regulated 
oncogene (GRO) 
• MCP-1 (monocyte chemotactic protein 1) 
5.2.2.4. Treatment of cells to investigate cell morphology 
Cells were seeded into wells (six-well tissue culture plates (Costar™ 
3506); 7.6 ×105 cells in 1.5 mL), incubated for two to four hours. An 
equal volume of medium containing p38 MAPK inhibitor was added 
(final concentrations of 50 or 400 µg/mL) and the treated cells were 
incubated for 72 hours. Controls were similarly treated, by addition of 
an equal volume of media alone (untreated control) or chloroquine 
diphosphate (final concentration 10 µg/mL; catalogue number C6628; 
Sigma Aldrich, Dorset, UK) as a positive control for phospholipidosis. 
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On completion of the 72-hour treatment period, cells were harvested 
from the six-well plates by gently scraping the cells using a plunger 
from a syringe and then transferring the cells to a 15 mL tube. The 
contents of replicate wells for a given treatment were pooled. The 
harvested cells were centrifuged (340×g for five minutes) and the 
supernatant discarded. The cells were resuspended and fixed in 1 mL 
of phosphate buffered 4% formaldehyde with 1% glutaraldehyde and 
the cells processed for transmission electron microscopy. 
5.2.2.5. Processing cells for examination of morphology by 
transmission electron microscopy 
Cells fixed in 4% formaldehyde and 1% glutaraldehyde (v/v) were 
transferred to a 1.5 mL eppendorf tube and centrifuged. For each of the 
washings or manipulations stated below, the supernatant was carefully 
removed (by pipette) and discarded, taking care not to disturb the pellet 
of cells, and approximately 1 mL of reagent was added.  
The fixed cells were washed with three changes of Millonig’s 
phosphate buffer (Millonig, 1961), which was prepared as follows: 
Stock solutions of 2.26% (w/v) sodium dihydrogen 
orthophosphate (NaH2PO4) in distilled water, and 2.52% (w/v) 
sodium hydroxide (NaOH) in distilled water were prepared and 
stored refrigerated (approximately 4ºC for up to three months). 
Millonig’s phosphate buffer was prepared by mixing 83 mL of 
2.26% (w/v) NaH2PO4, 17 mL of 2.52% NaOH, 10 mL of distilled 
water and 0.54g of sucrose. The resultant formulation was 
mixed well and accepted for use if pH was within 7.0 to 7.4. 
The Millonig’s phosphate buffer was carefully removed and the cells 
treated for 60 minutes with 1% aqueous osmium tetroxide (OsO4) 
reduced with 1.5 % aqueous potassium ferrocyanide (K4[Fe(CN)6]); the 
reaction mixture was prepared shortly before use by mixing stock 
solutions (1:1 v/v) of 2% (w/v) OsO4 and 3% (w/v) K4[Fe(CN)6]. 
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The OsO4 and K4[Fe(CN)6] reaction mixture was carefully removed and 
the cell pellet washed with two changes of distilled water (each of five 
minutes). The cells were then treated with 0.1% (w/w) aqueous sodium 
thiocarbohydrazide for 10 minutes and again washed with two changes 
of distilled water (each of five minutes). The water was removed and 
discarded, and the cell pellet treated with aqueous 1% OsO4 reduced 
with aqueous 1.5 % K4[Fe(CN)6] for 15 minutes. 
The OsO4 and K4[Fe(CN)6] reaction mixture was discarded and the cell 
pellet washed with three to four changes of distilled water, and 
dehydrated in two washes of 30% ethanol (five minutes each), one 
wash with 70% ethanol (five minutes), one wash in 90% ethanol (five 
minutes), three washes in absolute ethanol (10 minutes each) and two 
washes in dried acetone (each of five minutes; moisture was removed 
from acetone through storage over a molecular sieve). 
The acetone was discarded and cell pellet was treated with 50% Agar 
100 resin (product code AGR1031; Agar Scientific Ltd, Essex, UK) in 
acetone (v/v) for two hours, 80% Agar 100 resin in acetone (v/v) 
overnight, and then four changes of 100% Agar 100 resin for a total 
period of at least seven hours. The resin embedded cells were then 
cured in an oven at 65ºC for 24 hours. 
Preparation of slides and transmission electron microscopy 
Sections approximately 1 µm thick were cut using a microtome and 
stained with 1% toluidine blue in 1% aqueous sodium 
tetraboratetoluidine (w/w/v) and examined by light microscopy to locate 
areas of interest for electron microscopy. Ultra-thin sections (80 to 
90 nm thick) were then prepared, stained with 0.5% uranyl acetate and 
3% lead citrate using an automated grid stainer and examined using a 
Hitachi H7500 transmission electron microscope (TEM), operated at 
80KV. The AMT XR41 Digital Camera System was used to capture 
representative TEM digital images and 100 cells were assessed for 
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morphological changes including vacuolation. Representative images 
of the macrophages are shown in Section 5.3. 
5.2.3. Investigating the toxicopathology and exposure of 
inhaled p38 MAPK inhibitors in rats 
In order to investigate the toxicopathology of p38 MAPK inhibitors in 
the respiratory tract of rats and to put potential findings in context with 
concomitant pharmacokinetics, groups of rats were administered fixed 
‘doses’ of the test aerosol, once daily by snout-only inhalation 
exposure, for up to 28 consecutive days (Figure 5.1). 
 
Figure 5.1: Generic outline of experimental design to investigate 
pulmonary toxicology following inhaled administration of p38 MAPK 
inhibitors for 28 days. Rats (n=6/dose) inhaled a p38 MAPK inhibitor (dry 
powder or aqueous formulation) or vehicle (control) for 1 hour daily for 28 
days. Rats were euthanized on Day 29 and the respiratory tract was 
preserved in formalin for histological processing and examination by light 
microscopy. Satellite groups (3 rats/dose/timepoint) were sampled for plasma 
and lung for analysis of drug concentrations after a single dose and 28 days 
of treatment (* rats administered a single dose were exposed concurrently 
with repeat dose animals on Day 28 of treatment). In most instances, an 
additional rat for each aerosol form was treated for 3 days and euthanized 
(Day 4) for bronchoalveolar lavage (BAL) of lungs with saline to harvest 
macrophages for examination by transmission electron microscopy (TEM). 
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Blood and tissue samples were obtained for three key investigations as 
follows: 
• Toxicopathology changes in the respiratory tract after 28 days of 
treatment, with reference to a vehicle control (n = 6 rats/group). 
• Systemic exposure measured in rat plasma sampled post 
exposure on Days 1 and 28 of treatment (n = 3 rats/group/day). 
Drug concentrations in lungs taken as soon as practicable after 
exposure on Day 1, and 24 hours post exposure on Days 1 and 28 of 
treatment (n = 3 rats/group/timepoint). 
In addition, the lungs of a few animals at selected doses were sampled 
by bronchoalveolar lavage (BAL; flushing of lungs with saline) and the 
harvested macrophages were examined by TEM for particle uptake. 
Datasets were generated from a series of experiments, in which one of 
the p38 MAPK inhibitors (GSK-899, GSK-677 or GSK-361) was 
administered to rats as a given aerosol form, i.e. crystalline powder (or 
amorphous GSK-899) or nebulised aqueous formulation. 
5.2.3.1. Dose selections for investigating pulmonary 
toxicopathology in rats 
Target doses (≤45 mg/kg/day GSK-899) were initially selected with 
reference to unpublished toxicopathology data for inhaled GSK-899 
and then dose range studies conducted in support of this research. 
Where practicable, target doses of 1 and 15 mg/kg/day were applied 
for each p38 MAPK inhibitor for each aerosol form. Nebulised doses of 
GSK-899 and GSK-361 were limited by the relatively low solubility of 
each test article in aqueous vehicle, and the maximum practicable 
dose for these experiments was 1 mg/kg/day. A dose of 1 mg/kg/day in 
rats equated to a 17-fold overage for a nominal clinical dose of 1 mg 
with application of conservative scaling factors for lung deposition 
(Degeorge et al., 1997, Jones and Baldrick, 2013). Details of dose 
selections for each experiment are summarised below. 
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GSK-899 (crystalline): 1 and 15 mg/kg/day 
Doses of 1 and 45 mg/kg/day were initially selected for evaluation of 
crystalline GSK-899. A high dose of 45 mg/kg/day was based on 
unpublished data (Freke, 2010) and was expected to induce adverse 
(harmful) toxicopathology in rat lungs (findings consistent with 
interstitial pneumonia were seen in rats administered 49.7 mg/kg/day 
for 28 days). A low dose of 1 mg/kg/day was anticipated to be a 
non-adverse dose, i.e. a dose that does no harm to the test animals 
(Kerlin et al., 2016). 
Whilst defining compound requirements to support this research, it 
became clear insufficient GSK-899 was available to prepare the mass 
of amorphous GSK-899 required to sustain doses up to 45 mg/kg/day 
for 28 days. Dose range experiments performed using crystalline 
GSK-899 indicated toxicopathology findings at 15 or 45 mg/kg/day after 
three days were similar (Appendix 5) and a dose of 15 mg/kg/day was 
adopted as the high dose for further investigations of toxicopathology. 
GSK-899 (amorphous): 0.02, 1 and 15 mg/kg/day 
Doses of 1 and 15 mg/kg/day were selected for comparison with 
toxicopathology findings in rats administered crystalline GSK-899. A 
low dose of 0.02 mg/kg/day was included for the amorphous powder 
and represented a theoretical threshold above which accumulation of 
GSK-899 may occur, based on the solubility of GSK-899 in simulated 
lung fluid and published estimates for the volume of epithelial lung fluid 
in rats (Rennard et al., 1986). 
GSK-899 (nebulised): 1 mg/kg/day 
Nebulised doses were limited by the relatively low aqueous solubility of 
GSK-899. Rats were first exposed using a solution of GSK-899 in 3% 
(v/v) Solutol HS 15 in 10% (w/v) aqueous 2-hydroxypropyl-B-
cyclodextrin (Solutol-HPβCD). However, lung pathology changes in 
control animals examined after 28 days of treatment were ascribed to 
the vehicle and exacerbated by GSK-899. The experiment was 
repeated using another vehicle, 3% (v/v) Solutol HS 15 in 0.9% (w/v) 
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aqueous sodium chloride (Solutol-NaCl), to determine what findings 
could be ascribed to GSK-899 alone when administered in solution. 
Before undertaking this second experiment, a preparatory study was 
performed in which rats (n=6) were exposed to the latter vehicle alone 
for 14 days; an absence of lung pathology changes after 14 days of 
treatment indicated vehicle-related changes would be unlikely after 
completion of the 28-day treatment period in the main experiment. 
GSK-677 (crystalline): 1, 6.7 and 15 mg/kg/day 
Doses of 1 and 15 mg/kg/day were selected to facilitate comparison of 
systemic and lung exposure following inhaled administration of 
crystalline GSK-677 to rats, with comparable data for GSK-899. An 
intermediate dose of 6.7 mg/kg/day represented a theoretical threshold 
above which accumulation may potentially occur, again based on the 
solubility of GSK-677 in simulated lung fluid and published estimates 
for the volume of epithelial lung fluid in rats (Rennard et al., 1986). 
Additional animals were not used to evaluate the inhalation toxicity of 
crystalline GSK-677 because unpublished data (Freke, 2007) were 
available to the sponsor, citing a no observed adverse effect level of 
67.8 mg/kg/day (Table 5.22). 
GSK-677 (nebulised): 1, 6.5 and 15 mg/kg/day 
Nebulised doses of 1, 6.5 and 15 mg/kg/day were selected to compare 
systemic and lung exposure data for GSK-677 with comparable data 
for the crystalline form, and for comparison of potential toxicopathology 
findings with changes seen following administration of GSK-899 to rats. 
GSK-361 (crystalline): 0.25, 1 and 15 mg/kg/day 
Doses of 1 and 15 mg/kg/day were selected to facilitate comparison of 
potential findings in rats administered crystalline GSK-361 with the lung 
changes and exposure (drug concentrations in lung tissue and plasma) 
after administration of GSK-899 to rats for 28 days. A low dose of 
0.25 mg/kg/day was included and represented a theoretical threshold 
above which accumulation of GSK-361 may potentially occur, based on 
the solubility of GSK-361 in simulated lung fluid and published 
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estimates for the volume of epithelial lung fluid in rats (Rennard et al., 
1986). 
GSK-361 was not developed for clinical administration via the inhaled 
route. In the absence of inhalation toxicology or exposure data, a dose 
range study (R31034N) was performed in which doses of 5 or 
15 mg/kg/day were administered to groups of rats (n=4) for 14 days. 
Doses were well tolerated with no lung changes to preclude 
progression of the 28-day study (Appendix 6), i.e. no indication that an 
onset of toxicity would prevent completion of the treatment period. 
GSK-361 (nebulised): 0.25 and 1 mg/kg/day 
The high dose of nebulised GSK-361 was limited by its relatively low 
solubility in vehicle (20:20:60 (v/v/v) Solutol HS 15, ethanol and 60 mM 
phosphate buffer). Doses of 0.25 and 1 mg/kg/day were selected to 
facilitate comparison of potential lung changes and exposure in rats 
administered crystalline GSK-361 or aerosols of p38 MAPK inhibitors 
(1 mg/kg/day) at these doses. 
5.2.3.2. Investigating mechanisms of toxicopathology seen 
in rats inhaling p38 MAPK inhibitors 
Key findings for the 28-day inhalation toxicology studies included 
toxicopathology findings observed in the lungs of rats administered 
GSK-899 or GSK-677, not only as dry powder formulations but also as 
nebulised solutions (Section 5.3). Although these p38 MAPK inhibitors 
were administered as aqueous formulations that remained in solution 
when diluted in simulated lung fluid, it is possible the airborne drug may 
have precipitated prior to deposition of droplets in the respiratory tract. 
In order to investigate the mechanism of action, i.e. to determine if the 
lung changes were attributable to the presence of particulate material 
or the chemical (pharmacological) action of the compound per se, two 
experimental approaches were considered for further evaluation. 
Inhaled administration of a pharmacologically ‘inert’ analogue 
Histopathological examination of the lungs of rats administered an inert 
analogue of GSK-899 for 28 days would facilitate a means of 
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determining if lung toxicopathology observed following repeated 
exposure of rats to GSK-899 was attributable to the molecular action of 
the drug per se (pharmacology or ‘off-target toxicity’) or due to a more 
generic mechanism such as the presence of drug particulate in the 
lungs of affected rats; a reduced incidence and/or severity of lung 
findings would implicate a molecular mechanism for the p38 MAPK 
inhibitors. GSK2656081A (GSK-081) is a p38 MAPK inhibitor and an 
isomer of GSK-899 (Figure 5.2), with a potency approximately 100-fold 
lower than the latter compound.  
5.2A: GSK2656081A (GSK-081) 
 
5.2B: GSK258899A (GSK-899) 
 
Figure 5.2: Chemical structures of two structurally similar isomers with 
different pharmacological potencies. Differences in the position of the 
carbonyl group are shown by an arrow. Fig 5.2A: GSK2656081A (free base). 
Fig 5.2B: GSK258899A (free base) is approximately 100-fold more potent. 
Approximately 1 kg of crystalline GSK-081 was required to produce 
sufficient micronised material for the comparative target inhaled doses 
for a 28-day inhalation toxicology study. However, the cost of 
production in 2013 was estimated at £186,000 and prohibitive for this 
research project. 
Examination of rat lungs following repeated systemic exposure 
Administration of GSK-899 or GSK-677 to rats using an alternative 
route remote from the respiratory tract would provide a means for in 
situ perfusion of lungs by the p38 MAPK inhibitors. An absence of 
toxicopathology findings after 28 days of treatment would imply the 
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changes observed in lungs after 28 days of inhalation exposure were 
attributable to a localised effect of deposited aerosol particulates.  
Intravenous infusion of the p38 MAPK inhibitor into the caudal vein, for 
one hour daily, was initially considered as the surrogate exposure route 
of choice to achieve a similar drug-time concentration profile in plasma 
to that anticipated for a one-hour inhalation exposure period, i.e. a 
profile with steady state achieved during a one-hour dosing period 
followed by a post dose decline in plasma concentration. However, 
intravenous infusion of aqueous formulations for 28 days presents 
significant technical challenges including surgical preparation of rats 
and maintaining the patency of cannulae throughout the treatment 
period. Such studies require extensive experience in the use of this 
technique for prolonged treatment periods, a capability that was not 
available locally. The cost of funding the proposed experiment at a 
contract research organisation ($169,600 CDN in 2016, equating to 
£106,000) was prohibitive for this research project. 
Subcutaneous injection was subsequently evaluated as an alternative 
exposure route. A single dose of GSK-899 or GSK-677 (5 mg/kg) in 
Solutol-NaCl was administered dorsally as a bolus injection to groups 
of rats (n=3) to evaluate the systemic exposure (Appendix 7) and 
tolerability of the test article at the injection site (Appendix 8). Rats 
were euthanized after a four-day off-dose period and the injection site 
taken for histopathological examination. The injection site was sampled 
after an off-dose period to evaluate the potential degree of recovery 
between consecutive injections at a site if repeated dosing (injection 
once daily) was rotated across four dorsal injection sites. Observations 
indicated subcutaneous administration of GSK-899 was likely to be 
tolerated for 28 days according to the proposed dosing regimen. 
However, degenerative and inflammatory changes at the injection site 
of two rats administered a single subcutaneous dose of GSK-677 
precluded progression of this compound for repeated administration. 
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Figure 5.3: Outline of experimental design to investigate pulmonary 
toxicology after subcutaneous administration of GSK-899 for 28 days. 
Rats were dosed 5 mg/kg/day (n=6 rats) or the vehicle (control; n=5 rats) 
once daily for 28 consecutive days; four dorsal injection sites were used in 
rotation (7 injections/site with off-dose periods of 3 consecutive days). Rats 
were euthanized on Day 29 and the respiratory tract was preserved in 
formalin for histological processing and examination by light microscopy. 
Satellite groups (3 rats/dose/timepoint) were sampled for plasma and lung for 
analysis of drug concentrations after a single dose and 28 days of treatment. 
In order to investigate the pulmonary toxicopathology of systemically 
exposed rats and to put potential findings in context with concomitant 
pharmacokinetics, groups of rats were dosed GSK-899 at 5 mg/kg/day 
subcutaneously, once daily, for up to 28 consecutive days (Figure 5.3). 
Blood and tissue samples were obtained for three key investigations as 
follows: 
• Toxicopathology changes in the respiratory tract after 28 days of 
treatment, with reference to vehicle controls (n = 6 rats/group). 
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• Systemic exposure measured in rat plasma sampled post 
exposure on Days 1 and 28 of treatment (n = 3 rats/group/day). 
• Drug concentrations in lungs taken one hour post dose on 
Day 1, and 24 hours post dose on Days 1 and 28 of treatment 
(n = 3 rats/group/timepoint). 
A dose of 5 mg/kg/day was selected with reference to pharmacokinetic 
plasma data in rats sampled after a single subcutaneous dose of 
5 mg/kg (Appendix 7), equating to systemic exposure at least 6-fold 
higher than that achieved following inhaled doses of 15 mg/kg/day. 
5.2.4. Test system and animal husbandry 
Male Crl:CD(SD) rats (Charles River UK Ltd, Margate, Kent) were 
randomly allocated to groups and accommodated under standard 
laboratory conditions (Home Office, 2014) with access to food and 
water as described in Chapter 2 (Section 2.2.4.1). Rats were identified 
by a number written in indelible ink on the tail, except for animals of the 
first study performed using crystalline GSK-899 (study R29413) in 
which rats were tattooed in line with local practices at that time. 
Rats were accommodated for at least five days before undertaking the 
first licensed procedure (tube restraint) and were approximately 
10 weeks old on the first day of aerosol administration (Day 1). Satellite 
animals administered a single inhaled exposure for measurement of 
p38 MAPK inhibitor in plasma and/or lung tissue were maintained in 
the animal holding room and then exposed concurrently with repeat 
dose animals on Day 28 of treatment; single dose animals were thus 
approximately 14 weeks old on the day of exposure. 
The Crl:CD(SD) strain of rat was used for non-clinical safety studies 
performed using GSK-899 and GSK-677 before termination of the 
respective drug development programmes. This strain of rat was thus 
selected for continuity with and reference to historical (unpublished) 
toxicopathology data for these p38 MAPK inhibitors. 
Chapter Five 
261 
 
Clinical observations and body weight measurements were maintained 
for all animals to ensure their general wellbeing during the experiment 
and to facilitate key procedures or investigations such as dosing. 
5.2.5. Subcutaneous dosing of rats 
Rats were dosed GSK-899 (1 mg/mL in Solutol-NaCl adjusted to within 
pH 4 to 6; dose volume of 5 mL/kg) for up to 28 days. Rats were 
injected at one of four dorsally located sites, used in rotation, such that 
a period of three days elapsed between consecutive injections at the 
same location. This facilitated a degree of recovery from any trauma 
associated with the dosing procedure. Chemical analysis (HPLC-UV) of 
samples taken from formulations dosed on Days 1 and 28 confirmed 
satisfactory accuracy of preparation. 
5.2.6. Aerosol generation of p38 MAPK inhibitors and 
inhalation exposure of rats 
Groups of rats were administered an aerosol of the p38 MAPK inhibitor 
for 60 minutes, either once or repeatedly for up to 28 days, by 
snout-only inhalation exposure. Aerosols were generated from dry 
powder formulations or aqueous solutions and directed into the top of 
the snout-only inhalation exposure chamber as described in Chapter 2 
(Section 2.2.5).  
Target aerosol concentrations (Tables 5.2 and 5.4) for the exposure of 
animals were calculated from the required doses using Equation 3 
(Chapter 2, Section  2.2.5). 
5.2.6.1. Dry powder formulations of p38 MAPK inhibitors  
For aerosol administration of crystalline p38 MAPK inhibitors or 
amorphous GSK-899, aliquots of dry powder formulations were packed 
into the dust feed canisters (Table 5.2) using the method described in 
Chapter 2 (Section 2.2.5.1). 
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Table 5.2: Volume of dust feed canisters, target doses and aerosol 
concentrations for exposure of rats to p38 MAPK inhibitors 
Test article 
Study 
number 
Target 
dose 
(mg/kg) 
Test article 
concentration 
in lactose 
(% w/w) 
Aerosol 
generator 
canister 
size (cm3) 
Target aerosol 
concentration 
(µg/L) 
GSK-899 
(crystalline) 
R29413 1 40 5 24 
R29739 45 40 40 1080 
R30353N 15 40 5 360 
R30662N 15 40 5 360 
GSK-899 
(amorphous) 
R30662N 
0.02 0.5 1.3 0.5 
1 5 5 24 
15 40 5 360 
GSK-677 
(crystalline) 
R31037N 
1 5 5 24 
6.7 40 5 160 
15 40 5 360 
GSK-361 
(crystalline) 
R31034N 
5 40 5 120 
15 40 5 360 
R31035N 
0.25 1 5 6 
1 5 5 24 
15 40 5 360 
5.2.6.2. Liquid formulations of p38 MAPK inhibitors 
For nebulisation of aqueous solutions of each p38 MAPK inhibitor, the 
crystalline test article was dissolved in vehicle (Table 5.3) to achieve a 
concentration anticipated to achieve the target aerosol concentration 
and inhaled dose (Table 5.4). Methods for preparing formulations are 
stated in Chapter 2 (Section 2.2.5.3). 
Table 5.3: Vehicles used for nebulisation of p38 MAPK  
inhibitors and repeated inhalation exposure of rats 
Test article Study No. Vehicle for nebulisation 
GSK-899 
R31038N 
3% (v/v) Solutol HS 15 in 0.9% (w/v) 
aqueous sodium chloride (pH 5.9) 
R31039N 
3% (v/v) Solutol HS 15 in 10% (w/v) 
aqueous 2-hydroxypropyl-B-cyclodextrin 
GSK-677 R31038N 
3% (v/v) Solutol HS 15 in 0.9% (w/v) 
aqueous sodium chloride (pH 5.9) 
GSK-361 R31036N 
20:20:60 (v/v/v) Solutol HS 15, ethanol 
and 60 mM phosphate buffer (pH 7) 
Solutol HS 15 and 2-hydroxypropyl-B-cyclodextrin or ethanol were 
used to solubilise p38 MAPK inhibitors of low solubility (GSK-899 and 
GSK-361). Solutol HS 15 was also formulated with GSK-677 for 
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concurrent exposure of rats to nebulised GSK-899 or GSK-677 for 
comparison of the toxicopathology for these compounds. Potential 
implications for the enhanced absorption of p38 MAPK inhibitors were 
discussed in Chapter 2 (Section 2.2.5.3) and inclusion of these 
reagents in the vehicle does not undermine the fundamental 
hypothesis that changing the aerosol form of a drug changes the 
pharmacokinetics of exposure and concomitant toxicopathology. 
Table 5.4: Formulation concentrations, target doses and aerosol 
concentrations for exposure of rats to p38 MAPK inhibitors 
Test 
article 
Study 
number 
Target 
dose 
(mg/kg) 
Concentration 
in vehicle 
(mg/mL) 
Target aerosol 
concentration 
(µg/L) 
GSK-899 
R31038N 1  1.4 to 2.9 24 
R31039N 1  1.9 to 2.5 24 
GSK-677 R31038N 
1  1.4 to 2.4 24 
6.5  8.5 to 14.0 130 
15  25.0 to 35.0 360 
GSK-361 R31036N 
0.25  0.8 to 1.0 6 
1  1.6 to 1.75 24 
5.2.6.2. Aerosol Generation and formulation details 
Groups of rats were administered an aerosol of the p38 MAPK inhibitor 
once or for up to 28 consecutive days, by snout-only inhalation 
exposure, as a dry powder aerosol or nebulised solution as appropriate 
(Chapter 2, Sections 2.2.5.2 and 2.2.5.4 respectively).  
For nebulisation of GSK-899 and GSK-677 (study R31038N) in 
Solutol-NaCl, a single nebuliser of nominal airflow 6 L/min was used to 
disperse each solution at the target aerosol concentration; a chamber 
exhaust of 15 L/min was applied to vent the test atmosphere. For 
dispersal of GSK-899 in Solutol-HPβCD (study R31039N) or GSK-361 
in 20:20:60 (v/v/v) Solutol HS 15, ethanol and 60 mM phosphate buffer 
(study R31036N), dual nebulisers were used to disperse the 
formulations and mitigate against limited solubility of each test article in 
the respective vehicle to achieve the target aerosol concentration. 
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5.2.6.3. Inhalation exposure of rats 
Animals were exposed to test aerosols using the apparatus and 
methods described in Chapter 2 (Section 2.2.5.5). The chambers were 
operated under conditions of dynamic airflow, with a chamber exhaust 
flow of typically 15 to 16 L/min. For logistical reasons, different airflows 
were used for the experiments employing dual nebulisers: an exhaust 
airflow of 12 L/min was applied during nebulisation of GSK-899 in 
Solutol-HPβCD (study R31039N) and an exhaust flow of 18 L/min was 
applied during nebulisation of GSK-361 in 20:20:60 (v/v/v) Solutol 
HS 15, ethanol and 60 mM phosphate buffer (study R31036N). 
Rats were restrained for exposure in polycarbonate restraint tubes and 
attached to the chamber; the vertical position (chamber level) of each 
animal was documented. It is not uncommon for a gradient in aerosol 
concentration to form down a flow-through design of snout-only 
exposure chamber, as animals recycle the exhaled aerosol into the 
chamber atmosphere as it progresses down the chamber. This is less 
pronounced in chambers of narrower internal diameter, since the air 
velocity is faster for a given volumetric airflow. Nevertheless, in order to 
minimise a potential bias in achieved lung dose for treatments requiring 
repeated concurrent exposure of more than six rats per chamber (i.e. 
loading more than one chamber level), animals were rotated through 
the chamber levels day by day such that mean doses would be similar 
for all animals over the 28-day treatment period. Unused animal 
exposure or sampling ports were closed using blanking plugs. 
Animals were exposed to the aerosol for 60 minutes each day, during 
which time operational settings (airflow and aerosol generation) and 
animals were formally checked and documented at 15-minute intervals. 
5.2.6.4. Aerosol characterisation 
‘Pre-study’ aerosol characterisation work was conducted without 
animals to establish the operating conditions needed to generate target 
aerosol concentrations and to ensure aerosols were in line with 
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particulate size criteria for exposure of rodents (OECD[412], 2009, 
OECD[413], 2009, US-EPA[3645], 1998). The operating conditions of 
the dust generator (speed of canister advancement) or concentration of 
p38 MAPK inhibitor in the solution for nebulisation were adjusted as 
necessary during the study, with reference to HPLC-UV analysis 
results of aerosol concentration, to maintain the desired aerosol 
concentration on target. 
Aerosols were also sampled using predefined air sampling volumes 
(Table 5.5) during exposure of rats to determine the aerosol 
concentration and particle size distribution of p38 MAPK inhibitors as 
described in Chapter 2 (Section 2.2.5.6). For aerosol concentration, 
filter samples were taken in duplicate on representative days of 
treatment (approximately half of the exposure periods including days of 
blood sampling for pharmacokinetic investigations). 
Table 5.5: Target aerosol concentrations and aerosol sampling volumes  
Test 
article 
Aerosol 
form 
Study 
No. 
Target aerosol 
concentration 
(μg/L) 
Sampling volume (L) 
Aerosol 
concentration 
Particle size using 
cascade impactor 
Aerosol (L) 
Aerosol 
(L) 
Solvent 
(mL) 
GSK-899 
crystalline 
R29413 24 10 10 5 
R29739 1080 2 2 5 
R30353N 360 6 10 3 
R30662N 360 4 6 3 
amorphous R30662N 
0.5 30 50 3 
24 6 10 3 
360 4 6 3 
nebulised 
R31038N 24 4 30 5 
R31039N 24 4 8 5 
GSK-677 
crystalline R31037N 
24 4 8 3 
160 4 8 3 
360 4 8 3 
nebulised R31038N 
24 4 30 5 
130 4 8 5 
360 4 8 5 
GSK-361 
crystalline 
R31034N 
120 4 8 5 
360 4 4 5 
R31035N 
6 8 8 5 
24 6 6 5 
360 4 4 5 
nebulised R31036N 
6 8 8 5 
24 6 6 5 
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Additional samples were taken using cascade impactors, typically once 
for each dose level in Weeks 1 and 3 of treatment, for determination of 
the particle size distribution; some cohorts of animals (e.g. single dose 
animals) were exposed concurrently with repeat dose animals but not 
necessarily on days of aerosol sampling for particle size analysis. 
5.2.6.5. Calculation of the estimated inhaled dose 
The estimated inhaled dose was calculated using Equations 1 and 2 
(Chapter 1, Section 1.3.4) for an inhalation exposure period of 60 
minutes. 
5.2.6.6. Bioanalysis of p38 MAPK inhibitors in rat plasma 
and lung 
Groups of rats (n=3/dose) were sampled for plasma following a single 
exposure or after the final exposure (Day 28). In addition, lungs 
(n=3/dose/timepoint) were taken as soon as practicable after a single 
exposure and at 24 hours, relative to the start of a single exposure 
(Day 1) or the end of treatment (Day 28) for HPLC-MS/MS analysis of 
the test article. 
Plasma sampling for chemical analysis of p38 MAPK inhibitors 
A series of blood samples (approximately 400μL) were taken from 
groups of rats (3/dose/timepoint) immediately post exposure 
(60 minutes) and at 1.5, 2.5, 4.5, 8.5 and 24 hours relative to the start 
of inhalation exposure, or 0.5, 1, 2, 4, 8 and 24 hours after a 
subcutaneous dose as appropriate. Blood was sampled by jugular 
venepuncture or caudal venepuncture (tail warmed to induce 
vasodilation) if further sampling from the jugular vein was not 
technically feasible, or from the abdominal aorta under isoflurane 
anaesthesia for the final (terminal) sample. The blood was processed 
for preparation of plasma and analysed by HPLC-MS/MS as described 
in Chapter 2 (Section 2.2.5.8); plasma was stored in a freezer at 
approximately -20°C or below prior to analysis. 
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Sampling of lung for homogenisation and chemical analysis of p38 
MAPK inhibitors  
Groups of rats (3/dose/timepoint) were euthanized (deep anaesthesia 
under isoflurane followed by exsanguination) at one hour on Day 1 (as 
soon as possible after inhalation exposure, or one hour post 
subcutaneous dose) or at 24 hours on Days 1 and 28. The lungs were 
taken and processed for HPLC-MS/MS analysis of p38 MAPK inhibitor 
in lung homogenate as described in Chapter 2 (Section 2.2.5.8). 
Determination of pharmacokinetic parameters 
For each p38 MAPK inhibitor, statistical analysis of the 
drug-concentration profiles in lung and plasma was performed 
(Statistica, version 12.0.1133.40) using two-way analysis of variance 
(ANOVA) for lung concentrations and multivariate analysis of variance 
(MANOVA) for plasma concentrations, with post hoc analysis using 
Tukey’s honestly significant difference test (Abdi and Williams, 
2010[B]) to determine degrees of statistical significance between doses 
and timepoints. 
Pharmacokinetic evaluations of plasma concentration data for each 
p38 MAPK inhibitor were performed using a non-compartmental 
method to estimate the maximum observed concentration (Cmax), time 
to Cmax (Tmax) and the area under the concentration-time curve (AUC) 
approximated using the trapezoid rule (linear-up, log-down method). 
5.2.7. Terminal investigations 
On completion of the required treatment period (approximately 
24 hours after the final dose), rats were euthanized by exsanguination 
via the abdominal aorta under isoflurane anaesthesia. Death was 
confirmed by cutting major blood vessels (cessation of circulation). 
5.2.7.1. Bronchoalveolar lavage of lungs for transmission 
electron microscopy of macrophages 
Methodology for the harvesting of macrophages for transmission 
electron microscopy (TEM) was adapted for incorporation into 
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experiments as the research progressed. Differences in experimental 
design or techniques are summarised in Table 5.6. 
Table 5.6: Summary of inhaled doses, duration of treatment and 
sampling of lungs by bronchoalveolar lavage  
Test 
article 
Aerosol 
form 
Study No. 
Inhaled dose 
(mg/kg/day) 
Days of 
treatment 
Lung lobes 
sampled 
Volume 
of BALF 
GSK-899 
crystalline R29413 1, 45 3 all 4× 5mL 
amorphous R30662N 15 3 intermediate 3× 1mL 
nebulised R31038N 1 3 all 3× 5mL 
GSK-677 
crystalline R31037N 15 3 all 3× 5mL 
nebulised R31038N 15 3 all 3× 5mL 
GSK-361 nebulised R31035N 0.25, 1, 15 28 left 3× 2mL 
Notes 
BALF bronchoalveolar lavage fluid: volume of aqueous 0.9% (w/v) sodium 
chloride used to flush lungs 
The thoracic cavity was opened by excision of the sternum and the 
lungs removed. For sampling the left lung of GSK-361 treated rats, the 
right bronchi were first clamped. The trachea (or bronchus of the 
intermediate lobe for rats administered amorphous GSK-899) was 
cannulated, with the cannula securely tied in place with thread. 
The lung/lobe was gently lavaged with an appropriate volume of ice 
cold aqueous 0.9% (w/v) sodium chloride. The lobe(s) were gently 
massaged prior to removal of the lavageate (BALF), which was 
transferred to a tube suitable for centrifugation. BALF samples were 
kept chilled on ice between processing steps and successive washes 
were pooled to form one sample per animal. 
BALF samples were centrifuged for five minutes at 1500 rpm 
(approximately 395×g), at approximately 4°C with no brake. The 
supernatant was discarded and the pellet of cells resuspended in 1 mL 
formaldehyde glutaraldehyde (4% formaldehyde and 1% 
glutaraldehyde in a phosphate buffer; pH 7.2 to 7.4) and processed for 
TEM as described in Section 5.2.2.5. 
5.2.7.2. Histopathological examination of tissues 
Animals were subjected to a macroscopic examination (visual 
appraisal) during necropsy. The thoracic cavity was opened by excision 
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of the sternum and tissues required for preservation were 
systematically removed and preserved in an appropriate fixative. A 
generic tissue preservation list for rodent inhalation toxicology studies 
was used and included but was not limited to the respiratory tract 
(including head for nasal cavities), vital organs, gastrointestinal tract, 
reproductive organs, lymphoid tissues, skeletal muscle, nerves, femur, 
skin and animal identification. Eyes and optic nerves were preserved in 
Davidson’s fixative (2:35:10:53 (v/v) 40% formaldehyde solution, 
ethanol, glacial acetic acid and distilled water). Testes were preserved 
in modified Davidson’s fixative (30:15:5:50 (v/v) 40% formaldehyde 
solution, ethanol, glacial acetic acid and distilled water) for 
approximately 24 hours and were then transferred to 70% industrial 
methylated spirits (IMS) in water. Otherwise, tissues were fixed in 10% 
buffered formalin for at least 4 days (liver), 24 hours (other soft tissues) 
or 48 hours (hard tissues) before further processing was performed; 
lungs were inflated with fixative prior to immersion. 
After fixation, tissues required for examination by light microscopy were 
trimmed in accordance with standardised procedures to expose areas 
of interest, ready for further processing (Figure 5.4). The head (for 
examination of nasal cavities) was decalcified in Kristenson’s fluid 
(43 mg/mL (w/v) sodium formate in 19.6% (v/v) formic acid) for eight 
days, with trimming of tissue performed half way through the 
decalcification process (Figure 5.4A). Trimmed tissues were placed 
into labelled cassettes, in accordance with an embedding guide 
(Figure 5.4B) to standardise orientation of the tissues presented for 
examination. The cassettes containing tissues were stored in 70% IMS 
(eyes, optic nerves or testes) or 10% buffered formalin until processed. 
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5.4A:  
 
5.4B: 
 
Figure 5.4: Trimming patterns for standardization of tissue sections for 
histopathological examination. 5.4A: rat head trimmed to expose three 
standard sections of the nasal cavities. 5.4B: rat lungs inflated with fixative 
showing the right anterior lobe (1), right mid lobe (2), right posterior lobe (3), 
intermediate lobe (4) and left lung (5). The trimming pattern of fixed lung 
tissue and arrangement in a cassette for embedding in paraffin wax 
(intermediate lobe not routinely processed) are also shown. 
Tissue processing for preparation of slides 
Tissues were processed using an automated schedule during which 
the tissues were immersed in a series of reagents, each for one hour. 
The tissues were first dehydrated by immersing the cassettes in 70% 
IMS (once), 90% IMS (once) and then absolute IMS (five cycles). The 
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cassettes were then immersed in xylene (three cycles). Xylene is 
miscible with paraffin wax and is used to “clear” the dehydrant (IMS) 
from the tissue. The tissues were then impregnated with molten 
paraffin wax maintained at ≤63ºC (four cycles). For embedding, a 
mould base was filled with molten paraffin wax in a working area 
(“embedding centre”) maintained at 60ºC. The trimmed tissues in a 
cassette were transferred to the mould and orientated in accordance 
with a blocking pattern with the surface of interest downwards. The 
mould was then chilled on a cold plate, the position of the tissues 
adjusted if necessary, and the lid of the mould closed using the labelled 
cassette base. The mould was then further cooled until the paraffin wax 
had set, and the mounted wax block removed from the mould. 
Preparation of slides for microscopic examination 
The wax blocks were mounted onto a microtome, coarse trimmed to 
expose the area of interest and cooled on ice. After removing any 
‘coarse trimming artefacts’, sections of 3 to 5 µm thickness were cut 
and floated onto warm distilled water (47 to 50ºC), and picked up onto 
a clean glass slide pre-labelled with study, animal and block 
identification numbers. 
The sections were stained with haematoxylin and eosin according to an 
automated sequence as follows: warming in the respective fixative 
(five minutes; oven maintained at 60ºC) to melt the paraffin wax; 
immersion in xylene (1× five minutes; 3× three minutes), IMS (3× one 
minute), water (1× one minute), haematoxylin (2× three minutes; 1× 
two minutes), water (2× two minutes; 1× one minute), eosin (2× 2.5 
minutes), water (1× 30 seconds), IMS (3× 30 seconds) and xylene (2× 
30 seconds; 3x one minute). 
Occasionally, at the request of the study pathologist, 
immunohistochemical staining was performed to confirm the phenotype 
of leukocytes observed in the lung sections (CD68, CD3 or CD79 
glycoproteins for monocytes/macrophages, T-lymphocytes and 
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B-lymphocytes respectively). A coverslip was then applied and set 
using Entellan® rapid mounting medium (catalogue number 
1079610100; Sigma Aldrich). 
Microscopic examination of tissues 
A pathologist examined selected tissues by light microscopy (up to ×40 
magnification) and subjectively graded the incidence and severity of 
observations in rats administered the p38 MAPK inhibitors and control 
animals administered the vehicle alone. Histopathological findings were 
graded according to a qualitative scale of increasing severity as 
follows: minimal < mild < moderate < marked < very marked. 
Selected tissues (Table 5.7) included the exposure route (respiratory 
tract for inhalation studies; injection site for subcutaneously 
administered GSK-899), macroscopic abnormalities observed at 
necropsy and potential target organs identified with reference to 
unpublished data (Freke, 2007, Freke, 2010, Rush, 2007). Tissues 
were examined for control rats and the highest dose administered. 
Tissues affected by treatment were then examined for animals of lower 
doses. 
Table 5.7: Summary of tissues examined by  
light microscopy after treatment of rats for 28 days 
Tissue type Tissues Studies examined 
Respiratory 
tract 
nasal cavities, 
nasopharynx, lungs 
all studies 
larynx, trachea 
(+bifurcation), TBLN 
all inhalation studies 
Key organs heart, kidney, liver all studies 
Reproductive 
organs 
prostate GSK-899 (R30662N, R31697N) 
testes all studies 
Miscellaneous 
abnormalities and thymus all studies 
adrenals 
GSK-361 (R31035N, R31036N); 
GSK-899 (R31038N, R31039N, 
R31697N) 
eyes, optic nerve, jejunum, 
duodenum or colon 
GSK-361 (R31035N, R31036N); 
GSK-899 (R31038N, R31039N) 
injection site (subcutis) GSK-899 (R31697N) 
Notes 
TBLN tracheobronchial lymph node 
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5.3. Results and discussion 
5.3.1. In vitro analysis of cytotoxicity, cytokine release and 
morphology of cells incubated with particles 
Results of in vitro investigations with NR8383 rat alveolar macrophage 
cells incubated with p38 MAPK inhibitors for 72 hours are detailed in 
Appendices 3 and 4 and reproduced below. High median effective 
concentrations (EC50) for particles of p38 MAPK inhibitors selected for 
subsequent in vivo investigations ranked GSK-361 > GSK-899 > 
GSK677 (Table 5.8), and indicated a relatively low potential for cellular 
toxicity for the compounds (EC50 >100 µg/mL); criteria for 
categorisation of drugs are summarised in Section 5.2.2.2. 
Table 5.8: In vitro cytotoxicity (EC50) data for p38 MAPK inhibitors 
Test article 
Lactate dehydrogenase 
EC50 (µg/mL) 
Study Numbers 
GSK-899 316.2 
V31206N, V31257N 
GSK-677 144.2 
GSK-361 462.8 
V31292N, V31307N 
SB-323 93.74 
Variability in GSK-899 dose responses for duplicate assays to measure 
lactate dehydrogenase leakage (Figure 5.5A) was ascribed to relative 
insolubility of GSK-899. None of the p38 MAPK inhibitors induced 
release of cytokines in vitro (Appendices 3 and 4). This was expected 
given the anti-inflammatory pharmacology described for p38 MAPK 
inhibitors (Chung, 2011) and the compounds were thus considered to 
represent a relatively low potential for inflammatory mediator release in 
vivo. Morphological assessment of NR8383 rat alveolar macrophage 
cells by transmission electron microscopy after incubation with p38 
MAPK inhibitor particles for 72 hours revealed endocytosed particles at 
400 µg/ml of GSK-899 (Figure 5.6A) and GSK-361 (Figure 5.6B). This 
was consistent with the high solubility of GSK-677 and low solubility of 
GSK-361 and GSK-899 (Chapter 2, Table 2.6). 
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5.5A: GSK-899 
 
5.5B: GSK-677 
 
5.5C: GSK-361 
 
Figure 5.5 Cytotoxicity assessed by leakage of lactate dehydrogenase 
(LDH) from NR8383 rat alveolar macrophage cells incubated with a p38 
MAPK inhibitor. NR8383 cells in supplemented Kaighn’s modification of 
Ham’s F12 medium were incubated at 37ºC in a humidified atmosphere 
containing 5% CO2. For LDH analysis, cells were seeded into wells, 
incubated for ≤4 hours and treated with an equal volume of the p38 MAPK 
inhibitor in medium for 72 hours. LDH leakage was expressed as a 
percentage of total with reference to media of control cells treated with 
Triton-X (to release LDH into media) at 71.5 hours. 5.5A: GSK-899. 
5.5B: GSK-677. 5.5C: GSK-361. 
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5.6A: GSK-899 (400 µg/mL) 
 (V31206N) 
5.6B: GSK-361 (400 µg/mL) 
 
(V31307N) 
5.6C: GSK-677 (50 µg/mL) 
 
(V31257N) 
5.6D: GSK-677 (50 µg/mL) 
 
(V31257N) 
Figure 5.6: Transmission electron microscopy of NR8383 rat alveolar 
macrophage cells incubated with a p38 MAPK inhibitor. NR8383 cells 
in supplemented Kaighn’s modification of Ham’s F12 medium were 
incubated at 37ºC in a humidified atmosphere containing 5% CO2. For 
particulate exposure, cells were seeded into wells, incubated for ≤4 hours 
and treated with an equal volume of p38 MAPK inhibitor in medium for 72 
hours. Cells were then harvested and processed for transmission electron 
microscopy. 5.6A: GSK-899 (400 µg/mL); crystalline inclusions (Cr) were 
evident within macrophage cells. 5.6B: GSK-361 (400 µg/mL); crystalline 
inclusions (Cr) were evident within macrophage cells. 5.6C: GSK-677 (50 
µg/mL); membrane-bound bodies (MB) containing lamellar material, 
vesicles or nondescript material lacking a clear shape or structure were 
evident within the cell. 5.6D: GSK-677; higher magnification of membrane-
bound body showing concentric lamellar (L) and nondescript (ND) material. 
 
Cr 
Cr 
Cr 
Cr 
MB 
MB 
L 
ND 
L 
Chapter Five 
276 
 
Crystalline inclusions were not seen in NR8383 cells incubated with 
GSK-677, but there was evidence (50 and 400 µg/ml) of secondary 
lysosomes containing lamellar or vesicular material that occasionally 
appeared to be developing lysosomal lamellar bodies (Figures 5.6C 
and 5.6D). This is consistent with lysosomal storage disorders such as 
drug-induced phospholipidosis (Anderson and Borlak, 2006, Dake et 
al., 1985), an accumulation of phospholipid in lamellar bodies, or 
Niemann-Pick disease, an inherited disease causing accumulation of 
sphingolipid or cholesterol (Ikonen and Hölttä-Vuori, 2004). 
5.3.2. Toxicopathology of p38 MAPK inhibitors in rats 
following 28 days of inhalation exposure 
Lung and plasma concentration profiles, transmission electron 
microscopy (TEM) of macrophages and representative sections of 
toxicopathology findings (viewed by light microscopy) are presented for 
each p38 MAPK inhibitor and aerosol form (indexed in Table 5.9). 
Table 5.9: Index of figures and tables for dosimetry, drug-lung and 
plasma concentrations and representative microscopy images in rats 
p38 MAPK inhibitor and 
particle/dose form 
 
Figure/table numbers 
Inhaled 
doses 
Concentration Macro-
phages 
Toxico-
pathology  Lung Plasma 
GSK-899 
crystalline 
Figures - 5.7 5.8 5.10 5.11 - 5.13 
Tables 5.10 - 5.12 - 5.13 
amorphous 
Figures - 5.14 5.15 5.16 5.17 - 5.18 
Tables 5.10 - 5.14 - 5.15 
nebulised 
Figures - 5.19 5.20 5.21 5.22 - 5.23 
Tables 5.11 - 5.16 - 5.17 
Injection 
(subcutis) 
Figures - 5.24 5.25 - 5.26 - 5.29 
Tables - - 5.18 - 5.19 
GSK-677 
crystalline 
Figures - 5.30 5.31 5.32 - 
Tables 5.10 - 5.20 - 5.21 
nebulised 
Figures - 5.33 5.34 5.35 5.36 - 5.39 
Tables 5.11 - 5.22 - 5.23 
GSK-361 
crystalline 
Figures - 5.40 5.41 5.42 5.43 
Tables 5.10 - 5.24 - - 
nebulised 
Figures - 5.44 5.45 - 5.46 
Tables 5.11 - 5.25 - - 
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5.3.2.1. Inhalation exposure of rats to p38 MAPK inhibitors 
and estimation of the inhaled dose 
Generally, achieved mean aerosol concentrations were in agreement 
with target (±12%) and all groups were ±18% of target. This was 
reflected in the estimated inhaled doses for each p38 MAPK inhibitor 
(±11% of respective targets), with all doses within ±20% of target and 
clear separation between doses (Tables 5.10 and 5.11). The mass 
median aerodynamic diameter (MMAD) for all aerosols can be ranked: 
amorphous GSK-899 > crystalline GSK-677 > nebulised (study 
R31039N) and crystalline GSK-899 > crystalline GSK-361 and 
nebulised p38 MAPK inhibitors. The MMAD for nebulised aerosols and 
crystalline GSK-899 and GSK-361 were within the range 
recommended for repeat exposure studies, i.e. MMAD of 1 to 3 μm 
(OECD[412], 2009, OECD[413], 2009, US-EPA[3645], 1998). Although 
slightly greater, the MMAD for amorphous GSK-899 and crystalline 
GSK-677 was within the range 1 to 4 µm recommended for acute 
(single exposure) inhalation toxicity testing (US-EPA[1300], 1998, 
OECD[403], 2009), with the mid dose for amorphous GSK-899 on the 
cusp of this range (4.2 µm). 
Estimates of fine particle fraction in Chapter 2 (Section 2.3.6.1) suggest 
minor differences (≤6%) in fine particle mass for MMAD of 2 to 3 µm 
but a difference of approximately 20% of the aerosol between an 
MMAD of 3 and 4 µm at the observed geometric standard deviations, 
and Raabe et al. (1988) described enhancement of nasal-pharyngeal 
deposition in rats for particles larger than 3 μm in aerodynamic 
diameter. Whilst this has implications for the proportion of particulate 
likely to be deposited in rat lungs, the separation of achieved estimated 
inhaled doses was sufficient to permit investigation of the dose 
response of toxicopathology. 
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Table 5.10: Estimated inhaled doses and characterisation of dry powder 
aerosols administered to rats over 28 days 
Test article 
(bold) and 
aerosol 
form 
Study 
number 
Test article 
concentration 
(% w/w in 
lactose)  
Estimated 
inhaled 
dose 
(mg/kg) A 
Mean aerosol 
concentration 
(µg/L) B 
Particle size 
distribution C 
MMAD 
(µm)  
σg 
GSK-899 
Crystalline 
R29413 44% 1.06 25.6 2.9 2.1 
R30662N 44% 14.5 358 3.0 2.0 
Amorphous R30662N 
0.50% 0.024 0.592 3.9 2.0 
5.0% 1.10 26.9 4.2 1.9 
39% 15.6 380 3.7 2.3 
GSK-677 
Crystalline R31037N 
4.4% 1.04 25.0 3.3 2.1 
38% 7.28 175 3.5 1.7 
38% 16.7 403 3.3 2.2 
GSK-361 
Crystalline R31035N 
0.95% 0.222 5.26 1.7 2.7 
5.0% 1.04 24.7 1.6 2.4 
43% 15.2 358 1.8 2.2 
Notes 
MMAD mass median aerodynamic diameter 
σg geometric standard deviation 
A Estimated inhaled doses calculated for a 60-minute exposure period using 
mean data (aerosol concentration and body weight) and a body-weight 
derived estimate of respired minute volume (Alexander et al., 2008). 
Estimation of mean inhaled doses of GSK-899, GSK-677 and GSK-361 are 
summarised in Appendices 163 to 165 respectively. 
B Aerosol concentration: aerosols were typically analysed twice per exposure 
on representative days of the 28-day treatment period (Study R29413 
sampled daily). 
C Particle size distribution: aerosols containing a p38 MAPK inhibitor (analyte) 
were sampled using a cascade impactor on two to four occasions per dose 
during the 28-day treatment period (median values presented). 
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Table 5.11: Estimated inhaled doses and characterisation of nebulised 
aerosols administered to rats over 28 days 
Formulation 
vehicle (bold) 
and test article 
Study 
number 
Test article 
concentration 
in vehicle 
(mg/mL) 
Estimated 
inhaled 
dose 
(mg/kg) A 
Mean aerosol 
concentration 
(µg/L) B 
Particle size 
distribution C 
MMAD 
(µm)  
σg 
3% (v/v) Solutol HS 15 in 10% (w/v) Aqueous 2-Hydroxyproyl-B-Cyclodextrin 
GSK-899 R31039N 1.8 to 2.5 1.10 26.3 3.1 2.2 
3% (v/v) Solutol HS 15 in 0.9% (w/v) aqueous sodium chloride 
GSK-899 R31038N 1.4 to 2.9 0.842 20.0 2.1 2.0 
GSK-677 
R31038N 
1.4 to 2.3 1.08 25.7 1.8 2.1 
8.6 to 14 4.92 118 1.9 2.1 
25 to 35 14.8 352 1.8 2.1 
20:20:60 (v/v/v) Solutol:EtOH:60 mM phosphate buffer 
GSK-361 R31036N 
0.79 to 1.0 0.248 5.88 1.8 2.4 
1.8 1.18 28.0 1.9 2.5 
Notes 
MMAD mass median aerodynamic diameter 
σg geometric standard deviation 
A Estimated inhaled doses calculated for a 60-minute exposure period using 
mean data (aerosol concentration and body weight) and a body-weight 
derived estimate of respired minute volume (Alexander et al., 2008). 
Estimation of mean inhaled doses of GSK-899, GSK-677 and GSK-361 are 
summarised in Appendices 163 to 165 respectively. 
B Aerosol concentration: aerosols were typically analysed twice per exposure 
on representative days of the 28-day treatment period. 
C Particle size distribution: aerosols containing a p38 MAPK inhibitor (analyte) 
were sampled using a cascade impactor on two or three occasions per dose 
during the 28-day treatment period (median values presented). 
5.3.2.2. Pulmonary and systemic exposure of rats to 
GSK-899 and toxicopathology after 28 days 
GSK-899 concentrations in lung homogenate showed persistence of 
the analyte in lungs of rats administered crystalline GSK-899, with no 
significant reduction from 1 to 24 hours relative to the start of aerosol 
administration (Figure 5.7). Accumulation of GSK-899 in lungs was 
evident after repeated exposure, with an approximate 10-fold increase 
in trough concentrations (24 hours) from Days 1 to 28 of treatment, 
which by inference indicated approximately 60% of the lung deposited 
dose of GSK-899 was cleared from the lungs during this period. 
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Figure 5.7: Drug-lung concentrations in rats following inhaled 
administration of crystalline GSK-899 for one or 28 days. Mean GSK-899 
concentrations with standard deviations (error bars; n=3) are shown for rat 
lung homogenate data for samples taken immediately after a single 1-hour 
exposure and at 24 hours after single or repeat doses. Statistical analysis 
(2-way ANOVA with post hoc analysis using Tukey’s honestly significant 
difference test (Abdi and Williams, 2010[B])) of log10-transformed data 
achieved significance (p<0.01) for Days 1 vs 28 (24 hours); no statistical 
difference achieved between 1 and 24 hours. 
Mean drug-plasma concentrations were generally similar for a given 
dose after inhaled administration of crystalline GSK-899 to rats on 
Days 1 and 28 of treatment (Figure 5.8). A relatively high degree of 
variability was apparent for rats administered 1 mg/kg on Day 1, which 
was reflected in wide error bars representing standard deviation for 
each timepoint (Figure 5.8A). 
Chapter Five 
281 
 
5.8A 
0 5 1 0 1 5 2 0
1 0 - 3
1 0 - 2
1 0 - 1
1 0 0
1 0 1
1 0 2
1 0 3
C ry s ta ll in e  G S K 2 5 8 8 9 9 B
T im e  (h o u r s )  a f te r  s ta r t  o f  1 -h o u r  e x p o s u r e
P
la
s
m
a
 c
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/m
L
)
1 .0 6  m g /k g /d a y  : D a y  1
1 4 .8  m g /k g /d a y  : D a y  1
 
5.8B  
0 5 1 0 1 5 2 0
1 0 - 3
1 0 - 2
1 0 - 1
1 0 0
1 0 1
1 0 2
1 0 3
C ry s ta ll in e  G S K 2 5 8 8 9 9 B
T im e  (h o u r s )  a f te r  s ta r t  o f  1 -h o u r  e x p o s u r e
P
la
s
m
a
 c
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/m
L
)
1 .0 6  m g /k g /d a y  : D a y  2 8
1 4 .8  m g /k g /d a y  : D a y  2 8
 
Figure 5.8: GSK-899 concentrations in rat plasma up to 24 hours after 
inhaled doses of crystalline GSK-899 on Days 1 and 28. Rats inhaled an 
aerosol of crystalline GSK-899 once daily (1-hour exposure) for up to 28 
days; mean plasma concentrations with standard deviations (error bars; n=3) 
are shown for samples taken up to 24 hours after the start of inhalation 
exposure. 5.8A: plasma concentrations after a single exposure (Day 1). 
5.8B: plasma concentrations after repeated administration (Day 28). 
Statistical analysis (MANOVA with post hoc analysis using Tukey’s honestly 
significant difference test (Abdi and Williams, 2010[B])) of log10-transformed 
data achieved significance (p<0.01) for Days 1 vs 28. 
Systemic exposure to GSK-899 was higher on Day 28, with AUC0-t 
increasing five-fold and three-fold for crystalline doses of 1 and 
15 mg/kg/day respectively (Table 5.12) and minor differences in peak 
plasma concentration (Cmax), which occurred at the first sampled 
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timepoint immediately post exposure. Increases in systemic exposure 
were under proportional for an increase in dose, i.e. AUC0-t increased 
≤7-fold for a 15-fold increase in the estimated inhaled dose, suggesting 
saturation of mechanisms for absorption. 
Table 5.12: Pharmacokinetics of GSK-899 in plasma after inhaled 
administration of micronised crystals (n=3) 
Study 
No. 
Estimated 
Inhaled Dose 
(mg/kg/day) A 
Period 
(Day) 
Statistical 
parameter 
Pharmacokinetics (plasma) 
AUC0-t 
(h.ng/mL) B 
Cmax 
(ng/mL) B 
Tmax 
(h) C 
R29413 1.06 
D1 
Mean 6.34 1.60 2 
sd 2.77 0.60 - 
CV (%) 44% 38% - 
D28 
Mean 32.5 2.28 1 
sd 1.08 0.35 - 
CV (%) 3% 15% - 
R30662N 
14.6 D1 
Mean 41.5 7.74 1 
sd 12.6 1.25 - 
CV (%) 30% 16% - 
16.2 D28 
Mean 106 9.00 1 
sd 25.2 1.91 - 
CV (%) 24% 21% - 
Notes 
A Overall estimated inhaled dose for toxicopathology animals over the 28-day 
treatment period. 
B Mean calculated from parameter for each rat (n=3): parameter dose-
normalised (division by estimated inhaled dose on day of sampling) and 
re-normalised with the overall estimated inhaled dose A. 
C Median time presented relative to start of the 1-hour exposure period. 
CV Coefficient of variation (%) = sd/mean 
TEM of macrophages sampled from control rats administered lactose 
alone revealed normal cells with no evidence of particle uptake 
(Figure 5.9). The control macrophages were of normal appearance, 
typically spherical with lamellipodia at their surface and a large 
pleomorphic nucleus (size and shape varied). Many primary lysosomes 
were present (medium electron density and highly pleiomorphic), with 
fewer secondary lysosomes that were generally larger and often 
contained lamellar-like material considered likely to be derived from 
pulmonary surfactant. Lipid was often present (seen as an electron 
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dense core with an electron lucent periphery, representing artefactual 
extraction of lipid during sample processing) and other features 
included frequent prominent Golgi and mitochondria (typically spherical 
to ovoid and containing well defined cristae). 
 
(R29413; Rat 026)  
Figure 5.9: Normal macrophage sampled from a rat (control) after 
inhaled administration of lactose vehicle for 3 days. Rats were exposed 
to lactose vehicle alone for 3 days. Macrophages were harvested post 
mortem in saline by bronchoalveolar lavage and processed for transmission 
electron microscopy. The image shows a normal macrophage containing 
primary (L1) and secondary (L2) lysosomes, partly extracted lipid droplets 
(LPD) and lamellar bodies (S) likely to be lung surfactant. Additional features 
include the nucleus (N), vacuoles (V) and lamellipodia (P). 
TEM of macrophages harvested from rats administered crystalline 
GSK-899 (1.05 or 45.3 mg/kg/day) revealed a dose-related increase in 
rectangular inclusions (Figure 5.10). The shapes of inclusions were 
LPD 
L1 
S 
L2 
N 
L2 
S 
V 
P 
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consistent with the cross section of micronised crystals imaged by 
scanning electron microscopy (SEM) in Chapter 2 (Figure 2.16A) and 
phagocytosed inclusions seen in vitro (Figure 5.6A). The ultrastructure 
of macrophages from rats administered crystalline GSK-899 was 
otherwise similar to controls administered the vehicle (lactose) alone. 
5.10A: 1.05 mg/kg/day 
 
(R29413; Rat 043) 
5.10B: 45.3 mg/kg/day 
 
(R29413; Rat 056) 
Figure 5.10: Macrophages containing crystalline particles after 
inhalation of GSK-899 for 3 days. Rats were exposed to lactose vehicle 
alone or in combination with crystalline GSK-899 for 3 days. Macrophages 
were harvested post mortem in saline by bronchoalveolar lavage and 
processed for transmission electron microscopy. 5.10A: macrophage 
containing partly extracted lipid droplets and a few crystal-like ‘rectangular’ 
inclusions (Cr). 5.10B: macrophage containing numerous crystal-like 
inclusions (Cr) consistent with a dose dependent increase for a higher 
GSK-899 dose. 
Rats administered micronised crystalline GSK258899B for 28 days 
presented dose-dependent increases in the incidence and severity of 
multifocal foamy macrophage aggregates (Table 5.13 and Figure 5.11) 
at administered doses (mild at 1.06 mg/kg/day and minimal to marked 
at 14.5 mg/kg/day) with foamy macrophage degeneration/necrosis and 
intra-alveolar neutrophils (minimal at 14.5 mg/kg/day; a few aggregates 
at 1.06 mg/kg/day). At 14.5 mg/kg/day, the macrophage aggregates 
were associated with inflammatory changes characterised by interstitial 
mononuclear inflammatory cell infiltration (mild to marked); 
immunohistochemical staining confirmed the inflammatory cells were 
Cr 
C r 
C r 
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macrophages (CD68 positive) and T lymphocytes (CD3-positive) and, 
in 2/6 animals, B-lymphocytes (CD79 positive). 
Table 5.13: Histopathology of the respiratory tract of rats  
exposed to micronised crystalline GSK-899 for 28 days 
Vehicle for powder dispersal: lactose Incidence of findings  
Study Numbers R29413 R30662N 
Estimated inhaled dose (mg/kg/day) 0 
(control) 
1.06 0 
(control) 
14.5 
Number of rats on study Grading of 
observation 
6 6 6 6 
Initial examination 6 0A 6 6 
Lung No finding 5 3 4 0 
Aggregate, foamy 
macrophage; multifocal 
Minimal 1 1 2 0 
Mild 0 2 0 3 
 Moderate 0 0 0 2 
 Marked 0 0 0 1 
Inflammatory cell infiltrate;       
alveolus; neutrophilic, 
multifocal 
Minimal 0 0 0 6 
interstitium; mononuclear 
cell, multifocal 
Mild 0 0 0 4 
Moderate 0 0 0 1 
 Marked 0 0 0 1 
Degeneration/necrosis; 
foamy macrophage, 
multifocal 
Minimal 0 0 0 6 
Cellularity increased; BALT Minimal 0 0 0 1 
(bronchus-associated 
lymphoid tissue) 
Mild 0 0 0 2 
Lymph node, tracheo-
bronchial 
No finding 3 3 4 0 
(no section) (0) (1) (1) (1) 
Cellularity increased; 
paracortex 
Mild 0 0 0 5 
Aggregate; macrophage; 
paracortex; multifocal 
Minimal 0 0 0 2 
Mild 0 0 0 3 
Larynx No finding 6 6 6 1 
Squamous metaplasia Minimal 0 0 0 5 
Notes 
No treatment related findings: trachea and nasopharynx (animals of study R30662N 
only examined), tracheal bifurcation, nasal cavity. 
A Study R29413: target doses of 0, 1 and 45 mg/kg/day administered; tissues of 
rats administered 1 mg/kg/day examined if findings were seen at 45 mg/kg/day. 
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Increased cellularity of bronchus-associated lymphoid tissue (BALT) 
was seen at 14.5 mg/kg/day, with multifocal macrophage aggregates 
(minimal or mild) and increased cellularity (mild) of BALT (Table 5.13 
and Figure 5.12). In the tracheobronchial lymph node, there was mild 
increased cellularity of the paracortex and minimal or mild multifocal 
macrophage aggregates with mild enlargement of the nodes. 
5.11A: Vehicle control (lactose) 
 
(R29413; Rat 001) 
5.11B: 1.06 mg/kg/day 
(R29413; Rat 010) 
5.11C: Vehicle control (lactose) 
 
(R30662N; Rat 002) 
5.11D: 14.5 mg/kg/day 
 
(R30662N; Rat 025) 
Figure 5.11: Representative histology of control rat lung and treatment 
related changes after inhalation of crystalline GSK-899 for 28 days. Rats 
were exposed to lactose vehicle alone or in combination with crystalline 
GSK-899 for 28 days. Sections of tissue (3 µm thick) were stained with 
haematoxylin and eosin; anatomical features are described in italics. 
5.11A: histologically normal rat lung showing alveolar duct and alveoli. 
5.11B: mild macrophage aggregates (M) larger than those typically seen in 
concurrent controls. A cross-section of a small airway (A) is also evident in 
section. 5.11C: control rat lung showing minimal macrophage aggregates (M). 
5.11D: moderate macrophage aggregates (M) and marked interstitial 
macrophages, T and B-lymphocytes (I); phenotype of inflammatory cells was 
confirmed by immunohistochemical staining for CD68, CD3 or CD79 
glycoproteins. 
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5.12A: Vehicle control (lactose) 
 
(R30662N; Rat 002) 
5.12B: 14.5 mg/kg/day 
 
(R30662N; Rat 025) 
Figure 5.12: Representative histology of control rat bronchus 
associated lymphoid tissue (BALT) and increased cellularity after 
inhalation of crystalline GSK-899 for 28 days. Rats were exposed to 
lactose vehicle alone or in combination with crystalline GSK-899. Tissue 
sections (3 µm thick) were stained with haematoxylin and eosin; anatomical 
features are described in italics. 5.12A: normal cellularity (C) showing alveoli 
(A), bronchus (BR) and vein (V) in cross-section. 5.12B: cellularity (C) 
increased relative to control with multifocal macrophage aggregates (M). 
Bronchus (BR) in cross-section. 
5.13A: Vehicle control (lactose) 
 
(R30662N; Rat 001) 
5.13B: 14.5 mg/kg/day 
 
(R30662N; Rat 025) 
Figure 5.13: Representative histology of control rat larynx and changes 
after inhalation of crystalline GSK-899 for 28 days. Rats were exposed to 
lactose vehicle alone or in combination with crystalline GSK-899. Tissue 
sections (3 µm thick) were stained with haematoxylin and eosin; an 
artefactual feature is described in italics. 5.13A: normal respiratory epithelium 
(RE); haemorrhage (H) was agonal (post mortem artefact). 5.13B: minimal 
squamous metaplasia. 
In the larynx, squamous metaplasia (minimal) was evident for most rats 
administered 14.5 mg/kg/day. The rodent larynx is more susceptible to 
aerosol damage than primates and metaplastic changes are likely to 
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represent a defence mechanism in which a susceptible epithelium is 
replaced by more durable cell types (Gopinath and Mowat, 1987). 
Amorphous GSK-899 was cleared from lung tissue after a single 
inhalation exposure (Figure 5.14). The mean lung concentration for rats 
administered 14.6 mg/kg at 24 hours (relative to the start of exposure) 
was approximately 0.7% of that determined immediately post 
exposure, and lung concentrations at 24 hours for rats administered 
0.024 or 1.04 mg/kg were not quantifiable (<120 ng/g). GSK-899 
concentrations were not quantifiable in lungs at 24 hours following 
completion of the 28-day treatment period for doses ≤1.09 mg/kg/day. 
This contrasted with lung concentrations following administration of 
crystalline GSK-899, which were approximately seven-fold higher 
immediately post exposure and persisted at 24 hours.  
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Figure 5.14: Drug-lung concentrations in rats following inhaled 
administration of amorphous GSK-899 for one or 28 days. Mean 
GSK-899 concentrations with standard deviations (error bars; n=3) are shown 
for rat lung homogenate data for samples taken immediately after a single 
1-hour exposure and 24 hours after single or repeat exposures. Lung 
concentrations at 24 hours for doses of ≤1 mg/kg/day (*) were below the limit 
of quantification (<120 ng/g lung tissue). Statistical analysis (2-way ANOVA 
with post hoc analysis using Tukey’s honestly significant difference test (Abdi 
and Williams, 2010[B])) of log10-transformed data achieved significance for 1 
vs 24 hours (p<0.01) and Days 1 vs 28 (24 hours; p<0.05). 
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These findings are in line with expectations based on results 
summarised in Chapter 2 for in vitro dissolution (Figure 2.14) and in 
vivo lung concentration data (Figure 2.21). However, accumulation of 
GSK-899 in lungs was evident after repeated administration of 
14.6 mg/kg/day, with an approximate nine-fold increase in trough 
concentrations from Days 1 to 28 of treatment. Although the degree of 
apparent accumulation was similar to that observed for crystalline 
GSK-899 at this dose, the absolute mean lung concentration following 
the last exposure to amorphous GSK-899 was <0.1% that measured 
after exposure to crystalline GSK-899. The apparent accumulation and 
the magnitude of difference between the particle forms of GSK-899 
suggests sequestration of amorphous particles, for example lysosomal 
trapping, rather than saturation of clearance mechanisms per se. 
Mean plasma concentrations of GSK-899 were similar on Days 1 and 
28 of treatment for a given dose following inhaled administration of 
amorphous GSK-899 (Figure 5.15) and approximately three-fold higher 
than following administration of crystalline GSK-899 on Day 1 
(Figure 5.8A). The plasma concentration profile on Day 28 for animals 
administered 0.02 mg/kg/day was lower at two hours than at 
subsequent timepoints (Figure 5.15B), which was probably a 
consequence of data variability exacerbated when 2/3 values at two 
hours were not quantifiable (<0.05 ng/mL), skewing calculation of the 
mean (zero values were entered for non-quantifiable sample results). 
Systemic exposure (AUC0-t and Cmax) of rats administered amorphous 
GSK-899 at 15 mg/kg/day was similar for Days 1 and 28 of treatment 
but approximately two-fold lower on Day 28 for animals administered 
1 mg/kg/day (Table 5.14). For animals receiving 0.02 mg/kg/day, 
insufficient data were quantifiable on Day 1 (plasma concentrations 
<0.05 ng/mL from three hours) to enable determination of AUC0-t. 
Although more samples were quantifiable on Day 28 for animals 
administered 0.02 mg/kg/day, permitting estimation of an AUC0-t, the 
paucity of data precludes assessment of any changes between Days 1 
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and 28 at the low dose. Nevertheless, there was no evidence for 
systemic accumulation at higher doses (≥1 mg/kg/day). 
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Figure 5.15: GSK-899 concentrations in rat plasma up to 24 hours after 
inhaled doses of amorphous GSK-899 on Days 1 and 28. Rats inhaled an 
aerosol of amorphous GSK-899 once daily (1 hour) for up to 28 days; mean 
plasma concentrations with standard deviations (error bars; n=3) are shown 
for samples taken up to 24 hours after the start of inhalation exposure. 
5.15A: plasma concentrations after a single exposure (Day 1). 5.15B: plasma 
concentrations after repeated administration (Day 28). Statistical analysis 
(MANOVA with post hoc analysis using Tukey’s honestly significant difference 
test (Abdi and Williams, 2010[B])) of log10-transformed data indicated no 
statistical difference between Days 1 and 28. 
Systemic exposure (AUC0-t and Cmax) generally increased under 
proportionally for an increase in dose in line with data for crystalline 
GSK-899 at these doses. 
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Table 5.14: Pharmacokinetics of GSK-899 in plasma after inhaled  
administration of amorphous powder (n=3) 
Study 
No. 
Estimated 
Inhaled Dose 
(mg/kg/day) A 
Period 
(Day) 
Statistical 
parameter 
Pharmacokinetics (plasma) 
AUC0-t  
(h.ng/mL) B 
Cmax  
(ng/mL) B 
Tmax 
(h) C 
R30662N 
0.022 D1 
Mean ND D 0.27 1 
sd - 0.14 - 
CV (%) - 52% - 
0.024 D28 
Mean 1.24 0.89 1 
sd 0.4 0.57 - 
CV (%) 35% 65% - 
1.30 D1 
Mean 16.7 9.10 1 
sd 10.9 5.88 - 
CV (%) 65% 65% - 
1.05 D28 
Mean 10.5 5.93 1 
sd 6.39 3.49 - 
CV (%) 61% 59% - 
15.9 D1 
Mean 134 62.6 1 
sd 82.0 36.7 - 
CV (%) 61% 59% - 
14.6 D28 
Mean 134 59.5 1 
sd 110 46.1 - 
CV (%) 82% 78% - 
Notes 
A Overall estimated inhaled dose for toxicopathology animals over the 28-day 
treatment period. 
B Mean calculated from parameter for each rat (n=3): parameter dose-
normalised (division by estimated inhaled dose on day of sampling) and 
re-normalised with the overall estimated inhaled dose A. 
C Median time presented relative to start of the 1-hour exposure period. 
D  Not determined: insufficient data were available to permit calculation of the 
AUC0-t (concentrations for only two timepoints >0.05 ng/mL)  
CV Coefficient of variation (%) = sd/mean 
TEM imaging of macrophages obtained from rats administered 
amorphous GSK-899 (10.9 mg/kg/day) revealed angular inclusions in a 
small proportion of macrophages (Figure 5.16B) consistent with the 
cross section of the dimpled spheres characterised by SEM in 
Chapter 2 (Figure 2.17A). Lamellar material and other inclusions were 
present but the shape was less distinct and these probably represent 
neutral lipid partially extracted during processing of the samples and 
similar to that seen in the lactose control (Figure 5.9). 
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5.16A: 10.9 mg/kg/day 
 
(R30662N; Rat 034) 
5.16B: 10.9 mg/kg/day 
 
(R30662N; Rat 034) 
Figure 5.16: Macrophages containing amorphous particles after 
inhalation of GSK-899 for 3 days. Rats were exposed to lactose vehicle 
alone or in combination with amorphous GSK-899 for 3 days. Macrophages 
were harvested post mortem in saline by bronchoalveolar lavage and 
processed for transmission electron microscopy. 5.16A: macrophage showing 
evidence of artefactually extracted neutral lipid (LPD) and numerous 
lysosomes (L) of which some contain lamellar material likely to be lung 
surfactant (S). 5.16B: macrophage with angular inclusions (A) likely to be 
amorphous GSK-899. Additional features in section include the Golgi body 
(G), primary lysosomes (L1), secondary lysosomes (L2) containing lamellar 
material, neutral lipid (LPD) with artefactual extraction (X), and ribosomes (R) 
that appear granular. 
Rats administered amorphous GSK-899 for 28 days presented dose-
dependent increases in the incidence and severity (minimal or mild) of 
multifocal foamy macrophage aggregates at ≥0.024 mg/kg/day 
(Table 5.15). Aggregates were associated with minimal interstitial 
mononuclear inflammatory cell infiltration in a proportion of animals 
receiving ≥1.10 mg/kg/day (Figure 5.17); immunohistochemical staining 
confirmed that inflammatory cells were macrophages (CD68-positive) 
at ≥1.10 mg/kg/day with T-lymphocytes (CD3-positive) also present at 
15.6 mg/kg/day. The aggregates occurred in alveolar lumens bordering 
terminal bronchioles/alveolar ducts. Although the severity of the 
inflammatory cell infiltration was minimal following administration of 
amorphous GSK-899 (compared with mild to severe for crystalline 
GSK-899), the presence, incidence and nature of the finding were 
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sufficient for a dose of 14.6 mg/kg/day to be considered adverse, i.e. 
detrimental to the health status of the treated animals. 
Squamous metaplasia (minimal) was observed in the larynx of most 
rats administered amorphous GSK-899 at ≥1.10 mg/kg/day 
(Figure 5.18), indicating that rats were more sensitive to irritation by the 
amorphous particle form. 
Table 5.15: Histopathology of the respiratory tract of  
rats exposed to amorphous GSK-899 for 28 days 
Vehicle for powder dispersal: lactose Incidence of findings  
(Study R30662N) 
Estimated inhaled dose (mg/kg/day) 0 
(control) 
0.024 1.10 15.6 
Number of rats on study Grading of 
observation 
6 6 6 6 
Initial examination 6 0 0 6 
Lung No findings 4 2 2 1 
Aggregate, foamy 
macrophage; multifocal 
Minimal 2 3 3 2 
Mild 0 1 1 3 
Inflammatory cell 
infiltrate; interstitium; 
mononuclear cell, 
multifocal 
Minimal 0 0 2 4 
Larynx No findings 6 6 1 1 
Squamous metaplasia Minimal 0 0 5 5 
Notes 
No treatment related findings (control and high dose animals examined): lymph 
node (tracheobronchial), tracheal bifurcation, trachea, nasopharynx, nasal cavity. 
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5.17A: Vehicle control (lactose) 
 
(R30662N; Rat 001) 
5.17B: 0.024 mg/kg/day 
 
(R30662N; Rat 009) 
5.17C: 1.10 mg/kg/day 
 
(R30662N; Rat 015) 
5.17D: 15.6 mg/kg/day 
 
(R30662N; Rat 021) 
Figure 5.17: Representative histology of control rat lung and treatment 
related changes after inhalation of amorphous GSK-899 for 28 days. 
Rats were exposed to lactose vehicle alone or in combination with amorphous 
GSK-899 for 28 days. Sections of tissue (3 µm thick) were stained with 
haematoxylin and eosin; anatomical features are described in italics. 5.17A: 
normal rat lung showing minimal macrophage aggregates (M). 
5.17B: minimal macrophage aggregates (M). An airway (A) in cross-section 
and a blood vessel (B) cut longitudinally are shown. 5.17C: mild macrophage 
aggregates (M); several aggregates seen in the plane of the section were 
bigger than those seen in concurrent controls. Minimal interstitial 
accumulation of macrophages (I) was confirmed by immunohistochemical 
staining for CD68 glycoprotein. Airways (A) and a blood vessel (B) containing 
erythrocytes (E) are visible in cross-section. 5.17D: mild macrophage 
aggregates (M) and minimal interstitial accumulation of macrophages and 
T lymphocytes (I) (immunohistochemical staining for CD68, CD3 or CD79 
glycoproteins confirmed interstitial cell phenotypes). Terminal bronchioles 
were evident opening up into alveolar ducts (T). 
 
M 
M I 
I 
A 
A 
A 
 
E 
B 
M 
B 
T 
M 
Chapter Five 
295 
 
5.18A: Vehicle control (lactose) 
 
(R30662N; Rat 001) 
5.18B: 0.024 mg/kg/day 
 
(R30662N; Rat 009) 
5.18C: 1.10 mg/kg/day 
 
(R30662N; Rat 015) 
5.18D: 15.6 mg/kg/day 
 
(Study R30662N; Rat 020) 
Figure 5.18: Representative histology of control rat larynx and treatment 
related changes after inhalation of amorphous GSK-899 for 28 days. 
Rats were exposed to lactose vehicle alone or in combination with amorphous 
GSK-899 for 28 days. Sections of tissue (3 µm thick) were stained with 
haematoxylin and eosin; artefactual and anatomical features are described in 
italics. 5.18A: rat larynx showing normal respiratory epithelium (RE); the 
haemorrhage (H) evident in section was agonal (post mortem artefact). 
5.18B: rat larynx showing normal cartilage (Ctg) and respiratory epithelium 
(RE); no GSK-899 related changes evident. 5.18C: minimal squamous 
metaplasia (S). Separation of the tissue layers (X) was an artifact of the 
sectioning process post mortem. 5.18D: minimal squamous metaplasia (S). 
Cartilage (Ctg and erythrocytes in a blood vessel (B) are visible in-section; 
erythrocytes in the lumen were agonal in origin. 
Mean concentrations of GSK-899 in rat lung after a single exposure 
(one hour) were similar for nebulised aerosols using either vehicle 
(Figure 5.19) and approximately half that of rats administered 
amorphous GSK-899 at this dose. Lung clearance of GSK-899 was 
evident at 24 hours (mean concentration ≤8% of that at one hour), with 
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an increase in trough concentrations from Days 1 to 28 (eight-fold 
when concentrations were also quantifiable at 24 hours on Day 1). 
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Figure 5.19: Drug-lung concentrations in rats following inhaled 
administration of nebulised GSK-899 for one or 28 days. Rats inhaled a 
nebulised aerosol of GSK-899 once daily (1 hour) for up to 28 days; mean 
dose normalised GSK-899 concentrations with standard deviations (error 
bars; n=3) are shown for rat lung homogenate data of samples taken 
immediately after a single exposure (1 hour) and at 24 hours after single or 
repeat exposures. Lung concentrations for a dose of 1 mg/kg/day in Vehicle B 
(*) were below the limit of quantification (<120 ng/g lung tissue) 24 hours after 
a single exposure. Statistical analysis (2-way ANOVA with post hoc analysis 
using Tukey’s honestly significant difference test (Abdi and Williams, 
2010[B])) of log10-transformed data achieved significance for 1 vs 24 hours 
(p<0.01) and Days 1 vs 28 (24 hours; p<0.05); no statistical difference 
between the two nebulised formulations of GSK-899. 
• Vehicle A = 3% (v/v) Solutol HS 15 in 0.9% (w/v) aqueous sodium chloride. 
• Vehicle B = 3% (v/v) Solutol HS 15 in 10% (w/v) aqueous 2-hydroxypropyl-B-
cyclodextrin. 
Mean concentrations of GSK-899 in rat plasma were similar on Days 1 
and 28 of treatment for each of the nebulised formulations, with Tmax 
observed immediately post exposure (Figure 5.20 and Table 5.16). 
Plasma AUC0-t following exposure of rats to GSK-899 nebulised in 
Solutol-NaCl was similar to that achieved following administration of 
amorphous powder (Table 5.14), but was approximately half that of the 
dose normalised AUC0-t achieved with nebulisation of GSK-899 in 
Solutol-HPβCD. This confirmed that inclusion of the hydrophilic 
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cyclodextrin in the vehicle enhanced systemic uptake of GSK-899 
(Chapter 2, Section 2.2.5.3). 
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Figure 5.20: GSK-899 concentrations in rat plasma up to 24 hours after 
inhalation of nebulised doses on Days 1 and 28. Rats inhaled a nebulised 
aerosol of GSK-899 once daily (1 hour) for up to 28 days; mean dose 
normalised plasma concentrations with standard deviations (error bars; n=3) 
are shown for samples taken up to 24 hours after the start of inhalation 
exposure. 5.20A: plasma concentrations after a single exposure (Day 1). 
5.20B: plasma concentrations after repeated administration (Day 28). 
Statistical analysis (MANOVA with post hoc analysis using Tukey’s honestly 
significant difference test (Abdi and Williams, 2010[B])) of log10-transformed 
data achieved significance between the two nebulised formulations (p<0.01); 
no statistical difference between the Days 1 and 28 when dose normalised. 
• Vehicle A = 3% (v/v) Solutol HS 15 in 0.9% (w/v) aqueous sodium chloride. 
• Vehicle B = 3% (v/v) Solutol HS 15 in 10% (w/v) aqueous 2-hydroxypropyl-B-
cyclodextrin. 
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Table 5.16: Pharmacokinetics of GSK-899 in plasma after  
inhaled administration of nebulised solutions (n=3) 
Study No. 
Estimated 
Inhaled Dose 
(mg/kg/day) A 
Period 
(Day) 
Statistical 
parameter 
Pharmacokinetics (plasma) 
AUC0-t 
(h.ng/mL) B 
Cmax 
(ng/mL) B 
Tmax 
(h) C 
R31038N 0.842 
D1 
Mean 18.5 10.5 1 
sd 3.88 2.40 - 
CV (%) 21% 23% - 
D28 
Mean 21.5 10.7 1 
sd 7.37 3.65 - 
CV (%) 34% 34% - 
R31039N 1.099 
D1 
Mean 53.1 35.5 1 
sd 9.58 7.84 - 
CV (%) 18% 22% - 
D28 
Mean 57.7 31.0 1 
sd 11.69 11.76 - 
CV (%) 20% 38% - 
Notes 
A Overall estimated inhaled dose for toxicopathology animals over the 28-day 
treatment period. 
B Mean calculated from parameter for each rat (n=3): parameter dose-
normalised (division by estimated inhaled dose on day of sampling) and 
re-normalised with the overall estimated inhaled dose A. 
C Median time presented relative to start of the 1-hour exposure period. 
CV Coefficient of variation (%) = sd/mean 
Examination of macrophages from rats administered nebulised 
GSK-899 (0.842 mg/kg/day) by TEM showed no evidence of particulate 
GSK-899. The appearance of these macrophages was similar to those 
of the vehicle control (Solutol-NaCl). A proportion of cells contained 
neutral lipid droplets or angular clefts (Figure 5.21) that were 
artefactual and ascribed to extraction of lipid during processing and/or 
cholesterol crystals (Lupu et al., 1987). 
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5.21A: Vehicle control (nebulised) 
 
(R31038N; Rat 067) 
5.21B: 0.65 mg/kg/day 
 
(R31038N; Rat 068) 
Figure 5.21: Macrophages after inhalation of nebulised vehicle or 
GSK-899 for 3 days. Rats were exposed to vehicle alone (3% (v/v) Solutol 
HS 15 in 0.9% (w/v) aqueous sodium chloride) or a solution of GSK-899 for 3 
days. Macrophages were harvested post mortem in saline by bronchoalveolar 
lavage and processed for transmission electron microscopy. 
5.21A: macrophage containing lipid droplets (LPD). Angular electron lucent 
crystal-like areas (C) associated with lipid droplets were consistent with 
extracted neutral lipid or cholesterol clefts (Lupu et al., 1987). 
5.21B: macrophage containing lipid droplets (LPD) and crystal-like inclusions 
(C); no GSK-899 related ultrastructural changes were evident. 
Multifocal bronchioloalveolar aggregates of macrophages (minimal or 
mild) were seen in the lungs of most rats administered 1 mg/kg/day 
GSK-899 nebulised in Solutol-NaCl (Table 5.17). In one rat, some 
macrophage aggregates were associated with alveolar wall thickening 
and scattered rare neutrophils. The macrophage aggregates were of 
similar grading to those seen following administration of crystalline or 
amorphous GSK-899 at this dose. 
The macrophage aggregates (mild) were also seen in the lungs of all 
control rats exposed to Solutol-HPβCD, and were associated with 
neutrophils and interstitial mononuclear inflammatory cells (minimal) 
and macrophage degeneration/necrosis (minimal in 5/6 rats; mild in 
one rat). The same lung pathology changes were seen in rats 
administered GSK-899 in Solutol-HPβCD but the macrophage 
degeneration/necrosis was more pronounced (minimal in one rat; mild 
LPD 
C 
LPD 
LPD 
C 
LPD 
LPD 
C 
C 
C 
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in five rats) indicating exacerbation of the vehicle-related finding by 
GSK-899 (Table 5.18). 
At the tracheal bifurcation of one rat administered 1 mg/kg/day 
nebulised in Solutol-NaCl, epithelial degeneration (minimal), 
characterised by deciliation and basophilia, was noted. However, the 
larynx showed no evidence of irritancy unlike that of rats exposed to 
crystalline or amorphous powders of GSK-899. 
Table 5.17: Histopathology of the respiratory tract of  
rats exposed to nebulised GSK-899 for 28 days 
 Incidence of findings  
Study Numbers  R31038N R31039N 
Vehicle for nebulised solution 3% (v/v) Solutol 
HS 15 in 0.9% 
(w/v) aqueous 
sodium chloride 
3% (v/v) Solutol 
HS 15 in 10% 
(w/v) aqueous 
2-hydroxyproyl-
β-Cyclodextrin 
Estimated inhaled dose (mg/kg/day) 0 
(control) 
0.84 0 
(control) 
0.84 
Number of rats on study Grading of 
observation 
6 6 6 6 
Initial examination 6 6 6 6 
Lung No finding 5 2 0 0 
Aggregate, foamy 
macrophage; multifocal; 
 † bronchioloalveolar 
Minimal 1† 2† 0 0 
Mild 0 2† 6 6 
Inflammatory cell infiltrate;      
alveolus; neutrophilic, 
multifocal 
Minimal 0 0 6 6 
interstitium; mononuclear 
cell, multifocal 
Minimal 0 0 6 6 
Degeneration/necrosis; 
macrophage 
Minimal 0 0 5 1 
Mild 0 0 1 5 
Tracheal bifurcation No finding 5 5 6 6 
 (no section) (1) (0) (0) (0) 
Degeneration; epithelium Minimal 0 1 0 0 
Liver No finding 6 6 6 3 
Cytoplasmic rarefaction; 
hepatocellular 
Mild 0 0 0 3 
Notes 
No treatment related findings (control and high dose animals examined): larynx, 
lymph node (tracheobronchial, mandibular), trachea, nasopharynx, nasal cavity. 
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5.22A: Vehicle control 
 
(R31038N; Rat 001) 
5.22B: 0.84 mg/kg/day 
 (R31038N; Rat 010) 
Figure 5.22: Representative histology of control rat lung and treatment 
related changes after inhalation of nebulised GSK-899 for 28 days. Rats 
were exposed to the vehicle alone (3% (v/v) Solutol HS 15 in 0.9% (w/v) 
aqueous sodium chloride) or as a solution of GSK-899 for 28 days. Sections 
of tissue (3 µm thick) were stained with haematoxylin and eosin; anatomical 
features are described in italics. 5.22A: normal rat lung showing alveolar duct 
and alveoli. 5.22B: minimal bronchioloalveolar foamy macrophage 
aggregates (M). 
 
5.23A: Vehicle control 
 
(R31039N; Rat 001) 
5.23B: 0.84 mg/kg/day 
 
(R31039N; Rat 007) 
Figure 5.23: Representative histology of rat lung and treatment related 
changes after inhalation of nebulised GSK-899 and/or vehicle for 28 
days. Rats were exposed to the vehicle alone (3% (v/v) Solutol HS 15 in 10% 
(w/v) aqueous 2 hydroxypropyl-B-cyclodextrin) or as a solution of GSK-899 
for 28 days. Sections of tissue (3 µm thick) were stained with haematoxylin 
and eosin; anatomical features are described in italics. 5.23A: lung of a 
control rat showing mild foamy macrophage aggregates (M) ascribed to 
administration of the nebulised vehicle. A blood vessel (B) is also evident, this 
time in cross-section. 5.23B: mild foamy macrophage aggregates (M). A 
blood vessel (B) is also evident, this time in longitudinal-section. 
The mean lung concentration of GSK-899 in lungs taken one hour after 
a single subcutaneous dose of 5 mg/kg was approximately half that 
M 
M 
B 
M 
E B 
E 
M 
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achieved after administration of a single nebulised dose of 1 mg/kg. A 
reduction in lung concentration was evident at 24 hours (10% of mean 
value at one hour) with a two-fold increase in trough concentrations 
form Days 1 to 28 of treatment (Figure 5.24). 
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Figure 5.24: Drug-lung concentrations in rats after subcutaneous 
administration of GSK-899 for one or 28 days. Mean GSK-899 
concentrations with standard deviations (error bars; n=3) are shown for rat 
lung homogenate data for samples taken 1 and 24 hours after a single dose 
and 24 hours after repeated administration. Statistical analysis (1-way 
ANOVA with post hoc analysis using Tukey’s honestly significant difference 
test (Abdi and Williams, 2010[B])) of log10-transformed data achieved 
significance (p<0.01) between 1 and 24 hours, and between Days 1 and 28 
(24 hours). 
Cmax of GSK-899 in plasma was observed at one or two hours after 
subcutaneous injection of 5 mg/kg on Days 1 and 28 respectively, with 
elimination of the analyte from plasma at 24 hours and no obvious 
accumulation over the 28-day treatment period (Figure 5.25).  
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Figure 5.25: GSK-899 concentrations in rat plasma up to 24 hours after 
subcutaneous administration on Days 1 and 28. Mean GSK-899 
concentrations in plasma with standard deviations (error bars; n=3) are 
shown for plasma samples taken up to 24 hours post dose. 5.25A: plasma 
concentrations after a single dose (Day 1). 5.25B: plasma concentrations 
after the final dose (Day 28). Statistical analysis (2-way ANOVA with post hoc 
analysis using Tukey’s honestly significant difference test (Abdi and Williams, 
2010[B])) of log10-transformed data achieved significance (p<0.05) between 
Days 1 and 28. 
Systemic exposure (AUC0-t) in plasma was similar on Days 1 and 28, 
and at least six-fold higher than that achieved with inhaled 
administration of 15 mg/kg/day crystalline or amorphous GSK-899 
(Table 5.18). 
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Table 5.18: Pharmacokinetics of GSK-899 in plasma after subcutaneous 
administration of a solution (n=3) 
Study 
No. 
Estimated 
Inhaled 
Dose 
(mg/kg/day) 
Period 
(Day) 
Statistical 
parameter 
Pharmacokinetics (plasma) 
AUC0-t 
(h.ng/mL) 
Cmax 
(ng/mL) 
Tmax 
(h) A 
R31697N 5 
D1 
Mean 803 157 2 
sd 197 46 - 
CV (%) 24% 30% - 
D28 
Mean 920 333 1 
sd 277 133 - 
CV (%) 30% 40% - 
Notes 
A Median time 
CV Coefficient of variation (%) = sd/mean 
There were no toxicopathology changes in the lungs of rats 
subcutaneously administered GSK-899 for 28 days (Table 5.19 and 
Figure 5.26). Minimal focal inflammatory cell infiltrate within the 
interstitium is a common background finding in Crl:CD(SD) rats; given 
the infiltration was not multifocal and also minimal, it was considered 
(in consultation with the study pathologist) not to be GSK-899-related. 
5.26A: Vehicle control 
 
(R31697N; Rat 002) 
5.26B: 5 mg/kg/day 
 
(R31697N; Rat 009) 
Figure 5.26: Representative histology of control rat lung and after 
subcutaneous administration of GSK-899 for 28 days. Rats were dosed 
the vehicle alone (3% (v/v) Solutol HS 15 in 0.9% (w/v) aqueous sodium 
chloride) or as a solution of GSK-899 for 28 days. Sections of tissue (3 µm 
thick) were stained with haematoxylin and eosin; anatomical features are 
described in italics. 5.26A: control rat lung showing occasional macrophages 
(M); a blood vessel (B) with erythrocytes (E) is evident in cross-section. 
5.26B: lung of rat administered nebulised GSK-899 showing normal lung with 
occasional macrophages (M). 
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Table 5.19: Histopathology of lungs and injection sites of  
rats dosed subcutaneously with GSK-899 for 28 days 
Vehicle for dosing: 3% (v/v) Solutol HS 15 in 0.9% (w/v) 
aqueous sodium chloride 
Incidence of findings  
(Study R31697N) 
Estimated inhaled dose (mg/kg/day) 0 (control) 5 
Number of rats on study Grading of 
observation 
5 6 
Initial examination 6 0 
Lung No findings 3 0 
Aggregate, foamy macrophage; BALT; 
multifocal 
Minimal 0 5 
   
Aggregate, macrophage; alveolar; focal Minimal 0 1 
Inflammatory cell infiltrate; interstitium; 
mixed cell, focal 
Minimal 2 4 
Thymus    
Haemorrhage; corticomedullary 
junction; focal 
Minimal 1 1 
Vacuolation, macrovesicular; cortex and 
medulla; multifocal 
Minimal 1 1 
Mild 2 3 
 Moderate 2 2 
Injection sites (x4): 
 28 doses were injected subcutaneously at four 
dorsal sites rotated daily (7 injections/site); severity 
of findings were higher for GSK-899 than vehicle 
  
Degeneration/regeneration; panniculus muscle; focal 
or multifocal 
5 + 6 +++ 
  
Inflammation; subcutis; lymphohistiocytic (lymphocytes 
and macrophages, predominantly the latter with 
GSK-899 doses); multifocal 
5 ++ 6 ++++ 
Fibroplasia; subcutis; diffuse 5 +++ 6 +++ 
Degeneration; subcutis (multifocal or diffuse) 4 +++ 6 ++++ 
Haemorrhage; subcutis; localised 2 ++ 6 +++ 
Pigmented macrophages; subcutis; focal at site 1 and 
multifocal at sites 2 to 4 
1 + 5 ++ 
  
Inflammatory (mononuclear) cell infiltrate; dermis; focal 1 + 
 
0 
 
Granuloma; dermis; focal 0 
 
1 + 
Notes 
Injection sites: the highest severity scored for observations in any animal and at any 
site is shown, graded as minimal (+), mild (++), moderate (+++) or marked (++++). 
No treatment related findings (control and high dose animals examined): lymph 
node (tracheobronchial), nasopharynx, nasal cavity. 
BALT bronchus associated lymphoid tissue 
A Injection sites: a summary of the incidence and severity of findings at the 
injection sites is presented in Appendix 9. 
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Foamy alveolar macrophages in the BALT of rats dosed with GSK-899 
(Figure 5.27B) were considered unlikely to be treatment related given 
the minimal grade (Table 5.19), variability in amount of BALT between 
rats and incidence of this finding in the hepatocytes and thymus 
(Figure 5.28A) of both control and GSK-899 treated rats.  
5.27A: Vehicle control 
 
(R31697N; Rat 002) 
5.27B: 5 mg/kg/day 
 
(R31697N; Rat 009) 
5.27C: Vehicle control 
 
(R31697N; Rat 002) 
5.27D: 5 mg/kg/day 
 
(R31697N; Rat 009) 
Figure 5.27: Representative histology of bronchus associated lymphoid 
tissue (BALT) after subcutaneous administration of GSK-899 and/or 
vehicle for 28 days. Rats were dosed the vehicle alone (3% (v/v) Solutol HS 
15 in 0.9% (w/v) aqueous sodium chloride) or as a solution of GSK-899 for 28 
days. Sections of tissue (3 µm thick) were stained with haematoxylin and 
eosin; anatomical features are described in italics. 5.27A: normal cellularity of 
rat BALT (C) showing alveoli (A) and a bronchus (BR) in cross-section; fat 
(Fa) appears as artefactual spaces due to depletion of fat from tissue during 
processing. 5.27B: BALT of rat administered GSK-899 showing minimal, 
multifocal aggregates of foamy macrophages (M); alveoli (A) and a blood 
vessel (B) with erythrocytes (E) are evident in cross-section. 5.27C: higher 
magnification showing normal cellularity of rat BALT. 5.27D: higher 
magnification of rat BALT showing aggregates of foamy macrophages (M). 
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5.28A: Vehicle control 
 
(R31697N; Rat 002) 
5.28B: 5 mg/kg/day 
 
(R31697N; Rat 009) 
5.28C: Vehicle control 
 
(R31697N; Rat 002) 
5.28D: 5 mg/kg/day 
 
(R31697N; Rat 009) 
Figure 5.28: Representative histology of thymus after subcutaneous 
administration of GSK-899 and/or vehicle for 28 days. Rats were dosed 
the vehicle alone (3% (v/v) Solutol HS 15 in 0.9% (w/v) aqueous sodium 
chloride) or as a solution of GSK-899 for 28 days. Sections of tissue (3 µm 
thick) were stained with haematoxylin and eosin; anatomical features are 
described in italics. 5.28A: thymus of a control rat showing occasional 
macrophages (M) in the medulla (Me) and cortex (Co). 5.28B: thymus of rat 
administered GSK-899 also showing occasional macrophages (M) in the 
medulla (Me) and cortex (Co). 5.28C: higher magnification of cortex showing 
macrovesicular vacuolation of macrophages (M). 5.28D: higher magnification 
of rat medulla and cortex also showing vacuolated macrophages (M). 
Injection sites were characterized by areas of localised haemorrhage 
and/or pigmented macrophages (stained for haemosiderin by Perl’s 
Prussian Blue) due to trauma of the dose route. These observations 
occurred within areas of multifocal or diffuse degeneration of the 
subcutis associated with varying degrees of lymphohistiocytic (T-cell 
predominant) inflammation and fibroplasia (Figure 5.29). Findings were 
consistent with local irritancy and seen in controls (Solutol-NaCl) but 
increased in severity and incidence for rats dosed GSK-899. 
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Degeneration and regeneration of the panniculus muscle in control and 
GSK-899 treated rats, and focal dermal granuloma in one GSK-899 
treated rat, were also related to needle trauma and post dose healing. 
5.29A: Vehicle control 
 
(R31697N; Rat 005) 
5.29B: 5 mg/kg/day 
 
(R31697N; Rat 012) 
5.29C: Vehicle control 
 
(R31697N; Rat 005) 
5.29D: 5 mg/kg/day 
 
(R31697N; Rat 012) 
Figure 5.29: Representative histology of subcutaneous injection site 
after administration of GSK-899 and/or vehicle for 28 days. Rats were 
dosed the vehicle alone (3% (v/v) Solutol HS 15 in 0.9% (w/v) aqueous 
sodium chloride) or as a solution of GSK-899 for 28 days using four dorsal 
injection sites in rotation. Tissue sections (3 µm thick) were stained with 
haematoxylin and eosin; anatomical features are described in italics. 
5.29A: skin of vehicle control rat showing the epidermis (E), dermis (D), 
panniculus muscle (M) and subcutis (S). 5.29B: GSK-899 treated rat skin 
showing areas of haemorrhage (H) and lymphohistiocytic inflammation (I) in 
the subcutis (S). Fat (Fa) appears as artefactual spaces in tissue due to its 
depletion during processing. 5.29C: high magnification of subcutis from a 
vehicle control rat showing lymphohistiocytic inflammation (I), characterized 
by macrophages and lymphocytes, and fibroplasia (Fi). Degeneration of 
subcutis is characterized by pale beaded collagen (P) and the formation of 
tracts (T). 5.29D: high magnification of subcutis of GSK-899 treated rat 
showing erythrocytes indicative of haemorrhage (H) and lymphohistiocytic 
inflammation (I), characterized mainly by macrophages. Degeneration of the 
subcutis is characterized by pale beaded collagen (P) and formation of 
tracts (T). 
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5.3.2.3. Pulmonary and systemic exposure of rats to 
GSK-677 and toxicopathology after 28 days 
Lung clearance of GSK-677 was evident after a single inhalation 
exposure of rats to the crystalline drug (Figure 5.30). The mean lung 
concentration for rats sampled at 24 hours (relative to the start of 
exposure) was less than 2% of that determined immediately post 
exposure. Slight accumulation of GSK-677 over the treatment period 
was evident (approximately two-fold increases in trough concentrations 
from Days 1 to 28), which contrasted slightly with expectations based 
on results summarised in Chapter 2 for in vitro dissolution (Figure 2.14) 
and in vivo lung concentration data (Figure 2.26) insofar as lung 
concentrations at 24 hours were not quantifiable and accumulation of 
GSK-677 in lung tissue was not anticipated. 
D
a
y
 1
:  
1
h
D
a
y
 1
:  
2
4
h
D
a
y
 2
8
:  
2
4
h
1 0 0
1 0 1
1 0 2
1 0 3
1 0 4
1 0 5
1 0 6
1 0 7
C ry s ta ll in e  G S K 6 1 0 6 7 7 B
L
u
n
g
 c
o
n
c
e
n
tr
a
ti
o
n
s
 (
n
g
/g
)
1  m g /k g /d a y
6 .5  m g /k g /d a y
1 5  m g /k g /d a y
Figure 5.30: Drug-lung concentrations in rats following inhaled 
administration of crystalline GSK-677 for one or 28 days. Mean GSK-677 
concentrations with standard deviations (error bars; n=3) are shown for rat 
lung homogenate data for samples taken immediately after a single 1-hour 
exposure and at 24 hours after single or repeat exposures. Statistical analysis 
(2-way ANOVA with post hoc analysis using Tukey’s honestly significant 
difference test (Abdi and Williams, 2010[B])) of log10-transformed data 
achieved significance between 1 and 24 hours (p<0.01); no significant 
difference for Days 1 vs 28 (24 hours). 
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Plasma concentration (Figure 5.31), AUC0-t and Cmax (Table 5.20) were 
similar for doses ≥7.29 mg/kg/day and lower at 1.04 mg/kg/day, with 
Tmax immediately post exposure. Differences in systemic exposure 
between Days 1 and 28 were minor, albeit statistically significant. 
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Figure 5.31: GSK-677 concentrations in rat plasma up to 24 hours after 
inhaled doses of crystalline GSK-677 on Days 1 and 28. Rats inhaled an 
aerosol of crystalline GSK-677 once daily (1-hour exposure) for up to 28 
days; mean plasma concentrations with standard deviations (error bars; n=3) 
are shown for samples taken up to 24 hours after the start of inhalation 
exposure. 5.31A: plasma concentrations after a single exposure (Day 1). 
5.31B: plasma concentrations after repeated administration (Day 28). 
Statistical analysis (MANOVA with post hoc analysis using Tukey’s honestly 
significant difference test (Abdi and Williams, 2010[B])) of log10-transformed 
data achieved significance between Days 1 and 28 (p<0.05). 
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Table 5.20: Pharmacokinetics of GSK-677 in plasma after  
inhaled administration of micronised crystals (n=3) 
Study No. 
Estimated 
Inhaled Dose 
(mg/kg/day) A 
Period 
(Day) 
Statistical 
parameter 
Pharmacokinetics (plasma) 
AUC0-t 
(h.ng/mL) B 
Cmax 
(ng/mL) B 
Tmax 
(h) C 
R31035N 
1.04 
D1 
Mean 32.1 17.9 1 
sd 11.4 9.0 - 
CV (%) 36% 51% - 
D28 
Mean 38.0 16.2 1 
sd 7.3 1.3 - 
CV (%) 19% 8% - 
7.29 
D1 
Mean 141.9 73.2 1 
sd 103.4 60.3 - 
CV (%) 73% 82% - 
D28 
Mean 180.5 88.8 1 
sd 94.3 48.3 - 
CV (%) 52% 54% - 
16.7 
D1 
Mean 98.6 62.1 1 
sd 68.9 64.3 - 
CV (%) 70% 104% - 
D28 
Mean 188.1 81.7 1 
sd 139.0 68.1 - 
CV (%) 74% 83% - 
Notes 
A Overall estimated inhaled dose for toxicopathology animals over the 28-day 
treatment period. 
B Mean calculated from parameter for each rat (n=3): parameter dose-
normalised (division by estimated inhaled dose on day of sampling) and 
re-normalised with the overall estimated inhaled dose A. 
C Median time presented relative to start of the 1-hour exposure period. 
CV Coefficient of variation (%) = sd/mean 
TEM imaging of macrophages from rats administered crystalline 
GSK-677 (19.2 mg/kg/day) showed crystal-like structures associated 
with neutral lipid droplets (Figure 5.32). The inclusions were unlikely to 
be crystalline drug substance because similar ‘structures’ were not 
evident in phagosomes (vacuoles containing phagocytosed material) or 
secondary lysosomes. Given their association with neutral lipid, it is 
considered likely these inclusions are cholesterol clefts similar to those 
described by Lupu et al. (1987) for lipid laden cells in atherosclerotic 
lesions. This is in line with in vitro results, which also showed lamellar 
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material but no obvious particulate drug substance within the 
macrophages (Figures 5.6C/D). 
5.32A: 19.2 mg/kg/day 
 
(R31037N; Rat 028) 
5.32B: 19.2 mg/kg/day 
 
(R31037N; Rat 028) 
Figure 5.32: Macrophages after inhalation of crystalline GSK-677 for 3 
days. Rats were exposed to lactose vehicle alone or in combination with 
crystalline GSK-677 for 3 days. Macrophages were harvested post mortem in 
saline by bronchoalveolar lavage and processed for transmission electron 
microscopy. 5.32A: vacuolated macrophage with lamellar material (Lm) 
considered to be phagocytosed surfactant; neutral lipid (LDP) and 
mitochondrion (M) also shown. 5.32B: higher magnification of macrophage 
showing neutral lipid (LPD) and associated crystal-like structures (C) 
considered consistent with extracted neutral lipid or cholesterol clefts (Lupu et 
al., 1987). 
Unpublished data (Freke, 2007) showed rats administered crystalline 
GSK-677 for 28 days presented dose-dependent increases in the 
incidence and severity (minimal or mild) of multifocal foamy 
bronchioloalveolar macrophage aggregates at ≥2.25 mg/kg/day 
(Table 5.21). In 3/10 rats administered 67.8 mg/kg/day, this finding was 
associated with mononuclear cell infiltration (mostly lymphocytic; 
minimal) and epithelial hyperplasia at the bronchioloalveolar junction. 
These findings are similar to those observed in rats administered 
GSK-899 at 1.1 mg/kg/day. 
A dose-related increase in the incidence of squamous metaplasia 
(minimal) was observed ventrally in the larynx of rats administered 
crystalline GSK-677 at ≥2.25 mg/kg/day (Table 5.21) indicating slight 
irritancy of crystalline GSK-677 in this tissue. 
L LPD 
C 
C 
Lm 
LPD 
M 
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Table 5.21: Histopathology of the respiratory tract of rats  
exposed to micronised crystalline GSK-677 for 28 days 
Vehicle for powder dispersal: lactose Incidence of findings  
(unpublished data: study R27090) 
Estimated inhaled dose (mg/kg/day) 0 
(control) 
0.016 0.20 2.25 67.8 
Number of rats on study Grading of 
observation 
10 10 10 10 10 
Initial examination 10 10 10 10 10 
Lung No finding 9 8 8 6 0 
Aggregate, foamy 
macrophage; 
bronchioloalveolar; 
multifocal 
1 (minimal) 1 2 2 3 3 
2 (mild) 0 0 0 1 7 
Infiltration, mononuclear 
cell 
1 (minimal) 0 0 0 0 3 
Hyperplasia, 
bronchioloalveolar 
1 (minimal) 0 0 0 0 3 
Larynx No finding 10 10 9 5 2 
Squamous metaplasia 1 (minimal) 0 0 1 5 8 
Notes 
Study performed at Charles River Laboratories, Montreal, Canada (Freke, 2007). 
No treatment related findings: bronchus, trachea, tracheal bifurcation, nasopharynx, 
nasal cavity. 
Mean GSK-677 concentrations in lungs of rats administered nebulised 
solutions were approximately half that of rats administered similar 
doses of crystalline GSK-677. 
Lung clearance of GSK-677 was evident after a single inhalation 
exposure of rats to nebulised solutions (Figure 5.33). The mean lung 
concentration at 24 hours (relative to the start of exposure) was less 
than 1% of that determined immediately post exposure. Accumulation 
of GSK-677 was evident from Days 1 to 28 of treatment (six or 14-fold 
increases in trough concentrations for mid and high doses respectively) 
in line with observations for crystalline GSK-677. 
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Figure 5.33: Drug-lung concentrations in rats following inhaled 
administration of nebulised GSK-677 for one or 28 days. Mean GSK-677 
concentrations with standard deviations (error bars; n=3) are shown for rat 
lung homogenate data for samples taken immediately after a single 1-hour 
exposure and at 24 hours after single or repeat exposures. Lung 
concentrations for a dose of 1 mg/kg/day (*) were below the limit of 
quantification (<120 ng/g lung tissue) 24 hours after a single exposure. 
Statistical analysis (2-way ANOVA with post hoc analysis using Tukey’s 
honestly significant difference test (Abdi and Williams, 2010[B])) of 
log10-transformed data achieved significance (p<0.01) for 1 vs 24 hours and 
Days 1 vs 28 (24 hours). 
Median Tmax was immediately post exposure. GSK-677 concentrations 
in plasma increased with an increase in the nebulised dose 
(Figure 5.34). There was no obvious or consistent change in systemic 
exposure between Days 1 and 28 of treatment (Table 5.22).  
Chapter Five 
315 
 
5.34A 
0 5 1 0 1 5 2 0
1 0 - 3
1 0 - 2
1 0 - 1
1 0 0
1 0 1
1 0 2
1 0 3
N e b u lis e d  G S K 6 1 0 6 7 7 B
T im e  (h o u r s )  a f te r  s ta r t  o f  1 -h o u r  e x p o s u r e
P
la
s
m
a
 c
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/m
L
)
1 .0 8  m g /k g /d a y  : D a y  1
4 .9 2  m g /k g /d a y  : D a y  1
1 4 .8  m g /k g /d a y  : D a y  1
 
5.34B 
0 5 1 0 1 5 2 0
1 0 - 3
1 0 - 2
1 0 - 1
1 0 0
1 0 1
1 0 2
1 0 3
N e b u lis e d  G S K 6 1 0 6 7 7 B
T im e  (h o u r s )  a f te r  s ta r t  o f  1 -h o u r  e x p o s u r e
P
la
s
m
a
 c
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/m
L
)
1 .0 8  m g /k g /d a y  : D a y  2 8
4 .9 2  m g /k g /d a y  : D a y  2 8
1 4 .8  m g /k g /d a y  : D a y  2 8
 
Figure 5.34: GSK-677 concentrations in rat plasma up to 24 hours after 
nebulised doses on Days 1 and 28. Rats inhaled a nebulised aerosol of 
GSK-677 once daily (1 hour) for up to 28 days; mean plasma concentrations 
with standard deviations (error bars; n=3) are shown for samples taken up to 
24 hours after the start of inhalation exposure. 5.34A: plasma concentrations 
after a single exposure (Day 1). 5.34B: plasma concentrations after repeated 
exposure (Day 28). Statistical analysis (MANOVA with post hoc analysis 
using Tukey’s honestly significant difference test (Abdi and Williams, 
2010[B])) of log10-transformed data achieved significance (p<0.01) between 
Days 1 and 28. 
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Table 5.22: Pharmacokinetics of GSK-677 in plasma after  
inhaled administration of a nebulised solution (n=3) 
Study No. 
Estimated 
Inhaled Dose 
(mg/kg/day) A 
Period 
(Day) 
Statistical 
parameter 
Pharmacokinetics (plasma) 
AUC0-t 
(h.ng/mL) B 
Cmax 
(ng/mL) B 
Tmax 
(h) C 
R31038N 
1.08 
D1 
Mean 18.9 10.4 1 
sd 3.32 2.16 - 
CV (%) 18% 21% - 
D28 
Mean 33.2 17.7 1 
sd 2.15 1.65 - 
CV (%) 6% 9% - 
4.92 
D1 
Mean 254 157 1 
sd 239.8 159.6 - 
CV (%) 94% 101% - 
D28 
Mean 320 191 1 
sd 48.3 32.7 - 
CV (%) 15% 17% - 
14.8 
D1 
Mean 481 232 1 
sd 152.7 145.3 - 
CV (%) 32% 63% - 
D28 
Mean 345 225 1 
sd 143.5 160.8 - 
CV (%) 42% 72% - 
Notes 
A Overall estimated inhaled dose for toxicopathology animals over the 28-day 
treatment period. 
B Mean calculated from parameter for each rat (n=3): parameter dose-
normalised (division by estimated inhaled dose on day of sampling) and 
re-normalised with the overall estimated inhaled dose A. 
C Median time presented relative to end of the 1-hour exposure period. 
CV Coefficient of variation (%) = sd/mean 
Examination of macrophages by TEM from rats administered nebulised 
GSK-677 (12.6 mg/kg/day) revealed no evidence of particulate drug 
substance within the cells in line with results for crystalline GSK-677. 
Macrophages appeared similar to the vehicle control (Solutol-NaCl) 
with a proportion of cells containing neutral lipid droplets or angular 
clefts (Figure 5.35) ascribed to lipid extraction during processing and/or 
cholesterol clefts (Lupu et al., 1987). 
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5.35A: Vehicle control (nebulised) 
 
(R31038N; Rat 067) 
5.35B: 12.6 mg/kg/day 
 
(R31038N; Rat 068) 
Figure 5.35: Macrophages after inhalation of nebulised vehicle or 
GSK-677 for 3 days. Rats were exposed to nebulised vehicle alone (3% (v/v) 
Solutol HS 15 in 0.9% (w/v) aqueous sodium chloride) or a solution of 
GSK-899 for 3 days. Macrophages were harvested post mortem in saline by 
bronchoalveolar lavage and processed for transmission electron microscopy. 
5.35A: macrophage containing lipid droplets (LPD). Angular shaped electron 
lucent areas (C) associated with the lipid droplets are considered consistent 
with extracted neutral lipid or cholesterol clefts (Lupu et al., 1987). 
5.35B: macrophage containing lipid droplets (LPD) and crystal-like inclusions 
(C) consistent with extracted neutral lipid or cholesterol clefts; no GSK-677 
related ultrastructural changes were evident. 
Multifocal bronchioloalveolar aggregates of macrophages (minimal to 
mild) were seen in most rats at all doses of nebulised GSK-677 
(Table 5.23 and Figure 5.36), in line with lung findings seen following 
administration of the crystalline aerosol form. 
Toxicopathology findings seen mainly at doses ≥4.92 mg/kg/day in the 
nasal cavity, larynx and tracheal bifurcation, a ‘hot spot’ for impaction 
of particulates, were indicative of chemical irritancy (Gopinath and 
Mowat, 1987). In the nasal cavity (Figure 5.37), a dose dependent 
increase in the frequency of respiratory epithelial degeneration was 
seen in sections at levels 1 and 2 (Figure 5.4A) of most rats 
administered ≥4.92 mg/kg/day (minimal; mild for one rat administered 
15 mg/kg/day). This finding was accompanied by focal squamous 
metaplasia (minimal) in a rat administered 15 mg/kg/day (Table 5.23).  
LPD 
C 
LPD 
LPD 
C 
LPD 
C C 
LPD 
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Table 5.23: Histopathology of the respiratory tract of  
rats exposed to nebulised GSK-677 for 28 days 
Vehicle for nebulised solution: 3% (v/v) Solutol 
HS 15 in 0.9% (w/v) aqueous sodium chloride 
Incidence of findings  
(Study R31038N) 
Target dose (mg/kg/day) 0 
(control) 
1.08 4.92 14.8 
Number of rats on study Grading of 
observation 
6 6 6 6 
Initial examination 6 0 0 6 
Lung No finding 5 1 2 1 
Aggregate, foamy 
macrophage; bronchiolo-
alveolar; multifocal 
Minimal 1 4 3 4 
Mild 0 1 1 1 
Larynx No finding 6 5 0 0 
Squamous metaplasia Mild 0 0 4 4 
 Moderate 0 0 2 2 
Necrosis; ventral pouch 
cartilage 
Present 0 0 5 6 
Inflammatory cell infiltrate; 
submucosa; mononuclear 
cell 
Minimal 0 0 2 2 
Mild 0 0 4 4 
Epithelial alteration Minimal 0 1 0 0 
Tracheal bifurcation No finding 5 5 5 2 
 (no section) (1) (0) (0) (0) 
Degeneration; epithelium Minimal 0 1 1 4 
Nasal cavity No finding 6 6 4 0 
Degeneration; respiratory 
epithelium 
Minimal 0 0 2 5 
Mild 0 0 0 1 
Squamous metaplasia; 
respiratory epithelium; focal 
Minimal 0 0 0 1 
Notes 
No treatment related findings (control and high dose animals examined): trachea, 
lymph node (tracheobronchial), nasopharynx; adrenals, colon, eyes and optic nerve, 
heart, jejunum, kidneys, liver, lymph node (mandibular), pancreas, testes, thymus. 
In the larynx (Figures 5.38), squamous metaplasia (mild or moderate) 
was seen ventrolaterally in all rats administered ≥4.92 mg/kg/day and 
was accompanied by necrosis of the ventral pouch cartilage 
(Figure 5.39) and submucosal mononuclear inflammatory cell 
infiltration (minimal or mild) for most animals at these doses 
(Table 5.23). Epithelial alteration (minimal), characterised by focal 
flattening and stratification of the epithelium, was noted ventrolaterally 
in one rat administered 1 mg/kg/day. At the tracheal bifurcation of most 
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rats given 14.8 mg/kg/day and one rat at each dose ≥4.92 mg/kg/day, 
epithelial degeneration (minimal) was characterised by deciliation and 
basophilia (increased frequency of basophils). 
5.36A: Vehicle control 
 
(R31038N; Rat 001) 
5.36B: 1.08 mg/kg/day 
 
(R31038N; Rat 015) 
5.36C: 4.92 mg/kg/day 
 
(R31038N; Rat 024) 
5.36D: 14.8 mg/kg/day 
 
(R31038N; Rat 028) 
Figure 5.36: Representative histology of control rat lung and treatment 
related changes after inhalation of nebulised GSK-677 for 28 days. Rats 
were exposed to the vehicle alone (3% (v/v) Solutol HS 15 in 0.9% (w/v) 
aqueous sodium chloride) or as a solution of GSK-677 for 28 days. Sections 
of tissue (3 µm thick) were stained with haematoxylin and eosin; anatomical 
features are described in italics. 5.36A: normal rat lung showing alveolar duct 
and alveoli. A blood vessel (B) with erythrocytes (E) is also evident in cross-
section. 5.36B: minimal foamy bronchioloalveolar macrophage aggregates 
(M). 5.36C: minimal foamy bronchioloalveolar macrophage aggregates (M). 
5.36D: mild foamy bronchioloalveolar macrophage aggregates (M). An airway 
(A) is evident in cross-section. 
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5.37A: Vehicle control 
 
(R31038N; Rat 001) 
5.37B: 1.08 mg/kg/day 
 
(Study R31038N; Rat 015) 
5.37C: 4.92 mg/kg/day 
 
(R31038N; Rat 022) 
5.37D: 14.8 mg/kg/day 
 
(R31038N; Rat 030) 
Figure 5.37: Representative histology of control rat nasal cavity and 
mild irritancy after inhalation of nebulised GSK-677 for 28 days. Rats 
were exposed to the vehicle alone (3% (v/v) Solutol HS 15 in 0.9% (w/v) 
aqueous sodium chloride) or as a solution of GSK-677 for 28 days. Sections 
of tissue (3 µm thick) were stained with haematoxylin and eosin; anatomical 
features are described in italics. 5.37A: control rat nasal cavity showing 
respiratory epithelium (RE). 5.37B: rat nasal cavity at higher magnification 
showing respiratory epithelium (RE); no GSK-677 related changes evident. 
5.37C: rat nasal cavity at higher magnification showing minimal degeneration 
of the respiratory epithelium (D) characterised by deciliation and basophilia. 
5.37D: rat nasal cavity showing minimal degeneration and squamous 
metaplasia (S) of respiratory epithelium. 
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5.38A: Vehicle control 
 
 (R31038N; Rat 001) 
5.38B: 1.08 mg/kg/day 
 
(R31038N; Rat 015) 
5.38C: 4.92 mg/kg/day 
 
(R31038N; Rat 022) 
5.38D: 14.8 mg/kg/day 
 
(Study R31038N; Rat 030) 
Figure 5.38: Representative histology of control rat larynx and mild 
irritancy after inhalation of nebulised GSK-677 for 28 days. Rats were 
exposed to the vehicle alone (3% (v/v) Solutol HS 15 in 0.9% (w/v) aqueous 
sodium chloride) or as a solution of GSK-677 for 28 days. Sections of tissue 
(3 µm thick) were stained with haematoxylin and eosin; anatomical features 
are described in italics. 5.38A: rat larynx showing transitional epithelium 
typical for this location (TE). 5.38B: minimal alteration characterised by focal 
flattening and stratification of the epithelium (F/S). 5.38C: mild inflammatory 
cell infiltrate (I), characterised by mononuclear cells in the submucosa, and 
moderate squamous metaplasia (S). 5.38D: mild squamous metaplasia (S) of 
respiratory epithelium. 
The toxicopathology findings seen in the respiratory tract indicated that 
GSK-677 was more irritant when presented as an aqueous (nebulised) 
formulation. This was corroborated by observations at the injection site 
of rats dosed subcutaneously with GSK-677 during an enabling study, 
in which the severity of degenerative changes (mild necrosis) and 
inflammation of the dermis and subcutis precluded subcutaneous 
administration of GSK-677 for 28 days (Appendix 8). 
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5.39A: Vehicle control 
 
(R31038N; Rat 001) 
5.39B: 1.08 mg/kg/day 
 
(R31038N; Rat 015) 
5.39C: 4.92 mg/kg/day 
 
(R31038N; Rat 022) 
5.39D: 14.8 mg/kg/day 
 
(R31038N; Rat 030) 
Figure 5.39: Representative histology of control ventral pouch of rat 
larynx and mild irritancy after inhalation of nebulised GSK-677 for 28 
days. Rats were exposed to the vehicle alone (3% (v/v) Solutol HS 15 in 
0.9% (w/v) aqueous sodium chloride) or as a solution of GSK-677 for 28 
days. Sections of tissue (3 µm thick) were stained with haematoxylin and 
eosin; anatomical features are described in italics. 5.39A: ventral pouch of rat 
larynx showing normal cartilage (Ctg) and typical squamoid epithelium (SE). 
5.39B: ventral pouch showing histologically normal cartilage (Ctg) and 
squamoid epithelium (SE); no GSK-678 related changes evident. 5.39C: 
necrosis of ventral pouch cartilage (N) characterised by absence of cell 
nuclei. 5.39D: necrosis of ventral pouch cartilage (N), with overlying mild 
squamous metaplasia (S) of respiratory epithelium. 
5.3.2.4. Pulmonary and systemic exposure of rats to 
GSK-361 and toxicopathology after 28 days 
Lung clearance of GSK-361 was evident after a single inhalation 
exposure of rats to the crystalline drug (Figure 5.40); lung 
concentrations of rats administered 0.22 mg/kg were not quantifiable at 
24 hours, and mean lung concentrations for rats administered 
≥1.04 mg/kg were <0.1% of that determined immediately post 
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Ctg 
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exposure. There was no obvious increase in trough lung 
concentrations of GSK-361 from Days 1 to 28, although statistical 
significance was achieved due to one of three rats returning a 
non-quantifiable result at the mid dose. Clearance of GSK-361 with 
repeated administration was consistent with expectations based on in 
vivo lung concentration data summarised in Chapter 2 (Figure 2.30). 
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Figure 5.40: Drug-lung concentrations in rats following inhaled 
administration of crystalline GSK-361 for one or 28 days. Mean GSK-361 
concentrations with standard deviations (error bars; n=3) are shown for rat 
lung homogenate data for samples taken immediately after a single 1-hour 
exposure and at 24 hours after single or repeat exposures. Lung 
concentrations for a dose of 0.25 mg/kg/day were below the limit of 
quantification (<30 ng/g lung tissue) 24 hours after single or repeat exposure. 
Statistical analysis (2-way ANOVA with post hoc analysis using Tukey’s 
honestly significant difference test (Abdi and Williams, 2010[B])) of 
log10-transformed data achieved significance (p<0.01) for 1 vs 24 hours and 
Days 1 vs 28 (24 hours). 
Plasma-drug concentrations were similar for a given dose of crystalline 
GSK-361 on Days 1 and 28, and were not quantifiable at 24 hours for 
doses ≤1.04 mg/kg/day (Figure 5.41). Systemic exposure (AUC0-t and 
Cmax) to GSK-361 was similar on Days 1 and 28 for a given dose, and 
increased proportionally with increasing dose between 0.222 and 
1.04 mg/kg/day, less than proportionally between 1.04 and 
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15.2 mg/kg/day (Table 5.24), with median Tmax generally observed at 
1.5 hours, i.e. 30 minutes after the end of exposure.  
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Figure 5.41: GSK-361 concentrations in rat plasma up to 24 hours after 
inhaled doses of crystalline GSK-361 on Days 1 and 28. Rats inhaled an 
aerosol of crystalline GSK-361 once daily (1-hour exposure) for up to 28 
days; mean plasma concentrations with standard deviations (error bars; n=3) 
are shown for samples taken up to 24 hours after the start of inhalation 
exposure. 5.41A: plasma concentrations after a single exposure (Day 1). 
5.41B: plasma concentrations after repeated administration (Day 28). 
Statistical analysis (MANOVA with post hoc analysis using Tukey’s honestly 
significant difference test (Abdi and Williams, 2010[B])) of log10-transformed 
data achieved significance (p<0.05) between Days 1 and 28. 
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Table 5.24: Pharmacokinetics of GSK-361 in plasma after  
inhaled administration of micronised crystals (n=3) 
Study No. 
Estimated 
Inhaled Dose 
(mg/kg/day) A 
Period 
(Day) 
Statistical 
parameter 
Pharmacokinetics (plasma) 
AUC0-t 
(h.ng/mL) B 
Cmax 
(ng/mL) B 
Tmax 
(h) C 
R31035N 
0.222 
D1 
Mean 202 45.6 1 
sd 188.1 39.47 - 
CV (%) 93% 87% - 
D28 
Mean 230 52.4 1.5 
sd 86.1 20.90 - 
CV (%) 37% 40% - 
1.04 
D1 
Mean 1157 266 1.5 
sd 115.0 59.5 - 
CV (%) 10% 22% - 
D28 
Mean 899 267 1.5 
sd 32.3 34.4 - 
CV (%) 4% 13% - 
15.2 
D1 
Mean 7134 1126 1.5 
sd 5588 829.2 - 
CV (%) 78% 74% - 
D28 
Mean 12707 1977 3 
sd 3430 595.0 - 
CV (%) 27% 30% - 
Notes 
A Overall estimated inhaled dose for toxicopathology animals over the 28-day 
treatment period. 
B Mean calculated from parameter for each rat (n=3): parameter dose-
normalised (division by estimated inhaled dose on day of sampling) and 
re-normalised with the overall estimated inhaled dose A. 
C Median time presented relative to start of the 1-hour exposure period. 
CV Coefficient of variation (%) = sd/mean 
At all doses, examination of harvested macrophages by TEM 
revealed no evidence of phagocytosed crystalline GSK-361. This 
contrasted with the crystalline inclusions seen in vitro (Figure 5.6B). 
The appearance of macrophages was normal but varied, with some 
cells containing neutral lipid droplets or angular clefts 
(Figure 5.42B) that were and ascribed to artefactual lipid extraction 
during processing and/or cholesterol crystals (Lupu et al., 1987). 
Other macrophages presented fewer lipid droplets but more dense 
primary lysosomes (Figure 5.42C), phagosomes (vacuoles 
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containing phagocytosed material) or secondary lysosomes 
containing nondescript or lamellar surfactant (Figure 5.42D). 
5.42A: 0.22 mg/kg/day 
 
(R31035N; Rat 025) 
5.42B: 0.22 mg/kg/day 
 
(R31035N; Rat 025) 
5.42C: 1.04 mg/kg/day 
 
(R31035N; Rat 028) 
5.42D: 15.3 mg/kg/day 
 
(R31035N; Rat 031) 
Figure 5.42: Macrophages after inhalation of lactose vehicle or 
crystalline GSK-361 for 28 days. Rats were exposed to lactose vehicle 
alone or in combination with crystalline GSK-361 for 28 days. Macrophages 
were harvested post mortem in saline by bronchoalveolar lavage of the left 
lung and processed for transmission electron microscopy; no GSK-361 
related ultrastructural changes were evident. 5.42A: macrophage containing 
lipid droplets (LPD). Angular electron lucent areas (C) associated with these 
droplets were consistent with extracted neutral lipid or cholesterol clefts (Lupu 
et al., 1987). 5.42B: macrophage containing lipid droplets (LPD). Angular 
electron lucent areas (C) associated with these droplets were consistent with 
extracted neutral lipid or cholesterol clefts. 5.42C: macrophage containing 
dense lysosomes (L). 5.42D: macrophage containing vacuoles containing 
lamellar surfactant material (Lm). 
L 
Lm 
C LPD 
C 
C 
C 
LPD 
LPD 
Lm 
Lm 
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Histopathological examination of tissues by light microscopy revealed 
no treatment related findings after inhaled administration of crystalline 
GSK-361 at ≤15.2 mg/kg/day to rats for 28 days (Figure 5.43). 
5.43A: Vehicle control (lactose) 
 
(R31035N; Rat 002) 
5.43B: 15.2 mg/kg/day 
 
 (R31035N; Rat 019) 
Figure 5.43: Representative histology of control rat lung and after 
inhalation of crystalline GSK-361 for 28 days. Rats were exposed to 
lactose vehicle alone or in combination with crystalline GSK-899 for 28 days. 
Sections of tissue (3 µm thick) were stained with haematoxylin and eosin; 
anatomical features are described in italics. 5.43A: histologically normal rat 
lung showing alveolar duct and alveoli. A longitudinal-section of a blood 
vessel (B) and erythrocytes (E) is also evident in section. 5.43B: histologically 
normal rat lung; no GSK-361 related changes evident (lower doses not 
examined). 
GSK-361 concentrations in lungs sampled immediately post exposure 
from rats administered nebulised solutions were quantifiable for 2/3 
rats at each dose but were less than 5% of mean values for rats 
administered corresponding doses of crystalline GSK-361. GSK-361 
was not quantifiable at 24 hours on Day 1 or Day 28. 
E 
B 
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Figure 5.44: Drug-lung concentrations in rats following inhaled 
administration of nebulised GSK-361 for one or 28 days. Mean GSK-361 
concentrations with standard deviations (error bars; n=3) are shown for rat 
lung homogenate data for samples taken immediately after a single 1-hour 
exposure. Lung concentrations at 24 hours post exposure (*) were below the 
limit of quantification (<30 ng/g lung tissue); insufficient quantifiable data for 
log10-transformation of data for statistical analysis (2-way ANOVA). 
Mean systemic exposure (AUC0-t and Cmax) to GSK-361 was similar on 
Days 1 and 28 at a dose of 0.25 mg/kg/day, but was approximately 
three-fold higher on Day 28 at a nebulised dose of 1.18 mg/kg/day 
(Table 5.25). Mean systemic exposure increased approximately 
proportionally with increasing dose on Day 1 and greater than 
proportionally on Day 28. Median Tmax was immediately post exposure. 
There were no treatment related histopathological findings in rats 
administered nebulised GSK-361 at ≤1.18 mg/kg/day for 28 days 
(Figure 5.46). 
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Figure 5.45: GSK-361 concentrations in rat plasma up to 24 hours after 
nebulised doses on Days 1 and 28. Rats inhaled a nebulised aerosol of 
GSK-361 once daily (1 hour) for up to 28 days; mean plasma concentrations 
with standard deviations (error bars; n=3) are shown for samples taken up to 
24 hours after the start of inhalation exposure. 5.45A: plasma concentrations 
after a single exposure (Day 1). 5.45B: plasma concentrations after repeated 
exposure (Day 28). Statistical analysis (1-way ANOVA) of log10-transformed 
data indicated no significant difference between Days 1 and 28. 
 
Chapter Five 
330 
 
Table 5.25: Pharmacokinetics of GSK-361 in plasma after inhaled  
administration of nebulised solution (n=3) 
Study 
No. 
Estimated 
Inhaled Dose 
(mg/kg/day) A 
Period 
(Day) 
Statistical 
parameter 
Pharmacokinetics (plasma) 
AUC0-t 
(h.ng/mL) B 
Cmax 
(ng/mL) B 
Tmax 
(h) C 
R31036N 
0.248 
D1 
Mean 119 32.3 1 
sd 10.5 10.47 - 
CV (%) 9% 32% - 
D28 
Mean 62 18.6 1 
sd 74.6 22.20 - 
CV (%) 120% 119% - 
1.18 
D1 
Mean 435 91 1 
sd 49.4 13.1 - 
CV (%) 11% 14% - 
D28 
Mean 955 254 1 
sd 121.3 65.9 - 
CV (%) 13% 26% - 
Notes 
A Overall estimated inhaled dose for toxicopathology animals over the 28-day 
treatment period. 
B Mean calculated from parameter for each rat (n=3): parameter dose-
normalised (division by estimated inhaled dose on day of sampling) and 
re-normalised with the overall estimated inhaled dose A. 
C Median time presented relative to start of the 1-hour exposure period. 
CV Coefficient of variation (%) = sd/mean 
5.46A: Vehicle control (nebulised) 
 
 (R31036N; Rat 004) 
5.46B: 1.18 mg/kg/day 
 
(R31036N; Rat 017) 
Figure 5.46: Representative histology of control rat lung and after 
inhalation of nebulised GSK-361 for 28 days. Rats were exposed to 
nebulised vehicle alone (20:20:60 (v/v/v) Solutol HS 15, ethanol and 60mM 
phosphate buffer) or a solution of GSK-361 for 28 days. Sections of tissue 
(3 µm thick) were stained with haematoxylin and eosin; anatomical features 
are described in italics. 5.46A: histologically normal rat lung showing alveolar 
duct and alveoli. 5.46B: histologically normal rat lung; no GSK-361 related 
changes evident. An airway (A) is evident in cross-section. 
A 
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5.4. Conclusion 
The objectives of this chapter were to assess the pulmonary 
toxicopathology of three p38 MAPK inhibitors in the context of their 
systemic and pulmonary exposure. Differences in the resultant in vivo 
findings were to be considered with respect to each drug’s 
physicochemical properties, aerosol presentation and correlation with 
in vitro endpoints. Key findings are summarised in Table 5.26. 
Table 5.26: Key findings for in vitro and in vivo assessment of 
toxicopathology and exposure of p38 MAPK inhibitors 
In vitro particles GSK-899 GSK-677 GSK-361 
Cellular toxicity low risk  low risk  low risk  
Endocytosed 
particles 
present  no  present  
Cytokine release no  no  no  
In vivo data        
Aerosol form Crys Am Neb Crys Neb Crys Neb 
Target doses A 1, 15 0.02 - 15 1 1 - 15 1 - 15 0.25 - 15 0.25, 1 
Lung concentration        
 D1: 24h vs 1h ≤26% ↓ ≥99% ↓ ≥92% ↓ ≥98% ↓ >99% ↓ >99.9% ↓ 100% ↓ 
 D28 vs D1 A ≥ x10 ↑ 
x9 ↑ 
(14.6) 
X8 ↑  
(1) 
≥ x2 ↑ 
≥ x6 ↑ 
(≥4.92) 
similar NQ 
Plasma AUC0-t        
 D28 vs D1 ≥ x3 ↑ similar similar similar similar similar NQ 
Endocytosed 
particles 
present present no no no no - 
Lung AB        
Macrophage 
aggregates 
≤ mkd 
(≥1) 
≤ mild 
(≥0.024) 
≤ mild  
(1) 
≤ mild 
(≥2.25) 
≤ mild 
(≥1.08) 
- - 
Inflammation 
≤ mkd 
(14.5) 
min 
(14.6) 
- 
min 
(67.8) 
- - - 
Larynx AB        
Squamous 
metaplasia 
min 
(14.5) 
min 
(≥1.10) 
- 
min 
(≥2.25) 
≤ mod 
(≥4.92) 
- - 
Inflammation - - - - 
≤ mild 
(≥4.92) 
- - 
Necrosis VPC - - - - ≥4.92 - - 
Nasal AB        
Epithelial 
degeneration 
- - - - 
min 
(≥4.92) 
- - 
Notes 
A Estimated inhaled doses in parentheses expressed as mg/kg/day 
B Findings graded minimal (min) < mild < moderate (mod) < marked (mkd) 
NQ Lung and plasma concentrations at 24 hours were non-quantifiable 
VPC Ventral pouch cartilage of larynx 
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Trends for differences in measured lung exposure between aerosol 
forms and p38 MAPK inhibitors following a single one-hour inhalation 
exposure were consistent with in vivo results described in Chapter 2, 
but were more pronounced (GSK-361 lung concentrations notably 
lower for nebulised solution than crystalline aerosol). This is probably 
associated with the longer exposure period applied and hence a 
broader range of lung residence times (20 to 80 minutes) for deposited 
particles undergoing solvation, dissolution and then absorption, as 
opposed to droplets undergoing absorption alone prior to isolation of 
lungs post exposure. Increases in trough concentrations were evident 
for GSK-899 and GSK-677 from Days 1 to 28, although only crystalline 
GSK-899 persisted to a significant extent in terms of the proportion of 
analyte in lungs at one hour remaining at 24 hours (Table 5.26). 
An increased incidence of multifocal foamy macrophage aggregates 
was observed for all aerosol forms of GSK-899 and GSK-677 (minimal 
to mild for all aerosol forms; mild to marked for crystalline GSK-899 at 
14.5 mg/kg/day) but was not seen in rats administered GSK-361 by 
inhalation or GSK-899 by subcutaneous injection. Alveolar 
macrophages play a key role in clearance of particles from the alveolar 
spaces of lungs, and migrate towards deposition sites and 
phagocytosed particles (Warheit and Hartsky, 1993). The increased 
incidence of macrophage aggregates is consistent with an adaptive 
response in rats to clear particulate GSK-899 and GSK-677, with the 
more pronounced grading (mild to marked) correlating with the highest 
and most persistent lung concentrations evident for crystalline 
GSK-899 at 14.5 mg/kg/day. Given that almost 100% of micron-sized 
particles are endocytosed at 24 hours (Geiser, 2010), it is likely that 
most of the GSK-899 accumulating in rat lungs was trapped as crystals 
within macrophages and not available for solvation and dissolution in 
the epithelial lung fluid. Toxicopathological implications for particle 
overload include impairment of particle clearance and tumourigenesis 
(Morrow, 1988). Under such extreme circumstances, it is plausible that 
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a higher proportion of free crystals may be present in the epithelial lung 
fluid at high doses. Ultrastructural investigation of lung sections using 
the high resolution possible by secondary ion mass spectrometry 
(SIMS; (Benabdellah et al., 2010, Guerquin-Kern et al., 2004)) would 
enable determination of the precise location of p38 MAPK inhibitors 
within cell types or fluid compartments in frozen rat lung sections. 
However, unlike reported findings for nuisance particles, aggregates of 
alveolar macrophages in rats administered GSK-899 (mainly at 
15 mg/kg/day) or GSK-677 (67.8 mg/kg/day) were associated with 
infiltration of macrophages in the lung interstitium, graded “marked” for 
crystalline GSK-899 and “minimal” for amorphous GSK-899 or 
crystalline GSK-677. The incidence and severity of this inflammatory 
change was considered (in consultation with the study pathologist) 
adverse for GSK-899 only and was not predicted in vitro (low risk of 
cellular toxicity indicated, with no treatment-related release of 
inflammatory cell mediators). Although macrophages were exposed to 
GSK-899 in vitro for up to 72 hours, it is noteworthy that cells were not 
in their natural (in vivo) environment and the 28-day treatment period 
for rats inhaling GSK-899 was significantly longer. Such in vitro 
investigations provide a means of identifying candidate drugs with a 
potential in vivo liability, and perhaps screening out compounds 
considered “high risk”. However, the differences in vitro and in vivo still 
support an assertion that the complexity of respiratory drug delivery 
and the biological responses of intact animals to pharmaceuticals are 
such that the most complete assessment of pulmonary drug delivery 
and toxicity is currently achieved in vivo (Fernandes and Vanbever, 
2009, Holländer, 1988). 
Adaptive lung changes and adverse lesions associated with lung 
burden have been described in detail for nuisance particulates such as 
titanium dioxide (TiO2), a white pigment of low toxicity commonly used 
for investigating lung clearance of particulate (Lee et al., 1985). 
Warheit et al. (1997) conducted a four-week inhalation toxicology study 
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in which groups of rats were exposed to TiO2 or iron particles at 
aerosol concentrations of 5, 50 or 250 mg/m3 but of differing particle 
size distributions for each test material (TiO2-MMAD of 1.4 to 1.9 µm; 
iron-MMAD of 2.9 to 3.4 µm), which were similar to the range of MMAD 
achieved for the p38 MAPK inhibitors (1.6 to 4.2 µm). Such toxicity 
studies with industrial materials are typically performed to facilitate risk 
assessment of potential occupational exposure and the experimental 
design thus reflected guidelines for the testing of chemicals in rodents 
including longer exposure periods (6 hours/day), a ‘working week’ 
(exposure 5 days/week) and targeting aerosol concentrations instead 
of inhaled doses (OECD[413], 2009, OECD[412], 2009, US-EPA[3645], 
1998). Nevertheless, doses of 0.9, 9 and 45 mg/kg/day could be 
approximated for an assumed body weight (350 g) and the published 
aerosol concentrations of TiO2 or iron adjusted for frequency and 
duration of exposure. These doses covered a similar range to those 
investigated for p38 MAPK inhibitors. Histopathological lung changes 
seen at 5 mg/m3 (approximately 0.9 mg/kg/day) were minimal and 
similar to those observed in rats administered amorphous or crystalline 
GSK-899 at 1 mg/kg/day. Lung lesions described at the higher 
exposure concentrations of 50 or 250 mg/m3 (approximately 9 or 
45 mg/kg/day) were ‘dose-related’ in severity and included aggregates 
of particle-laden macrophages adjacent to focal cellular hypertrophy 
and hyperplasia, but appeared less severe than the infiltration of 
inflammatory cells observed in the lung interstitium after inhaled 
administration of crystalline and, to a lesser extent, amorphous 
GSK-899 at 15 mg/kg/day. 
In vitro, endocytosed particles of GSK-899 (low solubility; low passive 
membrane permeability) and GSK-361 (low solubility; high passive 
membrane permeability) were seen in macrophages incubated in 
aqueous media with the particles for 72 hours; rectangular inclusions 
were not evident for macrophages incubated with GSK-677 (high 
solubility; low passive membrane permeability). However, only particles 
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of GSK-899 (both crystalline and amorphous) were evident in 
macrophages harvested from the lungs of rats administered dry 
powder aerosols (24 hours post exposure). Given that GSK-899 and 
GSK-361 were both of relatively low solubility, it appears likely the lung 
clearance of GSK-361 and the apparent absence of crystalline particles 
in vivo is attributable to its lipophilic properties facilitating absorption. 
The composition of the principal fluid lining the respiratory tract 
changes with anatomical location. Mucous, which is 95% water 
(Eixarch et al., 2010), lines the conductive airways (trachea and 
extrapulmonary bronchi in rats (Harkema et al., 2013)) and contrasts 
with lung surfactant prevalent in the distal respiratory region (terminal 
bronchioles and alveoli) consisting of 85% phospholipid, 5% 
cholesterol and 10% surfactant proteins (Eixarch et al., 2010). 
Dissolution of the p38 MAPK inhibitors was assessed in vitro using 
simulated lung fluid (Section 2.2.3.2), which is approximately 95% 
water and consistent with mucous found in the conductive airways. 
Mucous secreting cells extend into the tracheobronchial airways of 
primates and dogs (Harkema et al., 2013) and the mucous-like medium 
may be pertinent when considering the fate of particles in these 
species and the clinical context in particular. However, drug solubility in 
the respiratory tract is likely to be affected by significant differences in 
composition of the media onto which particles are deposited. Whilst 
transporter systems and efflux pumps potentially have a role in the 
pulmonary pharmacokinetics of the p38 MAPK inhibitors investigated in 
this thesis, the high lipophilicity of GSK-361 compared with GSK-899 is 
noteworthy and underpins its high passive membrane permeability 
measured in vitro. It can therefore be hypothesised that the 
composition of lung surfactant in rat lungs in combination with the 
transmembrane migration of GSK-361 from the ‘lung fluid 
compartment’ may have facilitated sink conditions for in vivo dissolution 
of GSK-361 particles deposited in the pulmonary region as opposed to 
non-sink conditions for GSK-899. Approximately 50% to 75% of 
Chapter Five 
336 
 
particles are typically endocytosed within 2 to 3 hours of deposition 
(Geiser, 2010) and a faster lung clearance rate for GSK-361 in vivo 
may explain, at least in part, absence of endocytosed particles in the 
examined macrophages harvested from lungs 24 hours post exposure. 
Squamous metaplasia, an adaptive response to irritancy (Gopinath and 
Mowat, 1987), was evident in the larynx of rats administered GSK-677 
(crystalline at ≥2.25 mg/kg/day; nebulised ≥4.92 mg/kg/day) or dry 
powder aerosols of GSK-899 (amorphous ≥1.10 mg/kg/day; crystalline 
14.5 mg/kg/day). This finding was associated with inflammation and 
necrosis in the larynx and degeneration of the nasal epithelium of rats 
administered nebulised GSK-677 (≥4.92 mg/kg/day). This is consistent 
with the irritancy observed at the injection sites of rats administered 
GSK-899 or GSK-677. It was anticipated that administration of 
nebulised solutions of the p38 MAPK inhibitors would not induce lung 
pathology changes due to presentation of a solution facilitating a faster 
rate of absorption from lungs. The absence of macrophage aggregates 
from the lungs of rats administered GSK-899 subcutaneously for 28 
days (to perfuse lungs with solubilised GSK-899 in situ) suggests that 
this finding was not due to the chemical activity of the molecule per se, 
but may be a response to deposited droplets containing mild irritants.  
The test article-related lung changes were clearly more severe in rats 
administered crystalline GSK-899 at 14.5 mg/kg/day compared to a 
similar dose of amorphous GSK-899 or GSK-677 at 67.8 mg/kg/day. 
The severity of findings was more pronounced than that reported for 
TiO2 or iron Warheit et al. (1988) at comparable doses. It is therefore 
likely that the inflammatory changes observed in the lungs of rats 
administered GSK-899 is a function of the persistence of nuisance 
particles in combination with a mildly irritant effect of GSK-899. 
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This chapter characterised the pulmonary toxicopathology of three p38 
MAPK inhibitors administered to rats as nebulised solutions, 
amorphous (GSK-899) or crystalline dry powder formulations. Key 
conclusions of experiments described in this chapter are: 
• Differences in aerosol presentation of the evaluated drugs 
modulated the incidence and severity of toxicopathology findings 
(shift in dose response), but did not change the nature of the 
findings per se.  
• Administering nebulised solutions of compounds of relatively low 
solubility may preclude detection of findings at higher doses 
exceeding the maximum practicable dose for limited solubility. 
• Lung pathology changes after 28 days of treatment correlated 
with persistence and/or accumulation of the drug in lung tissue, 
which wasn’t always predicted in vitro. 
• Passive membrane permeability in vitro may be more predictive 
than solubility for predicting the potential for lung clearance and 
pulmonary toxicology. 
These in vivo data indicate a clear relationship between drug 
accumulation and the onset of inflammation at higher doses that 
overpowered the anti-inflammatory pharmacology of p38 MAPK 
inhibition. The clinical relevance of adverse changes at high doses 
associated with particle overloading of alveolar macrophages should 
be considered when evaluating results of inhalation toxicity studies. 
 
  
 
CHAPTER SIX 
General discussion
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6.1. General discussion 
Chronic obstructive pulmonary disease (COPD) accounted for 3.2 
million deaths worldwide in 2015, with lower respiratory tract infections, 
the most deadly communicable disease, accounting for a further 3.2 
million deaths (WHO, 2017). GSK was the market leader in terms of 
revenue ($9.4 billion) from respiratory disease products in 2015, 
accounting for 33.6% of this drug market (Research-Markets, 2016). 
Despite such commercial and therapeutic successes since the launch 
of the first pressurised metered dose inhaler 60 years ago (Anderson, 
2005), there is still an unmet need for inhaled medicines, particularly in 
the developing world where general access to healthcare is poor and 
resources are limited (Aït-Khaled et al., 2001). The cost and time 
required to develop and release a new drug onto the market varies, 
with estimates of seven to 12 years (Shankar et al., 2006) and costs of 
up to $2.0 billion (Adams and Brantner, 2006) cited in the literature. 
However, just one in 40,000 compounds tested in animals reaches the 
clinical market (Kapetanovic, 2008). Therefore, in addition to an ethical 
obligation to minimise the use of animals in medical research, 
pharmaceutical companies are under increasing pressure to reduce the 
price of new drugs to meet the need for lower costs in healthcare. 
For chronic pulmonary diseases like asthma or COPD, it is desirable to 
develop drugs with a prolonged duration of action and to combine 
therapies to simplify and minimise the frequency of administration (Buhl 
et al., 2003, RNS-LSE#1, 2017). Reducing the frequency of dosing can 
be achieved through a variety of mechanisms to prolong the duration of 
action. Drug design strategies include very low aqueous solubility 
(e.g. inhaled corticosteroids), tissue retention due to hydrophobicity 
(e.g. salmeterol) or particle engineering and/or encapsulation to slow 
dissolution (Patton and Byron, 2007). However, this has potential 
implications for safety as accumulation of insoluble material at the 
respiratory epithelium may impair lung function (Fröhlich, 2017).  
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Adaptive lung changes and adverse lesions associated with lung 
burden have also been described in detail for nuisance particulates 
such as minerals (Pauluhn, 2008), environmental pollutants (Miller, 
2000) and pigments (Lee et al., 1986), the mechanisms of which are 
independent of pharmacology-mediated toxicology. Differences in toxic 
potency of relatively inert materials may be associated with differences 
in particle clearance, dissolution rate in lung fluid or initiation of a 
self-perpetuating inflammation (Pauluhn, 2008). 
Many inhaled drugs have been developed as dry powder formulations, 
notably micronised crystals, to prolong physical stability and improve 
the control of drug delivery (Crompton, 1991). Combining the molecule 
with a salt facilitates modulation of the physicochemical properties and 
resultant biological activity of the drug (Gould, 1986). Characterisation 
and selection of the salt can take time and development programmes 
for inhaled compounds also consume high masses of drug, relative to 
other exposure routes (primarily due to impaction or sedimentation of 
test article within exposure systems and the drug-lung deposition 
fraction in animals). Consequently, there is a balance between 
selecting the appropriate salt form and pharmacokinetic-
pharmacodynamic (PK/PD) profile, and discharging liabilities such as 
toxicity or human efficacy. Use of surrogate exposure routes and/or 
formulations (differing from intended clinical presentation) to reduce 
drug requirements and expedite early non-clinical experiments may be 
attractive but is potentially at odds with developing drugs with an 
extended duration of action. This is because such strategies may 
significantly alter the pharmacokinetics and defer de-risking of 
potentially altered efficacy, tolerability or toxicopathology of the final 
formulation until later in development. 
Leukocyte recruitment to sites of tissue injury and activation of 
inflammatory and immune cells are common features of inflammatory 
diseases such as COPD (Herlaar and Brown, 1999). p38 mitogen 
activated protein kinase (MAPK) performs a central regulatory function 
Chapter Six 
342 
 
in the synthesis and modulation of proinflammatory mediators. The 
p38α MAPK isoform is expressed in the cytoplasm and nucleus of cells 
(Cuenda and Rousseau, 2007) in the airway smooth muscle, 
respiratory epithelium and immune system (Williams et al., 2008, 
Mayer and Callahan, 2006). Given the ubiquitous distribution of this 
pharmacological target in the respiratory tract, p38 MAPK inhibitors can 
be administered prophylactically by inhalation (diffuse pulmonary 
deposition pattern) before administering an antigen by intratracheal 
instillation (more focal) to investigate inhibition of acute inflammation. In 
addition, the pulmonary toxicopathology of micronised crystalline 
GSK-899 and GSK-677 in rats was known to the sponsor (Freke, 2007, 
Freke, 2010). p38 MAPK inhibitors were therefore selected as tool 
compounds to investigate the implications of changing aerosol 
presentation for in vivo endpoints of efficacy and toxicopathology. By 
administering aerosols of p38 MAPK inhibitors to rats, by snout-only 
inhalation exposure, the experimental objectives of this thesis were to: 
• Measure systemic exposure (plasma) and lung exposure (tissue 
homogenate) in rats administered a single inhaled ‘dose’ of a 
dry powder aerosol or nebulised solution of each test article. 
• Rank the median effective doses (ED50) of three inhaled drugs 
presented as a dry powder formulation or nebulised solution 
using a rat model to assess acute lung inflammation. 
• Determine the pulmonary toxicopathology of three compounds 
presented as dry powder or nebulised aerosols for 28 days. 
Principal component analysis was used to select p38 MAPK inhibitors 
of differing physicochemical properties for evaluation of efficacy and 
pulmonary toxicopathology in vivo. The most diverse compounds within 
the ‘physicochemical space’ (Figure 6.1) were: 
• GSK-899, which had the most aromatic molecular structure 
(Figure 6.1A), was of relatively low aqueous solubility and had a 
propensity for protein binding; 
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• GSK-677, a polar, basic molecule of high aqueous solubility; 
• GSK-361, a lipophilic molecule of relatively low aqueous 
solubility but high passive membrane permeability. 
A: GSK-899 
 
 
B: GSK-677 
 
C: GSK-361 
 
Figure 6.1: Chemical structures of three p38 MAPK inhibitors selected 
for investigation of in vivo endpoints. Figures 6.1A to 6.1C show 
molecular structures for the parent compounds (free base). 
By administering micronised crystals, amorphous powder (GSK-899) or 
nebulised solutions of the three most diverse p38 MAPK inhibitors, with 
respect to their physicochemical properties, the following hypotheses 
were evaluated in vivo: 
• physicochemical properties influence lung or systemic (plasma) 
exposure, and hence resultant efficacy and/or toxicopathology. 
• changing presentation of a drug to rats will affect its absorption 
and hence alter the resultant efficacy and/or toxicopathology. 
Addressing these hypotheses was expected to increase understanding 
of the relationship between physicochemical properties and the 
therapeutic index, i.e. the margin between doses of non-clinical efficacy 
(ED50) and no observed adverse effects in animals (toxicopathology). 
The cost of equipping and maintaining research facilities for inhalation 
exposure of laboratory species is expensive and such laboratories are 
often operated by contract research organisations, pharmaceutical 
corporations or publicly funded agencies. Given the confidential nature 
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of research undertaken by such institutions, much of the work remains 
unpublished. In addition, pharmaceutical companies often progress a 
pre-selected salt form of a drug through the non-clinical and clinical 
development programmes. In the event of adverse findings, the 
development programme is often terminated with no further work 
undertaken and no data published. Consequently, it is unusual to find 
published data comparing in vivo efficacy or toxicity of different 
formulations of the same drug. This thesis thus represents an original 
contribution to the field by characterising the in vivo efficacy and 
respiratory toxicopathology of three compounds administered to rats as 
dry powder and aqueous aerosol forms. 
The seminal publication of Snipes (1989) describing a lung deposition 
fraction of 7% in rats is still cited today. This article referenced 
historical data for laboratory species exposed to industrial materials 
such as inorganic nuisance particles and radionuclides, which differ to 
the small organic molecules and biopharmaceuticals developed by 
pharmaceutical companies. Approximately 85% of particles of 
aerodynamic diameter 2 µm are “inhalable” to rats (Miller, 2000) but 
most particles are deposited in the nasal cavities or exhaled (Snipes, 
1994). Persistence of crystalline GSK-899 in rat lung tissue post 
exposure made it suitable as a tool compound for investigating lung 
deposition of a small organic molecule (minimal drug clearance likely 
before isolation of the lungs). The mean lung deposited dose of 
GSK-899 (mass median aerodynamic diameter of 2.1 ± 0.4 µm) was 
12% of the inhaled dose estimated from the measured minute volume 
(MV). This was consistent with the deposition fraction used by the 
US-FDA for reviewing regulatory submissions of inhaled drug safety 
data (Jones and Baldrick, 2013, Owen, 2013, Forbes et al., 2011). 
Ranking of lung exposure, in terms of AUC (area under the drug 
concentration-time curve), after single inhalation exposure of crystalline 
p38 MAPK inhibitors was consistent with ranking of in vitro dissolution 
rates (Table 6.1). Lung exposure of the two p38 MAPK inhibitors of 
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lowest aqueous solubility was highest for crystalline aerosols and 
lowest for nebulised droplets, with amorphous GSK-899 ranked 
between these two particulate forms. Lung exposure of GSK-677, the 
most soluble drug, was similar for crystalline and nebulised aerosols.  
Table 6.1: Ranking of key findings for in vitro and  
in vivo assessment of p38 MAPK inhibitors 
In vitro data 
Dissolution rate GSK 677(c) > GSK 899(a) > GSK 361(c) > GSK 899(c) 
Potency GSK-677 ≈ GSK-899 ≈ GSK-361 
Pgp substrate A GSK-677 > GSK-899 > GSK-361 
Cellular toxicity B low risk  low risk  low risk 
Endocytosed 
particles B 
no  present  present 
Cytokine release B no  no  no 
In vivo data 
Lung exposure      
crystalline GSK-677 < GSK-361 < GSK-899 
nebulised GSK-361 < GSK-677 < GSK-899 
GSK-899 nebulised < amorphous < crystalline 
GSK-361 nebulised < crystalline 
GSK-677 nebulised ≈ crystalline 
Systemic (plasma) 
exposure 
GSK-677 ≤ GSK 899 < GSK-361 
Efficacy: ED50 
GSK-677 
(least effective) 
> GSK-361 > 
GSK-899 
(most effective) 
‘Safety margin’ C 
GSK-361 
(NEL) 
> 
GSK-677 
(NOAEL) 
> 
GSK-899 
(NOAEL) 
Endocytosed 
particles 
no  no  present (c/a) 
Drug-lung 
accumulation 
GSK-361 < GSK-677 < GSK-899 
Notes 
A Flux of compound measured across hMDR1-MDCK (type II) cell 
monolayer (Pgp expressed at apical surface of cells) 
B Incubation of particles with NR8383 rat alveolar macrophage cell line 
C Ratio of rat:human lung doses ranked (see Table 6.2), with presence 
or absence of non-adverse rat lung findings taken into account; 
NEL = No Effect Level; NOAEL = No Observed Adverse Effect Level 
ED50 Extrapolated from dose response for reduction of neutrophils in 
bronchoalveolar lavage fluid taken four hours after LPS-challenge 
(c/a) crystalline / amorphous 
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In these experiments, rats were exposed to an aerosol for 30 minutes. 
An additional period of 20 minutes elapsed (logistics of animal transfer 
and euthanasia) before lungs could be removed from the carcass for 
drug analysis. Particulates thus resided in lungs for 20 to 50 minutes 
before tissue samples were disconnected from the systemic circulation. 
Solubilisation of crystalline solutes first requires disruption of the crystal 
lattice (Van den Mooter, 2012). A faster dissolution rate for amorphous 
powder was observed in vitro due to the disrupted, random 
organisation of molecules in the inhaled particles requiring less energy 
to facilitate solvation and subsequent absorption from the lung surface. 
Presentation of GSK-361 and GSK-899 in solution eliminated solvation, 
expediting absorption of these compounds from the lung. The potential 
for underestimating the achieved drug-lung exposure is therefore 
greatest for the nebulised aerosols and higher for amorphous GSK-899 
than crystalline GSK-899 because a proportion of the lung-deposited 
drug was absorbed systemically before the lungs could be isolated for 
analysis of the drug-lung concentration at the first timepoint.  
Ranking of lung exposure (AUC) for nebulised aerosols of each 
compound differed to that of crystalline aerosols, with GSK-361 
achieving the lowest apparent exposure. This is again consistent with 
drug absorption during the particulate-lung residence period before the 
first timepoint resulting in an underestimate of lung exposure and a 
relatively higher systemic exposure (Table 6.1). GSK-361 was the most 
lipophilic compound and, in vitro, exhibited greatest transmembrane 
permeability. It therefore appears that GSK-361 in solution (nebulised 
aerosol) crossed the respiratory epithelium faster than aqueous 
GSK-677, resulting in a lower measured lung exposure. However, lung 
exposure following administration of crystalline GSK-361 was higher 
than for crystalline GSK-677, consistent with a slower dissolution rate, 
which resulted in reversal of the ranking for measured lung exposure. 
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Ranking of the median effective doses (ED50) indicated GSK-899, a 
drug of relatively low solubility and persistent in lung tissue, most 
effectively inhibited lung inflammation at four hours post challenge. 
GSK-677 was least effective, indicating high aqueous solubility 
presented a physicochemical barrier between the drug and intracellular 
pharmacological target (due to reduced transmembrane movement) 
and/or expedite elimination of the drug from the lungs. There was no 
obvious difference in efficacy for presentation of the p38 MAPK 
inhibitors as crystalline or nebulised aerosols. Although ED50 values 
appeared close for each compound, a more robust (less variable) 
endpoint for inflammation and/or improved precision of dose delivery 
would increase the confidence (statistical significance) of this result. 
The distribution and extent of particle deposition in the respiratory tract 
is size dependant (Snipes, 1994). Differences in particle size and, by 
inference, the lung deposited dose of amorphous GSK-899 correlated 
with modulation of the dose response for neutrophil counts in 
bronchoalveolar lavage fluid (BALF), i.e. an increase in median particle 
size was concurrent with a decrease in ED50. 
Presentation of p38 MAPK inhibitors to rats in different aerosol forms 
modulated the incidence and severity of pulmonary toxicopathology 
findings (shift in dose response for GSK-899), but did not change the 
nature of the findings per se. Lung toxicopathology changes seen after 
28 days of treatment correlated with the persistence and/or 
accumulation of GSK-899 in rat lung tissue and presence of 
endocytosed particles in macrophages viewed by scanning electron 
microcoscopy. Warheit et al. (1997) administered TiO2 or iron particles 
to rats for four weeks, using a protocol based on guidelines designed 
for risk assessment of occupational exposure (OECD[412], 2009, 
OECD[413], 2009, US-EPA[3645], 1998) at inhaled doses (body weight 
not published; 350 g used for calculation) similar to those administered 
for the p38 MAPK inhibitors. Toxicopathology lung changes at 
approximately 0.9 mg/kg/day TiO2/iron were similar to those seen in 
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rats administered amorphous or crystalline GSK-899 at 1 mg/kg/day. 
Lung lesions at inhaled TiO2/iron doses of 9 or 45 mg/kg/day were 
dose-related in severity and included aggregates of particle-laden 
macrophages adjacent to focal cellular hypertrophy and hyperplasia 
(Warheit et al., 1997). However, the published findings for TiO2 and iron 
appeared less severe than the infiltration of inflammatory cells 
observed in rat lung interstitium after inhaled administration of 
crystalline or amorphous GSK-899 at 15 mg/kg/day. Squamous 
metaplasia, an adaptive response to irritancy (Gopinath and Mowat, 
1987), was evident in the larynx of rats administered high doses of 
GSK-677 or GSK-899. The absence of macrophage aggregates from 
lungs of rats subcutaneously administered GSK-899 (perfusing lungs in 
situ) for 28 days and the inflammation observed at injection sites 
suggests the inflammatory changes seen in the lungs of rats inhaling 
GSK-899 were not due to the pharmacology of the molecule but may 
be a function of the persistence of nuisance particles in combination 
with a mildly irritant effect of GSK-899. 
In contrast to GSK-899, there were no treatment-related changes in the 
respiratory tract of rats administered similar doses of GSK-361, 
correlating with no drug accumulation in lung and an apparent absence 
of endocytosed particles in macrophages (contrary to in vitro data). 
Passive membrane permeability in vitro may therefore be more 
predictive than aqueous solubility for predicting the potential for 
liabilities associated with lung clearance and toxicopathology. 
Taken together, the single dose efficacy and repeat dose toxicity data 
indicate designing molecules of relatively low aqueous solubility 
(GSK-899) results in persistence of the drug in lung tissue concurrent 
with an increase in single-dose efficacy (lower ED50) for suppression of 
neutrophils in BALF (Table 6.2). However, there is a trade-off insofar 
as repeated once-daily administration of the drug at high doses 
resulted in accumulation of the drug in lung tissue concurrent with a 
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pulmonary toxicopathology that overwhelmed the anti-inflammatory 
pharmacology of p38 MAPK inhibition. 
For regulatory submissions, ‘lung safety margins’ are based on a ratio 
of lung dose in animals relative to that of humans for a given dose; the 
US-FDA assumes 10% deposition in rat lungs and 100% deposition in 
human lungs (Forbes et al., 2011, Jones and Baldrick, 2013, Owen, 
2013). If the lung dose ratio was based upon a no effect level (NEL), 
i.e. a dose at which no treatment-related findings were seen in animals, 
this 10-fold ratio would normally suffice for the ‘lung safety margin’. 
However, if ratios were submitted to a regulatory agency based upon 
no observed adverse effect levels in animals (NOAEL; non-harmful 
treatment-related findings evident), further adjustments may be applied 
(Degeorge et al., 1997) including an additional margin if the findings 
could not be monitored clinically; the US-FDA historically require a 
10-fold margin for unmonitorable histopathological changes in rats. For 
worked examples of the p38 MAPK inhibitors (Table 6.2), crystalline 
GSK-677 achieved the highest rat:human lung ratio (1806) based on a 
NOAEL. However, crystalline GSK-361 achieved a margin based on a 
NEL (350), which would be unlikely to incur a 10-fold reduction in 
‘safety margin’ due to the absence of GSK-361-related findings in the 
respiratory tract. It is noteworthy these ratios are driven by the NEL or 
NOAEL established at the evaluated doses, which were dose limiting 
for nebulised GSK-361. These data suggest ‘lung safety margins’ for 
different aerosol forms of the p38 MAPK inhibitors were influenced 
more by technical limitations than biological effects of the aerosol forms 
per se. It would therefore be prudent to use the intended clinical 
aerosol form (e.g. micronised crystals or nebulised solution with 
excipients as appropriate) for early non-clinical evaluations of general 
toxicology. For preclinical safety programmes, the exposure route and 
aerosol form may not always be critical for specific investigations, such 
as reproductive toxicology in which test subjects are exposed to the 
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drug in utero and the method of drug administration to the dam is 
therefore less important. 
Table 6.2: Median effective dose (ED50; single exposure) and non-effect 
levels (28 days) for inhaled p38 MAPK inhibitors administered to rats 
Compound Aerosol form 
ED50 
estimate 
(µg/kg) A 
Effect 
level B 
Dose of 
effect level 
(µg/kg/day)  
Ratio of 
ED50 to 
effect level 
Ratio of rat 
to human 
lung dose C 
GSK-899 
crystalline 23.38 NOAEL 1058 2.2% 27.1 
amorphous-1 65.88 NOAEL 1102 6.0% 31.9 
amorphous-2 10.08 - - - - 
nebulised 44.66 NOAEL 844 5.3% 20.8 
GSK-361 
crystalline 172 NEL 15200 1.1% 350 
nebulised 165 NEL 1180 14% 27.6 
GSK-677 
crystalline 366 NOAEL 67800 0.54% 1806 
nebulised 356 NOAEL 14800 2.4% 351 
Notes 
A ED50 from dose response for neutrophil counts in bronchoalveolar 
lavage fluid sampled four hours after intratracheal LPS-challenge. 
B NOAEL (no observed adverse effect level) or NEL (no effect level) in 
rats after 28 days of treatment. 
C Ratio of rat lung dose at N(OA)EL to human lung dose (for an inhaled 
dose of 1000 µg). 
Lung accumulation from Days 1 to 28 presents a liability for a drug 
intended for chronic clinical administration. Further work could 
determine the dose threshold and time taken to achieve steady state 
(the point at which lung deposition is matched by clearance) and the 
progression of pulmonary toxicopathology. In addition, efficacy could 
be evaluated after repeated administration of p38 MAPK inhibitors 
since potential drug-lung accumulation at pharmacologically relevant 
doses may affect the dose response. However, demonstrating drug 
efficacy in humans is the primary objective (proof of concept) in drug 
development, as opposed to further investigating efficacy in animal 
models. In the pharmaceutical industry, the decision to use an animal 
model to investigate efficacy following repeated administration and/or 
other liabilities (or to terminate development) would depend upon a 
risk-benefit analysis for the drug development programme based on 
pertinent factors including therapeutic indication (disease, clinical dose 
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regimen etc), non-clinical findings and their relevance to humans, and 
ethical review of further in vivo experiments. In an industrial context, it 
is unlikely drug efficacy would be evaluated as a principal endpoint in 
animals after repeated administration of the inhaled drug. 
Nebulised doses of GSK-899 and GSK-361 were limited by the 
relatively low solubility of these compounds in aqueous vehicles. It was 
therefore not possible to investigate the pulmonary toxicopathology at a 
nebulised dose of 15 mg/kg/day for 28 days to confirm if inflammatory 
changes were confined to dry powder aerosols (crystalline or 
amorphous GSK-899) at this dose. Failure to identify toxicopathology 
liabilities in preliminary non-clinical studies may have significant 
implications for later development, such as development of an alternate 
salt form or formulation, or termination of the development programme. 
This reaffirms the conclusion that aerosol forms anticipated for clinical 
administration should be used in early non-clinical drug development.  
Optimisation of the challenge using small numbers of rats 
(n=3/treatment) suggested intratracheal instillation of 
lipopolysaccharide (LPS) produced a higher neutrophil count in BALF 
and a more consistent proportion of neutrophils in leukocytes than 
inhalation exposure (Appendix 1). The variability of this biological 
response could be interpreted in part as an indication of the precision 
of dose delivery and infer that intratracheal instillation leads to more 
consistent results. However, neutrophil counts were also more variable 
after intratracheal instillation of dry powders of GSK-899 or GSK-677 
and an aqueous suspension of GSK-677, suggesting differences in 
data variability between experiments utilising intratracheal 
administration may be associated with the paucity of data. 
Whilst inhalation exposure may be the most relevant exposure route to 
that intended for clinical administration of a drug, there are technical 
limitations for the precision of dose administration to animals. Animals 
were not “dosed” per se but passively inhaled the p38 MAPK inhibitors 
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mixed with air. In line with industry practices, inhaled “doses” were 
calculated using an equation that includes an algorithm for estimating 
the volume of air inhaled by the animals (Alexander et al., 2008). 
Measurement of MV by head-out plethysmography indicated this 
algorithm, under the experimental conditions, may have 
underestimated mean inhaled doses by approximately 15%. Additional 
plethysmography data generated in this thesis showed this can be 
mitigated by allowing rats to settle in restraint tubes for approximately 
15 minutes prior to initiating aerosol generation; local (GSK) practices 
for inhalation exposure of rodents have been adapted accordingly. With 
adequate animal handling (settling period before each exposure and 
(re)acclimatisation of rats to plethysmograph restraint over two 
consecutive days), changes in MV were in line with normal body weight 
development over a 28-day period. This supports the general 
application of the algorithm of Alexander et al. (2008) for estimating 
inhaled doses in healthy rats. However, the relationship between MV 
and body weight concurrent with an adverse effect of treatment (weight 
loss or reduced gain due to toxicity) was not established since the body 
weight development of rats was unaffected by p38 MAPK inhibitors at 
the evaluated doses. 
The overall proportion of BALF recovered from whole rat lung 
(71±10%) was consistent with reported values for lavage of human 
lungs (Ettensohn et al., 1988). However, it is noteworthy that mean 
recoveries of 58%, 76% and 80% were achieved for successive BAL 
cycles in rats. It is plausible the second and third washes did not 
adequately mix with residual fluid from the first wash, compromising 
sampling of the alveolar region. Completion of image analysis for 
CAE-stained sections of lungs (Design D) from rats administered 
GSK-361 with or without being sampled for BALF would indicate the 
extent to which neutrophils were harvested from lungs by 
bronchoalveolar lavage. In addition, results of image analysis 
(Designs C and D) of lung sections stained for CAE would indicate if 
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data variability was consistent with that evident for neutrophil counts 
across three experiments and aerosol forms, i.e. for a larger dataset. If 
confidence limits for neutrophil counts and lung image analysis data 
were similar, further investigations could consider potential sources of 
inter-animal variability such as the immune status of rats (monitoring 
for sub-clinical infections) and pulmonary dosimetry following 
intratracheal instillation or inhalation exposure of drugs to rats. If the 
confidence limits for lung image analysis were narrower, a more robust 
ranking may be possible for the efficacy of p38 MAPK inhibitors and 
their aerosol forms. Furthermore, if results showed neutrophil counts in 
BALF lacked precision or did not correlate with inflammatory changes 
in lung sections, then automated histological processing and image 
analysis may provide advantages for investigating inhibition of 
inflammation provided lung sections can be prepared consistently and 
of sufficient quality for software to accurately distinguish between the 
biomarker for inflammation and the lung tissue. 
6.2. Limitations and future work 
Drug-lung deposition: matrix assisted laser desorption/ionization of 
lung sections with mass spectrometry imaging (MALDI-MSI) 
demonstrated an even distribution of GSK-361 and GSK-899 across 
lung sections and concentration of GSK-677 in the main airways. 
However, this lacked the resolution required to differentiate between 
compartments within the lung section (≤13 µm) such as the epithelium, 
fluid and macrophages (Krombach et al., 1997, Patton and Byron, 
2007)). Ultrastructural investigation of lung sections using a higher 
resolution technique such as secondary ion mass spectrometry (SIMS; 
(Benabdellah et al., 2010, Guerquin-Kern et al., 2004)) in concert with 
MALDI-MSI (to identify areas of interest for SIMS analysis) may identify 
precise locations of p38 MAPK inhibitors within cell types or fluid 
compartments in frozen rat lung sections. Higher resolution mapping of 
drug-lung distribution would improve understanding of the 
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compartmentalisation of p38 MAPK inhibitors after inhalation exposure 
and how this affects efficacy or pulmonary toxicopathology. 
Drug-lung concentrations: differences in the rate of lung clearance 
were evident between compounds and aerosol forms, with different 
drug-lung concentrations evident in lungs taken as soon as practicable 
post exposure. However, a period of 20 minutes elapsed between 
cessation of aerosol generation and isolation of the lungs from the rat’s 
circulatory system, during which time different proportions of GSK-899 
(low solubility), GSK-677 (high solubility) and GSK-361 (lipophilic) were 
absorbed from lungs. The logistics and proximity of procedures for 
inhalation exposure and euthanasia should be considered with a view 
to minimizing the interval elapsing between these procedures for rats 
sampled ‘immediately post exposure’ without compromising animal 
welfare. For example, animals are handled carefully before euthanasia 
to minimize anxiety, and euthanasia should be performed “away from 
the immediate presence of other animals” to minimize stress (Home 
Office, 2014). In practice, euthanasia is normally performed in a 
dedicated room but transit time could be reduced if suitable apparatus 
were available in a room adjacent to the inhalation exposure systems. 
In addition, reducing the duration of inhalation exposure (by increasing 
aerosol concentration if practicable) would reduce the ‘lung residence 
period’ for deposited particles prior to isolation of the lung samples. 
The potential underestimation of mean inhaled doses by approximately 
15% due to excitability of animals prior to aerosol administration do not 
fully account for the observed variability in neutrophil data determined 
in the LPS model or generally in lung concentration data. For logistical 
reasons (sample size and apparatus), it was local practice to 
homogenise right lung lobes and omit the left lung. Further work could 
determine potential heterogeneity in lung deposition between the lobes 
or quantify potential sources of experimental error for drug-lung 
measurements such as incomplete homogenisation of lung tissue, 
which may potentially affect extraction of the analyte for analysis. 
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However, these potential sources of error in drug-lung concentration 
analyses did not affect biomarkers for neutrophils in the efficacy model. 
Efficacy: neutrophil counts in BALF for rats administered prophylactic 
doses of p38 MAPK inhibitors were variable, as indicated by the range 
of 95% confidence limits for each compound and aerosol form. Whilst 
ED50 values for GSK-899 treated rats were significantly lower than for 
GSK-361 and GSK-677, it was not possible to distinguish between the 
latter compounds or different aerosol forms with confidence. 
Completion of experiments described in Chapter 4 (Designs C and D) 
indicated staining of chloroacetate esterase lacked the specificity 
required to assess histological sections of rat lung for LPS-induced 
neutrophil infiltration. Identification of an alternative biomarker of 
neutrophils or refinement of existing methodology to increase the 
contrast between stained neutrophils and background cells or tissue 
would be required before the viability of image analysis of lung sections 
as an alternative method to BALF-neutrophil counts for evaluation of 
lung inflammation could be evaluated. Similarly, with identification of a 
robust biomarker for neutrophils, the efficiency of bronchoalveolar 
lavage for harvesting neutrophils and implications for variability in cell 
count data could be investigated. 
The animal model used for assessing efficacy required construction of 
a dose response for single prophylactic doses inhibiting an infiltration of 
neutrophils into the lungs after LPS-challenge. COPD is a chronic lung 
disease requiring repeated administration of inhaled medicines. 
Although adverse lung changes in rats administered GSK-899 for 28 
days were confined to the high dose of 15 mg/kg/day, further work 
could be conducted to investigate how efficacy is affected by repeated 
inhaled administration and potential drug accumulation in lungs. 
Pulmonary toxicopathology: relatively low aqueous solubility of 
GSK-899 and GSK-361 precluded inhalation exposure of rats to 
nebulised solutions of the test articles, precluding evaluation of an 
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inhaled dose of 15 mg/kg/day. Although it was not possible to confirm if 
administration of this dose would have induced the adverse 
inflammatory changes observed following administration of amorphous 
(graded “minimal”) or crystalline (“marked”) GSK-899, it nevertheless 
illustrated a technical complication for evaluating the dose response of 
a compound by changing the aerosol form. 
6.3. Summary 
This thesis describes results of experiments conducted using dry 
powder and nebulised aerosols of three anti-inflammatory drugs of 
common pharmacology but different physicochemical properties. 
These experiments were conducted to test the following hypotheses: 
1. The physicochemical properties of a drug influence its lung or 
systemic exposure in vivo, and hence the resultant efficacy 
and/or toxicopathology. 
2. Changing the presentation of a drug to rats will affect its 
absorption and hence alter the resultant efficacy and/or 
toxicopathology in vivo. 
The first hypothesis was accepted. Of the crystalline forms of the three 
p38 MAPK inhibitors investigated, GSK-899 (low aqueous solubility) 
was the most persistent in rat lung tissue after inhaled administration 
and GSK-361 (low solubility; high passive membrane permeability) was 
the least. The longer lung residence time for GSK-899, relative to 
GSK-677 (high solubility; low passive membrane permeability) or 
GSK-361, correlated with a more effective dose (lower ED50) for 
inhibition of LPS-induced pulmonary infiltration by neutrophils at four 
hours post challenge. However, at higher doses, this ‘improved’ 
efficacy was overpowered with repeated administration resulting in 
accumulation of GSK-899 in lung and adverse pulmonary inflammation. 
The second hypothesis was accepted given the severity of respiratory 
tract toxicopathology for two of three p38 MAPK inhibitors differed with 
a change in aerosol form. Irritancy of the upper respiratory tract (larynx 
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and nasal cavity) was more pronounced in rats administered a 
nebulised solution of GSK-677 than those administered crystalline 
GSK-677. Conversely, pulmonary inflammation seen after 
administration of crystalline GSK-899 (15 mg/kg/day) was more 
pronounced than that seen in rats administered the more readily 
soluble amorphous aerosol form; evaluation of this dose as a nebulised 
solution of GSK-899 was precluded by low aqueous solubility of this 
compound. Furthermore, an increase in aerosol particle size and, by 
inference, a decrease in lung deposited dose diminished the 
effectiveness of amorphous GSK-899 to inhibit LPS-induced acute lung 
inflammation (evident as a higher ED50 value). However, for GSK-361 
and GSK-677, there was no obvious difference between ED50 values 
for the respective crystalline and nebulised aerosol forms. Dose 
responses for nebulised or dry powder aerosol forms of GSK-899 (for 
similar median particle sizes) were also statistically indistinguishable.  
Although much has been published about nuisance particulates in 
relation to adaptive and adverse pulmonary changes, the described 
experiments were largely undertaken during the late twentieth century 
using industrial materials or environmental pollutants that are strikingly 
different from organic molecules developed as inhaled medicines. 
Laboratories performing inhalation exposure of laboratory species are 
typically found within industry or publicly funded agencies undertaking 
commercially or strategically sensitive research. In addition, 
pharmaceutical companies expedite termination of programmes (to 
optimise resources) when drug developability is jeopardised; such 
laboratories normally archive unpublished data and rarely undertake 
empirical research. This thesis therefore represents an original 
contribution to the field by utilising industrial laboratories in support of 
academic research investigating the in vivo efficacy and respiratory 
toxicopathology of three drugs of common pharmacology when 
administered to rats as dry powder or aqueous aerosol formulations. 
This thesis supports the conservative approach of using an aerosol 
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formulation during early non-clinical development that is as near to the 
anticipated medicine as possible, and to eschew expediting strategies 
that potentially necessitate mitigation of liabilities identified when 
bridging data to the final clinical formulation (delaying timings and using 
additional animals). Changing aerosol form or particle size resulted in a 
shift in the dose response and/or severity of toxicopathology for two of 
the three p38 MAPK inhibitors investigated. Furthermore, technical 
limitations (dose limited by low solubility) precluded characterisation of 
toxicity for nebulised aqueous solutions at a higher dose, which had 
implications for defining the NOAEL and thereby reduced the safety 
margin for a nebulised clinical dose. 
The seminal publication of Snipes (1989) describing a lung deposition 
fraction of 7% in rats, which is still cited today, referenced in vivo data 
for airborne inorganic nuisance particles and radionuclides. For 
regulatory review of non-clinical safety, the US-FDA assumes 10% of 
an aerosol is deposited in rat lungs. This thesis presents data 
confirming 12% of an inhaled organic molecule (crystalline GSK-899; 
MMAD 2.1 ± 0.4 µm and GSD 2.0 ± 0.1) was retained in rat lungs, 
which corroborated the deposition fraction used by the US-FDA.  
Minute volume measurements of rats restrained in tubes supported use 
of an allometric equation to estimate inhaled doses of compounds in 
healthy rats, provided the animals were adequately acclimatised to the 
restraint procedure and allowed to settle prior to aerosol administration; 
implications of toxicity (including body weight loss) or drug-induced 
changes in respiratory pharmacology were not investigated. Based on 
these data, the sponsor now applies a 15-minute pre-exposure period 
to allow rodents to settle in restraint tubes before the start of aerosol 
administration. Lung function data can also be interpreted as a 
surrogate indicator of activity or stress and the sponsor refined tube 
restraint protocols at their laboratory following a review of lung function 
data presented in this thesis. Acclimatisation of rodents for inhalation 
exposure (30 to 60 minutes) or intravenous infusion (up to four hours) 
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have been harmonised such that rats are now subjected to tube 
restraint for a 30-minute period on each of two consecutive days before 
the first dose, irrespective of the dose route or duration of dose 
administration. The data in this thesis demonstrated that 30 minutes 
was sufficient time to ensure rats achieved a calm state before their 
removal from the restraint tube. Longer restraint periods were shown to 
be of no obvious benefit before the first dose and were discontinued, 
representing benefits for animals and technical resources (protocols 
formerly applied incremental restraint periods over five days). 
In conclusion, administration of three anti-inflammatory drugs with 
similar in vitro potencies but differing physicochemical properties 
resulted in a range of biological outcomes. Increasing lung persistence 
improved efficacy at four hours post LPS-challenge but also resulted in 
the onset of pulmonary toxicopathology with repeated administration of 
the drug. Similar work to investigate non-clinical efficacy and toxicity of 
other pharmacological classes of inhaled drugs would expand this 
dataset and establish the extent to which these findings are generic for 
inhaled drugs or standalone results for the investigated compounds. 
Results of this thesis also underpinned refinement of the restraint 
procedure for rodents during dose administration and considerations 
for experimental design for non-clinical development of inhaled drugs. 
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Appendix 1: Optimisation of exposure route for administration 
of lipopolysaccharide to induce acute lung inflammation 
In an experiment, two operators administered lipopolysaccharide 
(LPS) to groups of rats (n=6/group) via the trachea using a Portex® 
cannula. Neutrophil counts in BALF were inconsistent, with a significant 
proportion of rats (1/6 to 5/6) not responding to the LPS-lung challenge. 
This indicated the cannula had been misplaced and LPS discharged 
into the oesophagous in error. Subsequent investigations confirmed a 
difference between operators for the frequency of successful 
placement of the cannula into the trachea.  
Before progressing with experiments summarised in Chapter 4, three 
methods for administering LPS were evaluated. Groups of rats (n=3) 
were dosed by intratracheal instillation (2 µg/rat; 0.2 mL/rat; 10 µg/mL 
LPS in phosphate buffered saline) using a Penn Century microsprayer 
(Figures A1A and A1B) or by inhalation of a nebulised aerosol for 
15 minutes (150 µg/mL; airflow 9 L/min) in a whole-body chamber 
(Figure A1C) or restrained in tubes attached to a snout-only exposure 
chamber (Figure A1D). The aerosol concentration of LPS was not 
measured but the guesstimated inhaled dose was 100 µg/rat (based on 
knowledge of the apparatus) and equivalent to a lung dose of 10 µg/rat 
assuming 10% aerosol deposition. Neutrophil counts were determined 
in bronchoalveolar lavage fluid taken four hours post challenge. 
Methodological outcomes for LPS challenge 
Intratracheal instillation was selected as the preferred method for 
administration for LPS challenge. Under the experimental conditions, 
intratracheal instillation produced the highest neutrophil counts of the 
three methods (Figure A1E) and had the highest and most consistent 
proportion of neutrophils as a percentage of leukocytes (Figure A1F). 
However, careful placement of the cannula in the trachea was critical 
for successful dose administration of LPS. 
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Appendix 1: Optimisation of exposure route for administration of 
lipopolysaccharide to induce acute lung inflammation (continued) 
A1A 
 
A1B 
 
A1C 
 
A1D 
 
A1E 
 
 
A1F 
 
Figure A1: Induction of inflammation in rat lungs after administration of 
lipopolysaccharide via three exposure routes. Rats (n=3/group) were 
administered lipopolysaccharide in phosphate buffered saline by intratracheal 
instillation (2 g/rat; bolus) or inhalation (150 g/mL nebulised; 15 minutes). 
Rats were euthanized four hours post dose and lungs lavaged for cell counts. 
A1A: Penn Century microsprayer (without syringe). A1B:  intratracheal 
dosing of a rat under light anaesthesia; vocal folds were visualized by a cold 
light source to facilitate passage of the cannula into the trachea. A1C: whole 
body inhalation exposure of rats. A1D: snout-only inhalation exposure of rats. 
A1E: absolute neutrophil counts in bronchoalveolar lavage fluid (BALF). 
A1F:  neutrophils as percentage of leukocytes in BALF. 
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Appendix 2: Examples of technical issues that compromised 
image analysis of rat lungs 
A2A 
 
 
A2B 
 
 
Figure A2: Contaminant dust erroneously identified as lung tissue. Rat 
lungs (formalin-fixed, paraffin wax-embedded) were sectioned and stained for 
chloroacetate esterase (CAE; biomarker of neutrophils); cell nuclei were 
counterstained blue with haematoxylin. A2A: fine particles (G) in empty areas 
of the slide and superimposed over tissue; the dust was generated during 
etching of the glass slide with sample identification details. A2B: colour 
overlay during image analysis identified fine particles (G) as part of the lung 
tissue (green) or cell nuclei (blue). 
G 
G 
G 
G 
G 
G 
G 
G 
G 
G 
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Appendix 2: Examples of technical issues that compromised 
image analysis of rat lungs (continued) 
A2C 
 
 
A2D 
 
 
Figure A2: Translucent structures erroneously identified as lung tissue. 
Rat lungs (formalin-fixed, paraffin wax-embedded) were sectioned and 
stained for chloroacetate esterase (CAE; biomarker of neutrophils); cell nuclei 
were counterstained blue with haematoxylin. A2C: translucent structures (T) 
overlaying tissue were associated with the dehydration and drying of sections; 
CAE-stained neutrophils (N) also shown. A2D: translucent structures could 
be dissolved using an organic solvent (industrial methylated spirits or tertiary 
butanol used) but this depleted the CAE stain (red) and haematoxylin stain. 
T 
T 
N 
T 
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Appendix 2: Examples of technical issues that compromised 
image analysis of rat lungs (continued) 
A2E 
 
 
A2F 
 
 
Figure A2: Air bubbles trapped beneath a glass coverslip compromised 
image analysis of lung tissue. Rat lungs (formalin-fixed, paraffin wax-
embedded) were sectioned and stained for chloroacetate esterase (CAE; 
biomarker of neutrophils); cell nuclei were counterstained blue with 
haematoxylin. A2E: air bubbles trapped when a coverslip was applied and set 
using Entellan® rapid mounting medium (Sigma Aldrich). A2F: aqueous hard-
setting mount warmed to 40ºC and used to fix the coverslip eliminated 
bubbles. CAE-stained neutrophils (N) shown; staining of lung tissue is pale 
but sufficient for lung image analysis. 
T 
N 
N N 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 rat alveolar 
macrophage cells treated with GSK-899 or GSK-677 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
 
Appendices 
410 
 
Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 3: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-899 or GSK-677 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 rat alveolar 
macrophage cells treated with GSK-361 or SB-323 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 4: In vitro assessment of cytotoxicity, morphology and 
pro-inflammatory mediator release of NR8383 cells treated with 
GSK-361 or SB-323 (continued) 
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Appendix 5: Histopathology of the respiratory tract of rats 
exposed to micronised crystalline GSK-899 for 3 days 
 
 Incidence of observations 
Vehicle for powder dispersal Lactose 
GSK Study Numbers R29739 R30353N 
Target dose (mg/kg/day) Grading of 
observation 
0 
(control) 
45 15 
Number of rats on study  6 6 6 
Initial examination  6 6 6 
Treatment-related findings (TRF) 
Lung NAD 3 0 0 
Macrophage infiltration; 
interstitium; multifocal 
Minimal 0 6 6 
Degeneration/regeneration; 
bronchiole; epithelial, multifocal 
Minimal 0 0 6 
Incidental findings (no affect of treatment) 
Lung (TRF only)   (5) 
Aggregate; foamy macrophage; 
bronchioloalveolar  
Minimal 1 0 0 
Foamy alveolar macrophages Minimal 1 1 0 
Haemorrhage; alveolus; focal Minimal 0 1 1 
Hyperplasia; neuroendocrine cell; 
bronchiole; focal 
Minimal 1 0 0 
Inflammation; alveolus Minimal 1 0 0 
Lymph node, mandibular (examined) (2) (0) (2) 
Cellularity increased Minimal 0 - 1 
Mild 0 - 1 
Moderate 2 - 0 
Notes 
NAD no abnormality detected: unaffected tissues include tracheal bifurcation, lymph 
node (tracheobronchial) 
TRF treatment-related findings 
Appendices 
441 
 
Appendix 6: Histopathology observations in rats exposed to 
micronised crystalline GSK-361 for 14 days 
GSK Study No. R31034N Incidence of 
observations 
Vehicle for powder dispersal Lactose 
Target dose (mg/kg/day) Grading of 
observation 
5 15 
Number of rats on study  4 4 
Initial examination  0 4 
Treatment-related findings (TRF) 
Lung NAD/NTRF 1+1 1+1 
Alveolar macrophages 
aggregate 
Minimal 2 2 
Incidental findings (no affect of treatment) 
Lung NAD 1 1 
 (TRF only) (1) (2) 
Alveolar macrophages 
prominent; focal 
Minimal 1 1 
Haemorrhage; focal Minimal 1 0 
Larynx NAD - 3 
Epithelial alteration; focal Minimal - 1 
Lymph node (tracheobronchial) NAD - 2 
 (no section) - (1) 
Haemorrhage Minimal - 1 
Heart NAD 4 2 
Necrosis/inflammatory cell 
infiltrate; multifocal 
Minimal 0 2 
Thymus (examined) - (1A) 
Haemorrhage Mild - 1 
Notes 
NAD no abnormality detected: unaffected tissues include trachea, tracheal 
bifurcation, nasopharynx, nasal cavity; skeletal muscle 
NTRF no treatment related findings 
A Thymus: macroscopic abnormality (red discolouration on left lobe) seen at 
necropsy for one animal; tissue examined microscopically for affected animal 
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Appendix 7: Systemic exposure of rats following a single 
subcutaneous dose of 5 mg/kg GSK-899 or GSK-677 
 
 
Pharmacokinetic parameters (plasma) on Day 1 
Analyte GSK-899 GSK-677 
Parameter  
AUC0-t 
(ng.h/mL) 
Cmax 
(ng/mL) 
Tmax 
(h) 
AUC0-t 
(ng.h/mL) 
Cmax 
(ng/mL) 
Tmax 
(h) 
1st rat 735 292 1 1260 399 0.5 
2nd rat 582 287 0.5 1630 604 1 
3rd rat 1070 366 0.5 1690 518 0.5 
Mean 796 315 0.5 A 1530 507 0.5 A 
 
 
Drug concentrations in plasma (ng/mL) on Day 1 
Analyte GSK-899 GSK-677 
Rat no. 001 002 003 004 005 006 
Time (h)       
0.5 266 287 366 399 534 518 
1 292 183 293 357 604 478 
2 140 124 185 309 354 409 
4 54.1 38.3 27.4 119 132 159 
8 21.4 14.1 38.4 25.5 34.3 40.1 
24 NQ NQ 6.18 NQ NQ NQ 
Notes 
A Median Tmax 
NQ Not quantifiable (<2.5 ng/mL) 
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Appendix 8: Histopathology of injection sites in rats administered 
a single subcutaneous dose of GSK-899 or GSK-677 
 
Vehicle for dosing: 3% (v/v) Solutol HS 15 in 0.9% 
(w/v) aqueous sodium chloride 
Incidence of observations  
(Study R31711N) 
Dose (mg/kg/day) A Grading of 
observation 
5 
GSK-899 
5 
GSK-677 
Number of rats on study  3 3 
Treatment-related findings (TRF) 
Injection site NAD 2 1 
Necrosis; dermis; subcutis; multifocal Mild 0 1 
Inflammatory cell infiltrate; subcutis; 
dermis; mononuclear cell, 
multifocal 
Mild 0 1 
Inflammatory cell infiltrate; subcutis; 
mononuclear cell, localised 
Minimal 1B 1 
Procedural-related findings (injection) 
Inflammatory cell infiltrate; dermis; 
neutrophilic, focal 
Minimal 1 0 
Haemorrhage; subcutis; dermis; 
multifocal 
Minimal 0 1 
Haemorrhage; subcutis; focal Minimal 0 1 
Notes 
NAD no abnormality detected 
A Animals were dosed (Day 1) and euthanized after completion of an off-dose 
period of four days (necropsy on Day 5) 
B Observation may have been due to a combination of the needle passage, 
GSK-899 and/or formulation 
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Appendix 9: Histopathology observations at injection sites of rats 
dosed subcutaneously with GSK-899 for 28 days 
 
Vehicle for dosing: 3% (v/v) Solutol HS 15 in 0.9% 
(w/v) aqueous sodium chloride 
Incidence of observations  
(Study R31697N) 
Dose (mg/kg/day) 0 (control) 5 
Number of rats on study Grading of 
observation 
5 on study 6 on study 
Initial examination 5 examined 6 examined 
Injection sites (identified no. 1 to 4)A  1 2 3 4 1 2 3 4 
Number of rats Examined 5 0 1 5 6 3 3 6 
 NAD 1 - - - 1 - - - 
Degeneration/regeneration; 
panniculus muscle; focal 
Minimal 1 - 0 0 3 0 0 0 
Mild 0 - 0 0 0 0 0 0 
Moderate 0 - 0 0 0 0 0 0 
Degeneration/regeneration; 
panniculus muscle; multifocal 
Minimal 0 - 0 3 0 1 2 1 
Mild 0 - 0 1 0 0 1 2 
Moderate 0 - 0 1 0 1 0 2 
Inflammation; subcutis; 
lymphohistiocytic, multifocal 
Minimal 1 - 1 3 1 0 1 0 
Mild 2 - 0 2 2 2 1 1 
Moderate 0 - 0 0 2 0 1 5 
Fibroplasia; subcutis; diffuse Minimal 2 - 0 4 2 3 1 1 
Mild 1 - 1 1 2 0 0 4 
Moderate 1 - 0 0 1 0 1 1 
Degeneration; subcutis; multifocal Minimal 3 - 0 0 0 2 0 0 
Mild 0 - 1 0 0 0 0 0 
Moderate 1 - 0 0 3 1 2 0 
Marked 0 - 0 0 1 0 1 0 
Degeneration; subcutis; diffuse Minimal 0 - 0 1 0 0 0 0 
Mild 0 - 0 2 0 0 0 1 
Moderate 0 - 0 1 0 0 0 2 
Marked 0 - 0 0 0 0 0 3 
Haemorrhage; subcutis; localised Minimal 0 - 1 2 2 2 2 4 
Mild 1 - 0 0 1 0 1 1 
Moderate 0 - 0 0 0 0 0 1 
Pigmented macrophages; subcutis; 
focal (site 1) or multifocal (sites 2 
and 4) 
Minimal 0 - 0 1 2 2 0 4 
Mild 0 - 0 0 0 0 1 0 
Inflammatory cell infiltrate; dermis; 
mononuclear cell, focal 
Minimal 0 - 1 0 0 0 0 0 
Granuloma; dermis; focal Minimal 0 - 0 0 0 0 1 0 
Notes 
NAD no abnormalities detected 
A Rats were dosed once daily using four sites in rotation, i.e. each site was 
injected 7 times with a 3-day interval between consecutive injections. 
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Appendix 10: Image analysis of lung sections stained for 
chloroacetate esterase (new data available post submission) 
Table A1: Estimated inhaled dose of GSK-899 to achieve 50% reduction 
(ED50) in inflammation 4 hours after challenge of rats with LPS 
Parameter 
and medium 
Presentation 
of GSK-899 
ED50 
estimate 
(µg/kg) A 
95% confidence 
interval (µg/kg)  
ED50 
outside 
dose 
range? lower upper 
CAE stain 
(4h) lung 
crystalline 211 75.8 1046.7 No 
amorphous-1 B 15.8 x104  NC NC Yes 
amorphous-2 34.0 NC 518.1 No 
nebulised 14.7 NC NC No 
Notes 
A ED50 values extrapolated from net data (mean value of PBS-
challenged control deducted from result for LPS-challenged animal). 
B ED50 value 10-fold higher than dose inducing adverse lung 
toxicopathology after 28 days (Chapter 5). 
NC Not calculable 
Table A2: Estimated inhaled dose of GSK-361 to achieve 50% reduction 
(ED50) in inflammation 4 hours after challenge of rats with LPS 
Parameter 
and medium 
Presentation 
of GSK-361 
ED50 
estimate 
(µg/kg) A 
95% confidence 
interval (µg/kg)  
ED50 
outside 
dose 
range? lower upper 
CAE stain 
(4h) lung 
Crystalline 60.3 x10
4 NC NC Yes 
Nebulised 1375 169.6 2.48 x10
12 Yes 
Notes 
A ED50 values extrapolated from net data (mean value of PBS-
challenged control deducted from result for LPS-challenged animal). 
NC Not calculable 
Image analysis to investigate the efficiency of bronchoalveolar lavage 
in harvesting neutrophils from GSK-361-treated rats was inconclusive, 
with no obvious dose response for inhibition of LPS-induced 
inflammation. 
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Appendix 10: Image analysis of lung sections stained for 
chloroacetate esterase (continued) 
Methods: lung image analysis for CAE: Design C and D  
Digitalized images of slides were imported into HALO software (version 
2.1.1637.10; Indica Labs). Image analysis gave insufficient contrast to 
differentiate CAE-staining of neutrophils from erythrocytes (Figure A1). 
A1A 
 
A1B 
 
Figure A1: Example of image analysis of rat lungs for chloroacetate 
esterase (CAE), a biomarker of inflammation. Rats (n=6/treatment) were 
administered lipopolysaccharide in phosphate buffered saline by intratracheal 
instillation (2 g/rat; bolus). Lungs taken four hours later were fixed in 10% 
buffered formalin and embedded in paraffin wax. Lung sections were stained 
for CAE and lung tissue counterstained with haematoxylin and eosin. Colour 
overlays were applied to areas of interest: yellow indicated ‘moderate 
intensity’ of CAE-stain and red a ‘strong intensity’ of CAE-stain. The ratio of 
CAE-stained area to remaining tissue area was determined with exclusion of 
air spaces. A1A: lung section with CAE-stained neutrophil (N). A1B: lung 
section with erythrocytes ‘stained’ by CAE (E). 
Three representative areas (1.5 mm square) proximal, mid and distal to 
a main airway were selected for quantification for each lung section 
(Figure A2A), avoiding clusters of erythrocytes; the first square was 
situated next to the most central bronchus with additional areas at 
1 mm intervals. Most connective tissue (submucosa, lymphoid tissue, 
arteries and veins) were excluded from the region of interest using the 
HALO exclusion drawing tool (x3 magnification); a classifier layer (‘train 
by example’ algorithm with manual definition of pertinent or irrelevant 
textures or colours) was used to detect the tissue area omitting alveolar 
air spaces, glass and bubble artifacts (Figure A2B). Threshold intensity 
for detecting CAE stain was set at 0.138 (moderate) and 0.359 
(strong); red-green-blue colour detection set at 0.142, 0.411 and 0.299. 
N 
N E 
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Appendix 10: Image analysis of lung sections stained for 
chloroacetate esterase (continued) 
A2A  
Figure A2: Processing of rat lung images for analysis of chloroacetate 
esterase (CAE), a biomarker of inflammation. Rats (n=6/treatment) were 
administered lipopolysaccharide in phosphate buffered saline by intratracheal 
instillation (2 g/rat; bolus). Formalin-fixed paraffin-embedded lungs were 
stained for CAE and the lung tissue counterstained with haematoxylin and 
eosin. A classifier layer was applied to define areas of interest. The ratio of 
CAE-stained area to remaining tissue (region of interest) was determined. 
A2A: definition of areas in lung section proximal, mid and distal to a main 
airway for quantification of CAE-staining area, relative to the evaluated region 
of interest. A2B:  classifier layer applied to demarcate tissue area (pink) and 
exclude alveolar air spaces, glass and bubble artifacts (blue). 
Determination of 50% effective dose (ED50) for inhibition of 
LPS-induced lung inflammation 
The baseline CAE-stain value (mean for PBS-challenged rats) was 
deducted from the datum for each LPS-challenged rat. Net values were 
plotted against Log10 of estimated inhaled doses of p38 MAPK inhibitor 
and a linear regression line was fitted. The regression line was then 
used to estimate the inhaled dose for a 50% response (ED50) of net 
mean LPS-control response and corresponding 95% confidence 
intervals of this estimate; analyses conducted using SAS (version 9.3). 
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1. External presentations 
1.1. Oral presentations 
Defining dosimetry & markers of exposure in inhalation drug 
development. GSK Inhaled Sciences Symposium, 23-Nov-2011. 
Stevenage, Hertfordshire, UK. 
Influence of aerosol presentation on lung pathology changes induced in 
rats. 31st Annual Meeting of the British Society of Toxicological 
Pathology held jointly with the Association of Inhalation Toxicologists, 
11-Nov-2016. Alderley Edge, Cheshire, UK. (Addendum 1) 
Head-out plethysmography and estimation of inhaled doses in rats. 
31st Annual Meeting of the British Society of Toxicological Pathology 
held jointly with the Association of Inhalation Toxicologists, 
11-Nov-2016. Alderley Edge, Cheshire, UK. (Addendum 2) 
Aerosol presentation and implications for non-clinical development of 
inhaled drugs. Postgraduate Research Day, 28-Apr-2017. School of 
Pharmacy and Pharmaceutical Sciences, Cardiff University, UK. 
(Addendum 3) 
Multivariate-based selection of drugs and implications of aerosol 
presentation for inhalation toxicology in rats. 14th Annual Meeting of the 
Association of Inhalation Toxicologists, 27-Oct-2017. Copenhagen, 
Denmark. (Addendum 3) 
Cascade impaction data and the devil in the detail. 14th Annual Meeting 
of the Association of Inhalation Toxicologists, 27-Oct-2017. 
Copenhagen, Denmark. (Addendum 4) 
Cascade impaction data and in silico modelling of drug-lung deposition 
in rats. Chemical Aspects of Toxicology (CHAOTIC70), 09-May-2018. 
Ware, Hertfordshire, UK. 
Aerosol characterisation of spray-dried constructs. Chemical Aspects 
of Toxicology (CHAOTIC70), 09-May-2018. Ware, Hertfordshire, UK. 
1.2. Poster presentations and associated abstracts 
Paul GR, Somers GI, Moore SA, Goodway RE (2012). The Capsule 
Based Aerosol Generator - Conserving Test Article in Small Scale 
Inhalation Exposures. Respiratory Drug Delivery 2012, 2, 525-530. 
(Addendum 5) 
Paul GR (2015). Defining dosimetry & markers of inhaled exposure in 
drug development. Society of Biology (Beds, Essex & Herts branch) 
early career biologist event, 29-Jun-2015. Ware, Hertfordshire, UK. 
Paul GR (2015). Inhalation dosimetry and environmental factors 
investigated in rats using head-out plethysmography. 12th Annual 
Meeting of the Association of Inhalation Toxicologists, 13-Oct-2015. 
Cambridge, UK. 
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Paul GR, Somers GI and Taylor G (2016). Implications for Room 
Lighting and the Duration of Acclimation Protocols on the Dosimetry of 
Inhaled Drugs in Rats. Respiratory Drug Delivery 2016, 2, 327-332. 
(Addendum 6) 
1.3. Journal articles 
Paul GR, Gumbleton M and Somers GI (2017). Effect of Conditioning 
on Rat Lung Function Measurements and Implications for Exposure 
and Dose Estimation of Inhaled Drugs. Inhalation Magazine. 
(Addendum 7) 
2. Internal presentations for sponsor (GSK) 
2.1. Oral presentations 
Paul GR (2014). Permeability solubility data review: overview of 
non-clinical studies performed in rats to investigate pharmacokinetic 
profiles of 12 inhaled compounds in blood and lung. Inhaled Sciences 
Forum, 26-Jun-2014. GSK R&D, Stevenage, Hertfordshire, UK. 
Paul GR (2015). Rats; inhalation dosimetry and environmental factors. 
CPD event, 15-Sep-2015. GSK R&D, Ware, Hertfordshire, UK. 
Paul GR (2016). Feasibility and scale-up of spray drying to support 
safety studies: influence of aerosol presentation on lung exposure and 
pathology changes in rats. Modelling Community Forum (Chemistry 
and Pharmaceutical Development), 22-Nov-2016. GSK R&D, 
Stevenage, Hertfordshire, UK. 
Paul GR (2017). Aerosol form and Pathology; experiences with 
GSK258899B in rats. Inhaled Sciences Forum, 25-Jan-2017. GSK R&D, 
Stevenage, Hertfordshire, UK. 
Paul GR (2017). Head-out plethysmography and estimation of inhaled 
doses in rats. Inhaled Sciences Forum, 22-Mar-2017. GSK R&D, 
Stevenage, Hertfordshire, UK. 
2.2. Abstracts 
Paul GR, 2015. Environmental factors and their implications for 
dosimetry of inhaled drugs in rats. GSK 3Rs Quarterly Newsletter (Q3: 
September 2015); in house online publication. 
Paul GR (2016). Rat lung function, inhaled dose and refining tube 
restraint. GSK 3Rs Quarterly Newsletter (Q1: March 2017); in house 
online publication. 
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Addendum 1 
Influence of Aerosol Presentation on Lung Pathology Changes 
Induced in Rats 
Graham R. Paul, GSK 
Many inhaled drugs are developed as crystalline dry powder formulations for 
prolonged stability and to improve clinical control of drug delivery. Pre-clinical 
development of inhaled drugs consumes large masses of material, relative to 
other dose routes. Surrogate formulations or administration routes are 
sometimes proposed to expedite evaluation (first time) in humans. Such 
strategies defer the discharging of liabilities such as altered PK/PD or 
tolerability of the final (particulate) formulation until later in development.  
Male rats were administered GSK258899B by snout-only inhalation exposure 
for 28 consecutive days. The drug was presented as micronised crystals or 
amorphous powder blended in lactose (≤15 mg/kg/day) or as a nebulised 
solution (1 mg/kg/day; limited by solubility) in 3% (v/v) Solutol HS15 in 0.9% 
(w/v) aqueous sodium chloride. 
Dose dependent increases in severity and incidence of multifocal foamy 
macrophage aggregates were evident in rats administered all forms of 
GSK258899B, with changes in animals exposed to the crystalline aerosol 
form being most pronounced. This was associated with inflammatory changes 
characterised by minimal interstitial mononuclear inflammatory cell infiltration 
at amorphous doses of ≥1 mg/kg/day, and foamy macrophage 
degeneration/necrosis and intra-alveolar neutrophils (minimal), interstitial 
mononuclear inflammatory cell infiltration (mild to marked), and increased 
cellularity and enlargement of bronchus-associated lymphoid tissue (minimal 
or mild) at the crystalline dose of 15 mg/kg/day. 
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Changes for all aerosol forms at 1 mg/kg/day were considered non-adverse. 
The crystalline form of GSK258899B was persistent in lung tissue and 
produced more severe lung changes at 15 mg/kg/day compared to the 
amorphous powder. Nonetheless, the changes were considered adverse for 
both aerosol forms at this dose and the NOAEL was not affected by changing 
the aerosol form. 
All animal studies were ethically reviewed and conducted in accordance with the 
Animals (Scientific Procedures) Act 1986 and GSK Policy on the Care, Welfare and 
Treatment of Animals. 
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Addendum 2 
Head-out Plethysmography and Estimation of Inhaled Doses in 
Rats 
Graham R. Paul, GSK 
Non-clinical studies often report ‘doses’ calculated using an equation to 
estimate respired minute volume (RMV) from bodyweight, which may 
overlook habituation of animals to procedures. The influence of bodyweight 
development and procedural conditioning on the breath frequency (BF) and 
minute volume (MV) of rats was investigated over a 28-day treatment period 
(1-hour snout-only inhalation exposure). Rats were allowed to settle in 
restraint tubes for 15 minutes before aerosol administration; BF and MV were 
measured using head-out plethysmography. 
A reduction in mean BF and MV was evident during the 15-minute settling 
period. Animals appeared to take longer to settle when diaphragms used for 
maintaining a neck-seal during head-out plethysmography were omitted from 
restraint tubes for preceding days of aerosol administration. 
Measured MV was more variable than corresponding bodyweight-derived 
estimates, especially for Day 1 of treatment (first exposure) or following 
several days of treatment when diaphragms were omitted during restraint. 
Omission of diaphragms for a prolonged period also resulted in lower MVs, 
relative to bodyweight-derived estimates. Parity of these parameters, and 
hence ‘dose’ estimates, was achieved after three days of reintroducing the 
diaphragms.  
Results suggest a desire to minimize the degree of restraint applied to 
animals during inhalation exposures between days of lung function 
measurement needs to be weighed against a potential impact on parameters 
and the need for reconditioning animals. 
All animal studies were ethically reviewed and conducted in accordance with the 
Animals (Scientific Procedures) Act 1986 and GSK Policy on the Care, Welfare and 
Treatment of Animals. 
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Addendum 3 
Multivariate-based selection of drugs and implications of 
aerosol presentation for inhalation toxicology in rats  
Graham R Paul 
GSK R&D, Park Road, Ware, Hertfordshire, SG12 0DP 
Many inhaled drugs have been developed as crystalline dry powder formulations for 
prolonged stability and to optimise clinical drug delivery. Inhalation exposure of 
animals requires large masses of drug, relative to other dose routes in pre-clinical 
development. Surrogate formulations or administration routes are sometimes 
proposed to expedite early clinical evaluation. Such strategies defer discharging of 
liabilities such as altered pharmacokinetics-pharmacodynamics (PK/PD) or 
tolerability of the final formulation until later in development. Using three 
compounds of common pharmacology but differing physicochemical properties, the 
aim of this work was to determine if altered presentation of an inhaled drug affected 
exposure or toxicology and hence if such shortcuts are prudent. 
Rats (n=6/group) were administered GSK-899, GSK-677 or GSK-361 for up to 28 
days by snout-only inhalation exposure (one hour daily) at target doses of 
≤15 mg/kg/day. The compounds were administered to rats as aerosols generated from 
dry powder formulations of micronised crystals (all compounds) or amorphous 
powder (GSK-899 only) blended with lactose, or as nebulised aqueous solutions. Rats 
were euthanized after 28 days of treatment and the lungs were fixed in 10% buffered 
formalin, embedded in paraffin wax, sectioned and stained with haematoxylin and 
eosin for examination by light microscopy. Additional rats (n=3/group/timepoint) 
were exposed and the lungs taken following a single dose or 28 days of treatment for 
homogenisation and HPLC-MS/MS analysis of the parent compounds. Macrophages 
were also harvested from satellite animals (one rat per compound and aerosol form) 
by bronchoalveolar lavage using 0.9% (w/v) aqueous sodium chloride. The cells were 
fixed in 4% formaldehyde and 1% glutaraldehyde (v/v/v) in phosphate buffer, 
embedded in Agar 100 resin, sectioned and stained with uranyl acetate and lead 
citrate for examination by transmission electron microscopy. 
In vitro dissolution rates in simulated lung fluid were relatively fast for amorphous 
GSK-899 and crystalline GSK-677, and relatively slow for crystalline GSK-899 and 
GSK-361. In vivo, crystalline GSK-899 (low solubility) was most persistent in rat 
lung tissue, with no appreciable decrease in drug-homogenate concentration at 24 
hours and a 7-fold increase from Days 1 to 28. Post dose drug-lung concentrations for 
amorphous GSK-899, GSK-677 (crystalline and nebulised aerosols) and crystalline 
GSK-361 were similar and reduced at 24 hours. However, GSK-677 (most soluble) 
increased from Days 1 to 28 indicating a degree of accumulation. Conversely, 
crystalline GSK-361 was least persistent in lung tissue with no evidence of 
accumulation Days 1 to 28; drug-lung homogenate concentrations were lowest for 
nebulised GSK-361 (≤1 mg/kg/day evaluated) and non quantifiable at 24 hours. This 
correlated with no GSK-361-related lung pathology. A non-adverse dose dependent 
increase in the severity and incidence of multifocal foamy macrophage aggregates 
was evident for nebulised and dry powder formulations of GSK-899 and GSK-677.  
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Administration of GSK-899 at 15 mg/kg/day was also associated with adverse 
inflammatory changes characterised by interstitial mononuclear inflammatory cell 
infiltration, which was marked for the crystalline form. Transmission electron 
microscopy confirmed the presence of particles in macrophages harvested from rats 
administered amorphous or crystalline GSK-899 only. 
Crystalline GSK-361, which was of low solubility but high membrane permeability in 
vitro, showed no drug-lung accumulation in vivo or pulmonary toxicity. Differences 
in dissolution rate for amorphous and crystalline GSK-899 correlated with drug-lung 
concentrations and a shift in the severity of lung pathology suggesting that the 
physical state of a drug can influence observed toxicity. However, inflammatory 
changes at 15 mg/kg/day were nevertheless adverse for both dry powder aerosol 
forms of GSK-899 and the safety margin between the no observed adverse effect 
level (NOAEL) and the hypothetical clinical exposure was thus unaffected. This 
suggests that membrane permeability may be a greater driver than in vitro solubility 
for mitigating toxicopathology when designing inhaled drugs. 
All animal studies were ethically reviewed and performed in accordance with the UK Animals (Scientific 
Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals. 
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Addendum 4 
Cascade impaction data and the devil in the detail 
Graham R Paul 
GSK R&D, Park Road, Ware, Hertfordshire, SG12 0DP 
Formal guidelines for the testing of chemicals in rodents have been in place since the 
early 1980s. These stipulate a requirement to characterise aerosols for the particle size 
distribution, specifically the mass median aerodynamic diameter (MMAD) and 
geometric standard deviation (GSD). These parameters are commonly determined by 
linear regression analysis of the cumulative mass of test article collected by cascade 
impaction plotted against the log-transformed cut-point, assuming linearity of the 
data. 
Samples (n=45) of dry powder and aqueous nebulised formulations of drugs collected 
using a Marple 296 cascade impactor illustrated that log-transformed data are often 
non-linear (device-specific calibrated cut points used for calculation). Whilst 
interpolation of two data points provides a pragmatic means of estimating the 
MMAD, this does not adequately describe the variability of the dataset and hence the 
particle size distribution. Mathematical methods of modelling a curved line to fit the 
non-linear data provide a means for determining MMAD. Although the Smoothed 
Spline method provided a means of determining the MMAD for study-specific 
samples, such mathematical methods are more complex and thus present challenges 
for the routine processing of data in preclinical studies. 
In silico lung models can be used to predict lung deposition in various species. The 
drug deposition in rats was estimated using the MPPD model with reference to 
measured rat lung function (breath frequency and minute volume) and cascade 
impaction data (MMAD = 1.8µm; GSD = 2.0). The MPPD model predicted total lung 
deposition of 2.5% of the aerosol in rats, which was lower than the value published 
by Snipes in 1989 (7% for 2µm particles) and the proportion of the estimated inhaled 
dose of a drug measured in lung tissue by HPLC-MS/MS (11-13%). The results 
indicate refinement of in silico models and a good understanding of lung deposition 
through high resolution image analysis techniques are key to a holistic approach for 
understanding particle size distribution and implications for pulmonary exposure. 
All animal studies were ethically reviewed and performed in accordance with the UK Animals (Scientific 
Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals. 
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